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ABSTRACT 
 
Adolescence is a significant period of change in physical and psychosocial development of 
human beings. Being HIV positive and growing up on a dynamically multifaceted HAART 
treatment, adds to the complexity of adolescence. This study was aimed at exploring the nature 
of experiences of adolescents who are on long-term Highly Active Antiretroviral Therapy 
(HAART) in Tembisa, Gauteng province. The study is based on a qualitative research method 
using in-depth semi-structured open-ended interviews and a focus group for data collection. The 
sample consisted of seven individual adolescent participants, three parents, guardians and 
caregivers, as well as 11 health care professionals. The thematic data analysis and the 
phenomelogical analysis methods were used to analyse data qualitative data while descriptive 
statistics were used to analyse quantitative biographical data. 
 
The study findings cover the negative and positive experiences and the perceived role of HAART 
treatment over a long period of time. The predominant themes identified from adolescent 
participants were disclosure of HIV positive status and the stigma surrounding a positive status, 
early childhood experience of parental death, challenges of taking HAART treatment, factors 
influencing adherence and non-adherence to HAART treatment, and lastly, the impact of religion 
on HAART treatment adherence. The findings suggest that adolescents who are on HAART 
treatment over an extended period of time experience drug fatigue. Drug fatigue has far-reaching 
implications for the health of an adolescent, as it has a higher likelihood that poor adherence or 
even complete refusal to take HAART treatment will occur. Poor adherence or refusal to take 
HAART treatment will most likely lead to cross infection and further spread of HIV and AIDS.  
 
A recommendation was made to include the establishment of a youth and adolescent-
friendly centre by the hospital – one that is designated for the provision of tailored 
adolescent services and sensitive to adolescent developmental stages so as to minimise the 
likelihood of infected adolescents falling through the health care cracks. The introduction of a 
hospital-based school, an education unit run by dedicated and qualified facilitators focusing 
on aiding hospitalised learners with catch-up scholarly programmes, was a further 
recommendation. It was further recommended that reproductive health care needs of 
adolescents who grow up on HAART treatment be given attention in further research. 
 
Key terms: 
Adherence; Adolescent; Adolescents on HAART; Experience; HAART treatment; HIV/AIDS; HIV-
Infected Adolescents; Phenomenology; Qualitative Study; Subjective; Tembisa Hospital.   
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CHAPTER 1: BACKGROUND TO THE STUDY 
1.1 INTRODUCTION 
 
The study focused on adolescents‟ experiences of the Highly Active Antiretroviral Therapy 
(HAART) treatment, a universally recommended aggressive medication for treating the 
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) 
(United Nations Programme on HIV/AIDS [UNAIDS], 1997). When the use of HAART 
treatment is inevitable, then the life of the affected individual is at stake. If at the age of 
adolescence the person is ailing with HIV and/or AIDS, then the chance of reaching 
adulthood is generally slim. According to several authors (Regnerus, Smith, & Smith, 2004; 
Pressley & McCormick, 2007; Simons-Morton, 2007; Rice & Dolgin, 2008; Steinberg, 2011), 
the first use of the term adolescence appeared in the 15th century. The term was a 
derivative of the Latin word adolescere, which means to grow up or to grow into maturity 
(Sigelman & Rider, 2009). Although Feldman and Elliot (1990) define adolescence as the 
period that extends from the age of 10 to 18 years, and it encompasses profound physical 
and social changes, late adolescence may occur beyond the age of 18. 
 
Adolescence is therefore a time of significant change in human development from youth to 
adulthood, including physical growth and psychosocial transition, usually encompassing the 
second decade of life. The most common health problems of adolescents relate to growth 
and development, and childhood illnesses continuing into adolescence. As such, congenital 
HIV status usually finds expression in this period. The desire for experimentation and 
exploration with new behaviours is another challenge navigated by adolescents. As 
adolescents try new behaviours, they become vulnerable to certain conditions related to 
behaviours which further complicate their health status (Berkow, Beers, Bogin, & Fletcher, 
1997).  
 
Adolescence is further subdivided into early, middle and late sub-stages. Early adolescence 
occurs between age 10 and 14 years and is characterised by profound physical changes 
that occur with puberty, as maturation begins and social interactions become increasingly 
centred on members of the opposite sex. Middle adolescence ranges from 15 to 17 years, 
and it is a time of increasing independence. Late adolescence occurs between 18 and 20 
years, and it occurs for those individuals who, because of educational goals or other social 
factors, delay their entry into adult roles (Feldman & Elliott, 1990).  
2 
 
HIV and AIDS is a terrible scourge. Because of HIV and AIDS and an uneven economic and 
political development, much of sub-Saharan Africa seems stuck in continued, widespread 
poverty (Badri & Bekker, 2004). The region is the epicentre of the continuing pandemic, and 
unfortunately, South Africa is not immune to problems affecting the rest of the African 
continent. Although the prevalence of the disease was somewhat smaller in 2011 than it was 
in 2005, in numbers, people are still dying on a large scale (Dohertey & Colvin, 2004). Many 
are young, and as parents die, according to Ojikvth and Zheng (2008), the number of 
orphans keeps increasing. Most of these orphans are left with the burden of HIV positive 
status, which they have to navigate by themselves or with minimum support (Phiri & Webb, 
2002). It is within this context that the study aimed at exploring the adolescents‟ experiences 
of being HIV positive and having to grow up, literally, on HAART treatment, with its 
multifaceted dynamics on the growing young person. 
 
HAART treatment is defined as a combination of at least three drugs from at least two 
classes: nucleoside and non-nucleoside reverse transcriptase inhibitors and protease 
inhibitors (Van Sighem, van de Wiel, Ghani, Jambroes, Reiss, Gyssens, Brinkman, Lange & 
De Wolf, 2003). Since the year 1996, the introduction of antiretroviral (ARV) drugs 
transformed the treatment of HIV and AIDS, improving the quality of life of those with HIV 
and AIDS, and greatly prolonging the lives of many infected people. Velasco-Hernandez 
(2002) explains that HIV is the virus that is believed to cause AIDS. On the other hand, AIDS 
is the collection of illnesses or symptoms that ultimately result in death (Sieleunou & 
Souleymanou, 2009).  
 
HAART is the treatment that has been applied to combat advanced HIV in a bid to slow 
down the progression towards AIDS and ultimately to help prolong the life of the infected 
individual. Also, HAART is a treatment that possesses the basic medications in ARVs and 
has been advanced to treat a more severe stage of the HIV and AIDS progression. 
Adolescents form a significant part of the population receiving HAART treatment at Tembisa 
Hospital, thereby creating a need for special research focus aimed specifically at 
investigating the adolescents‟ experiences of HAART treatment. 
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1.2 MOTIVATION FOR THE STUDY 
 
The study was influenced by the high rate of non-adherence to HAART treatment by the HIV 
positive adolescents who were taking treatment at the Masakhane Clinic of Tembisa 
Provincial Tertiary Hospital, in Gauteng. The researcher, who observed the non-adherence 
behaviour first-hand, works as a Clinical Psychologist in the hospital. Acknowledgement is 
made that despite the perceived high rate of non-adherence, some adolescents seemed to 
adhere to their treatment properly. However, there were indications that among the 
adolescent group, a high percentage struggled with adherence to their HAART prescriptions. 
As a result, they were referred to the psychology department at the hospital for intervention. 
Such referrals thus initiated interest in determining what influences adherence and non-
adherence by adolescents on HAART treatment. The experiences of defaulting adolescents 
could provide enlightenment on the factors contributing to adherence and non-adherence. 
The factors for adherence might then be applied in order to assist adolescents struggling 
with treatment adherence. 
 
The study appreciates that advancement in the medical field has given some hope to those 
living with HIV and AIDS for long-term survival and a better quality of life. These include the 
young and the old who have been on long-term HAART treatment. The primary goal of 
HAART treatment for children is to increase survival and decrease HIV and AIDS related 
morbidity and mortality. The child‟s CD4 count should rise and remain above the baseline 
count. On the other hand, the child‟s viral load should become undetectable (< 400 copies 
and ml) and remain undetectable on HAART treatment. In some children, a suppressed 
though detectable viral load with sustained elevation in CD4 count and absence of inter-
current and/or opportunistic infection may be the best achievable goal (Department of Health 
[DoH], 2014). For those on HAART treatment, adherence to medication can assist in 
maintaining the high CD4 count and the low viral load. 
 
At present, the majority of children are diagnosed on the basis of symptomatic HIV disease 
and on the positive HIV antibody test of the mother of the child. The child of an HIV-infected 
mother acquires HIV antibodies from his or her mother during pregnancy. These HIV 
antibodies may persist in an adolescent‟s blood until 15-18 months of age, even if the child is 
not infected with HIV. Thus, a child may test HIV positive without actually being infected 
(DoH, 2014). 
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The development of HAART treatment has helped turn HIV and AIDS infection into a 
relatively manageable, though still serious, chronic disease. Proper use of HAART treatment 
has been seen to lengthen life and sustain the good health of HIV patients. Hence, HAART 
treatment could be seen as a basis for hope of a longer and healthier life for those living with 
HIV and AIDS, and taking HAART treatment according to schedules and doses prescribed 
by professional medical and health practitioners. On the other hand, non-adherence to 
HAART medication for HIV and AIDS has been cited as a major problem in South African 
health care, resulting in high rates of relapse, hospitalisation, and mortality (Venter, 2006). 
 
There is a shortage of literature on the experiences of adherence and non-adherence among 
adolescents who are on HAART treatment. For instance, research by Karamagi (2007) 
focused on outcomes of HAART treatment among children under six years of age. No child 
of this age can personally express their experiences. The study of Masokoane (2009) on 
adherence and non-adherence to HAART treatment focused on adults‟ experiences. The 
research displayed that both psychosocial and economic factors can positively or negatively 
affect adherence levels. 
 
The Treatment Action Campaign (TAC) has created a handbook for people living with HIV 
and AIDS, and treatment advocates ARVs in people‟s lives (Geffen, 2010). This handbook 
describes personal experiences of people who are HIV positive and those on HAART 
treatment. Nonetheless, it falls short of focusing on the experiences of adolescents. 
 
It is on record that adolescents receiving treatment comprise almost half of the patient 
population referred for counselling due to poor adherence to HAART treatment at the 
Masakhane Clinic at the Tembisa Provincial Tertiary Hospital (Isithembiso, 2011). It is 
assumed that positive or negative experiences of young people regarding ARV treatment 
differ with that of adult patients. Therefore, reasons for non-adherence will likely be unique. It 
is therefore important to gain insight into the nature of experiences of non-adhering 
adolescents separately. It is hoped that gaining insight into the experiences of long-term 
usage of HAART treatment by adolescents could lead to a better understanding of the 
factors influencing non-adherence and those affecting adherence to HAART treatment. 
 
The HIV and AIDS endemic is severe and generally life-reducing. However, with current 
medical development and continuing researches, there is hope in the future for HIV and 
AIDS to be a manageable illness. At this point, HAART treatment has already improved the 
clinical status of many patients with HIV infection dramatically. The attention has been 
focused on the role of treatment adherence to this therapy (Turner, 2002). Adherence to 
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prescribed medication is necessary for the medication to be effective and to minimise the 
viral load and prevent drug resistance. At the same time, it is vital to get a better perspective 
of those taking such treatment properly and of those not adhering in order to intervene. This 
study finds it essential to view adherence or non-adherence from the patient‟s vantage point. 
Achieving and maintaining the health benefits of HAART treatment requires near-perfect 
adherence, which some of the HIV and AIDS adolescents do not achieve. 
 
Adolescents at the Tembisa Hospital represent a clinically significant catharsis to the HIV 
and AIDS epidemic. This is another reason warranting further research in this area because 
a large proportion of HIV positive adolescents can be assisted. In addition, adolescents 
present an important dynamic in the long-term management of the HIV and AIDS epidemic. 
On that account, researching adolescents‟ experiences regarding HAART treatment might 
have significant contributions towards management of the epidemic. 
 
Besides the Tembisa Provincial Tertiary Hospital situation, nationally, HIV positive 
adolescents seem to be becoming a progressively more sizeable and prominent subgroup in 
the South African HIV and AIDS epidemic (Lam, Seekings, & Sparks, 2006). As HAART 
treatment becomes increasingly available, mother-to-child infected children can be expected 
to survive into adolescence and then to adulthood. Additionally, sexual transmission of HIV 
remains a problem, and incidence and prevalence rates among South African youth are 
high. Experience from the developed world indicates that providing effective care and 
treatment for youth is a challenging task. The contribution of this study is on adherence to 
the HAART medications for HIV positive adolescents, with the ultimate aim of helping in the 
long life and good health of infected adolescents. 
 
In light of the HAART treatment roll-out in South Africa, this study aimed to identify the 
experiences of adolescents growing up on treatment for HIV and AIDS in and around 
Tembisa Township. There has only been limited research exploring the lives of HIV positive 
adolescents or the ways in which the virus affects their outlook on the future. Understanding 
the perceptions, experiences and needs of this group is integral in order to inform policy and 
interventions that can help adolescents to live healthily and happily with HIV positive status. 
The starting point of receiving the benefits for HIV positive adolescents is to adhere to the 
medications prescribed, especially HAART treatment. 
 
This study took a preliminary step towards filling the knowledge gap by reviewing existing 
literature and reporting on what a group of young people stated about their treatment in 
relation to their illness. South Africa is currently the country with the highest number of the 
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youngest and HIV positive adolescent people in the world (UNAIDS, 1997; WHO, 2007b). 
The virus affects individuals of all ages, including adolescents. According to a nationally 
representative 2012 Human Sciences Research Council (HSRC) survey, prevalence in 0 to 
14-year-olds was 2.4%, the lowest rate of any age group (Shisana, Rehle, Simbayi, Zuma, 
Jooste, Zungu, Labadarios, Ononya & Team, 2014). This low figure was not surprising 
considering the fact that prior to the roll-out of HAART treatment, the vast majority of mother-
to-child infected children died before reaching adolescence. 
 
Most younger adolescents are not yet sexually active, resulting in low rates of horizontal 
infection. As individuals enter late adolescence and the likelihood of sexual initiation 
escalates, HIV prevalence rises steeply. In the HSRC survey, prevalence was 5.6% for 
females and 0.7% for males between ages 15-19 and 7.1% among 15 to 24-year-olds 
(Shisana et al., 2014), while a previous national survey measured rates of 15.5% and 4.8% 
in 15 to 24-year-old females and males respectively (Pettifor et al., 2005). Both studies show 
that adolescent females who are more biologically susceptible to contracting the virus 
experience higher rates of sexual abuse and are more likely to have a relationship with an 
older partner (Pettifor et al., 2005); they are therefore at higher risk of being sexually infected 
than young males. In absolute terms, South Africa also has the greatest number of people 
on HAART treatment. In September 2012, over 2,002,000 people were receiving HAART 
treatment through the public sector, 166,000 of whom were children under the age of 15 
(Shisana et al., 2014). 
 
There are no accurate statistics on the number of adolescents who are currently on or in 
need of treatment, as data about this population is most often subsumed into child or adult 
categories. However, using demographic modelling, it is possible to generate estimates of 
figures pertaining to adolescents. The Actuarial Society of South Africa (ASSA) has 
developed the ASSA2003 AIDS and Demographic Model (Davies & Kijko, 2003), which uses 
empirical HIV research in order to make projections about a wide range of epidemiological 
data. ASSA2003 can be used to estimate treatment needs and coverage for adolescents 
between the ages of 10 and 19 years.  
 
When compared to the total adolescent population needing HAART treatment, the proportion 
of 15 to 19-year-olds needing treatment is also expected to increase, from 7% of all 
adolescents in need of treatment in 2008 to 22% in 2020 (DoH, 2008). This increase will be 
attributable to the ageing of the mother-to-child infected population, as the need for 
treatment in the horizontally infected population is expected to remain constant or to decline. 
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This study was based on the assumption that young people have the ability to speak about 
their experiences and are capable of contributing to the worlds in which they live. In the past, 
decisions about young people have been made by adults, and minors have been excluded 
from research. In addition to learning about the experiences of adolescents related to 
HAART treatment from the work of other researchers, this study explored the issue from the 
perspectives of young people themselves. 
 
1.3 AIM AND OBJECTIVES OF THE STUDY 
 
1.3.1 Aim of the Study 
 
The aim of the study was to explore the nature of experiences of adolescents who are on 
long-term HAART treatment in Tembisa, Gauteng province. 
 
1.3.2 Objectives of the Study 
 
The objectives of the study were 
 
 to understand the adolescents‟ perspectives of being on HAART treatment; 
 to understand experiences leading to adherence and non-adherence to HAART 
treatment; 
 to determine factors contributing to adherence and non-adherence to HAART 
treatment; and 
 to explore the meanings that these adolescents attach to HAART treatment. 
 
1.4 SIGNIFICANCE OF THE STUDY 
 
The decision to study adolescents‟ experiences of HAART treatment was inspired by the 
changing nature of the global HIV and AIDS epidemic and the recognition that adolescents 
have distinct needs. The advent of HAART treatment has essentially transformed HIV from a 
fatal disease to a chronic condition. When the virus is left to its natural course, fewer than 
50% of mother-to-child infected children survive beyond the first two years of life, and only a 
fraction are still alive at five years of age (Brahmbhatt et al., 2006; Dabis & Ekpini, 2006). 
However, HAART treatment has proved remarkably effective in delaying disease 
progression and reducing the risk of death in both adults and children (Aber & Aboulker, 
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1996). Hence, efforts to understand failure to adhere to HAART treatment and 
understanding determinants of adherence can be of benefit to long quality life. 
 
In recent years, initiatives of groups such as the World Health Organization (WHO) have 
generated mounting political and financial support for treatment roll-out in resource-limited 
settings, resulting in a sevenfold increase in the number of individuals on HAART treatment 
since the year 2003 (WHO, 2004; UNAIDS, 1997; UNICEF, 2006). Because of improving 
treatment access, the population of mother-to-child infected children surviving to 
adolescence is expected to rise in the near future. HIV positive youth have been called a 
„hidden population‟ because they tend to occupy marginalised positions in society and are 
difficult to distinguish from their uninfected peers (Bell, Devarajan, & Gersbach, 2003).  
 
During adolescence, young people move from a more protected experience of childhood into 
a period of extremely rapid physical, psychological and social change. A successful 
transition into adulthood requires that the adolescents develop and practise new social skills, 
redefine and negotiate their places in the families, move towards adult decision-making and 
self-determination, and develop more mature patterns of interpersonal intimacy (McNeely & 
Blanchard, 2010). Unfortunately, contemporary adolescents are making decisions that can 
have life-threatening implications. Sexual experimentation may serve to fulfil normal 
developmental needs, but they can also have dire consequences, especially so for HIV 
positive adolescents who have been on HAART treatment. However, increased adherence 
to HAART treatment can offset some of the possible deadly results of HIV and AIDS. 
 
Similar to young adults as investigated by Ijadunola, Abiona, Odu, and Ijadunola (2007), 
adolescents significantly underestimate risk levels in their assessment of personal 
vulnerability to harm. This attitude may include unprotected sexual intercourse, thereby 
putting them and their sexual partners at potential risk respecting the spread and reinfection 
of HIV. One of the important tasks that preventive efforts may need to address, therefore, is 
to convince adolescents that they are vulnerable while eluding to raise their fears to levels 
that encourage denial, inhibit preventive actions or negatively affect healthy sexual 
development.  
 
In addition to dealing with standard human developmental processes, HIV positive 
adolescents should also confront a number of extra challenges. For adolescents on HAART 
treatment, the transition from childhood to adulthood is interlaced with concerns about 
medication regimens, doctor‟s appointments, life expectancy, disclosure, and transmitting 
HIV to others. Of course, the virus poses similar concerns for HIV positive individuals at 
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other life stages. However, the extensive changes that characterise adolescence make the 
second decade of life particularly unique.  
 
The combination of ordinary developmental issues with HIV related worries creates a 
distinctive environment, which frames adolescents‟ daily experiences and their HIV interact 
with the normative changes that occur during adolescence. This stimulates research which 
examines adolescent HIV on its own merits, rather than as a subset of paediatric or adult 
knowledge about the virus‟ interactions with health care systems (Murimba, 2014). From a 
developmental perspective, it is thus important to consider ways in which adjustments 
associated with HIV interact with normative changes that occur during adolescence.  
 
Furthermore, the research study sought to produce results that may enable the multi-
disciplinary team at Masakhane Clinic, Tembisa Provincial Tertiary Hospital to design 
suitable interventions to address the specific problems of non-adherence. 
 
1.5 RESEARCH PROBLEM AND RESEARCH QUESTION 
 
1.5.1 Problem Statement 
 
Mother-to-child infected adolescents have been exposed to HAART, and in some studies, 
many adolescents had successful viral controls that resulted in longer and healthier lives. 
However, these adolescents have multiple risk factors for mental illness (WHO, 2007a). 
Living with a chronic disease is associated with increased rates of mental illness. Many older 
adolescents were infected prior to the advent of HAART treatment and may have had a 
period of ineffective therapy with resultant uncontrolled viral infection in the central nervous 
system (Li, 2009). Many other adolescents have lost a biological parent to HIV and AIDS, 
and they may be living with another relative or foster parent. These adolescents are also 
frequently subjected to environments of poverty, crime, and substance abuse. The impact of 
these factors on adherence to HAART treatment can be far-reaching. Failure to adhere to 
prescribed HAART treatment should be offset by seeking intervention measures. Hence, the 
study searches for determinants leading to non-adherence in order to design intervention 
measures based on that knowledge and understanding of the causes. This study also 
sought to impact onto the deficient research literature relating to the experiences of 
adherence and non-adherence among adolescents who are on HAART treatment. 
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1.5.2 Research Questions 
 
Experiences, challenges, feelings, frustrations and positive encounters of being on HAART 
treatment for the communities surrounding Tembisa and Ekurhuleni have not been 
investigated formally through research. Furthermore, the current research generally 
illuminate on the health care professionals who are more concerned with scientific 
measurement of CD4 count and viral load and the realities of patients who do not fit the 
medical bill are automatically dismissed as a medical challenge, without necessarily 
understanding the patients‟ own subjective experiences of such treatment (Li, 2009). 
 
It is essential to gain a better understanding of experiences that promote adherence while at 
the same time gaining a better view of experiences that contribute to non-adherence among 
adolescents. The research study aimed to address the following questions: 
 
 What are the common (prevalent) experiences of being on long-term HAART? 
 When you adhere, how do you feel? (When you default, what do you think?) 
 What factors influence, motivate or lead you to adhere (or not adhere) to HAART 
treatment? 
 As an adolescent, what are your perceptions on long term use of HAART treatment? 
 
1.6 STRUCTURE OF THE THESIS 
 
This thesis is presented in five chapters, organised in the order described below. 
 
Chapter 1 presents the introduction to the study, covering background information about the 
research problem, statement of the research design, motivation and aim of the study, 
rationale for the study, research problem and research question. 
 
Chapter 2 discusses various aspects of literature which deal with adolescents, HIV and 
AIDS, and issues related to HAART treatment. 
 
Chapter 3 presents the theoretical orientation of the study. The models related to treating 
HAART, in particular, the Health Belief Model and the bio-psychosocial model, are discussed 
with application to adolescents‟ experiences with regard to adherence and non-adherence to 
HAART treatment. 
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Chapter 4 deals with the research setting, design, methods, population, sample, data 
collection, data analysis, validity and reliability, as well as ethical considerations of the study. 
 
Chapter 5 delves into data analyses using descriptive statistics and phenomenology at 
various sections of the study. Descriptive methods apply graphs, tables, and some chi-
square statistical tests. The phenomenology part used units of meaning in which chunks of 
data were derived from some direct meanings emerging from the feelings and experiences 
of the adolescent participants of the study. 
 
Chapter 6 concludes the study by providing the necessary conclusions, critiques, exposing 
limitations and strengths of the study, and reflecting on the extent of achievement of the 
study objectives. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
The previous chapter provided an introduction and background to the study. This chapter will 
focus on a literature review. The literature review is a critical summary of research on a topic 
of interest, to put a research problem in context and to provide a basis for the 
implementation of a research project (Machi & McEvoy, 2012). It provides a foundation on 
which to base new knowledge. The primary purpose of reviewing relevant literature is to gain 
a broad background or understanding of the available information about a research problem. 
This background enables a researcher to build upon the work of others, since major 
breakthroughs or discoveries of new information in a field are based on previous works (Polit 
& Beck, 2006).  
 
Moreover, a literature review can play a pivotal role in shaping the research by helping a 
researcher to conceptualise the research problem clearly and precisely. It also informs the 
researcher if others have used procedures and methods similar to the ones that he or she is 
proposing, which procedures and methods have worked well for them, and what problems 
they encountered. By becoming aware of potential problems and pitfalls, a researcher will be 
in a better position to select a methodology that is capable of providing valid answers to the 
questions (Burns & Grove, 2005). 
 
This chapter presents a review of literature related to HAART treatment. The chapter further 
discusses, among other things, the impact of HIV and AIDS on the development of 
adolescents and HAART treatment with reference to adolescents. Also, the focus will be on 
indicators to effective HAART treatment as well as when to change treatment. Factors 
contributing both to non-adherence and adherence to HAART as viewed by adolescents will 
also be discussed. Lastly, the experiences of caregivers and health care workers are 
discussed. 
 
2.2 HIV AND AIDS WITH REFERENCE TO ADOLESCENTS 
 
Adolescence is a formative period in a young person‟s life during which physical, emotional, 
and mental processes, as well as sexual identity, are evolving and maturing. Further, the 
social environment and responses of peers and parents have to be constantly integrated into 
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this evolving concept of self (Li, 2009). HIV and AIDS is only one among many potential 
health hazards the young person is expected to respond to and is especially challenging to 
youth who are facing marginalisation and stigma related to sexual orientation, poverty, and 
desperate living situations, abuse, as well as disparities in the provision of prevention and 
health care services based on race and ethnicity (Fielden, Chapman & Cadell, 2011) 
 
Thirty years ago, it was difficult to imagine that one day children and youth with HIV and 
AIDS would be making plans for employment, raising families and other tasks of adulthood. 
Preparation for this new and welcome phase of their lives involves learning necessary skills, 
coping with social and emotional aspects of HIV and AIDS, and monitoring the effects of the 
virus. Psychologists, through research and clinical care, can play a role in helping shape the 
long-term outcomes for these youth (Nichols, 2013). 
 
HIV and AIDS have a tremendous impact on adolescents, both those infected by HIV and 
AIDS as well as those affected by the illness of their loved ones. Pharoah (2004) states that 
it is often difficult to determine the full impact of HIV and AIDS on infected adolescents. This 
is due to the fact that these impacts occur in a number of overlapping and interdependent 
domains that affect their psychosocial development. Adolescents may experience a wide 
range of impacts including, but not limited to, poor health and nutrition, economic need, 
reduced levels of care, new responsibilities, and school dropout (Ndubuka, 2008). As 
children and adolescents infected with HIV continue to live longer, normal developmental 
milestones and educational needs will take on new significance. Many children will continue 
to be adversely impacted by non-HIV factors such as poverty, inadequate medical services, 
and a lack of social support (Brown, Lourie, & Pao, 2000; McCree, Wingood, DiClement, 
Davies & Harrington, 2002). 
 
The term “adolescence” literally means “to emerge” or “to attain identity” and is essentially 
the period of rapid physical and psychological development starting from the onset of 
puberty to complete growth. All adolescents go through a myriad of physical, psychological, 
neuro-behavioural, hormonal and social developmental changes. Given the social taboos 
often surrounding puberty, the lives of millions of adolescents worldwide are at risk because 
they do not have the information, skills, health services and support they need to go through 
the enormous, rapid changes that adolescence brings. HIV-infected adolescents are 
particularly presented with enormous challenges (Mothi, Swamy, Lala, Karpagam, & 
Gangakhedkar, 2012, p1642). 
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The distinct groups of adolescents in the context of HIV and AIDS are those who were 
infected at birth and survived and those who became infected during adolescence. Risk 
factors and situations for adolescents contracting HIV infection are life on streets, lack of 
adult love/care and support, extreme poverty, child trafficking, migrant population, 
exploitation with reference to sex and labour. HIV-infected adolescents with long-standing 
HIV infection often face considerable physical challenges, such as delayed growth and 
development, late puberty, stunting/wasting, and malnutrition (Krauss, Letteney, Da Baets, 
Baggaley & Okero, 2013). Added to this are many other challenges related mainly to 
disclosure of HIV status, developmental delay, and transition from paediatric to adult care, 
including the choice of appropriate treatment regimens and adherence. Psychological and 
social factors deeply impact the ability to deal with the illness and must be addressed at all 
levels to encourage and support this vulnerable group (Mothi et al., 2012).  
 
With widespread access to antiretroviral therapy in the United States, many perinatally HIV-
infected (PHIV) children are surviving into adolescence and adulthood, becoming sexually 
active and making decisions about their reproductive health. The literature focusing on the 
reproductive decisions of individuals behaviourally infected with HIV can serve as a 
springboard for understanding the decision-making process of PHIV youth. Still, there are 
many differences that critically distinguish reproductive health and related decision-making 
of PHIV youth. Given the potential public health implications of their reproductive decisions, 
a better understanding of factors inﬂuencing the decision-making process is needed to help 
inform the development of salient treatment and prevention interventions (Fair et al., 2013). 
 
A study revealed that the psychosocial issues associated with HIV infection in adolescents 
coalesce around five central themes: knowledge and understanding about personal 
serostatus, mental health, networks of support, treatment management, and healthy 
behaviour. These issues present challenges to HIV positive adolescents in the present and 
affect their outlook on the future. Findings reveal that despite the fact that young seropositive 
South Africans live in a country where social contexts, available resources and health care 
systems differ markedly from those in developed countries; they share similar concerns and 
face many of the same challenges as other HIV positive young people around the world (Li, 
2009). The use of antiretroviral therapy has greatly increased the long-term survival of 
perinatally infected children so that AIDS is becoming a manageable chronic illness. These 
growing children are left facing the challenges of lifelong adherence with complex treatment 
regimens compounded by complex psycho-social, mental and neuro-cognitive issues. These 
unique challenges must be recognised and understood in order to provide appropriate 
medical management (Merchant & Lala, 2012). 
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Adolescents are critical in making efforts to end the HIV and AIDS epidemic. HIV and AIDS 
will continue to paralyse the growth potential of countries if adolescent HIV and AIDS is not 
given sufficient attention. Currently, adolescents are largely invisible in global, regional, and 
country HIV and AIDS reports, making it difficult to assess progress in this population. There 
is unprecedented knowledge to guide investment towards a greater impact on HIV and AIDS 
prevention, treatment, and care in adolescents, but it has not been applied to reach those 
who are most vulnerable. The cost of this is increasing HIV and AIDS-related deaths and 
largely unchanged levels of new HIV and AIDS infections in adolescents (Lowenthal, 
Bareeka-Kitaka, Marukutira, Chapman, Goldrath & Ferrand, 2014).  
 
Adolescents form a pivotal role in the development of countries, thus posing a serious threat 
to the overall growth of such communities, societies and the world. In most countries, youth 
represent the potential for growth. However, such growth could be significantly paralysed 
because of the current youth HIV and AIDS infection rates (Harper & Riplinger, 2012). Long-
term solutions will need to be crafted for these adolescents because the impact of HIV and 
AIDS will linger for decades after the epidemic begins to wane. Even if rates of new 
infections were to level off in the next few years, the long incubation period means mortality 
rates will plateau in a few decades. Greater understanding of the impact of HIV and AIDS on 
adolescents is important in the design and evaluation of programmes to support adolescents 
living in difficult circumstances (Kasedde, Luo, McClure, & Chaddan, 2013). Kasedde et al. 
(2013) further state that an HIV and AIDS-free generation will remain out of reach if the 
global community does not prioritise adolescents. National HIV and AIDS responses must be 
accountable to adolescents, invest in strengthening and monitoring protective and supportive 
laws and policies, and access for adolescents to high impact HIV and AIDS interventions. 
 
Although HIV and AIDS is a life-changing experience for adolescents who have acquired the 
infection, the role of psychosocial support cannot be underestimated. Being diagnosed with 
HIV and AIDS is often accompanied by depression, low self-esteem, and fear of hurting or 
being rejected by family, friends, and loved ones. Many HIV and AIDS-positive teens 
overcome these barriers with the help of supportive family, friends, a multidisciplinary health 
care team, and their own inherent strength and creativity. This also holds true for youth with 
perinatally acquired HIV and AIDS infection who have to cope with treatment fatigue, crisis 
of trust due to delayed diagnosis disclosure, parental guilt and overprotection, as well as 
stigma (Li, 2009). 
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The formation of an individualised identity is considered by many theorists to be the primary 
developmental goal of the adolescent years and is one facet of adolescent development that 
may interact with receiving an HIV and AIDS diagnosis (Harper, Fernandez, Bruce, Sybil, 
Hosek & Jacobs, 2011). In the subsection that follows, a review of current, unique medical 
and psychosocial impacts of care for adolescents who are living with HIV and AIDS infection 
is presented.  
 
2.2.1 The Psychosocial Impact of HIV and AIDS on Adolescents 
 
Before any psychosocial impact of HIV on adolescents, the issue of disclosure needs to be 
addressed. The need for supporting disclosure to the adolescent cannot be 
overemphasised. Disclosure is often the central issue that determines if, when, and how a 
child living with HIV and AIDS receives the services and support he or she needs. Lack of 
readiness and willingness – both on the parent/caregiver side (for example, reluctant to 
disclose their own HIV status) and the child‟s side – can be significant barriers to ensuring a 
child‟s well-being. There is no one formula for how disclosure to a child is managed, noting 
that there are multiple disclosures (of the child‟s status as well as the parents‟ status) over 
time. Disclosure is not a single event. Instead, disclosure needs to be a process over time 
that allows for appropriate action regarding what information is shared (for example, partial 
versus full disclosure), by whom, with whom, and when, factoring the readiness of the child 
and parent/guardian/caregiver (UNAIDS, 2007). 
 
In addition to wanting to be told the truth about their illness, many adolescents expressed 
clear preferences about how this should occur. They described the ideal scenario of being 
told about their HIV status as taking place at a health care setting that included 
communication with a doctor, nurse, or counsellor. For adolescents, both the clinical space 
and the presence of a health care worker served to reinforce the reality of the illness: “I 
wanted to be told at the clinic just so I know that it‟s really true, that I‟ve been tested, and it‟s 
true” (girl B, 17-year-old). Adolescents said that having a health care worker present was 
also important for obtaining accurate information about HIV and AIDS and answers to the 
many questions they might have at that time of uncertainty: “I wanted to be told by a nurse or 
a doctor because they are the ones who would be able to explain all about your disease, like 
what HIV is” (boy C, 18-year-old) (Kidia et al., 2014, p1). This indicates that the value of 
factual information about HIV and AIDS can be increased by giving adolescents the 
opportunity to discuss HIV and AIDS issues with health care professionals. 
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Because of the scale-up of antiretroviral therapy over the last decade, survival of perinatally 
infected children has improved dramatically, enabling them to live into adolescence and 
beyond. Such survival creates the need for addressing the issue of informing adolescents 
about their HIV and AIDS status.  Although status disclosure can also refer to the act of a 
person living with HIV and AIDS sharing his or her status with others, this study aimed to 
address the issue of informing adolescents about their status and making this status 
understood. HIV disclosure often makes a distinction between giving the adolescent all 
information relating to their status (full disclosure) and limiting the amount of information 
(partial disclosure) (De Baets, Sifovo, Parsons, & Pazvakavmba, 2007; Midtbo, Shirima, 
Skodval, & Daniel, 2012). In this study, full disclosure is defined as having been achieved 
not only when an adolescent has received all the information about his or her HIV status but 
also when he or she entirely understands the ramifications of this information  
 
Knowing one‟s HIV status is recognised as an important prerequisite for effective adherence 
to antiretroviral therapy. Disclosure has also been associated with a reduction in risk 
behaviour. Furthermore, while there is little evidence that disclosure causes psychological 
harm and research suggests that it may actually be beneficial for a young person‟s mental 
well-being, a recent study in Zimbabwe by Krauss et al., (2013) showed that learning about 
their HIV status is still one of the most difficult life events for adolescents living with HIV and 
AIDS. Despite these facts, the WHO guidelines for HIV status disclosure are limited to 
children under the age of 12 even though many perinatally infected children are not given 
disclosure until they are adolescents (WHO, 2013b). 
 
It is stated that between 2005 and 2012, HIV related deaths among adolescents increased 
by 50%, while the global number of HIV related deaths fell by 30% (WHO, 2013b). This 
increase in adolescent HIV related deaths is due primarily to a variety of factors. These 
include poor prioritisation of adolescents in national HIV plans, inadequate provision of 
accessible and acceptable HIV testing and counselling (HTC), and treatment services and 
lack of support for adolescents to remain in care and adhere to antiretroviral therapy. HTC 
and HIV and AIDS counselling and testing (HCT) are used interchangeably to mean HIV 
testing and counselling depending on referral sources. For some adolescents, their lives are 
lived within the imbrications of poverty, multiple bereavements, displacement, and 
disruptions in schooling, and the care associated with normative notions of kinship having 
been complicated by living with a chronic, life-threatening illness (Parsons, 2012). 
 
Children with HIV and AIDS experience more subjective distress than their peers and face 
multiple stressors related to HIV and AIDS. This is not only limited to the illness and death of 
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a parent, disclosure, stigma, discrimination, isolation, loneliness, and family conflict or 
uncertainty (Brown, Lourie & Pao, 2000). King, De Silva,Stein & Patel (2009) also note that 
children and youth living with HIV and AIDS (aged 4 to 21 years) are at an increased risk of 
experiencing mental health disorders. Compared with prevalence rates in the overall 
population, children living with HIV and AIDS have an increased risk of experiencing 
depression. HIV and AIDS infection creates an additional developmental challenge which 
adolescents have to contend with during this challenging stage. 
 
HIV and AIDS represent one of the major worldwide health problems that have had a 
shattering impact on many countries, especially those in sub-Saharan Africa (WHO, 2004). 
There are psychosocial impacts such as abuse, trauma, stress and loss of social 
connectivity. It is stated that youth who have lost one or both parents to AIDS are particularly 
vulnerable to infection themselves, and this applies to adolescents as well (UNICEF, 2004). 
Many face exploitation, including physical and sexual abuse. These adolescents may also 
be placed at a greater risk of reinfection. As a result of HIV related mortalities, more children 
under the age of 15 have lost a parent due to HIV and AIDS. There are also many children 
who have HIV positive parents or primary caregivers; these children are affected by HIV and 
AIDS and are potentially vulnerable to HIV transmission. Children affected by HIV and AIDS 
are more vulnerable and face greater challenges to their psychosocial well-being compared 
to other children of the same age (King et al., 2009). With weakened family support, some 
engage in risky sexual behaviour or inject drugs into their systems. Those forced to live on 
the streets may turn to sex work and crime as a means to survive. After suffering the 
emotional toll of losing their parents, many also face stigma and discrimination (UNICEF, 
2004). 
 
Adolescents affected or infected by HIV and AIDS are at a higher risk of school dropout, 
child labour, sexual exploitation and child trafficking; these present real dangers to children 
as well as to society, and adolescents form part of those who are vulnerable. These 
psychosocial factors reduce individual and national developmental potential, marginalise and 
dehumanise children, and separate them from available sources of help and support, 
engender widespread disregard for children, and lead them to have close association with 
crime (Richter, 2001). Without schooling, both individuals‟ potential and social capital are 
lost, leaving affected individuals vulnerable to unemployment, menial working conditions, 
and poverty. Similarly, child labour is often physically damaging, psychologically stunting and 
demeaning to the dignity of children whose labour is exploited (Foster & Williamson, 2000). 
Such labour has particularly damaging effects on adolescents who still have to find their own 
identity within society.  
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There is a general fear that the HIV and AIDS epidemic may create generations of 
disenfranchised and potentially dysfunctional youth who lack the socialisation necessary for 
constructive social engagement. Uncared-for HIV and AIDS orphans may also behave 
irrationally due to stress and lack of guidance (Rotheram-Borus, Stein, & Lester, 2006). 
Mburu, Ram, Oxeham, Haamujonmpa, Iorpenda & Ferguson, 2001) further assume that 
children raised in difficult circumstances almost always suffer negative psychological, social 
and behavioural outcomes. Psychosocial distress, which includes anxiety, loss of parental 
love and nurture, depression, grief and separation of siblings among relatives to spread the 
economic burden of their care, can never be quantified. 
 
Almost as lethal as the virus itself is the stigma and resulting discrimination faced by people 
living with, or affected by, HIV and AIDS. Because of the ignorance and denial that cloak the 
disease in many parts of the world, adolescents whose parents have died from HIV and 
AIDS are often singled out as targets of abuse in places they come to for support and care 
(Close & Rigamonti, n.d.). Adolescents are sometimes harshly treated in foster homes, 
denied access to schooling and health care, stripped of their inheritances, and left to the 
streets. Stigma and discrimination remain the most potent barriers to testing, treatment and 
prevention (Midtbo et al., 2012). These adolescents are often further traumatised by 
stigmatisation and rejection, which leave them still more vulnerable and isolated. 
Stigmatisation might prompt affected adolescents to stay away from school rather than 
enduring exclusion or ridicule by teachers and peers. Such stigmatisation might contribute to 
reluctance by adolescents to follow up with their HAART, thereby leading to poor treatment 
adherence. 
 
2.2.2 The Impact of HIV and AIDS on Adolescents’ Physical Well-being  
 
Initially, children born with HIV and AIDS did not grow beyond the age of seven years, but 
this has changed since the introduction of HAART treatment. However, adolescents living 
with HIV and AIDS live under the shadow of untimely death, unexpectedly and 
indeterminately deferred. Physically small for their ages, they often bear the outward signs of 
affliction and illness and constantly stand exposed to the unstable, potentially devastating 
possibilities of social stigma and rejection (Preda, 2005; Parsons, 2012). Steele, Nelson, and 
Cole (2007) reports that when compared to children from similar socio-economic situations, 
children with HIV and AIDS experience greater impairment of neurologic, cognitive and 
psychosocial functioning.  
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HIV and AIDS is carried on monocytes or macrophages and CD4 lymphocytes in the central 
nervous system early in infection. Some evidence suggests that the developing brain may be 
more susceptible to disruption and development of encephalopathy. By default, an 
adolescent would suffer a similar impact to their neurologic, cognitive and psychosocial 
functioning (Durham & Lashley, 2010). 
 
The immune system is a complex system of blood proteins and white blood cells which work 
together to repel attacks by invading organisms. HIV and AIDS attack a particular set of cells 
in the human immune system known as CD4 cells. There are two types of CD4 cells. The 
first type is CD4 positive T cells which organise the body‟s overall immune response to 
foreign bodies and infections. These T helper cells are the prime target of HIV. For a person 
to be infected, virus particles must enter the body and attach themselves to the CD4 cells. 
These cells engulf foreign invaders and ensure that the body‟s immune system will 
recognise them in the future. Once the virus has penetrated the wall of the CD4 cell, it is 
safe from the immune system because it occupies the cell‟s DNA and therefore cannot be 
identified and destroyed by the body‟s defence system. Virus particles lurk in the cells until 
their replication is triggered. Once this happens, they make new virus particles that bud from 
the surface of the host cell in vast numbers, destroying that cell as they do so. These viruses 
then go on to infect more CD4 cells (Barnett & Whiteside, 2002). 
 
When an adolescent is infected with HIV and AIDS, a battle starts between the virus and the 
immune system. There is an initial burst of activity during which many cells are infected, but 
the immune system fights back, manufacturing immense numbers of antibodies. This period 
is marked by an unseen and unfelt war in a person‟s body. The viral load is high, the 
immune system is taking a knock, and the person‟s HIV status cannot be detected using 
standard tests. This is commonly called „the window period‟ and lasts from several weeks to 
several months. At this stage, the adolescent is highly infectious, as his or her viral load (the 
number of viral particles they are carrying) is considerable. This fact is of epidemiological 
importance. The more people there are in the early stage of infection, the greater the chance 
of effective transmission between people (Claxton & Harrison, 1991). 
 
The window period is followed by the long incubation stage. During this stage, the viruses 
and the cells they attach to are reproducing rapidly and being destroyed as quickly by one 
another. Eventually, the virus is able to destroy the immune cells more quickly than they can 
be replaced, and slowly the number of CD4 cells starts falling. In a healthy person, there are 
1,200 CD4 cells per microlitre of blood. As infection progresses, the CD4 cell number will 
fall. When CD4 cell count falls below 200, opportunistic infections begin to occur, and a 
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person is said to have AIDS. Infections will increase in frequency, severity and duration until 
the person dies. It is these opportunistic infections that cause the syndrome referred to as 
AIDS (Claxton & Harrison, 1991). 
 
HIV and AIDS has a significant impact on the immune system of the adolescent. The 
progression of the disease is much faster in children than in adults as well as the risk of 
complications. Since most infections occur perinatally, the virus overcomes the capacity of 
the immature immune system to control the HIV replication, and dissemination occurs to all 
organ systems including the central nervous system.  
 
Physical changes of puberty make some aspects of medical management of HIV in 
adolescents different from management in adults or children. Profound anatomic and 
physiologic changes are occurring that may affect drug distribution, metabolism, and 
excretion. During adolescence, sex hormones initiate processes of growth and sexual 
maturity. Gender-related changes in body composition occur: girls develop higher 
proportions of fat, while boys develop higher proportions of bone and muscle mass 
(Schietinger, Sawyer, Futterman, & Rudy, 1999). 
 
The effects of physiological changes on the pharmacokinetics and pharmacodynamics of 
drug therapies are not well understood, but it is known that variables such as body 
composition and endocrine levels affect drug distribution, metabolism, and excretion. The 
physiological changes of early adolescence are markedly different from those of late 
adolescence, so that the metabolism of certain medications can vary considerably between 
a 13-year-old and an 18-year-old. Until more is understood about the interrelationships 
between developmental age and appropriate drug dosage, clinicians must rely on general 
guidelines in prescribing medications to adolescents (Schietinger et al., 1999; Shearer & 
Hanson, 2003). 
 
2.2.3 The Impact of HIV and AIDS on Cognitive and Emotional Functioning of 
Adolescents 
 
The cognitive and behavioural problems in children and youth with HIV and AIDS have a 
number of implications for their daily functioning. Many children and youth with HIV and 
AIDS have significant obstacles to success in school, including cognitive difficulties, losing 
school time due to illness, doctor visits or family disruption, and living in areas with 
disadvantaged school systems and high dropout rates (Nichols, 2013; Shearer & Hanson, 
2003). While antiretroviral therapy has significantly decreased HIV encephalopathy, as HIV 
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and AIDS-infected children survive into adolescence and young adulthood, more subtle 
manifestations of central nervous system disease are still seen.  
 
The aforementioned cognitive deficits, problems with attention and psychiatric disorders, are 
far less acutely devastating than encephalopathy but may well have a tremendous impact on 
these youth as they survive into adulthood. The etiologic factors are complex and may 
include the effects of HIV infection (both ongoing central nervous system viral replication as 
well as past impact of infection on the developing brain), chronic inflammation, antiretroviral 
drugs toxic effects, social factors and other exposures (Mofenson & Cotton, 2013). 
 
Researchers in Romania found a high rate of HIV and AIDS-associated neurocognitive 
disorders in a cohort of young adults who acquired HIV and AIDS infections parenterally 
during childhood. The study prospectively evaluated neurocognitive impairment in 49 
infected adolescents and 20 age- and sex-matched HIV and AIDS-negative control 
participants using HIV associated neurocognitive disorder diagnostic criteria. All were about 
18 years of age and had 10 to 11 years of education. Most of the participants had good 
immune status and undetectable viral loads at the time of evaluation. The investigators 
evaluated everyday functioning and assessed seven cognitive domains: verbal fluency, 
speed of information processing, attention and working memory, abstraction/executive 
functioning, learning, delayed recall, and motor function. Few confounders, such as previous 
drug abuse, brain injury, and other central nervous system conditions, were present. Overall, 
25% of the HIV and AIDS infected cohort had asymptomatic neurocognitive impairment, 
20% had mild neurocognitive impairment, 2% had HIV and AIDS associated dementia, and 
53% had normal functioning (Keller, 2011). 
 
Furthermore, more than half of the patients had impairment with regard to the speed of 
information processing (55%) and motor domain (53%). In contrast, 35% and 20% of the 
control participants showed impairment on each of these domains, respectively. Learning 
and abstraction domains were not greatly affected in the HIV-infected individuals (6% and 
12% were impaired, respectively). First, HIV infection might have induced irreversible brain 
injury before a combination of ART was initiated. Second, there could have been a persistent 
low level of viral replication in the brain because of poor drug penetration or the presence of 
drug-resistant viral strains. Third, inflammation and immune activation might have persisted 
in the brain. Finally, the drugs themselves might have had a neurotoxic effect (Keller, 2011). 
 
However, as a result of HAART, there are children who grow up to reach adolescence and 
beyond; thus, the impact of growing up with HIV and AIDS for adolescents has a significant 
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impact on society in general. Preda (2005) proclaims that from a medical viewpoint, HIV and 
AIDS is unique in the sense that it directly attacks and destroys the immune system which 
protects the body against viral, bacterial and parasitic infections. As a consequence, the 
clinical course is more accelerated in children and adolescents than in adults; hence, the 
immunological dysfunction is greater.  
 
To understand the danger of HIV and AIDS infection fully, the functioning of the immune 
system will be explained briefly. The functioning of the immune system may be described 
metaphorically as a war within the body. The immune system functions like the defense 
system of a country. Just as the soldiers defend their country, so does the immune system 
defend the body. 
 
Understanding the evolution of the adolescent‟s neurodevelopment in the context of active 
HIV infection is important. Factors associated with a central nervous system disease in 
children with HIV infection include maternal and child immune status, elevated cerebrospinal 
fluid and plasma viral load, and timing and route of infection. Risk is higher in those infants 
born to mothers with advanced disease (low CD4 count and high viral load) at the time of 
delivery. Also, children with immune suppression and high plasma load have higher rates of 
encephalopathy (Durham & Lashley, 2010).  
 
Concurrently, environmental factors including maternal drug use, poverty, low maternal 
education and foster care placement also influence adjustment and may contribute to 
developmental delay. HAART, which reduces plasma and cerebrospinal fluid viral load, also 
reduces the risk of encephalopathy. While HAART halts progressive HIV encephalopathy in 
children and adults, high rates of residual impairment remain, including behavioural 
problems as well as neurological, cognitive and scholastic impairments (Durham & Lashley, 
2010). 
 
Once the adolescent has been diagnosed HIV positive, it is important to do a full clinical 
assessment of his or her health. Regular check-ups (at least four to six months if a person is 
healthy, but more frequently if he or she has symptoms) should be done to monitor changes 
in the person‟s health. Regular check-ups can help health care workers to identify and treat 
physical as well as psychological problems at any stage and to promote the general health 
of the patient. Clinical assessment also helps the health care worker to make decisions on 
when to start prophylaxis and when to start antiretroviral treatment. Regular medical and 
growth checks (at least once every two to three months) are important for monitoring the 
health of HIV-infected adolescents (Van Dyk, 1999). 
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2.2.4 The Socio-economic Impact of HIV and AIDS on Adolescents 
 
The impact of HIV and AIDS on children and families is compounded by the fact that many 
families live in communities which are already disadvantaged by poverty, poor infrastructure 
and limited access to basic services. Strategies for coping of extended families have 
negative impacts on children in households indirectly affected by HIV and AIDS, thus 
enlarging the overall impact and number of children affected (Foster & Williamson, 2000). 
 
World Health Organization reports that adolescents (10-19 years) and young people (20-24 
years) continue to be vulnerable, both socially and economically, to HIV and AIDS infection 
despite efforts that have been made to date. This is particularly true for adolescents, 
especially girls, who live in settings with a generalized HIV and AIDS epidemic or who are 
members of key populations at higher risk of HIV and AIDS acquisition or transmission 
through sexual transmission and injecting drug use. In 2012, there were approximately 2.1 
million adolescents living with HIV and AIDS. About one-seventh of all new HIV infections 
occur during adolescence (WHO, 2013a, WHO, 2013b). Access to and uptake of HCT by 
adolescents is significantly lower than for adults. Survey data collected from sub-Saharan 
Africa indicate that only 10% of young men and 15% of young women (15-24 years) were 
aware of their HIV and AIDS status (Bekker & Hosek, 2015).  
 
Furthermore, there should be at least one identifiable caregiver who is able to supervise the 
child for administering medication. Disclosure of the child‟s treatment to another adult living 
in the same house should be encouraged. This adult can then assist with the child‟s HAART 
treatment to make sure that the child adheres to the medication. The child‟s caregiver or 
parent should be motivated and committed to the child‟s lifelong therapy. Caregivers should 
understand that adherence involves giving every dose of medication, exactly as prescribed 
every day of every year. Caregivers or parents should be counselled to anticipate and plan 
for weekends away, schooling and other activities which could mean that doses are missed. 
Caregivers or parents should understand that poor adherence is the single most important 
factor associated with drug failure and resistance. They should furthermore understand that 
resistance implies loss of future treatment options for the child. Good adherence is to be 
emphasised with every visit (Van Dyk, 2012). 
 
Further impact of HIV and AIDS on adolescents is seen most dramatically in the rising 
numbers of children and adolescents orphaned by HIV and AIDS. The United Nations 
Children‟s Emergency Fund (UNICEF) documents that such children face grave risks to their 
education, health, and well-being. These children may have to forgo schooling; there may be 
25 
 
less food or clothing for them in the household; they may suffer from anxiety, depression and 
even abuse (UNICEF, 2004). In households affected by HIV and AIDS, the school 
attendance of children, including adolescents, drops off because their labour is required for 
subsistence activities and, in the face of reduced income and increased expenditure, the 
money earmarked for school expenses is used for basic necessities, medication and health 
services. Even where adolescents are not withdrawn from school, education often begins to 
compete with the many other duties that affected children have to assume (Pharoah, 2004; 
Bill, 2006).  
 
Without schooling, both individuals‟ potential and social capital are lost, leaving affected 
individuals vulnerable to unemployment, menial working conditions, and poverty. Similarly, 
child labour is often physically damaging, psychologically stunting and demeaning to the 
dignity of children whose labour is exploited (Foster & Williamson, 2000). Such labour has 
particularly damaging effects on adolescents who still have to find their own identity within 
society. Children may also suffer from economic constraints as the household provider 
becomes sick, cannot work, and loses their job. The responsibility of earning money and 
providing food is left to the children. They often go hungry, become malnourished, and 
become unable to concentrate. Other economic impacts include no money for school fees, 
uniforms, materials, clothing and other necessities. Hunger is a common cause of poor 
school performance and dropout (Bezuidenhout , Elago, Kalenga, Klazen, Nghiphondoka & 
Ashton, 2005). 
 
Together with sexual exploitation and the trafficking of children, school dropout and child 
labour indicate the disintegration of social institutions that serve to protect and develop 
children and, by their existence, they further undermine fragile families and communities. 
Moreover, child labour and sexual exploitation fuel crime as children become traded for 
profit. Adolescents are vulnerable to school dropout, forced and legal labour, sexual 
exploitation and trafficking that face children of other age groups (Foster & Williamson, 
2000). 
 
As a consequence of the foregoing, isolation from family and peer group also results. Many 
adolescents affected by HIV and AIDS have to drop out of school because of financial 
problems or their new responsibilities as caregivers. This cuts them off from their peer group, 
robbing them of an influence crucial to their ongoing identity development. The loss of 
learning has equally serious implications for their development (WHO, 2013a). Adolescents 
who are responsible for their parents have little or no time to play or spend leisure time with 
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same-age friends. Pharoah (2004) further notes that despite their shortcomings, schools 
have significant potential to play a critical role in obviating the worst effects of the HIV and 
AIDS epidemic on children. Apart from the accrued personal and social benefits of education 
for work and national development, schooling provides stability, institutional affiliation and 
the normalisation of experience for children. It also places children in an environment where 
adults and older children are potentially available to provide social support. 
 
Adolescents who live with parents who are chronically ill live in households that have taken 
in orphans or have lost teachers and other adult members of the community to HIV and 
AIDS. As their parents become more ill and dependent on them, these adolescents find their 
roles changing from child to primary caregiver, as they have to take care of their parents. 
Older siblings have to take on the parenting of younger siblings, and the resultant loss of 
childhood has serious implications for normal childhood development (Mofenson & Cotton, 
2013). At certain instances, caregivers change and siblings may split up. 
 
Van Dyk (2012) reports that after their parents‟ death, children often lose their rights to family 
land or house. Relatives move in and often exploit the children by taking possession of their 
property but not providing support for them. Because these children no longer have access 
to education and because they lack work skills and family support of any kind, they often end 
up living on the streets with no money whatsoever. Richter (2001) points out that reduced 
financial and emotional resources available to children cause trauma and alienation. It 
effectively limits the realistic aspirations of the affected adolescents.  
 
Adolescents orphaned by HIV and AIDS suffer more frequently from malnutrition, illness, 
abuse and sexual exploitation than those who are orphaned by any other causes (Van Dyk, 
2012). Pharoah (2004) adds that a further impact of HIV and AIDS include deepening 
poverty, such as pressure to drop out of school, food insecurity, reduced access to health 
care services, deteriorating housing, worsening material conditions, loss of access to land 
and other productive assets. Vulnerable adolescents do not know how to protect 
themselves, and they have no access to doctors, nurses and other health care workers and 
facilities. As such, their risk of reinfection arises from the early onset of sexual activity, 
commercial sex and sexual abuse, all of which may be precipitated by economic need, peer 
pressure, lack of supervision, exploitation and rape (WHO, 2013a). In most cases, these 
adolescents have to live without basic human rights and dignity. Still, at other times, the 
pressures for basic survival far outweigh the future orientation required to avoid infection, 
and they find themselves having to worry more about food and shelter than consequences of 
unprotected sexual relations. 
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According to the United Nations Population Fund for every person living with HIV and AIDS, 
a family and community are affected. As the disease kills parents and caregivers, it fuels 
poverty and despair among children and adolescents and stretches family resources. 
Adolescent orphans infected or affected by HIV and AIDS frequently have their schooling 
disrupted. Dropping out is common, particularly for girls who have to care for sick family 
members or their siblings, to keep the family together. Inability to pay school fees also forces 
boys and girls to leave school. Others drop out because of stigma and discrimination by 
schools, teachers or classmates (UNICEF, 2006; WHO, 2007a). Loss of a parent in early 
childhood, at school age and in early or late adolescence affects children differently, both 
psychologically and developmentally (Foster & Williamson, 2000). The ripple effects of HIV 
and AIDS status of parents extend beyond just the physical health of parents but set the 
tone for generations to come. 
 
2.2.5 The Religious or Spiritual Impact on Adolescents Living with HIV and AIDS 
 
Religion and spirituality are often interchanged. In essence, they encompass one‟s belief in 
the existence of a supernatural or high power to escape to when faced with overwhelming 
challenges. HIV and AIDS form part of such an overwhelming challenge. Adolescents might 
resort to religion and spirituality to help them cope or simply explain challenges for 
themselves. Spirituality as a protective factor for coping with HIV has been understudied in 
adolescents; however, a mixed picture seems to prevail as far as the role of 
religion/spirituality in adolescent living with HIV and AIDS is concerned. 
 
Lippman and McIntosh (2010) state that spiritual beliefs and practices among youth are 
important to monitor, since research from developmental science, sociology, and character 
education has found that they are positively related to identity and moral development. They 
are also related to purpose and goal attainment; educational achievement and attainment; 
emotion and attention regulation; positive physical and mental health; life satisfaction and 
happiness; conflict resolution and social skills; prosocial behaviours; and a successful 
transition to adulthood. Spirituality can be experienced and expressed in diverse ways, 
including being or becoming aware of the sacredness of one‟s soul, a connection to a unity 
of life that transcends oneself and to a divine Creator and/or beings in a spiritual realm such 
as angels, ancestral spirits or guides. 
 
To date, population-level surveys of these spiritual dimensions have been limited, focusing 
on, for example, belief in God. Lyon, Garvie, He, Malow, McCarter, & D‟Angelo (2012) bring 
out that religion plays an integral part in the lives of adolescent patients in the United States. 
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A study by Lyon et al. (2012) assessed congruence in spirituality between HIV positive 
adolescent dyads and psychological adjustment and quality of life. The study used the 
Spiritual Well-Being Scale of the Functional Assessment of Chronic Illness Therapy, Beck 
Depression Inventory-II, Beck Anxiety Inventory and Paediatric Quality of Life Inventory at a 
baseline and 3-month post intervention. The study found that a high congruence existed for 
having a reason for living, rejection of life lacks meaning/purpose and „HIV is a punishment 
from God‟ (Lyon et al., 2012, p9). Positive religious coping has been associated with a sense 
of wellness, regardless of markers of disease severity and increased physical functioning in 
patients (Bernstein, Lyon, & D‟Angelo, 2012). 
 
Spirituality is difficult to define. It involves looking within and having an awareness that there 
is something sacred. Spirituality and religion are often central issues for patients dealing with 
chronic illness. A study by Cotton, Puchalski, Sheraman, Mrus, Peterman, Feinberg, 
Pargament, Justice & Tsevat (2006) revealed that most patients with HIV and AIDS 
belonged to an organised religion and use their religion to cope with their illness. Patients 
with greater optimism, greater self-esteem, greater life satisfaction, minorities, and patients 
who drink less alcohol tend to be both more spiritual and religious. 
 
Religion or spirituality may play a positive role among adolescents with HIV, acting as it does 
for other teens by decreasing risky behaviours, providing support, acting as a coping 
mechanism, and generating hope and comfort. Adolescent spirituality is associated with less 
anxiety and depression and adaptive coping with a chronic illness (McCree, Wingood, 
DiClemente, Davies, & Harrington, 2002). Having strong religious beliefs has been shown to 
be a protective factor against many risk behaviours, including tobacco, alcohol, drug use, 
violence, and initiation of sex. Spirituality is one of many ways teens with HIV and their 
families cope with the burdens of HIV (Cotton et al., 2006). Religion may protect youth from 
risky behaviours (McCree et al., 2002).  
 
Spirituality is often a central issue not only for them but also for their families (Lyon, Garvie, 
Kao, Briggs, He, Malow, McCarter & D‟Angelo, 2011). Surveyed HIV positive teens rated 
themselves as religious/spiritual (68%) (Garvie, He, Wang, D‟Angelo, & Lyon, 2012) and 
reported regular attendance at religious services (72%); the teens highlighted that 
religions/spirituality helped 80% of them face their fears. Furthermore, it emerged that 
although important areas of congruence emerged, equally important areas such as the 
timing of these conversations and adolescents‟ end of life needs and wishes are not known 
by their families. Families need help initiating conversations with affected teens to assure 
their adolescents‟ end of life wishes are known to them (Garvie et al., 2012).  
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On the other hand, religion or spirituality may be a negative or painful factor, especially if it is 
viewed as a punishment, leading to worsened outcomes (Berstein et al., 2012). Some 
patients feel that their disease is a punishment from God, which negatively affects their 
coping with the illness (Berstein et al., 2012). Youth living with HIV and AIDS (YLWHA) are 
more likely to wonder “whether God has abandoned me.” The research by FAmily CEntered 
(FACE) Advance Care Planning study hypothesised that high spirituality would predict high 
medication adherence and stage of illness and that the belief that “HIV is punishment from 
God” would decrease medication adherence. Religious beliefs can increase spiritual 
distress. HIV positive teens were more likely to report “God abandoned me” than HIV-
negative teens (Bernstein et al., 2012, p9). Fatalistic religious beliefs are associated with 
lower medication adherence. The belief that HIV was a punishment from God was 
associated with poor medication adherence among HIV positive teens (Lyon et al., 2011). 
 
A different view explores the role of a health professional in the spiritual lives of their 
patients. Ehman, Ott, Short, Ciampa & Hansen-Flaschen (1999) suggest that most patients 
would like physicians to ask about their spiritual beliefs in some situations. Research 
demonstrating the benefit of spirituality in the physical and mental health of adolescents has 
not established whether spirituality is a topic which adolescents find acceptable to explore 
with their health care providers (Cotton et al., 2006). Clinically, spiritual or religious themes 
emerge when adolescents with serious medical conditions such as cancer or HIV and AIDS 
are asked what sustains them through difficult situations (Lyon et al., 2011). Armed with a 
better understanding of conditions under which adolescents find spiritual questions or 
discussions acceptable, health professionals can better tailor their counselling and 
treatment. Taking a holistic approach to health care may offer a better opportunity to protect 
adolescent well-being. 
 
2.2.6 Section Synopsis 
 
This section was a discussion of the impact of HIV and AIDS on the development of 
adolescents who grow up with HIV and AIDS. HIV and AIDS-infected adolescents represent 
a unique, yet diverse, population requiring specialised medical and psychosocial HIV and 
AIDS care. Infected adolescents often have differing therapeutic needs but may share 
common difficulties, including medication non-adherence, high-risk sexual behaviour, and 
psychosocial stressors. The impact of HIV and AIDS on the functioning of adolescents is 
multifaceted and affects all aspects of the adolescent‟s life. The impacts are immense 
insofar as they compel adolescents to battle with adult responsibilities for which they are not 
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adequately prepared. These impacts will have far-reaching consequences for their 
development as well as outlook on life. 
 
2.3 HAART TREATMENT WITH REFERENCE TO ADOLESCENTS 
 
In the third decade of the HIV and AIDS epidemic, the prevalence of HIV and AIDS infection 
among adolescents and youth continues to increase as more youth become infected, and 
survival among perinatally infected adolescents has significantly increased since the 
introduction of HAART treatment (Li, 2009; WHO, 2007b). Health workers are just beginning 
to learn about the complications of chronic HIV infection and the toxicities associated with 
HAART treatment before and during sexual maturity. Understanding the effects on 
adolescents might be beneficial to their development. Managing the side effects while 
administering suitable and necessary active HAART treatment regimens in these heavily 
treated adolescents will be challenging, given the limited therapeutic options that are 
available. 
 
2.3.1 The Historical Background of HAART Treatment 
 
The introduction of HAART treatment has led to increased life expectancy among 
adolescents with HIV and AIDS; however, it poses challenges including complex drug 
regimens that require strict adherence by patients. Treatment adherence by adolescents 
with HIV is generally considered suboptimal, although adherence reports vary by the method 
of assessment used (Hans, Spiegel, Donna, & Futterman, 2009).  
 
Before the widespread introduction of HAART, most perinatally infected children did not 
survive beyond the first two years of life. With treatment, HIV positive children are living 
longer. In the developed world, where HAART treatment has been widely available since 
1996, survival of perinatally infected children into adolescence is now the norm. Regarding a 
French cohort of perinatally infected children born before 1993, 58% were still alive and 
receiving HIV care 13 years later. In the UK, the proportion of HIV-infected children in care 
aged 10-19 years increased from 11% to 44% between 1996 and 2005. As HAART 
treatment becomes increasingly available in South Africa, similar trends can be expected 
(Jaspan, Li, Johnson, & Becker, 2009). 
 
Hans et al. (2009) investigated the prevalence of post-traumatic stress symptoms (PTSS) in 
a sample of adolescents and young adults perinatally and behaviourally infected with HIV 
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and AIDS. The relationship of PTSS with treatment adherence and the role of internal health 
locus of control (IHLC) were explored. Twenty-eight participants (Mean age = 17.14, SD = 
3.05; Range = 12-22) recruited from a paediatric immunology clinic completed measures of 
life events, PTSS, and health locus of control. Measures of treatment adherence used 
included viral load count, CD4 count, and provider ratings of adherence. 
 
Findings revealed relatively good adherence levels and low disease severity among the 
sample. Eighty-two per cent of the participants reported experiencing at least one HIV 
related traumatic event, and 75% of the participants reported experiencing at least one non-
HIV related traumatic event (Hans et al., 2009). Post-traumatic stress symptom severity 
scores fell in the moderate range of severity for both HIV related and general traumas. No 
differences were found in trauma scores based on mode of transmission or developmental 
level (adolescents versus young adults).  
 
Provider ratings of adherence and viral load were correlated with PTSS. IHLC did not 
demonstrate a significant indirect effect on the relationship between treatment adherence 
and PTSS. Difficulties in recruitment for this study point to the many stressors facing youth 
with HIV and the barriers to successful recruitment of ethnic minority participants in 
research. Findings highlight the need to address psychosocial problems among youth with 
HIV, in particular, post-traumatic stress, in order to improve treatment adherence and health 
outcomes in data (Hans et al., 2009). 
 
From 1981 to 1986, treatment of HIV and AIDS focused on therapies to treat the 
opportunistic infections caused by organisms from protozoa, parasite, bacterial and viral 
families, such as Candida, Toxoplasmosis, Histoplasmosis, Cryptococcus, and Coccidioides. 
However, there was no drug that could halt or alter the progression of HIV in the body. AIDS 
activists loudly insisted on the need for a drug that would fight the virus, if not cure it, then at 
least halt the virus‟ progressive attack on the body (Pope, White, & Malow, 2009). 
 
Scientific discoveries in 1983-1984 by Robert Gallo and Luc Montagnier identified HIV as the 
cause of AIDS. Subsequent research showed that HIV causes AIDS primarily by destroying 
the body‟s immune system. HIV primarily infects white blood cells known as CD4+ T-cells but 
also infects macrophages and dendritic cells. During the first few weeks of infection, HIV 
replicates rapidly, and patients experience a sharp decline in CD4+ T-cells. As the body 
fights back, through the production of HIV antibodies and CD4+ T-cells, viral replication is 
contained (Nattrass, 2007).  
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First introduced in 1986, HAART (Health Policy Project, 2013) treatment has evolved from 
mono (single)-drug therapy (AZT or Zidovudine) to dual-drug regimens (including AZT plus 
ddl, or AZT and/or ddl with d4t and 3TC) to triple-drug therapy, usually adding a protease 
inhibitor, in 1996. Single-drug therapy has been shown to have little effect on morbidity, add 
less than one year of disease-free survival and have no real beneficial effect on the length of 
life (Nattrass, 2007). In 1986, people infected with HIV gleaned renewed hope for survival 
when the Food and Drug Administration (FDA) approved the use of an experimental drug, 
zidovudine (AZT; ZDV; Retrovir), for the treatment of HIV and AIDS. AZT was a nucleoside 
analogue reverse transcriptase inhibitor drug that had originally been developed for the 
treatment of cancer but had so many toxicities in animal studies that it was withdrawn from 
further study (Pope et al., 2009; WHO, 2013c). 
 
However, AZT became one of the first drugs tested in HIV clinical drug trials, and initial 
results showed great promise of efficacy. Over the next 10 years, AZT would become a 
household word, singularly associated with a deadly disease called AIDS. People taking AZT 
reported a variety of side effects, such as anaemia and fatigue, and drug toxicity became a 
concern. The AZT dosage initially recommended was replaced with a lower and less toxic 
dosage. However, a new problem arose. Some patients became drug resistant after 6 to 18 
months of AZT therapy. Hope for a cure began to fade in the AIDS community, and 
questions began to be raised about the safety and efficacy of AZT. At this point, researchers 
began to study medication adherence in HIV care (Pope et al., 2009). Nevertheless, the 
focus of HIV and AIDS infection at this stage was not yet directed towards young people and 
adolescents, as such impact of treatment on adolescents could not be specifically 
investigated. 
 
The rate of evolution of antiretroviral therapy has been phenomenal since the late 1980s 
when the first agent, zidovudine, was introduced. Huge amounts of research and investment 
have resulted in more than 20 licensed drugs from five individual classes, with more agents 
and classes in various stages of development. Highly active antiretroviral therapy as a 
combination of at least three drugs from two or more classes became possible with the 
advent of a second HAART treatment class, protease inhibitors. Following the introduction of 
HAART treatment in the mid- to late 1990s, dramatic reductions in both HIV and non-HIV 
related morbidity resulted (Hall, Hall, & Cockerell, 2011). 
 
The development of a multi-drug combination therapy for treatment of HIV disease is 
considered one of the great success stories of modern medicine. In a period of 
approximately 10 years, the death rate from HIV disease was reduced by 50 to 80% and 
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changed from a nearly universally fatal and catastrophic illness to what is now often a 
manageable chronic illness. The story of how this was accomplished, however, is less well 
known than the outcome itself, which has been widely heralded in the medical and public 
media. The story of this accomplishment, though, has often been widely distorted in the 
popular press and varies considerably between countries (DoH, 2008).  
 
HAART comprises a combination regimen to reduce viral load to undetectable levels. With 
HAART, the CD4 cell count rises and remains above the baseline count. Over time, HIV 
infection undermines the immune system through direct and indirect means, and the patient 
eventually develops AIDS. HAART treatment suppresses HIV, maintaining the integrity of 
the immune system and postponing development of opportunistic infections (DoH, 2008).  
 
Antiretroviral therapy in adolescents preserves or restores immune function and provides 
sustained suppression of viral load as it does in adults. The general guidelines for the 
treatment of adolescents are as follows: all HIV and AIDS-infected children should be started 
on HAART treatment immediately. Children between one and five years of age should be 
started on HAART treatment when they are symptomatic or if the CD4+ T-cell count is less 
than 750cells/mm3. Children who are five years and older should be treated with HAART 
treatment when they are symptomatic or with CD4+ T-cell counts less than 350cells/mm3 
(Van Dyk, 2012; WHO, 2013c).  
 
Today, four classes of antiretroviral medications are widely used, and several antiretrovirals 
are available in each class, but resistance and cross-resistance to these medications can 
occur very quickly if the patient does not adhere to strict medication dosing guidelines. One 
method to improve paediatric adherence to antiretrovirals is to focus on identified 
determinants of adherence at clinical visits, but very few studies have been conducted to 
identify determinants of adherence to antiretrovirals and the best methods to measure 
adherence in the paediatric population. This research synthesis found that adherence factors 
related to children can be divided into child-identified factors and caregiver-identified factors. 
Child-identified factors include medication-related, demographic-related, cognitive-related, 
psychosocial-related, and biological marker-related barriers to adherence. Caregiver 
identified factors include medication-related, cognitive-related, relationship-related, and 
psychosocial-related barriers to adherence (Delaney, 2006). 
 
Rather than being the work of any single group, the development of HAART treatment is 
seen to be attributed to a long string of discoveries by multiple groups and individuals 
beginning in the 1970s, built upon in the 1980s, and brought to their ultimate fruition in the 
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1990s. Major contributions came from people working in basic science, biochemistry, drug 
development and clinical testing in dozens of institutions and companies. It was only through 
these collective contributions that the success heralded in the mid-1990s came to be, and it 
is only through similar, continuing contributions that patients today are benefiting from the 
potency, durability and ease of use associated with today‟s best regimens. It is a disservice 
to science, however, to suggest, as the media has done, that any individual or group was 
primarily or most responsible for these advances. Instead, they are the work and 
accomplishment of the entire field of HIV medicine (Delaney, 2006). 
 
Historically, effective HAART treatment generally requires a minimum of three agents used 
in combination to show real benefits in disease-free survival times and quality of life. HAART 
treatment includes combinations of three and as many as five drugs, usually from one to 
three classes of drugs, multiple regimens and combinations, and intensive monitoring of 
patients for resistance. HAART treatment is an individualised treatment that evolves over 
time as patients develop resistance or side effects that cannot be tolerated, requiring 
alternative drug combinations. HAART treatment must be taken for life and requires high 
physician and patient compliance to be effective. For those who can comply with the 
therapy, it can greatly enhance the length and quality of life (Van Dyk, 1999). 
 
In the paediatric population, antiretroviral therapy increases survival and reduces 
complications of HIV and AIDS, including opportunistic infections, improves growth and 
neurocognitive function, and leads to better quality of life. HAART treatment has taken HIV 
infection from a rapidly terminal illness to one that is a slowly progressive, chronic illness. 
HIV and AIDS-infected children can now live long, normal lives (Durham & Lashley, 2010). 
The implementation of highly active antiretroviral therapy among HIV and AIDS-positive 
youth results in immune reconstitution, slower progression of HIV and AIDS disease, and a 
decrease in the occurrence of opportunistic infections (Shrestha, Sudenga, Smith, Bachman, 
Wilson & Kemp, 2010).  
 
2.3.2 Classes of Antiretroviral Treatment and their Mechanism of Action 
 
The main classes of antiretroviral treatment drugs that interfere with viral enzymes are 
nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs); non-
nucleoside reverse transcriptase inhibitors; protease inhibitors (PIs); and integrase inhibitors 
(not available in Southern Africa) (Hall, Hall & Cockerell, 2011). The combined use of these 
agents shows great promise in reducing viral load and increasing longevity; however, 
significant toxicities and drug-drug interactions complicate therapeutic decisions. Patients 
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tend to be on multiple drug regimens for a variety of HIV related conditions, and individuals 
with an AIDS diagnosis have a higher incidence of drug reactions than the general 
population (Hall et al., 2011). These reactions or effects are discussed below. 
 
2.3.2.1  Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
 
NRTIs remain the core of initial therapy and are also important in subsequent lines of 
treatment. NRTIs work by becoming part of HIV‟s DNA, thus derailing the HIV building 
process. Once damaged, HIV DNA cannot work to take control of the cell‟s DNA 
(Pope,White & Mallow, 2009). The four inhibitors are discussed next.  
 
2.3.2.1.1 Zidovudine 
The major toxicities associated with zidovudine are anemia and neutropenia. They are 
inversely related to the CD4 lymphocyte count, haemoglobin concentration, and granulocyte 
count and directly related to dosage and duration of therapy. Significant anemia most 
commonly occurs after four to six weeks of treatment. Granulocytopenia usually develops 
after six to eight weeks of therapy. Therefore, frequent monitoring of complete blood counts 
with differentials, haemoglobin, and haematocrit is recommended during the first eight weeks 
of treatment (Sande & Volberding, 1999).  
 
Although lithium and hematopoietic factors (for example, filgrastim, sargramostim) have 
been used in the management of neutropenia, the current data is insufficient to support the 
efficacy and safety of these agents. The treatment of anemia requires multiple blood 
transfusions. Erythropoietin (EPO) is indicated for the treatment of anemia associated with 
zidovudine. Severe headache, myalgia, nausea, malaise and insomnia also may occur in 
zidovudine-treated patients. These side effects tend to wane despite continued therapy. 
Seizures, macular edema, and the Stevens-Johnson syndrome were reported with 
zidovudine, although the causal relationship is uncertain. Zidovudine was also associated 
with rare but potentially fatal cases of lactic acidosis in the absence of hypoxemia, in addition 
to severe hepatomegaly with steatosis. If a patient receiving zidovudine develops tachypnea, 
dyspnea or a fall in serum bicarbonate concentrations, lactic acidosis should be suspected, 
and the drug should be discontinued. Caution should also be exercised when zidovudine is 
prescribed to patients with hepatomegaly, hepatitis, or other risk factors that could cause 
liver disease (Guilfoile, 2011). 
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2.3.2.1.2 Didanosine (2‘, 3‘-Dideoxyinosine) 
The major clinical toxicities associated with didanosine therapy include peripheral 
neuropathy and pancreatitis. Didanosine-associated neuropathy includes tingling, burning, or 
aching sensation in the hands and lower extremities, especially the soles of the feet. An 
intermittent, shooting „electrical‟ pain in the legs that lasts for longer than one hour is also 
described. The drug should be withheld in individuals developing severe neuropathic pain. 
Two to 12 weeks may be required before the peripheral neuropathy subsides. After the drug 
is discontinued, the pain tends to progress or worsen before it improves (Sande & 
Volberding, 1999). 
 
Pancreatic normally occurs during the first one to six months of didanosine therapy and 
resolves within one to three weeks after discontinuing the therapy. Patients present 
symptoms of vague abdominal pain, nausea and vomiting. Certain patients also experience 
an increase in serum triglyceride or glucose concentrations prior to the onset of pancreatitis. 
Amylase and lipase concentrations should be checked at baseline and then periodically or 
as needed if pancreatitis is suspected. Retinal changes, optic neuritis, and fulminant 
hepatitis have been associated with didanosine therapy. Patients should undergo periodic 
retinal examinations. Other dose-limiting toxicities include elevation in liver function test 
values, diarrhea, and asymptomatic hyperuricemia (Sande & Volberding, 1999). 
 
2.3.2.1.3 Zalcitabine 
The most common adverse effects reported with zalcitabine is a dose-dependent 
sensorimotor peripheral neuropathy, with a „stocking-glove‟ distribution primarily in the feet, 
occurring in 17% to 31% of treated patients. The neuropathy experienced with zalcitabine is 
characterised by numbness and burning dysesthesia. These symptoms usually become 
apparent during the first 7 to 24 weeks of therapy. If the drug is continued despite 
complaints, sharp shooting pains or severe continuous burning pain may develop, requiring 
opiate analgesics for relief. Additionally, patients may experience gait disturbances. When 
the drug is stopped, pain may progress or worsen for an additional three to four weeks. 
Recovery may require up to 3 to 18 weeks following interruption of therapy. Damage can 
become irreversible if the drug is not discontinued or the dose reduced as soon as the initial 
manifestations are noted (Schietinger et al., 1999). 
 
Other potential adverse effects include esophageal ulceration, congestive cardiomyopathy, 
arthralgias, and dermatologic eruptions. Rash occurs fairly commonly and develops during 
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the first four to six weeks of therapy but usually resolves despite continued therapy. Caution 
must be taken in patients with a prior history of pancreatitis and in those with other risk 
factors for pancreatitis, such as alcohol abuse. Baseline serum amylase and lipase 
concentration should be checked in these situations (Schietinger et al., 1999). 
 
2.3.2.1.4 Stavudine 
The most frequently reported adverse effect with stavudine is peripheral neuropathy, and it 
occurs in 15% to 21% of patients treated with stavudine. As with zalcitabine, the neuropathy 
is characterised by numbness, tingling or pain in the feet or hands. The drug should be 
withdrawn promptly at the onset of neuropathy. Patients should be counselled that 
symptoms may get worse when the drug is discontinued. Once the neuropathy comes to an 
end, the drug can be resumed at half the recommended dose (15 to 20mg twice daily). Other 
adverse effects that occur less frequently with stavudine include arthralgia, hypersensitivity, 
myalgia, anemia, asthenia, gastrointestinal disturbances, headache, and insomnia 
(Schietinger et al., 1999). 
 
2.3.2.1.5 Lamivudine 
In certain paediatric patients treated with lamivudine, monotherapy developed pancreatitis. 
Paresthesias and peripheral neuropathy have also been reported. Other side effects include 
rash, cough, dizziness, fatigue, GI distress, headache, insomnia, and hair loss (Schietinger 
et al., 1999). 
 
2.3.2.2  Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 
NNRTIs attached to the reverse transcriptase enzyme, preventing the enzyme from 
converting HIV RNA into DNA. NNRTIs hit the same target as the NRTIs but through a 
different mechanism that involves blocking a pocket of the RT enzyme. Insertion of an 
NNRTI into the pocket of the enzyme changes its shape, preventing the enzyme from 
making DNA. Since the NNRTIs and NRTIs have a different mechanism of action, often 
viruses that are resistant to one class of the drugs are not resistant to the other class of 
drugs. Side effects of these drugs include short-term central nervous system changes such 
as drowsiness, insomnia and hallucinations. There is also a risk of liver toxicity with all these 
agents. These drugs may also cause an increase in total cholesterol levels (Guilfoile, 2011). 
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2.3.2.2.1 Nevirapine 
The major side effect associated with nevirapine is rash, which occurs in 33% of patients. 
Stevens-Johnson syndrome, which may be a severe and even life-threatening reaction, may 
develop in up to 0.5% of patients. Liver toxicity was also noted with nevirapine (Schietinger 
et al., 1999). 
 
2.3.2.3 Protease Inhibitors (PIs) 
 
Protease inhibitors worked at a later stage in the replication process. The protease inhibitors 
drugs worked by preventing the protease enzyme from effectively cutting HIV viral proteins 
into virions. The defective virions were then unable to infect other CD4+ cells. The protease 
inhibitors bind competitively to the substrate site of the viral protease. This enzyme is 
responsible for the post-translational processing and cleavage of a large structural core 
protein during the budding from the infected cell. Pharmacokinetic enhancement of protease 
inhibitors by concomitant administration of low-dose ritonavir inhibits cytochrome P450-
meditated metabolism of protease inhibitors. Metabolic complications such as insulin 
resistance, hyperlipidaemia and truncal fat accumulation are well described with protease 
inhibitors (Adler, Edwards, Miller, Sethi, & Williams, 2012). 
 
2.3.2.3.1 Saquinavir 
Saquinavir produces diarrhea, nausea, abdominal discomfort, flatulence, and rash. In 
certain, cases, hypoglycaemia, hypertriglyceridemia, elevated calcium, potassium, and 
creatine kinase level have been noted (Guilfoile, 2011). 
 
2.3.2.3.2 Delavirdine 
As with nevirapine, rash is the most common adverse effect noted with delavirdine and 
generally occurs within the first three weeks of therapy (Maartens et al., 2012).  
 
2.3.2.3.3 Indinavir  
The most common, preventable adverse effects of indinavir are nephrolithiasis, which 
presents flank pain with or without hematuria within the first year of treatment. The formation 
of stones is generally painful but does not produce any permanent renal damage (Beal, 
Orrick, Lora, & Vandonkelaar, 2011). 
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The renal calculus is largely composed of a urinary precipitate of pure indinavir. Patients 
should be advised to drink 1.5 litres of fluids daily to prevent the development of stones. 
Patients should also stop indinavir therapy and call their physician immediately when severe 
back pain or bloody urine develops (Beal et al., 2011). 
 
2.3.2.3.4 Ritonavir 
Ritonavir is the least-tolerated protease inhibitor, as 4% to 17% of patients discontinue the 
drug within the first week of therapy because of adverse reactions. The most frequently 
reported adverse effects of ritonavir include nausea, diarrhea, vomiting, anorexia, abdominal 
pain, taste perversion, circumoral and peripheral paresthesias (Beal et al., 2011). Patients 
should be informed that these effects tend to be mild to moderate and diminish with time in 
most cases. Additionally, clinicians should monitor patients for significant elevations in 
triglycerides, blood glucose values (Beal et al., 2011). 
 
2.3.2.3.5 Nelfinavir 
Nelfinavir is the best-tolerated protease inhibitor. The most notable side effect of nelfinavir is 
diarrhea, which is generally controlled with oral antidiarrheal agents. In addition to diarrhea, 
patients may develop abdominal pain, nausea, flatulence or rash (Beal et al., 2011). 
 
2.3.3 Current Trends of HAART Treatment in South Africa 
 
SA Journal of Medicine (2013) reports that in late 2012, the South African Minister of Health, 
Dr Aaron Motsoaledi, announced that fixed-dose combination (FDC) antiretroviral drugs 
would be used in the first line treatment of HIV positive patients from 1 April 2013. FDC is a 
combination of two or more active drugs in a single pill. The FDC ARV that will be rolled out 
in South Africa is a single tablet which contains a combination of the tenofovir (TDF), 
emtricitabine (FTC) and efavirenz (EFV). FDC is simpler, more effective and cheaper than 
the current regimen. The National Department of Health managed to negotiate R89.37 per 
month for FDC treatment. This is a significant saving from the old, single-drug tender. 
 
The primary endpoints of FDC are adherence, especially of HAART treatment, and the 
quality of life of patients. The simplicity of the therapeutic regimen is an added value of 
HAART treatment that increases adherence and may improve long-term success (Tashima 
& Mitty, 2006; Maggiolo, Airoldi, Trotta, Sette, Bisi, Mussini, Bai, Bini, Orofino & Gori, 2008). 
The changeover to FDC will have a major impact on the quality of lives of people living with 
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HIV in South Africa. With the introduction of FDC, all new patients, pregnant women and 
breastfeeding mothers will be offered FDC. The main difference between FDC and the 
current ART regimen is that these patients will have to take one pill once a day instead of 
three or more pills multiple times a day (South African Journal of HIV Medicine 
[SAJHIVMED], 2013). Pill burden and scheduling are two of the factors associated with 
suboptimal adherence. An FDC combines the benefit of low pill burden (one pill) with the 
simplest scheduling (once daily) (Pujari, Dravid, Gupte, Joshi, & Belle, 2008; Agyarko-Poku, 
Sarkodie, & Atakorah-Yeboah, 2014). 
 
FDC is more convenient, easier to take and has fewer side effects. The patient will also have 
to undergo fewer laboratory tests once he or she is on treatment (SAJHIVMED, 2013). The 
patient‟s judgement about simplicity, convenience, tolerability and efficacy of the FDC is 
significantly more positive when compared with the use of the same drugs and single pills 
(Maggiolo et al., 2008). 
 
All HIV positive pregnant women, regardless of their CD4 count, will start FDC from 14 
weeks of pregnancy and continue throughout the breastfeeding period. Following the 
breastfeeding period, women with CD4 counts less than 350 will peripherally continue FDC 
for life. There is hope that this will reduce mother-to-child transmission during the infant 
feeding period (SAJHIVMED, 2013). Pujari et al. (2008), however, mentioned that a 
limitation is the teratogenic effect associated with EFV, which necessitates careful use or 
avoidance of this regimen in women who are pregnant or who may become pregnant. 
 
Although a majority of patients find the multiple dose regimes cumbersome, in a study by 
Agyarko-Poku et al. (2014), patients were found to be sceptical about the use of the fixed-
dose combination treatment regime. The new regime may result in overdosing if they find it 
inadequate to provide the needed protection. Fear of serious adverse reaction from a 
combination of ARVs compared with separate drugs may discourage them from taking the 
treatment. Intensive adherence counselling, taking care of the above concerns, is essential 
before patients are switched to the fixed-dose ARV regime. 
 
2.3.4 The Goals of Antiretroviral Treatment Therapy 
 
Antiretroviral treatment has four primary goals. The first is virological goal, which is to reduce 
the HIV viral load as much as possible, preferably to undetectable levels for as long as 
possible. The second is immunological goal, which aims to restore and preserve 
immunological function so as to improve immune functioning and delay the onset of AIDS. 
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The third goal is therapeutic, and it improves the quality of the HIV-infected person‟s life. 
Lastly, there is the epidemiological goal, which entails reducing HIV related sickness and 
death and to reduce the impairment of HIV transmission in the community (Van Dyk, 2012; 
WHO, 2010). 
 
The aforementioned four goals are achieved by suppressing viral replication as intensely as 
possible and for as long as possible by using tolerable and sustainable treatment for an 
indefinite period of time. By so doing, the CD4+ T-cell lymphocyte count usually increases 
progressively with partial restoration of the immune system, dramatically reducing the 
morbidity and mortality associated with HIV infection (Pope et al., 2009). 
 
Working together in combination, the drugs from different antiretroviral classes were able to 
block HIV at several points in its replication, slowing its spread in the body. This strategy 
became known as highly active (or highly aggressive) antiretroviral therapy (HAART). 
However, the powerful new drugs have side effects. Patients complained of nausea, inability 
to focus, and a general feeling of „feeling lousy.‟ More severe side effects included fat 
redistribution and elevated serum cholesterol and triglycerides, which could indicate 
increased risk for cardiac disease (Pope et al., 2009). 
 
Antiretroviral treatment is used mainly to treat established HIV infection and to prevent HIV 
infection of mother to child and post-exposure prophylaxis after occupational exposure, rape 
or sexual assault. HIV is currently treated with antiretroviral agents that block the actions of 
specific enzymes that are necessary for the interpretation of HIV ribonucleic acid (RNA) and 
the production of infectious virions. Genetic mutations of HIV occur spontaneously and 
frequently (Treisman & Angelino, 2004). A great many mutations are silent, that is, they 
produce an HIV particle that is less able to function or cease the production of an essential 
product, such that the virion produced is no longer viable. The troublesome mutations are 
those that alter the reverse transcriptase or protease enzymes slightly but significantly so 
that the antiviral drugs cannot stick to them and inhibit their action.  
 
This mutant virus can continue propagation in the presence of antiviral medication (Treisman 
& Angelino, 2004). A wild-type virus, or the virus as it evolves in the absence of antiviral 
drug, has the best ability to infect and reproduce in the host. A mutant virus is usually less 
well adapted and will not survive unless an antiviral drug is present. This means that ideally 
patients take either no antiviral drug or take sufficient antiviral drug to completely stop viral 
replication and prevent mutations from developing. Perfect adherence increases the 
likelihood that the medications will suppress the formation of the virus almost completely and 
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thus give the body‟s defences an advantage in the fight against HIV. With current treatment, 
HIV is not eradicated from the body, but with ideal adherence, viral production is nearly 
completely suppressed, and the disease process can be interrupted, perhaps indefinitely 
(Blanchardt et al., 2013). 
 
The first patients treated with antiretroviral medications received a single agent, zidovudine, 
because that was the only agent available. It was quickly discovered, however, that 
spontaneous mutations led to HIV strains that had less sensitivity to zidovudine in patients 
treated for six months or more. Such evidence led to the development of combination 
therapy or HAART. By using multiple agents, the rate of viral replication is slowed down so 
much that few mutations occur, and mutations that allow resistance to one agent do not 
protect the virus from another agent‟s effects (Treisman & Angelino, 2004). 
 
2.3.5 Indicators of the Effectiveness of HAART Treatment 
 
The effectiveness of antiretroviral therapy should be monitored by looking at the HI viral 
load. Viral load tests should be done on the following occasion: baseline, before 
commencing HAART treatment. They must also be carried out six to eight weeks after 
commencement of therapy and, thereafter, every four to six months (Reeves & Derdeyn, 
2007). It becomes clear that a patient‟s HAART treatment is effective when the viral load is 
low, preferably to undetectable levels. An increase in viral load indicates that the treatment is 
not working and that a patient‟s drug therapy needs to be re-evaluated and changed. The 
CD4+ T-cell count is not a good indicator of HAART treatment failure and should preferably 
not be used to indicate the effectiveness of HAART treatment (Adler, 2001; WHO, 2010). A 
person with optimal virological suppression can in some cases have low CD4+ T-cell count 
responses, and if the low CD4+ T-cell count is taken as evidence of HAART treatment 
failure, the HAART regime will be inappropriately switched. The Southern African HIV 
Clinicians Society recommends that failure of HAART should be defined only on the basis of 
viral load, irrespective of the CD4+ T-cell response (Reeves & Derdeyn, 2007). 
 
2.3.6 Regiment Adjustment of HAART Treatment  
 
Because there are only a limited number of drugs available, careful consideration should be 
taken before changing antiretroviral therapy. Antiretroviral medication should be changed 
under the following circumstances: when the patient shows intolerance to the medication, 
despite adequate and appropriated treatment. Furthermore, treatment can be changed when 
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there is drug toxicity or when virological failure occurs, or when the viral load increases or 
shows an insignificant decline despite treatment (Hall et al., 2011). 
 
Antiretroviral regimens imply a combination of certain drugs and range as follows: 
Regimen 1 2 NRTIs: for example, Zidovudine or Stavudine + Lamivudine or 
Didanosine Plus either 
  1 NRTI: Nevirapine or Efavirenz 
Or 
1 PI  : Nelfinavir, Saquinavir soft gel or a low dose Ritonavir boosted 
PI 
Or 
  2 PIs  : for example, Saquinavir + Ritonavir 
Regimen 2 3 NRTIs: Zidovudine, Lamivudine + Abacavair (Adler, 2001). 
 
When it comes to antiretroviral regimens for the initial treatment of chronic infection in adults, 
choice would depend upon efficacy, tolerability, and adherence and resistance profile of the 
regimen. Effective combination therapies are transforming HIV infection from an acute 
condition into a long-term chronic illness that is manageable and survivable. Regimens are 
becoming increasingly simple and tolerable, yet strict adherence is still required for optimal 
benefits for most regimes. Furthermore, regimens should also correspond to an individual‟s 
personal preferences and lifestyle to help ensure the high adherence that is required (Pope 
et al., 2009). 
 
2.3.7 Assessment of Immune Status and Viral Load 
 
To manage HIV infection, opportunistic infections and AIDS, it is important to monitor the 
individual‟s CD4+ T-cell lymphocyte count, as well as the viral load in the blood on an 
ongoing basis. CD4+ T-cell counts are important to evaluate the status of the immune 
system; they indicate when to start to prevent or treat opportunistic infections and diseases 
and indicate when to start antiretroviral treatment (Van Dyk, 1999). 
 
Viral load test is important to assess the severity of the HIV infection by revealing how far the 
immune system has been eroded; prescribe relevant antiretroviral medication; measure the 
person‟s response to antiretroviral treatment; and detect antiretroviral resistance (Van Dyk, 
2012). The viral load is usually undetectable after six months of treatment. 
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2.3.8 Section Synopsis 
 
Given that the developmental issues of adolescence challenge the likelihood of successful 
adherence to HAART treatment, that the social context of many adolescents with HIV is 
unsupportive of adherence, and that the medical consequences of non-adherence are 
extremely serious, it is important that adolescents receive assistance in adhering to HAART 
treatment.  
 
2.4 CONCEPTUALISATION OF ADHERENCE TO HAART TREATMENT WITH 
REGARD TO ADOLESCENTS 
 
This section looks at the conceptualisation of HAART treatment adherence by adolescents 
by focusing on the goals of HAART treatment. Furthermore, aspects contributing to both 
adherence and non-adherence to HAART treatment are also described.  
 
2.4.1 Measurements of Adherence to HAART Treatment 
 
HIV positive adolescents are becoming a progressively more sizeable and prominent 
subgroup in the South African HIV and AIDS epidemic. As HAART treatment becomes 
increasingly available, vertically infected children can be expected to survive into 
adolescence and adulthood. Additionally, sexual transmission of HIV and AIDS remains a 
problem, and incidence and prevalence rates among South African youth are high (Li, 2009).  
 
Adolescence, comprising roughly the second decade of life, is a key phase of human 
development during which children transition into adulthood. These years are characterised 
by major changes at the biological, psychological, and social levels, differentiating them from 
other stages of development. With the exception of early infancy, the changes which occur 
during adolescence are greater than in any other period of life (Li, 2009).  
 
At a biological level, adolescents undergo puberty, during which they develop primary and 
secondary sex characteristics, the capacity for reproduction, and a mature physical 
appearance. These physiological events also have psychosocial implications as adolescents 
adjust to their changing bodies, redefine their self-image, and learn to manage their 
emerging sexuality. At a cognitive level, adolescents develop decision-making skills, greater 
short and long-term memory, and the ability to think critically and abstractly (Williams, 
Holbeck, & Greenley, 2002). Cognitive development is accompanied by an enhanced ability 
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to self-conceptualise, and accordingly, identity formation is also a crucial task of this period. 
At a social level, parent-child relationships are transformed as adolescents learn to make 
decisions independently and function autonomously (Williams et al., 2002). Simultaneously, 
the peer group becomes increasingly important as young people seek intimacy and 
acceptance outside of the family unit.  
 
Adolescents have to navigate major demands placed upon them by society. Progression 
through school, entry into the labour force and all the adjustments which accompany these 
events also occur during this period. These local interactions take place within wider societal 
frameworks, which carry dominant streams of expectations, values and ideologies. 
Adolescents must learn how to navigate these structures in order to become successful and 
active participants in society. HIV affects adolescents at each of the three previously 
mentioned axes of development. Biologically, perinatally infected children go through 
puberty significantly later and are smaller than their HIV-negative peers. From a social 
standpoint, autonomy from parents, peer acceptance and participation in society are 
complicated by the desire for secrecy about serostatus and fears of stigma or rejection (Li, 
2009). 
 
In addition to dealing with these direct encumbrances to standard developmental processes, 
HIV and AIDS-positive adolescents must also confront a number of challenges. For these 
young people, the transition from childhood to adulthood is interlaced with concerns about 
medication regimens, doctor‟s appointments, life expectancy, disclosure, and transmitting 
HIV to others. Of course, the virus poses similar concerns for HIV positive individuals at 
other life stages. However, the extensive changes that characterise adolescence make the 
second decade of life particularly unique. The combination of ordinary developmental issues 
with HIV related worries creates a distinctive environment which frames adolescents‟ daily 
experiences and their interactions with health care systems (Li, 2009). 
 
Adherence entails sticking to the treatment plan by the patient. The prescribed HAART 
treatment must be taken at the right time and in the right dosage daily. The patient must 
meet scheduled medical appointments. The patient must collect medical repeats. Adherence 
arises from agreement, based on mutual understanding on the required action, between the 
patient and the experts as partners (Turner, 2002). Nothing could be more obvious than the 
simple fact that medications only work when people take them. The goal of antiretroviral 
therapies is the complete suppression of HIV replication. Although medication regimens vary 
in terms of just how much adherence is needed to achieve viral suppression, most 
combinations of medications require at least 85% adherence. Minimal levels of adherence 
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needed to sustain viral suppression are not necessarily the same across compartments of 
the immune system. Viral load can have transient spikes or rebound in the genital tract, even 
when blood plasma viral load remains undetectable. Studies show that the risk of HIV 
transmission among people receiving treatment can be as high as 22%. Another 
complicating factor is that treatment regimens vary in their penetration of the genital tract. 
High concentrations of most nucleoside and non-nucleoside reverse transcriptase inhibitors 
are recovered from the genital tract, whereas protease inhibitors achieve lower drug 
concentrations in this compartment (Kalichman, 2013). 
 
The goal and benefit of HAART treatment may be defined both clinically and biologically. 
Clinically, HAART prolongs life and improves the quality of life of those living with HIV and 
AIDS, by reducing, as much as possible, the frequency of the HIV and AIDS-related illness 
that is known as AIDS. By reducing the mortality rate due to HIV and AIDS, ARV drugs also 
have the controversial effect of increasing the number of people living with HIV and AIDS 
because they tend to live much longer than they would do without the treatment. Biologically, 
HAART treatment is responsible for the immune reconstitution that is both quantitative 
(referring to the CD4 cell count in normal range) and qualitative (referring to the pathogen-
specific immune response). HAART treatment also causes the greatest possible reduction in 
viral load (preferably to less than 50     ) for as long as possible, in order to halt disease 
progression and to prevent or to delay progression (Bartlett, Gallant, & Conradie, 2008). 
 
For teenagers with any chronic illness, adhering to treatment is particularly challenging from 
developmental and psychosocial reasons. Developmentally, teens often feel invincible, 
immortal, like they are living in the moment, and do not realise the long-term consequences 
of their actions (LaGreca, 1990). Perinatally infected adolescents have been exposed to 
HAART treatment, and in most studies, over 50% have successful viral control, resulting in 
longer and healthier lives. However, these adolescents have multiple risk factors for mental 
illness. Living with a chronic disease is associated with increased rates of mental illness and 
many older adolescents were infected prior to the advent of HAART treatment and may have 
had a period of ineffective therapy with resultant uncontrolled viral infection in the central 
nervous system. Many have lost a biological parent to HIV and AIDS and may be living with 
another relative or foster parent. These adolescents are also frequently subjected to 
environments of poverty, crime, and substance abuse. The HIV epidemic in adolescents now 
includes mostly those infected through high-risk behaviour. Similar to the perinatally infected 
adolescent, behaviourally infected teens generally live in areas of high poverty, crime, and 
substance abuse. Unlike those infected perinatally, these teens usually live with a biological 
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parent. Mental illness and substance abuse rates are predicted to be high in this population, 
since both are associated with high-risk sexual behaviours (Palmer, 2011). 
 
Understanding prevalence rates and types of mental illness is important to practitioners 
treating HIV-infected adolescents. Mental illness and substance abuse in the HIV and AIDS-
infected adolescent may lead to poor adherence to antiretroviral therapy and risky sexual 
practices. Prevalence rates for psychiatric disorders in perinatally infected children vary 
depending on the type of study but generally are 55-61%. The most common disorders 
found are anxiety disorders (24.3-49%) followed by attention deficit hyperactivity disorders 
(ADHD) (14-28.6%), conduct disorders (1-12%), oppositional defiant disorders (16.7%), and 
mood disorders (4.3-25%). Compared to the general population, psychiatric disorders are 
higher in HIV-infected children. The prospective cohort study of Gaughan, Hughes, Oleske, 
Malee, Gore & Nachman (2004) regarding the long-term effects of in utero and/or postnatal 
exposure to HIV and antiretroviral therapies found the rates of psychiatric hospitalisation in 
HIV-infected children (4-17 years of age) to be about six times higher than of infected youth 
reported ever having a substance abuse problem. Older adolescents are at a higher risk of 
substance abuse, which may increase risk-taking behaviours and medication non-adherence 
(Palmer, 2011). 
 
HIV and AIDS clinicians should, therefore, be aware of possible mental health problems 
such as anxiety disorders and ADHD in perinatally exposed/infected youth and mood 
disorders in behaviourally infected youth. Therapy for psychiatric conditions in HIV-infected 
youth includes both behavioural and pharmacologic therapy. Approximately 20% of HIV-
infected youth are treated with psychotropic drugs and between 25-50% receive some form 
of behavioural intervention. Psychotropic medications most frequently used include 
stimulants for ADHD, antidepressants, and antipsychotics for mood disorders. When 
compared to HIV-exposed but uninfected youth, HIV perinatally infected youth are more 
likely to be treated with medications and behavioural therapy for mental disorders. This 
difference may be explained by a disparity in interaction with health care providers between 
HIV positive and HIV-negative youth, although evidence to support this theory is needed. 
Selective serotonin reuptake inhibitors (SSRIs) are the most common pharmaceutical agents 
used for moderate to severe depression (Palmer, 2011). 
 
Palmer (2011) states further that practitioners should also be aware of the many drug 
interactions that can occur between psychotropic medications and certain antiretroviral 
agents, antibiotics, and antifungals. Studies evaluating the efficacy of behavioural therapy in 
HIV-infected youth are extremely limited but suggest that group intervention may decrease 
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stress and improve behaviours such as improved medication adherence and safe sex 
practices. Mental illness has been associated with poor medication adherence in adults. 
Poor adherence was associated with low self-efficacy (one‟s sense of being able to adhere 
to medications prescribed) and low outcome expectancy (one‟s sense of benefit from 
antiretroviral drugs). 
 
More than 50% non-adherence was seen in HIV-infected youth with low self-
efficacy/outcome expectancy, structural barriers, and a mental health disorder. These 
findings were consistent between youth infected perinatally and those infected through high-
risk behaviours. The only difference found between the two groups was more structural 
barriers related to non-adherence in the behaviourally infected group. It is not clear why a 
lack of association with poor medication adherence and a diagnosed mental health disorder 
in HIV-infected youth was not seen in these studies, but one explanation may be high rates 
of treatment for mental health disorders in their study population. Based on the results of 
these studies, the HIV clinician should address issues of self-efficacy, outcome expectancy, 
and structural barriers, in addition to treatment of mental disorders in order to maximise 
antiretroviral treatment adherence. HIV-infected adolescents have very high rates of mental 
illness (Palmer, 2011). 
 
For HAART treatment to work, it requires near-perfect (95%) adherence (Paterson et al., 
2000). Adherence plays a chief role in determining the quality of life, in either positive or 
negative ways. As social and behavioural factors affect adherent behaviour, these variables 
are likely to exert important influences on health care utilisation and therefore on health 
outcomes of people living with HIV (Abdool Karim & Abdool Karim, 2010). Adherence to 
HAART medication is the greatest patient-enabled predictor of treatment success and 
mortality of those who have access to drugs (Mills, Nachega, & Buchan, 2009). 
 
Strict adherence to HAART is extremely important to achieve viral suppression and avoid the 
risk of mutation, the development of resistant strains and drug failure (Van Dyk, 1999). Drug 
resistance can develop very rapidly with missed or inadequate doses of medication. Missing 
even a few doses a week may lead to the development of drug resistance. In the case of 
perinatally infected adolescents, the young person‟s relationship with his or her primary 
caregiver is integral in mediating adherence. Caregivers who use drugs or alcohol, or are 
HIV positive themselves, are more likely to have non-adherent children, while those with a 
higher level of education and who are knowledgeable about their child‟s antiretroviral 
regimen tend to have more adherent children (Li, 2009). 
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Many perinatally infected children have survived into their second or third decade of life 
because of the advent of combination HAART and effective viral suppression with 
immunologic reconstitution. In many ways, this group represents a unique population of HIV 
positive adolescents compared with their counterparts who acquired HIV infection 
horizontally. The medical field is just beginning to learn about the complications of chronic 
HIV infection and the toxicities associated with HAART before and during sexual maturity. 
Managing the toxicities while administering suitable and necessary active HAART regimens 
in these heavily treated adolescents will be challenging, given the limited therapeutic options 
that are available (Ross, Camacho-Gonzalez, Henderson, Abanyie, & Chakraborty, 2010). 
 
2.4.2 Factors Contributing to Adherence to HAART Treatment by Adolescents 
 
Adherence to HAART treatment entails taking all ARV pills in the correctly prescribed doses 
at the right time and in the right way, including observing any dietary restriction. Soloway and 
Friedland (2000, p.1) define it as “the act of taking medications as prescribe a highly 
complex clinical behaviour.” It has also been defined as the extent to which a person‟s 
behaviour (in terms of taking medications, following diets, or executing lifestyle changes) 
coincides with medical advice (Haynes, 1979).  
 
The foregoing definition expands the concept of adherence beyond merely taking 
medications and includes maintaining healthy lifestyle practices, such as eating properly, 
getting sufficient exercise, avoiding undue stress, abstaining from smoking cigarettes, not 
abusing alcohol, and always practising safer sex. The word “adherence” is preferred by 
many health care providers, because “compliance” suggests that the patient is passively 
following the doctor‟s orders. It is preferred that patients not be passive but rather follow a 
treatment plan based on a therapeutic alliance or contract between the patient and the 
physician (Levine, 1998). 
 
Practitioners and researchers alike recognise that patient adherence is associated with 
better outcomes than patient compliance. For the purpose of this research, the term 
“adherence” is used rather than “compliance,” although the researcher recognises that they 
are often used interchangeably. The three most commonly identified factors supporting 
adherence were the importance of having a supportive family and community environment; 
having strong support groups of people living with HIV, both as self-help and as counsellors; 
and the importance of food security and nutrition (Schietinger, Sawyer, Futterman, & Rudy, 
1999). A number of other factors were also identified which can be summarised as 
pertaining to accessibility (such as proximity of treatment centres, decentralised services, 
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timing, adapting to specific needs); affordability (of treatments, diagnostic tests, 
consultations, transport, child care); quality (practitioners‟ knowledge and skills, monitoring 
and support systems including psychological support); and the importance of employment or 
other income-generating opportunities for clients (Schietinger et al., 1999). 
 
Some recent studies have examined HAART treatment adherence among children (including 
adolescents) in the context of sub-Saharan Africa. In a sample of 170 Ugandan children 
between the age of 2 and 18 years, Nabukeera-Barungi, Kaylesubula, Kekitjinwa, Byakika-
Tusiime, and Musoke (2007) used multiple methods to measure the number of the 
participants who had > 95% adherence. Caregiver self-report indicated that 89.4% of 
children were adherent, clinic-based pill counts yielded a rate of 94.1%, and unannounced 
pill counts at the children‟s homes measured 72% compliance. The study also found that 
when the caregiver was the only person who knew the child‟s HIV status, the child was more 
than three times more likely to be adherent.  
 
Additionally, children who had been hospitalised on more than two occasions exhibited 
better adherence than those who had not. No relationship was found between adherence 
and any of the other child factors, including age, gender, distance between the child‟s home 
and the hospital, orphan-status and disclosure to the child. However, a second Ugandan 
study did observe a relationship between disclosure and adherence. In this study, 8/12 
children (aged 5-17) who knew their status had never missed a dose, compared to only 3/14 
who did not know their status and 1/16 who had undergone partial disclosure (Bikaako-
Kajura, Luyirika, Purcell, Downing, Kaharuza, Malamba & Bunell, 2006). As expressed by 
the caregiver of a 14-year-old girl, disclosure helped because even when she gets tired of 
taking the drug, then she remembers that it is good to take the drug, and she takes it 
(Bikaako-Kajura et al., 2006).  
 
2.4.3 Factors Contributing to Non-adherence to HAART Treatment by Adolescents 
 
Adolescents who are infected with HIV and AIDS also face challenges of adherence. Non-
adherence to HAART treatment can be described in a variety of ways, ranging from a person 
missing one dose of a given drug, missing a dose of all the three drugs, missing multiple 
doses, not observing the time intervals, not observing the dietary restrictions, or not taking 
the correct dose of any drug. Non-adherence can lead to poor clinical, immunological and 
virological outcomes. At an individual level, the consequences of non-adherence include 
incomplete viral suppression, continued destruction of the immune system and decrease of 
CD4+ cell count, progression of disease, emergence of resistant viral strains, limited future 
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therapeutic options, and higher cost for individual treatment which translates to higher 
programme costs (Wanjohi, 2009).  
 
Whereas HAART treatment has significantly improved the lives of many patients worldwide, 
the lack of adherence to treatment remains a major challenge to HIV and AIDS care 
(Kambale, 2013). The lack of ARV adherence is the second strongest predictor of 
progression to AIDS and death, after the CD4 count (Machtinger & Bangsberg, 2006). 
Regardless of the mode of acquisition of the HIV infection, infected adolescents might have 
very low self-esteem, leading to depression, chaotic lifestyles, and drug addictions, together 
with mental illness and poor adaptation to the social environment of their disease, due to a 
lack of family and social support. Depression, alcohol or drug abuse, school truancy, and 
experiencing advanced HIV disease are correlated with non-adherence (Murphy, Belzer, 
Durako, Sarr, Wilson & Muenz, 2005). 
 
Given the prevailing problem of treatment adherence in this population, research has 
focused on identifying factors contributing to non-adherence. Research on adults with HIV 
and children with other chronic illnesses suggests that post-traumatic stress disorder 
(PTSD), PTSS, and health beliefs may be important factors relating to non-adherence 
(Hans, Spiegel, Donna & Flutterman, 2009).  
 
Advances in HIV care have given rise to a population, including adolescents, that is living 
longer with HIV. With the advent of HAART treatment, HIV and AIDS is now considered a 
chronic condition. Adherence with approximately 95% of prescribed doses is required to 
prevent treatment failure and development of resistance to HAART treatment – outcomes 
that would affect not only the individual but also the community at large. Caring for 
adolescents living with HIV and AIDS is especially challenging considering the impact the 
disease has on their well-being which impacts on their adherence to medication. 
Adolescents are a heterogeneous group that need to be known well if optimal care is to be 
provided to them (Wanjohi, 2009). 
 
Non-adherence to HAART treatment is the leading cause of treatment failure. Not surprising, 
medicine adherence rates among HIV and AIDS-infected youth are poor. This population 
experiences many contributors to poor adherence, including mental health issues and 
substance abuse, caregiver fatigue and stress, HIV and AIDS stigma and disclosure, peer 
relations, and immature concrete reasoning. Strikingly, rates of depressive symptoms are 
consistently associated with lower adherence rates. For example, in the Reaching for 
Excellence in Adolescent Care and Health (REACH) cohort, depressed HIV and AIDS-
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infected adolescents had a 55% rate of non-adherence compared with 29% in the non-
depressed group. This statistic emphasises the need for depression screening and 
integrated mental health services for HIV and AIDS-infected youth. A recent study showed 
that unlike adult populations, health literacy has little effect on medication adherence among 
HIV and AIDS-infected youth, even after adjusting for age, education level, viral load, and 
self-efficacy to adhere to medication regimens. This finding underscores the uniqueness of 
the adolescent population and the need to identify novel solutions to improve adherence 
(Ross et al., 2010). 
 
The use of hand-held personal computers to assist adolescents with HIV medication 
regimens and the organisation of health care appointments was studied, and it was found 
that most participants were willing to try this new technology (Rolando et al., 2016). Further 
investigation is needed to assess if these creative solutions have effects on measurable 
outcomes (for example, CD4+ T-cell counts and plasma HIV-1 RNA levels). In the meantime, 
assessing barriers to medication adherence and frequent mental health screening on an 
individual patient level is critical to implementing strategies for improving adherence. Short-
stay, hospital-based, directly observed therapy may also help if adherence is in question 
because a rapid decline in plasma HIV-1 RNA viremia by the end of such therapy is highly 
suggestive of non-adherence to ART (Ross, Camacha-Gonzalez, Henderson, Abanyie & 
Chakraborty, 2010). 
 
Many perinatally infected adolescents have survived into their second or third decade of life 
because of the advent of combination HAART treatment and effective viral suppression with 
immunologic reconstitution. In many ways, this group represents a unique population of HIV 
and AIDS-positive adolescents compared with their counterparts who acquired HIV and 
AIDS infection horizontally. These are just the beginning stages of learning about the 
complications of chronic HIV and AIDS infection and the toxicities associated with HAART 
treatment before and during sexual maturity. Managing the toxicities while administering 
suitable and necessary active HAART treatment regimens in these heavily treated 
adolescents will be challenging, given the limited therapeutic options that are available (Ross 
et al., 2010). 
 
Sticking to the treatment instructions for a long-term illness poses a great challenge to 
patients in general and with HAART treatment in particular, and adolescents are not immune 
to these challenges. A person who takes HAART treatment erratically will receive only 
marginal benefit; however, they will suffer similar side effects and will potentially limit their 
future treatment options. It is important that all patients demonstrate an understanding of this 
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before starting treatment. An adolescent who stops taking HAART treatment entirely will 
rapidly lose any benefit they may have received in terms of increased immunity as the virus 
flourishes and CD4+ cells are destroyed. Adolescents must be made aware that HAART 
treatment is a lifelong treatment. Educating adolescents effectively and assessing their 
understanding can be time-consuming and labour-intensive, but it is never time wasted. 
Simply giving a prescription at the first visit without sufficient adherence counselling is 
clinically negligent, but unfortunately, this is a common practice and much more pronounced 
in adolescents who are inaccurately assumed to be ignorant; as a result, such education is 
subsequently ignored. HAART treatment providers who do not seriously address the 
complex issue of adherence will fail in their objective of helping their patient. At the public 
level, this may cause the development of multi-drug resistant strains within the population 
they serve, which would have dire public health implications. Adherence is therefore central 
to the success of HAART (Wanjohi, 2009). 
 
Many factors associated with non-adherence to prescribed medication regimens have been 
identified from numerous studies. These factors range from patient variables, treatment 
regimen, disease characteristics, patient-provider relationship to clinical setting. With respect 
to non-adherence to HAART treatment specifically, a number of empirical studies and 
reviews have found that several factors were often associated with non-adherence, including 
presence of adverse drug effects, neuropsychological dysfunction, psychological distress, 
substance use, lack of social or family support, low patient self-efficacy, inconvenience of 
treatment, and poor reading literacy skills (Pope et al., 2009).  
 
In a study by Tucker, Bien, Easterbrook, Doherty, Penazzato, Victoria & Peeling (2014), the 
most commonly cited barriers for adherence to HAART were as follows: 
 simply forgot (39%) 
 staying away from home (30%) 
 slept through dose time (22.5%) 
 busy with other things (18%) 
 did not have adequate food (18%) 
  
On the other hand, 10% of them reported that side effects prevented them from taking their 
medications.  
 
Several factors render the combination therapies an especially challenging treatment. These 
include the relative absence of significant symptoms related to HIV and AIDS until later in 
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the course of the disease; the often prophylactic nature of treatment; indefinite duration of 
treatment; questionable treatment efficacy; and frequent and serious adverse effects (Pope 
et al., 2009). A different study shows that adolescents commonly experience such 
challenges as the taking of complex medication regimens and the following of a continuous 
medical care routine. However, adolescents might have long histories of poor adherence. 
Regardless of the mode of acquisition of the HIV and AIDS infection, infected adolescents 
might have very low self-esteem, leading to depression, chaotic lifestyles, and drug 
addictions, together with mental illness and poor adaptation to the social environment of their 
disease, due to a lack of family and social support. Depression, alcohol or drug abuse, 
school truancy, and experiencing advanced HIV disease are correlated with non-adherence 
(Murphy et al., 2005).  
 
Botswana Ministry of Health notes that HIV and AIDS-infected adolescents have special 
psychosocial issues that often lead to a number of adherence problems. These include the 
denial of, and fear related to, HIV and AIDS diagnosis; misunderstanding related to 
diagnosis and health needs; lack of belief in the efficacy of HAART treatment; the distrust of 
family practitioners and the health care system; low self-esteem and an unstructured, chaotic 
lifestyle; and limited familial and social support (Kambale, 2013).  
 
Proper education of adolescents before the initiation of and during HAART treatment is 
critical for the success of adherence. However, proper education before initiation of HAART 
treatment seems to be questionable when it comes to adolescents. Most adolescents only 
learn about the true reasons behind their taking HAART treatment much later while they 
have been taking medication for a few years; therefore, education thereof seems to have 
been missed, thus impacting adherence negatively. More attention needs to be given to the 
timing of disclosing to adolescents their HIV status. The value of an HIV positive adolescent 
being properly prepared for their status disclosure, so that they might come to accept the 
fact that they have been infected, should not be underestimated in terms of future adherence 
quality (Kambale, 2013). 
 
The impact of the drug regimen on HAART treatment adherence is complex. The majority of 
those who are on HAART treatment are on a regimen of three or more ARVs. The likelihood 
of a patient‟s adherence to a given regimen declines with polypharmacy, the frequency of 
dosing, the frequency and severity of side effects, and the complexity of the regimen. Poor 
adherence has also been associated with patients‟ desire to avoid embarrassing side effects 
(like sweating) in certain situations such as on a date or at a job interview. Complicated 
regimens with rigid dosing intervals may also interrupt sleep. The physical aspects of a 
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particular medication (for example, taste, size or formulation) may also affect a patient‟s 
ability to adhere (Abdool Karim & Abdool Karim, 2010). Other factors cited as contributing to 
non-adherence relate to logistical concerns, such as missing an appointment for follow-up at 
the hospital. Some reasons given for missing such appointments range from being too busy 
or simply forgetting, to changes in the daily routines of patients (Dagnew, 2009).  
 
Logistical considerations beyond the adolescent‟s control may also impact adherence to 
HAART treatment. For instance, the effect that the clinic setting has on HAART treatment 
adherence should not be underestimated. Clinic characteristics that impact on adherence 
include proximity to the patient‟s home or place of work; the expense of getting there; 
lengthy delays between appointments; clinic opening and closing times; long waiting times; 
and lack of services such as child care, privacy, confidentiality, and unsympathetic or 
inconsiderate staff. It is doubtful that most patients receiving ART as part of the national roll-
out receive the same level of social, psychological, and instrumental support as their 
counterparts had in the MSF programme in Khayelitsha. Adherence levels of patients 
enrolled in the national HAART programme is not known. However, because of much lower 
levels of psychosocial support, they are assumed to be lower. In this study, attention has 
been called to the psychosocial barriers to optimal adherence that may potentially be faced 
by patients receiving HAART in the context of the national roll-out in South Africa. These 
barriers include poverty, health literacy, perceived social support, mental health, substance 
abuse, and stigma (Kagee, 2007). Adolescents also experience similar barriers as the adult 
population. 
 
Strategies such as education should cover basic information about HIV and its 
manifestations, the benefits and side effects of ARV medications, how the medications 
should be taken, and the importance of not missing any doses. Adherence assessment 
should be combined with adherence counselling at each visit. With regard to adolescents, 
they tend to experience confusion and stress as a result of their rapid emotional, physical 
and social development, and this may cloud their understanding of adherence. Because 
young adolescents are just beginning to develop skills for abstract thinking, the facts and 
information they are given about HIV and AIDS and adherence must be direct, specific, frank 
and concrete (Van Dyk, 2012). 
 
Adolescents who are infected with HIV and AIDS face diverse challenges with respect to 
adherence to HAART treatment. Several studies have identified the „burden‟ that is placed 
on them to continue with the medications, which restricts their lifestyle options, leading to a 
situation that discourages them from wanting to keep their medications with them. 
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Adolescents need a general and basic overview on HIV infection that includes a clear 
description of how HIV is transmitted, how HIV is not transmitted, and how they can protect 
themselves from reinfection. Because these adolescents have already had HIV 
transmission, it then becomes crucial to address the often ignored issue of how they have 
contracted the virus (Van Dyk, 2012). An emotionally explosive area of anger and blame 
should preferably be allowed and responded to in a manner that acknowledges their 
frustration. Adolescents often tend to be rebellious against adults, and this may also apply to 
the refusal to take HAART treatment. This could be for a range of possible reasons including 
simply stopping or interrupting treatment, death, or finding alternative sources of HAART. 
The nature of loss to follow-up is that very often a patient‟s eventual whereabouts or 
outcome is unknown, even if efforts are made to trace such patients. Other factors involve 
patients feeling they need to take a break from HAART (treatment fatigue) (Kambale, 2013).  
 
With the dramatic improvement in HIV and AIDS care over the past three decades, the 
infected adolescent and his or her caregivers are now faced with managing a chronic illness. 
In addition to caring for the physical needs of the HIV and AIDS-infected adolescent, it is 
imperative to recognise and address the psychosocial barriers to optimum health. 
Adolescence is a developmental stage characterised by immature concrete reasoning often 
manifested by denial of the diagnosis, a sense of invulnerability reflected by risk taking, and 
behaviours that are strongly influenced by peer norms. These characteristics all have a 
direct impact on the ability to adhere to medical recommendations in order to improve and 
maintain good health. Infants born early in the HIV and AIDS epidemic have now entered 
adolescence and young adulthood. Such individuals have lived with multiple stressors, which 
include having a socially stigmatised illness, the loss of one or both parents or siblings, and 
being raised by relatives, adoptive families, or within the foster care system (Ross et al., 
2010). 
 
As adolescents grow up, more studies are being conducted to address the impact of HIV 
and AIDS on the psychological and social functioning of this unique population. One study 
assessed 174 HIV-infected youth (aged 13-24 years) attending an inner-city clinic for 
exposure to violence and mental health disorders. They found rates of major depressive 
disorder (15%), generalised anxiety disorder (17%), and post-traumatic stress disorder 
(28%) to be much higher than national samples. In this study, 16% to 28% of the youth 
reported a history of physical or sexual assault, and 44% had witnessed family violence. HIV 
also has a direct impact on the child‟s physical and neurologic development, which may lead 
to cognitive delays and potential psychiatric disorders among long-term survivors (Ross et 
al., 2010).  
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A recent retrospective analysis of the psychological functioning of 81 participants (> 11 years 
of age) demonstrated an association of a history of severe HIV disease (Centers for Disease 
Control and Prevention [CDC] classification C) with psychiatric morbidity and neurocognitive 
delays among adolescents. In a pilot interview study of 47 perinatally infected HIV positive 
youth (aged 9-16 years) and their caregivers, more than 50% of the youth met diagnostic 
criteria for a psychiatric disorder, including anxiety disorder, conduct disorder, and attention-
deficit/hyperactivity disorder. Comprehensive health care for the HIV-infected adolescent 
must include assessment of mental health, social and environmental stressors, and support 
systems, because these factors all can affect the ability to adhere to medical care and may 
impair the ability to reduce secondary HIV transmission (Ross et al., 2010). 
 
Among the main challenges identified by Zuurmond (2008) were the need to tackle stigma 
and the need to address accessibility, affordability and quality concerns raised. Sustaining 
adherence of clients when these began to feel better posed huge challenges as did the 
disruptive nature of HAART treatment supplies in some countries. Issues specific to children 
and adolescents included lack of disclosure and consequent difficulty of explaining their 
need for medication, inadequate counselling skills for children and problems specific to 
guardians or grandparents. Adolescents want to explore sexual relationships, are reluctant 
to take medication in public, and do not want to differ from their peers (Zuurmond, 2008). 
Researching on experiences of HAART treatment will contribute to the understanding of 
factors contributing to non-adherence. The following are often cited factors related to the 
prescribed medication, health care system, patient and family/caregiver. Family/caregiver 
factors were crucial to paediatric adherence because infants and younger children depend 
almost entirely on a caregiver to administer medications. Their adherence to treatment, 
therefore, is largely determined by the resources and efficacy of caregivers. Caregivers who 
are biological parents of HIV positive children often share their diagnosis and confront 
challenges associated with their own illness and its comorbidities. In these cases, treatment 
can become a reminder of the parents‟ guilt about their role in their child‟s acquisition of 
infection, which is yet another challenge to adherence (Pope et al., 2009). 
 
2.4.4 Section Synopsis 
 
HAART treatment adherence is probably the most daunting challenge today‟s health 
professionals face. It can be a source of great concern and frustration. Drugs do not work in 
patients who do not take them, and in the management of HIV and AIDS infection, it is now 
well established that optimum adherence to HAART treatment is critical to the successful 
outcome of patients receiving treatment. As simplistic as it may seem to the observer, it 
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appears there are more challenges that compound the issues of both adherence and non-
adherence. For effective assistance to be rendered, each case must be looked at on its own 
merit. 
 
2.5 EXPERIENCES OF PARENTS AND CAREGIVERS CONCERNING THE 
ADOLESCENTS’ HAART TREATMENT 
 
The experiences of parents/caregivers for support and guidance to care for and counsel 
adolescents to grow into emotionally and physically healthy youth and adults are important if 
one is to have a holistic understanding of HAART treatment by adolescents. The 
psychosocial well-being of children and their caregivers can improve adherence to HAART 
treatment and clinical outcomes. Parents/caregivers need manageable, consistent, and 
hopeful information from the outset that can help them take some initial steps/decisions for 
the child‟s well-being (Sneed, 2008). This is also an opportunity to identify any support that 
the parent/caregiver may need regarding his or her own HIV situation, including provision of 
couples testing and counselling. 
 
In high HIV-prevalent, resource-constrained settings, limitations in human capacity, time and 
funds compound the challenge of providing psychosocial support at all levels – from clinics 
to communities, to families, and to individual caregivers and their children. Experts noted the 
reality that many families are struggling to meet basic needs, such as food, health care, 
shelter, and education costs, which leaves few resources (for example, time, caregiver 
energy, funds) to address the psychosocial needs of children. A few experts pointed out that 
finding ways to support providers/caregivers in meeting these basic needs also helps 
empower them to feel like they can make a tangible difference to a child. Experts stressed 
the importance of acknowledging and addressing these needs through holistic programmes 
or referral efforts (UNAIDS, 2007). 
 
For the child, pre- and post-test counselling must be tailored to the appropriate development 
stage, which requires skill in being able to correctly assess and adapt both the process and 
manner in which counselling is provided. For older, more mature children or adolescents, it 
is critical to engage with them directly. Youth in both South Africa and Uganda expressed 
their anger at being taken for testing without being told why or given true information before 
or after testing: “I was hurt. They did not tell me they were taking off the blood sample for 
HIV testing” (a youth in Uganda). “Doctors lied to me. They gave it a funny name, told me it 
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was malaria. They gave my father the results, not me” (McCleary-Sills, Anjala, Brackarsh & 
Browsky, 2013, p8).  
 
Many of the programmes reviewed dedicate specially trained child counsellors for this initial 
counselling, which youth, parents, and caregivers found helpful. Parents, caregivers, and 
children consistently noted the need for additional information, counselling, and support 
following initial HIV diagnosis to help them process emotions and develop care plans specific 
to the needs and situation of the child. Several HIV testing and counselling programmes 
have adopted standard protocols for children (dependent on age/developmental stage), 
including having time with both the child and the caregiver individually, as well as in a joint 
session. It is important to note that while guidelines exist, much depends on the individual 
assessment of the child (especially for younger children aged 4 to 10 years) to determine 
what information should be shared and how (Steele, Nelson & Cole, 2007). Creating time for 
joint counselling was highlighted as being a useful approach, allowing for the caregiver and 
child to hear and share information together with a trusted source, as well as providing an 
opportunity for the counsellor to observe the interactions between the caregiver and child. 
Some programmes, particularly those that did not offer testing and counselling services, 
have counsellors who can accompany a child and caregiver through testing, providing a 
valued touchstone and friend throughout the process and then linking children and parents 
to follow-up psychosocial support (Cooper, Risley , Drake & Bundy, 2007).  
 
Although adolescents expressed a preference for being disclosed to in a clinic, health care 
workers have been guided to encourage parents to disclose in the home environment. This 
method created barriers to the initiation and completion of this process, and health care 
workers described having to reinforce or correct poorly conveyed concepts from caregivers 
who attempted to disclose in the home environment but failed to do so adequately.  
 
Given the importance of psychosocial support to the long-term well-being of children living 
with HIV and AIDS, there is a critical need to ensure that continuous and individualised 
psychological and social services are fully integrated within a broad, integrated framework of 
care provided by parents, caregivers, and service providers (facility-, community-, and home-
based) and adapted over time as children develop and mature (Steele et al., 2007).  
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2.6 EXPERIENCES OF HEALTH CARE WORKERS WITH REFERENCE TO THE 
ADOLESCENTS’ HAART TREATMENT 
 
The experiences of health care workers respecting adolescent HAART treatment cannot be 
emphasised enough. Doctors and nurses are often confronted by adolescents whose 
adherence to HAART treatment is unsatisfactory, and it is often at these points where extra 
support is required to understand the circumstances of the adolescents and referral to social 
workers, dieticians and psychologists. Health care worker refers to any health service 
provider with whom the adolescent interacts with in the process of accessing health care 
services. Health care professionals range from medical doctors, nurses, pharmacists, 
psychologists, social workers, dieticians to other therapists whose goals is to improve the 
quality of life of the adolescents. 
 
Because of the scale-up of antiretroviral therapy, increasing numbers of HIV-infected 
children are living into adolescence. As these children grow and surpass the immediate 
threat of death, the issue of informing them of their HIV status arises (Fair, Osherow, Albright 
& McKenoe, 2014). In cases where disclosure was done earlier, it might have been partial 
disclosure, and as these adolescents start questioning their health, an informed conversation 
about HIV and AIDS becomes necessary. It is at this stage where the role of health care 
workers becomes significant in order to clarify issues and dispel misconceptions the 
adolescents might have about HIV and AIDS.  
 
Clinicians can improve the odds of youth succeeding with HAART treatment by incorporating 
psychosocial support into their practice. Furthermore, clinicians can enhance their 
psychosocial support by waiting to prescribe HAART to their adolescent clients until they 
have provided the appropriate preliminary groundwork (Brown & Lourie & Pao, 2000; Cluver 
& Garder, 2000). Psychosocial support is an essential component of ongoing care for all 
people living with HIV and AIDS. Psychosocial support is especially critical for children, 
creating the foundation from which they can establish their identity and place in society, 
manage their care and live positively, cope with challenges, and plan for their future (Lerner 
& Steinberg, 2009). The psychosocial needs of adolescents should preferably be identified 
based on needs specified by the adolescents.  
 
Although adolescents are treated according to adult treatment protocols, they have special 
needs resulting from their stage in social and emotional development. In traditional societies, 
adolescence is a time for preparation for marriage and having children. Adolescence is often 
a time for experimentation and risk taking, which includes sexual risk taking. Special effort 
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must be made to ensure that adolescents understand their own feelings and frustrations, 
and that they know how to protect themselves against STIs and unwanted pregnancy (Hope, 
2007). 
 
Counselling, peer education, and support groups are particularly important for HIV-infected 
adolescents. HIV-infected adolescents have the additional burden of needing to prevent the 
forward infection of others with HIV and AIDS. Such adolescents will need additional 
psychosocial support. Abstinence and delayed sexual debut are important aspects of sex 
education. However, adolescents who are sexually active or who are going to become 
sexually active need to have knowledge about their sexuality, condoms, partner negotiation 
skills, and youth-friendly services available and accessible to them to prevent unwitting 
onward transmission of HIV. Sexually active adolescents also need information and services 
to protect themselves against other STIs and unwanted pregnancy (Pettifor, Rees, 
Kleinschmidt, Steffenson, MacPhail, Hlongwane-Madikizela, Vermaak & Padian, 2005). 
 
Kidia, Mupambireyi, Cluver, Ndhlovu, Borok & Ferrand (2014) confirm that HIV-status 
disclosure to adolescents is distinct from disclosure to younger children and requires tailored 
age-appropriate guidelines. Disclosure to this age group in a health care setting may help 
overcome some of the barriers associated with caregivers disclosing in the home 
environment and make the HIV status seem more credible to an adolescent. The study of 
Kidia et al. (2014) also highlights the value of peer support among adolescents, which could 
help reduce the burden of psychosocial care on caregivers and health care workers. Health 
care workers and caregivers have minimal tailored guidance on how to approach the issue 
of disclosure to these adolescents, except that full disclosure is encouraged and that this 
should occur in developmentally appropriate stages.  
 
WHO recently developed new guidelines for HIV testing and counselling in adolescents; 
however, these guidelines do not address the issue of disclosure to adolescents and only 
deal with disclosure of adolescents‟ HIV statuses to others. This study uncovered 
approaches for disclosure to HIV positive adolescents that were highly varied and that did 
not follow any standard protocol. It was found that although health care workers encouraged 
parents to initiate disclosure to their children in the home environment, adolescents 
themselves preferred a clinical setting. In the clinic, adolescents had access to accurate 
information from health care workers and an environment that made the illness seem more 
real (Kidia et al., 2014). 
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Furthermore, Kidia et al. (2014) report that many adolescents did not learn much when they 
were first told about their illness. Instead, they turned to support from peers within the clinic, 
with whom they felt comfortable to share experiences and learn about HIV and AIDS. Health 
care workers explained that they did not have enough time to spend with each child, that this 
was how they work. They also assumed that adolescents were old enough to understand 
HIV related concepts and that they had been explained these concepts when they were 
younger, during post-test counselling.  
 
Therefore, rather than being involved in the first communications with adolescents about 
their illness, health care workers tended to play a delayed and auxiliary role in the 
adolescent disclosure process whereby they reinforced or corrected information that was 
communicated by caregivers at home: Health care workers encouraged caregivers to initiate 
disclosure in the home environment. Nevertheless, many adolescents preferred disclosure to 
take place in the presence of health care workers at the clinic because it gave them access 
to accurate information as well as an environment that made test results seem more 
credible. Adolescents learned more specific information about living with an HIV positive 
status and the meaning of that status from shared experiences among peers at the clinic 
(Close, 2006).  
 
According to Nichols (2013), what follows are some examples of ways in which 
psychologists, social workers and other professionals can assist with lessening the impact of 
these problems on the lives of affected young people. A neuropsychological evaluation can 
help detect problems with learning, attention, academic skills or other cognitive areas, as 
well as emotional issues such as depression or anxiety and describe the child or 
adolescent‟s strengths as well as weaknesses. Neuropsychologists and case managers can 
help identify the need for educational services and assist the youth or family in accessing 
them. They can also help youth obtain training in occupational and other life skills, an 
important aspect of making a successful transition to adulthood (Nichols, 2013). 
 
For infants, developmental evaluations can identify lags in the attainment of milestones and 
risk for further delays. The neuropsychologist may make recommendations for interventions 
such as speech, language, occupational therapy, special education services or counselling. 
If cognitive problems are related to psychiatric issues such as depression or attention deficit 
disorder, referrals for appropriate therapy and/or medication management can be made. In 
addition, new impairments suspected to be due to HIV and AIDS can be followed up to 
determine whether treatment changes are indicated. Individuals with HIV or their caregivers 
may wish to discuss such an evaluation with their health care providers if they have noticed 
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problems with school or daily functioning, emotional or behavioural issues, or cognitive 
changes such as memory problems or slow thinking (Cooper, et al., 2007).  
 
2.7 CHAPTER RÉSUMÉ 
 
This chapter discussed literature relevant to HIV and AIDS with regard to the 
conceptualisation of HAART treatment adherence with specific reference to adolescents. 
The impact of HIV and AIDS on the development of adolescents was elaborated. Impacts 
discussed included the psychosocial, the economic, and religious or spiritual effects on the 
adolescents. Factors contributing both to non-adherence and adherence to HAART 
treatment were also discussed. The goals and classes of HAART treatment, as well as their 
mechanism of actions, were further explained. Lastly, the experiences of caregivers and 
care workers were discussed. 
 
Adolescents with HIV and AIDS face challenges at the point when they are negotiating 
developmental challenges. Accordingly, to assist adolescents to effectively cope with this 
stage, many factors must be considered according to the viewpoint of the adolescent. Any 
attempt to support an adolescent would yield positive results once the experiences of 
adolescents are thoroughly considered. 
 
The chapter that follows will consider the theoretical framework employed in this study. 
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CHAPTER 3: THEORETICAL ORIENTATION 
 
3.1 INTRODUCTION 
 
The preceding chapter focused on a review of literature pertinent to this study. This chapter 
presents the theoretical framework used in the study. A theoretical framework consists of 
concepts, together with their definitions, and existing theories that are used for a particular 
study. The theoretical framework must demonstrate an understanding of theories and 
concepts that are relevant to the topic of the research and that will relate it to the broader 
fields of knowledge in the area of interest (Trochim, 2001). A common feature of theories is 
their proposition that attitudes and beliefs about a behaviour, as well as outcome 
expectancies, are critical determinants of health behaviour (Munro, Lewin, Swart & Volmink, 
2007). Applied to the study, the adolescents‟ beliefs and attitudes about HIV and AIDS and 
its relationship to adhering to HAART are presented. 
 
The theoretical framework strengthens the study in that it provides an explicit statement of 
theoretical assumptions that permit the reader to make a critical evaluation. The theoretical 
framework connects the researcher to existing knowledge. Guided by a relevant theory, it 
provides a basis for hypotheses and choice of research methods. Articulating the theoretical 
assumptions of a research study enables the researcher to address questions of why and 
how (Leshem & Trafford, 2007).  
 
Furthermore, a theoretical framework permits the study to move from simply describing a 
phenomenon observed to generalising about various aspects of that phenomenon. Having a 
theory helps one to identify the limits to those generalisations. A theoretical framework 
specifies which key variables influence a phenomenon of interest. It alerts the researcher to 
examine how those key variables might differ and under what circumstances. Theory in the 
social sciences is of value precisely because it fulfils one primary purpose – to explain the 
meaning, nature, and challenges of a phenomenon often experienced but unexplained in the 
world in which people live, so that they may use that knowledge and understanding to act in 
more informed and effective ways (USC LibGuide, 2014). 
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3.2 THEORETICAL MODELS 
 
In many fields, theories and propositions about concepts and relationships have been 
formulated to help give some kind of theoretical background about any study phenomena 
(Sinclair, 2007). For purposes of this study, the Health Belief Model and the bio-psychosocial 
model were applied to adolescents‟ experiences as regards adherence and non-adherence 
to HAART. Adolescence is a particularly vulnerable period for HIV-infected people in relation 
to mental health problems and engagement in high-risk behaviours, including non-
compliance with medical treatment. The bio-psychosocial model contributes to an 
understanding of the psychosocial challenges as well as protective influences promoting 
socio-emotional coping in HIV positive adolescents in order to inform mental health 
promotion and HIV prevention programming for this population in South Africa (Petersen et 
al., 2010). 
 
The Health Belief Model is a framework for explaining people‟s health-related behaviour, 
such as health care utilisation and adherence to a medical regimen (Polit & Beck, 2006). The 
model hypothesises that an individual‟s motivation to act depends on the perceived threat to 
their health and their belief that action will mitigate the threat. Individuals must first be 
convinced that they are personally susceptible, that the disease has serious consequences, 
that the recommended health action will prevent these consequences, and that the benefits 
of the new behaviour will outweigh the costs. Faced with a threat to their health, individuals 
evaluate all alternatives that can reduce the threat. To what extent do adolescents‟ 
understanding of personal susceptibility and seriousness of disease contribute to health-
promoting behaviour? 
 
Further, the bio-psychosocial model is juxtaposed alongside the Health Belief Model. The 
purpose is to render a comparative description of models in describing the unique 
experiences of adolescents as far as HAART is concerned. The bio-psychosocial model is a 
model that emphasises the biological, psychological and social changes of the adolescent 
developmental period (Williams et al., 2002). By utilising the bio-psychosocial model of care, 
illness impact on physical, psychological and social aspects of function is addressed and a 
wider range of therapeutic options offered that have meaning and relevance to the individual 
(Ryan & Carr, 2010).  
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The bio-psychosocial model is used in fields such as medicine, nursing, and sociology, and 
particularly in more specialist fields such as psychiatry, health psychology, family therapy, 
chiropractic, clinical social work, and clinical psychology. Moreover, the bio-psychosocial 
paradigm is also a technical term for the popular concept of the mind-body connection, 
which addresses more philosophical arguments between the bio-psychosocial and 
biomedical models, rather than their empirical exploration and clinical application (Sarno, 
2007). Behavioural issues, through their effect on adherence, often lie at the root of 
antiretroviral failure. If not addressed, these issues are likely to jeopardise the success of 
any future treatment; the bio-psychosocial model thereby enables behavioural issues to be 
contextualised (Soloway & Friedland, 2000). 
 
3.3 THE HEALTH BELIEF MODEL  
 
The Health Belief Model is probably the best-known model that attempts to explain health 
behaviour. It was developed in the 1950s to explain what makes healthy people engage in 
preventive behaviour – vaccination in particular. According to this model, individuals will 
choose to adopt behaviour depending on how much they value the goal and their belief that 
the behaviour will make it possible to achieve the goal. In other words, the key to 
understanding behaviour is to identify the person‟s health perceptions and beliefs (Mayer, 
2007).  
 
The Health Belief Model is still in its early stages. Adherence to this model is seen as a 
preventive health action. Patients will adhere more to treatment if they believe that they are 
susceptible to a disease they perceive as serious and that the treatment will be effective, 
provided the benefits outweigh the costs (Mayer, 2007). This model was appropriate for this 
study, as it provided a framework for understanding the adolescents‟ experiences of HAART 
and subsequent health-related decisions, such as adhering to treatment. As such, the extent 
to which adolescents‟ adherence to HAART is influenced by their personal perceptions about 
the seriousness of HIV and AIDS, their perceived benefits as opposed to perceived barriers, 
was explored. Adherence to HAART is also a challenge for HIV positive adolescents given 
their changing developmental stage, partial reliance on caregivers, interference with daily 
routines, peer affiliation needs and complex dosing regimens, all of which may lead to 
increased non-adherence and ultimately HAART resistance (Petersen et al., 2010). 
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The Health Belief Model is a psychological model that attempts to explain and predict health 
behaviours by focusing on the attitudes and beliefs of individuals. The Health Belief Model 
was developed in the 1950s as part of an effort by social psychologists in the United States 
Public Health Service to explain the lack of public participation in health screening and 
prevention programmes (for example, a free and conveniently located tuberculosis screening 
project). Since then, the Health Belief Model has been adapted to explore a variety of long- 
and short-term health behaviours, including sexual risk behaviours and the transmission of 
HIV and AIDS. The key variables of the Health Belief Model will be discussed (Rosenstock, 
Strecher, & Becker, 1994). 
 
The Health Belief Model was one of the first and remains one of the best-known social 
cognition models. It is a health behaviour change and psychological model developed by 
Irwin M Rosenstock in 1966 for studying and promoting the uptake of health services. The 
model was furthered by Becker and colleagues in the 1970s and 1980s. Subsequent 
amendments to the model were made as late as 1988 in order to accommodate evolving 
evidence generated within the health community about the role that knowledge and 
perceptions play in personal responsibility. Originally, the model was designed to predict 
behavioural response to the treatment received by acutely or chronically ill patients, but in 
more recent years, the model has been used to predict more general health behaviours. The 
Health Belief Model suggests that one‟s belief in a personal threat together with one‟s belief 
in the effectiveness of the proposed behaviour will predict the likelihood of that behaviour 
(Rosenstock et al., 1994). 
 
The Health Belief Model hypothesises that health-related action depends on the 
simultaneous occurrence of three classes of factors: 
 
 The existence of sufficient motivation (or health concern) to make health issues 
salient or relevant.  
 The belief that one is susceptible (vulnerable) to a serious health problem or to the 
sequelae of that illness or condition. This is often termed perceived threat. 
 The belief that following a particular health recommendation would be beneficial in 
reducing the perceived threat and at a subjectively acceptable cost. Cost refers to 
perceived barriers that must be overcome in order to follow the health 
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recommendation; it includes, but is not restricted to, financial outlays (Lizewski, 
2010). 
 
The Health Belief Model is a psychological model that attempts to explain and predict health 
behaviours. This is done by focusing on the attitudes and beliefs of individuals. The model 
was first developed in the 1950s by psychologists Hochbaum, Rosenstock and Kegels 
working in the U.S. Public Health Service. The model was developed in response to the 
failure of a free tuberculosis health screening programme. Since then, the Health Belief 
Model has been adapted to explore a variety of long- and short-term health behaviours, 
including sexual risk behaviours and the transmission of HIV and AIDS (Colby & Baker, 
1988; Rosenstock et al., 1994). Further developments allow the Health Belief Model to 
predict more general health behaviours. 
 
The Health Belief Model is a behavioural model that focuses on two important elements in 
health-related behaviour, namely, the threat of illness and the behavioural response to the 
perceived threat. In perceiving the threat, the individual considers his or her personal 
susceptibility to harm or illness, the perceived severity of the threat of the illness and the 
value of behaviour or line of action to overcome the perceived threat, and the barriers to the 
action (Feldman & Elliott, 1990). 
 
The Health Belief Model has identified many personal variables associated with adherence, 
namely, the patient‟s perception of susceptibility to disease, of the severity of the illness and 
of the efficacy of the proposed therapy. Other factors include perceptions of obstacles to 
adherence, attitudes towards therapeutic regimens, parents‟ and other significant adults‟ or 
peers‟ perception of the therapeutic regimen, and the level of influence of these people on 
the adolescent (Taddeo, Egedy, & Frappier, 2008).  
 
The other critical factor to consider when discussing adherence in teens is their 
developmental stage. Adolescence is a crucial time for physical, pubertal and cognitive 
maturation, in addition to psychosocial changes, including identity formation and the 
development of independent social relationships. During the teen years, the child will move 
from complete dependence to a more autonomous lifestyle. Adolescents are expected to 
take increasing responsibility for their health and health care. This gradual and progressive 
process is without major turmoil and rebellion for most young people (Taddeo et al., 2008). 
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Ayopo (2009) describes the Health Belief Model as proposing that health behaviour is a 
function of the individual‟s demographic characteristics, knowledge and attitudes. According 
to this model, a person must hold the following beliefs in order to change his or her 
behaviour: 
 
 The perceived susceptibility to a particular health problem, for example, „am I at risk 
of HIV and AIDS?‟ Adolescents in this study have already contracted HIV and AIDS. 
 The perceived seriousness of the health condition, namely, „How serious is HIV and 
AIDS? 
 The perceived benefits of specific behaviour, for example, regarding HAART 
adherence – „is it effective?‟ 
 Clues to action, namely, witnessing the illness or death of a close family member due 
to HIV and AIDS. 
 The barriers to taking action, for example, “I don‟t like taking HAART.” 
 
Proponents of this model argue that the belief elements produce in an individual some 
psychological readiness to act in the face of perceived threat to one‟s health (Becker, 1974). 
Specific factors are known that seem to influence psychological readiness, for example, peer 
pressure, which may be relevant in the case of adolescents. HIV and AIDS education, 
therefore, must build a sense of personal susceptibility to harm when educating adolescents 
about unsafe behaviour. It is believed based on this model that educational efforts must 
produce in recipients the belief that it is indeed in their best interest to change their ways of 
behaving, including adherence to HAART (Ayopo, 2009). 
 
The Health Belief Model is a framework for motivating people to take positive health actions 
that use the desire to avoid negative consequences as the prime motivation. The underlying 
concept of the original Health Belief Model is that health behaviour is determined by 
personal beliefs or perceptions about disease and strategies to decrease its occurrence. 
Personal perception is influenced by a whole range of intrapersonal factors affecting health 
behaviour (Hochbaum, 1958). The Health Belief Model can be applied to a variety of health 
behaviours. Interventions using this model usually aim to influence the „perceived threat of 
disease‟ variable and hence change the susceptibility/severity balance. The main way of 
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doing this tends to be directing information that has emotional appeal or contains a strong 
fear or emotional response (Corcoran, 2013). 
 
The Health Belief Model may be applied in many psychological and medical fields in order to 
help determine and come to an overall understanding of one‟s health thoughts, behaviours, 
and his or her wellness as a conclusion of these. Applying this model can provide context to 
many socially spread illnesses such as Influenza, STDs, and other contagions. The model 
also provides individual context of health behaviours and the perceived need or presence of 
health screenings, risky behaviours, and compliance to medication that also serve as 
preventative measures. 
 
The Health Belief Model, developed by researchers at the U.S. Public Health Service in the 
1950s, was inspired by a study of why people sought X-ray examinations for tuberculosis. 
The original model included these four constructs: 
 
 Perceived susceptibility (an individual‟s assessment of their risk of getting the 
condition). The greater the risk is of getting a certain medical condition, the more a 
person will engage in behaviours to decrease the risk. That is why people get 
vaccinations to prevent disease, brush their teeth to prevent gum disease, and work 
out to stay healthy. 
 Perceived severity (an individual‟s assessment of the seriousness of the condition 
and its potential consequences). For example, getting the flu seems like a fairly minor 
thing for most people, just bed rest for a few days and one is all better again. 
However, for people who cannot afford to take a few days off work or for people who 
already have a severity, the perceived severity will vary greatly between them. 
 Perceived barriers are the most influential construct because they determine if 
someone will adopt a new behaviour or not, depending on whether the benefits of the 
behaviour outweigh the consequences. 
 Perceived benefits (an individual‟s assessment of the positive consequences of 
adopting the behaviour). This is why people eat fruits and vegetables, use 
sunscreen, or get health screenings. Perceived benefits are opinion-based; not 
everyone adopts the same behaviours. A person only adopts behaviours that they 
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think will decrease the chance of getting a disease that they think they are more 
susceptible to (Rosenstock et al., 1994). 
 
Subsequent constructs include the following: 
 Underlying medical condition such as getting the flu could be a very serious thing. 
Kip (2008) presents a variant of the model as inclusive of the perceived costs of 
adhering to prescribed intervention as one of the core beliefs. Constructs of 
mediating factors were later added to connect the various types of perceptions with 
the predicted health behaviour. 
 Demographic variables (such as age, gender, ethnicity, occupation). 
 Socio-psychological variables (such as socio-economic status, personality, coping 
strategies). 
 Perceived efficacy (an individual‟s self-assessment of ability to successfully adopt the 
desired behaviour). 
 Cues to action (external influences promoting the desired behaviour may include 
information provided or sought, reminders by powerful others, persuasive 
communications, and personal experiences). 
 Health motivation (whether an individual is driven to stick to a given health goal). 
 Perceived control (a measure of level of self-efficacy). 
 Perceived threat (whether the danger imposed by not undertaking a certain health 
action recommended is great). 
 
The prediction of the model is the likelihood of the individual concerned undertaking 
recommended health action (such as preventive and curative health actions). Other reasons 
for this will be shown (Hayden, 2009). 
 
Simultaneous occurrence of three factors in Table 3.1 leads to adherence (Marandu, 2009). 
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Table 3.1: Summary of the Concepts of the Health Belief Model Identified for the Study 
These factors are the 
existence of sufficient 
motivation (or health 
concern) to make health 
issues salient  
The belief that one is 
susceptible to a serious 
health problem, that is, a 
sense of a perceived threat 
The belief that following a 
particular health 
recommendation would be 
beneficial in reducing the 
perceived threat at an 
acceptable cost, that is, the 
perceived barriers that must 
be overcome in order to 
follow the health 
recommendation 
Perceived self-efficacy for 
adherence to HAART by 
adolescents 
Perceived seriousness or 
severity of HIV and AIDS 
Perceived benefits of 
HAART by adolescents 
 
Perceived quality of life by 
adolescents due to HAART 
 Perceived barriers that 
interfere with adherence to 
the treatment regimen 
 
Perceived benefits of adherence to HAART by adolescents are generally associated with 
higher likelihood of adherence. If patients understand the purpose of the treatment and why 
they are taking it, they will be more inclined to do better with adherence. Furthermore, 
patients must perceive that there are threats to their health or believe that their health is at 
risk and that the events are potentially serious in terms of pain or discomfort, time lost to 
work, or economic difficulties (Feldman & Elliott, 1990).  
 
The Health Belief Model states that the perceptions of people‟s health behaviours are 
influenced by at least three factors. Some of these factors include general health values, 
which include interests and concerns about health, and beliefs about the consequences of 
the health problems. Once people perceive a threat to their own health and are 
simultaneously cued to action, their perceived benefits outweigh perceived barriers. These 
individuals are more likely to undertake the recommended preventive health actions than 
people without such perceptions. Thus, individuals must perceive or believe that the benefits 
of visiting the health care providers outweigh the costs (Kip, 2008). 
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The Health Belief Model is based on a sequence of events that occur in order for behaviour 
to change. It attempts to predict health-related behaviours regarding certain belief patterns. 
This model is used in explaining and predicting preventive health behaviours, as well as 
sick-role and illness behaviours or clinic use. Preventive health behaviours and sick-role 
behaviours with recommended medical regimens usually follow professional diagnosis of an 
illness and clinic use, including physicians‟ visit for a variety of reasons. People‟s motivation 
to undertake health behaviour is divided into three main categories: individual perceptions, 
modifying behaviours, and the likelihood of action (Kip, 2008). 
 
The Health Belief Model has been frequently used as the major theoretical or organising 
framework for explaining and predicting adherence to health and medical care 
recommendations. Knowledge and attitudes about AIDS are predisposing factors for 
behaviour change. Knowledge is one of the modifying variables mentioned in the Health 
Belief Model. These frameworks seek to identify the constellation of constructs that influence 
adherence and the manner in which these constructs coexist and influence one another. The 
development and evaluation of theoretical models have critical implications for intervention 
development and clinical practice. In practice, many efforts to understand the dynamics of 
HAART adherence have involved the application of health behaviour models developed 
outside of the domain of ARV adherence (Pope et al., 2009).  
 
As with HIV prevention programmes such as condom use, delay of sexual debut, and 
treatment of STIs, the conventional wisdom associated with the way HAART adherence is 
currently conceptualised is that given the facts and presented with alternatives, people will 
adhere to treatment. In large measure, this approach is encapsulated by the Health Belief 
Model, which states that health-related action depends on the simultaneous occurrence of 
three factors (Rosenstock et al., 1994). These factors are the existence of sufficient 
motivation (or health concern) to make health issues salient; the belief that one is 
susceptible to a serious health problem, that is, a sense of a perceived threat; and the belief 
that following a particular health recommendation would be beneficial in reducing the 
perceived threat at an acceptable cost, that is, the perceived barriers that must be overcome 
in order to follow the health recommendation (Marandu, 2009). 
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The Health Belief Model is an extensively studied model of health behaviour change. It 
posits that individuals must perceive themselves to be at risk of the health threat before they 
take action to reduce risky behaviours or to engage in healthy alternative behaviours. 
Additionally, the model postulates that an individual‟s actions are based on beliefs. It 
underlies main factors for decision-making such as perceived vulnerability or susceptibility, 
perceived severity of the outcomes or conditions, perceived efficacy or benefits of control 
measures, and the perceived barriers to prevention. It has been extensively used in 
behavioural sciences to predict behaviours and to design behavioural prevention 
programmes. Patients‟ beliefs about the disease and medications are crucial to their 
intentional adherence behaviours (Kip, 2008). 
 
3.3.1 The Health Belief Model Critique 
3.3.1.1 Strengths of the HBM 
HBM‟s use of simplified health-related constructs results in easier implementation, 
application and testing (Conner, 2010). The HBM provides a useful theoretical framework for 
investigating the cognitive determinants of a wide range of behaviors. It focuses researchers‟ 
and health care professionals‟ attention on variables that are prerequisites for health 
behavior. Hence, it has formed a basis for many practical interventions across a range of 
behaviors (Jones, Jones & Katz, 1987). HBM‟s flexibility makes the HBM adaptable and 
applicable to many health behavior and population groups. 
 
3.3.1.2  Limitations of the HBM 
The health benefit critique has its own limitations, among which are: 
 Common-sense framework simplifies health-related representational processes. 
 Theoretical components are broadly defined; therefore, different operationalisations may 
not be strictly comparable. 
 Lack of specification of a causal ordering. 
 Neglects social factors. 
 
Despite the success of HBM in informing and predicting a range of behaviors with health 
outcomes, previous research shows that HBM‟s determinants are insufficient predictors of 
behavior (Norman & Brain, 2005). On average, HBM‟s determinants predict approximately 
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20% of variance in healthy behavior, leaving 80% of the variance unaccounted for 
(Carpenter, 2010). 
 
The Health Belief Model has been applied to diverse sets of health behaviours. Research 
reviewed in this study suggests difficulties of the model in predicting future behaviours, 
especially behaviours related to HIV. Prominent features of adolescence that influence HIV 
related risk behaviours are discussed: cognitive immaturity, struggle for psychological 
autonomy, peer influences, and physical development. It is suggested that a model is 
needed to guide prevention efforts and that these adolescent-specific factors need to be 
incorporated into any such model (Brown, DiClemente & Reynolds, 1991).  
 
3.4 THE BIO-PSYCHOSOCIAL MODEL 
 
The bio-psychosocial model was developed at Rochester decades ago by Drs. George 
Engel and John Romano. While traditional biomedical models of clinical medicine focus on 
pathophysiology and other biological approaches to disease, the bio-psychosocial approach 
emphasises the importance of understanding human health and illness in their fullest 
contexts (Engel, 1977). The bio-psychosocial approach systematically considers biological, 
psychological, and social factors and their complex interactions in understanding health, 
illness, and health care delivery (Engel, 1980; Nassir Ghaemi, 2009). Recognition that 
understanding a patient‟s beliefs, feelings, thoughts and health behaviour is necessary to aid 
in understanding that the patient‟s condition has led to a move from a disease model to a 
bio-psychosocial model of care, which acknowledges the importance of psychological, social 
factors, as well as the physical impact of living with a chronic disease (Dogar, 2007; Ryan & 
Carr, 2010). 
 
The bio-psychosocial model is derived from the general systems theory. The biological 
system emphasises the anatomical, structural and molecular substrate of disease and its 
effects on the patient‟s biological functioning. The psychological system emphasises the 
effects of psychodynamic factors, motivation and personality on the experience of illness and 
the reaction to it. The social system emphasises the cultural, environmental and familial 
influences on the expression and the experience of illness. Psychosocial well-being result 
from a complex interaction of all these factors (Green & Shellenberger, 1991). 
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Engel (1977) describes the bio-psychosocial model as a general model or approach, positing 
that biological, psychological (which entails thoughts, emotions, and behaviours) and social 
(socio-economical, socio-environmental, and cultural) factors all play a significant role in 
human functioning in the context of disease or illness. Indeed, health is best understood in 
terms of a combination of biological, psychological, and social factors rather than purely in 
biological terms. The bio-psychosocial approach is of the view that well-being is as the result 
of the interaction of biological, psychological and social factors (Green & Shellenberger, 
1991) This is in contrast with the biomedical model of medicine that suggests that every 
disease process can be explained in terms of an underlying deviation from normal function 
such as a virus, gene or developmental abnormality, or injury (Engel, 1977).  
 
Engel (1977) submitted that each system affects and is affected by every other system. He 
further asserts that medical illness is a direct result of a person‟s psychological or 
sociocultural makeup, but, rather encourages a comprehensive understanding of disease 
and treatment. The patient-doctor relationship is a critical component of the bio-psychosocial 
model. Physicians must have both the working knowledge of the patient‟s medical status and 
be familiar with how the patient‟s individual psychology and sociocultural milieu affect their 
medical condition (Engel, 1977; Sadock & Sadock, 2007). 
 
The bio-psychosocial model is better established in psychiatry and health care for medically 
unexplained symptoms. This model emphasises an integration of mind, body and the social 
context of the illness. The psychological and social factors contribute to disease; therefore, 
the illness cannot be addressed in isolation without tackling the issues in the social and 
psychological sphere. HIV and AIDS is a medical condition which is impacted by 
psychological and social factors. Three types of psychological and social factors relevant to 
medical disorders can broadly be distinguished. These are adverse life experiences, such as 
life events and chronic stressors; psychological dispositions or traits, which are either 
protective or increase vulnerability to stress; and factors in the social environment such as 
social support and isolation. It is widely acknowledged that there is an interplay between 
exposure to adversity and psychosocial protective factors, such that the impact of negative 
experiences may be offset by adequate coping resources (White, 2005). Adolescence and 
HIV and AIDS form part of adverse life experiences and chronic stressors; that being the 
case, the interplay of medical illness and psychosocial factors cannot be underestimated. 
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It is important to note that the bio-psychosocial model does not provide a straightforward, 
testable model to explain the interactions or causal influences (that is, amount of variance 
accounted for) by each of the components (biological, psychological, or social). Rather, the 
model has been a general framework to guide theoretical and empirical exploration, which 
has amassed a great deal of research since Engel‟s 1977 article. McLaren (1998) concurs 
that the bio-psychosocial model enables the physician to extend the application of the 
scientific method to aspects of everyday practice and patient care heretofore not deemed 
accessible to a scientific approach. The biomedical model can make provision neither for the 
person as a whole nor for data of a psychological or social nature.  
 
The bio-psychosocial model is a model that emphasises the biological, psychological and 
social changes of the adolescent developmental period. Adolescence has historically been a 
developmental period of relative neglect with respect to research on both mental and 
physical health intervention and outcome (Williams et al., 2002; Sendangala, 2011). 
Adolescence is a transitional developmental period between childhood and adulthood that is 
characterised by more biological, psychological, and social role changes than any other 
stage of life except infancy (Holmbeck & Kendall, 2002). Other authors (Feldman & Elliot, 
1990; Fargher & Dooley, 2010) go on to describe adolescence as encompassing physical 
and social changes that occur during puberty as maturation begins and social interactions 
become increasingly centred on members of the opposite sex.  
 
The fundamental assumption of the bio-psychosocial model is that any health or illness 
outcome is a consequence of the interplay of biological, psychological and social factors. 
Naidoo (2011) agrees that this approach enables those with HIV and AIDS to develop 
strategies for coping; it helps to improve adherence to treatment, and it helps to prevent 
transmission of the disease and suicide. In adolescence, just as there is a burgeoning of 
sexuality given the changing body, so there may be an increase of aggressive feelings. It is 
during this period that adolescents begin questioning what medication they are taking and 
why they have to take such medication. General rebellion towards authority might include 
rebelling against taking such medication, thereby affecting adherence levels and 
subsequently compromising their health. Throughout peoples‟ lives, they have to deal with 
feelings of aggression and how to engage with them; however, during adolescence, such 
levels of aggression might be detrimental to the adolescent (Fargher & Dooley, 2010). 
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Moreover, there are two transition points during this single developmental period: the 
transition early adolescence from childhood and the transition to adulthood from late 
adolescence (Williams et al., 2002; Steinberg, 2008). Given the magnitude of such changes, 
it is not surprising that there are also significant changes in the types and frequency of health 
problems and psychological disorders during this developmental period, as compared to 
during childhood (Williams et al., 2002).  
 
During adolescence, a multifaceted developmental transition is set in motion; biological, 
psychological and social forces intersect as the individual advances from childhood towards 
adulthood. This transition is rarely smooth or straightforward; adolescence is perplexing and 
disquieting for many young people (Feldman & Elliott, 1990), without throwing in the 
challenge of coping with HIV and AIDS. While no single model has taken precedence, a 
large body of empirical literature has identified socio-cognitive (the psycho-social aspect of 
Engel‟s model) variables that appear to influence engagement in healthy behaviours and 
adhere to prescribed medical regimens, such as self-efficacy in chronic diseases such as 
type 2 diabetes, cardiovascular disease. By default, this could be applied to understanding 
adherence to HAART in adolescents living with HIV and AIDS (Williams et al., 2002). 
 
Some thinkers see the bio-psychosocial model in terms of causation. With this 
understanding, the biological component of the bio-psychosocial model seeks to understand 
how the cause of the illness stems from the functioning of the individual‟s body. The 
psychological component of the bio-psychosocial model looks for potential psychological 
causes for a health problem such as lack of self-control, emotional turmoil, and negative 
thinking. The social part of the bio-psychosocial model investigates how different social 
factors such as socio-economic status, culture, poverty, technology, and religion can 
influence health (Dogar, 2007). HAART is essential in the treatment of HIV and AIDS; 
however, a holistic approach to HIV and AIDS management is necessary. With that said, 
applying the bio-psychosocial approach provides a global view of the experiences of 
adolescents as far as HAART is concerned. 
 
Bio-psychosocial approach can be seen as the multi-pronged approach applied when it 
comes to HIV and AIDS and HAART management. Naidoo (2011) is of the same mind that 
all doctors, regardless of where they practice, have an essential role to play in the treatment 
and management of HIV and AIDS-infected patients. This management requires that both 
the doctor and patient have accurate knowledge and positive attitudes regarding the 
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disease; a multidisciplinary holistic approach can be considered and both pharmacological 
and non-pharmacological management can be instituted (Naidoo, 2011).  
 
Some of the non-pharmacological types of management include counselling on adherence 
to treatment, nutrition, side effects of medication, psychosocial issues, family and support 
systems. Counselling in HIV and AIDS has become a core element in a holistic model of 
health care with psychological and emotional support recognised as being integral to patient 
management and being essential at all stages of the HIV and AIDS infection. Despite the 
enormous benefits derived from HAART, the issue of non-adherence to treatment still 
remains unresolved. Adherence to medication and treatment is vital because it is one of the 
most important patient-enabling factors that is related to virological failure and drug 
resistance. Many factors seem to impact negatively on adherence such as the treatment 
regimen (complexity, heavy pill burden and food requirements), difficulty in taking 
medication, access to medication, side effects, stigma, forgetting to take pills, psychosocial 
issues, the disease itself, and concomitant substance abuse (Naidoo, 2011). 
 
Another important aspect in HIV and AIDS management is nutrition; as a result, the role of 
the dietician is important. Critical questions such as how well the antiretroviral drugs work in 
people who do not have access to adequate nutrition and the role of vitamins and other 
supplements in HIV and AIDS management are emerging as HIV and AIDS treatment 
becomes increasingly available in the poorest parts of the world. The role of micronutrients 
in immune function and infectious disease is well established. Researchers have found that 
people with HIV and AIDS are more likely to show signs of micronutrient deficiencies as 
compared to uninfected people. Various micronutrients have been linked to changes in the 
rate at which HIV infection progresses to AIDS. Without adequate food or the right nutrition, 
taking ARV drugs can be painful, causing people simply not to take the drugs (Pontali, Feasi, 
Toscanini, Bassetti, De Gol, Nuzzolese, & Bassetti, 2001; Naidoo, 2011).  
 
When chronic illnesses are congenital or begin in childhood, the manner in which the 
transition from childhood to adolescence to young adulthood is negotiated has significant 
implications for disease outcomes throughout the remainder of the lifespan. Given the 
unique developmental challenges of adolescence, an effective and theoretically sound 
approach to adolescent health psychology research and treatment must be firmly grounded 
in a developmental framework. A bio-psychosocial model of adolescent development is one 
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such framework that can inform primary, secondary, and tertiary prevention research and 
interventions targeting adolescents (Williams et al., 2002). 
 
Dietary advice should be tailored to individual circumstances; however, in general, the 
recommendations for people living with asymptomatic HIV and AIDS infection should be to 
follow a healthy, well-balanced diet. For some, appropriate food required to be taken 
alongside medication may not be easily affordable. The government has attempted to 
respond to some of these concerns to a certain extent. Many types of support systems are 
available in South Africa, ranging from simple availability of food parcels to disability grants, 
social grants and pension grants. South Africa‟s social grants target the elderly, disabled 
people, poor families with children, and citizens who are incapacitated and unable to work 
due to illness (Kagee, 2007). 
 
The bio-psychosocial model of health is based in part on the social cognitive theory. The 
model implies that treatment of disease processes requires that the health care team 
address biological, psychological and social influences upon a patient‟s functioning. In a 
philosophical sense, the bio-psychosocial model states that the workings of the body can 
affect the mind and the workings of the mind can affect the body. This means both a direct 
interaction between mind and body as well as indirect effects through intermediate factors. 
The bio-psychosocial model presumes that it is important to handle the three together, as a 
growing body of empirical literature suggests that patient perceptions of health and threat of 
disease, as well as barriers in a patient‟s social or cultural environment, appear to influence 
the likelihood that a patient will engage in health-promoting or treatment behaviours, such as 
medication taking, proper diet or nutrition, and engaging in physical activity (DiMatteo, 
Haskard & Williams, 2007). 
 
3.4.1 The Bio-psychosocial Model Critique 
3.4.1.1 Strength of the BPS Model 
The fundamental assumption of the bio-psychosocial model is that any health or illness 
outcome is a consequence of the interplay of biological, psychological and social factors. 
This approach enables people with HIV and AIDS to develop strategies for coping; it helps to 
improve adherence to treatment and it helps to prevent transmission of the disease and 
suicide (Naidoo, 2011). 
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3.4.1.2 Limitation of the BPS Model 
Some critics point out that a question of distinction and a question of determination of the 
roles of illness and disease run against the growing concept of the patient medical 
tradesperson partnership or patient empowerment, as „bio-psychosocial‟ becomes one more 
disingenuous euphemism for psychosomatic illness. This may be exploited by medical 
insurance companies or government welfare departments that are eager to limit or deny 
access to medical and social care. Some psychiatrists see the bio-psychosocial model as 
flawed, in either formulation or application to de-stigmatise mental health (Epstein & Borrell - 
Carrio, 2005). 
 
3.5 CHAPTER RÉSUMÉ 
 
The chapter explored the development of HIV and AIDS health promotion based on two of 
the existing health behaviour theories, namely, the Health Belief Model and the bio-
psychosocial model. It then applied it to the description of HAART with respect to 
adolescence.  
 
Adolescence is a developmentally challenging period, even without adolescents having to 
deal with adherence to chronic treatment. Adolescents living with HIV and AIDS need to 
successfully navigate the world of HAART adherence as well as other developmental 
challenges in order to achieve optimal adulthood. Adolescents find adherence to HAART to 
be particularly challenging as they enter a stage of life when they become self-aware and 
want to fit in with their peers. 
 
The Health Belief Model and the bio-psychosocial model jointly applied offer a relatively 
comprehensive description of adolescents‟ experiences of HAART, without necessarily 
overemphasising one area at the expense of another. Such was the focus of this chapter. 
 
The next chapter deals with the research design and methodology deemed appropriate for 
this study. 
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CHAPTER 4: RESEARCH DESIGN AND METHOD 
 
4.1 INTRODUCTION  
 
The foregoing chapter discussed the theoretical framework that was seen to be suitable for 
this study. This chapter presents the research design and methods used in this study. This is 
basically the research methodology, which is the logical, theoretical analysis of the methods 
applied to a field of study entailing the conjectural analysis of procedures and doctrines 
related to a branch of knowledge (Howell, 2013). Usually, it incorporates concepts such as 
paradigm, theoretical model, phases and quantitative and/or qualitative techniques. It 
discusses data analysis, ethical considerations and steps taken by the researcher to ensure 
trustworthiness of the research. Data was collected using semi-structured interviews as well 
as questionnaires. Data analysis consisted of both quantitative and qualitative methods in 
order to strengthen the study. The aim of the study was to explore the nature of experiences 
of adolescents who are on long-term HAART treatment in Tembisa Hospital, Gauteng 
province. 
 
4.2 RESEARCH APPROACH 
 
Research approach and methodology are often used interchangeably. In this study, the term 
research approach was selected. Creswell (2014) defines research approach as a plan and 
procedure for research that span the steps from broad assumptions to detailed methods of 
data collection, analysis, and interpretation. The overall decision should be the philosophical 
assumptions the researcher brings to the study, procedures of inquiry (called research 
designs) and specific research approaches of data collection, analysis and interpretation 
(Goodman, 2008). 
 
The study primarily applied a qualitative approach to capture the experiences of adolescents 
who were undertaking HAART as they personally experience it, in line with the aim of the 
study, which is to explore the experiences of adolescents who are on long-term HAART. 
This approach is most suitable for addressing the why questions to explain and understand 
issues or the how questions that describe processes or behaviour (Hennink, Hutter, & 
Bailey, 2011). Qualitative approaches are also particularly suitable for examining sensitive 
topics, as the process of rapport building provides a comfortable atmosphere for participant 
disclosure. 
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Only profiles of the health care professional participants‟ (HCPPs) demographic 
characteristics, work experience, qualifications, specific profession and experience tenure 
with adolescents on HAART were measured by quantitative approaches. Furthermore, the 
grades and ages of adolescent participants were also measured by quantitative approaches. 
The strengths of quantitative approaches are a greater precision of measurement, as they 
are tied in with explicit theories of psychological measurement and statistics; the ability to 
make comparisons, both among the HCPPs and across the study; and the ability to test 
causal hypotheses using experimental designs (Cooper et al., 2012). 
 
For research to be organised and systematic, a researcher needs to punctuate a specific 
angle from which he or she will study the phenomena of interest, and this punctuating is 
referred to as research approach (Punch, 2014). This study sets a systematic and organised 
effort to explore the experiences of adolescents with specific regard to their HAART 
treatment, how their HAART treatment has impacted and influenced their world view, thus 
the choice of a qualitative approach. For this study, only the qualitative approach will be 
discussed.  
 
4.3 RESEARCH DESIGN  
 
The study employed a qualitative methodology, as it was suitable because it needed to find 
an explanation of experiences in non-numeric form. Qualitative data analysis is a non-
mathematical analytical procedure that involves examining the meaning of people‟s words 
and actions (Haslam & McGarty, 2003). In this study, qualitative methods assisted in 
capturing the experiences of adolescents and HAART as the adolescents personally 
experienced the HAART treatment. Furthermore, the study was an exploratory design using 
a phenomenological approach. This approach was based on the assumption that to 
understand humans, it is best to discover their meaning world through interacting directly 
with them.  
 
Phenomenology is an investigative method that focuses on what individuals have actually 
experienced, how they personally interpret the situation and the way they narrate it in their 
own words (Creswell, 1998; Patton, 1990). Its major concern is to explore phenomena. It is 
also a philosophical effort that deals with human and social sciences such as psychology 
(and sociology) with regard to attitude, approach, design, strategy, method, or technique with 
lived experience (Edwards, 2001). Additionally, it facilitates an understanding of lived 
experiences in daily life. Thus, phenomenology advances the ways in which people make 
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sense of the social world and its political organisations and affiliations (Gubrium & Holstein, 
2000). 
 
Phenomenology reveals the phenomenon and is interventionistic, consciously suspending 
any assumptions in order to allow original reality to emerge or alternatively empathise with 
(or enter into) the world of another (as in existential psychotherapy) (Edwards, 2001). People 
intervene in one another‟s worlds and influence one another in that, as human beings, 
individual unique existences are essentially intersubjective and radically social. People 
continuously change social constructions and continuously influence one another through 
interpersonal encounters and interventions in one another‟s worlds. 
 
4.4 RESEARCH SETTING 
 
The study took place at a provincial tertiary hospital, in Tembisa, which is a public health 
facility. The collection of data was done in the field at the site where participants experience 
some of the issues under study (Polit & Beck, 2006; Creswell, 2014). Furthermore, the 
interaction entailed an up-close information gathering by actually talking directly to people, 
through the use of in-depth interviews (Boyce & Neale, 2006; Creswell, 2014).  
 
The area of the study was influenced by the high rate of non-adherence to HAART at the 
Masakhane Clinic of Tembisa Hospital, in Gauteng, where the researcher is employed as a 
clinical psychologist. While some adolescents are known to be adherent to their treatment, 
there is a high percentage of adolescents who struggle with adherence to HAART and as a 
result were referred to the psychology department for psychological intervention. The 
rationale for conducting this study in Gauteng was that the study inevitably provides results 
that may enable the multi-disciplinary team at Masakhane Clinic, Tembisa Hospital, to 
design suitable interventions to address the specific problems of non-adherence. 
 
4.4.1 Population and Sample Frame 
 
A population is simply every possible case that could be included in a study as a participant. 
However, the population is often too large to undertake; therefore, it is often a practice that a 
representative group, called a sample, needs to be selected (Spata, 2003). Sekaran (2003) 
defines a population as the entire group of people, events, or things of interest that the 
researcher wishes to investigate. The study was conducted among adolescents accessing 
public health facilities within the context of tertiary hospitals in the Gauteng province of South 
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Africa. The focal area was the Tembisa Provincial Tertiary Hospital in Ekurhuleni 
Metropolitan Municipality. The main aim of the study was to explore and describe the factors 
contributing to adherence and non-adherence to prescribed HAART treatment of individuals 
on treatment. Tembisa Hospital is a designated HAART roll-out hospital. For the purpose of 
HAART roll-out, the hospital has designated a section of the hospital, called Masakhane 
Clinic, as their roll-out point. According to Masakhane Clinic, the number of people receiving 
HAART is increasing significantly per month, ranging from between 2,000 and 3,000 patients 
– about 600 of these comprise adolescents (Isithembiso, 2011). These adolescents are thus 
the key focus of this study. Bailey (1994) concurs that a sample must always be viewed as 
an approximation of the whole rather than as a whole in itself. 
 
 
Figure 4.1: Participants and Mutually Influential Relationship 
 
The population of interest was adolescents who were on HAART treatment. To optimise a 
complex picture and enhance confidence in the findings of the research problem under 
study, a report from multiple perspectives was necessary. Participants of mutual influential 
relationships with the adolescents, as shown in Figure 4.1, in the context of the research 
study were approached. This process is referred to as triangulation. In this study, data 
triangulation was applied to collect data through several sampling strategies as well as 
through a variety of people (Denzin, 1970). 
 
Therefore, identifying the many factors involved in adolescent HAART experiences, it 
became crucial to include the experiences, impression, and reactions of parents, guardians, 
Parents/ 
Caregivers/ 
Guardians 
Health Care 
Workers 
Adolescents  
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caregivers (PGCPs) as well as HCPPs‟ expert observations on experiences, so as to arrive 
at a relatively holistic picture. The sampling frame, which entailed the subgroup from which 
the sample for this study was drawn (Zikmund & Babin, 2012), consisted of adolescents who 
were on HAART treatment at the Masakhane Clinic. PGCPs were included to give a broader 
perspective of the experiences of adolescents‟ HAART. Furthermore, HCPPs who deal with 
HAART were included so as to broaden the scope of experiences. Study populations 
comprising elements involved are too many in number and thus may be impossible to study. 
By making use of a variety of participants, the possibility of finding underlying constants or 
themes in the many forms of expression the experience takes was greatly increased. 
 
4.4.2 Inclusion Criteria 
 
Thinking about sampling requires thinking about inclusion and exclusion criteria for this 
study‟s sample. This entails who or what people want to hear from (Braun & Clarke, 2013). 
 
The inclusion criteria for the sample of adolescent participants were: 
 
 Adolescent participants must be aged between 12 and 19, inclusive. 
 Adolescent participants must have been on HAART for at least two years. 
 
The inclusion criteria for the sample of PGCPs were: 
 
 The participant should be a parent, guardian or caregiver to an adolescent on 
HAART for at least two years. 
 
The inclusion criteria for the sample of HCPPs were: 
 
 HCPPs should have received HAART-specific training. 
 HCPPs should be employed at the Masakhane Clinic.  
 HCPPs must have working experience with adolescents on HAART. 
 
4.4.3  Sampling 
 
Sampling is the scientific process researchers use to select cases for inclusion in a research 
study (Zechmeister, Zechmeister, & Shaughnessy, 2000). A sample is a subset of the 
population. In other words, some, and often not all elements of the population, would form 
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the sample. A sample is thus a subgroup or a subset of the population. By studying the 
sample, the researcher can draw conclusions that would provide light about the population of 
interest. Studying a sample rather than the entire population is less costly and mostly 
manageable. There is less fatigue and fewer errors in collecting data using a sample 
(Sekaran, 2003).  
 
Non-probability samples are used when it is difficult to identify all potential cases in the 
population (De Vos, Strydom, Fouche, & Delport, 2002; Sekaran, 2003). Convenience 
samples (prominently used in psychological research), purposive samples (selected 
deliberately to meet an often non-statistical goal), and quota samples (in which interviewers 
recruit and interview an assigned number of cases from each of several subgroups) were 
suitable for this study (Cooper et al., 2012). A non-probability sampling method can be used 
when no convenient sampling frames of the population are available or when time or cost 
restrictions make the surveying or a widely dispersed population impractical (Mook, 2001). 
 
Purposive or judgemental sampling is an acceptable sampling approach for special 
situations. It is useful in selecting members that are difficult to reach, such as a specialised 
population in sole possession of the information, knowledge and/or experience required by 
virtue of belonging to the targeted population (Cooper et al., 2012). Judgemental sampling 
involves the choice of participants who are in the best position to provide the information 
required.  
 
The sample was purposively selected, as the primary participants were patients attending 
HAART clinic at the hospital, with the secondary participants being the HCPPs and PGCPs. 
A secondary participant is someone who was not initially designated as a primary participant 
in a study, but about whom information is gathered from persons who are primary 
participants. Secondary participants are created when individuals provide information about 
other people whom they know or to whom they are related (Given & Saumure, 2008). In light 
of that, the purposive sampling method was the most convenient and appropriate to use. 
Furthermore, Sekaran (2003) confirms that having gone through the experiences and 
process of HAART themselves, the adolescent participants (together with PGCPs and 
HCPPs) were expected to have reliable knowledge and perhaps be able to provide good 
information to the researcher. Thus, the judgemental sampling design was used because a 
limited category of people had the information that was sought. 
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4.4.4 Sample Size 
 
The study needed to limit the number of cases in a sample or the size of the sample. Sample 
size explains how large or small the research interviewees should be. In this study, 
identifying a sample size large enough to gather enough evidence on the target group was 
sufficient for the study. Since the research study was a qualitative phenomenological 
method, it was preferable to have in-depth research than a large population. The guide was 
to interview participants until saturation of data was attained. Bowen (2008) defines 
saturation as the point when additional data fails to generate new information. The 
researcher stopped collecting data when the categories of themes were saturated, that is, 
when gathering fresh data no longer sparked new insights or revealed new properties 
(Creswell, 2014). Phenomenological study samples typically have fewer than 10 individuals 
(Polit & Beck, 2006). In this study, data saturation was reached after getting seven individual 
adolescent participants, a focus group of adolescent participants (FGAPs), three PGCPs and 
11 HCPPs. 
 
4.5 QUALITATIVE APPROACH 
 
The main objective of the study was primarily to gain an understanding of adolescents‟ 
perspective of being on HAART. The second objective was to gain broader insight of 
experiences leading to adherence and non-adherence to HAART. A qualitative research 
approach was thus employed in this study. A qualitative study is an inquiry into a social or 
human problem, and its objective is to gain a detailed understanding of underlying reasons, 
beliefs, and motivations of peoples‟ subjective experiences (Hennink et al., 2011). 
Qualitative approaches are typically used for providing an in-depth understanding of the 
research issues that embrace the perspectives of the study population and the context in 
which they live (Jaeger & Halliday, 1998). 
 
4.5.1 Exploration 
 
Exploratory research is undertaken when few or no previous studies exist. The aim is to look 
for patterns, hypotheses or ideas that can be tested and will form the basis for further 
research (Neville, 2007). Additionally, qualitative research methodology is useful for 
exploring new topics or understanding complex issues, for explaining cultural norms of a 
culture or society (Patton & Cochran, 2002). A qualitative research approach was chosen for 
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this study because of its usefulness as a tool for exploration related to knowledge 
development. It attempts exploration in a „naturalistic‟ way, under uncontrolled conditions. It 
focuses on behavioural or meaningfully understood action variables only (Shaughnessy, 
Zechmeister, & Zechmeister, 2012). The qualitative approach gives the texture of the 
person‟s responses, meaning one feels much greater acquainted with the participant hearing 
her words rather than just knowing her scores; in other words, the data is richer. 
 
4.5.2 Hard to Recruit Population 
 
Qualitative studies tend to have a small sample size and thus may be more appropriate for 
researchers working on their own or researching a hard-to-recruit population (Cooper et al., 
2012). In this study, it is a challenging task to obtain a sample of adolescents who are on 
HAART. Issues of confidentiality and the adolescents‟ rights to privacy compound 
accessibility of the sample, and these were also addressed in the study. 
 
4.5.3 Inductive Nature of Inquiry 
 
Qualitative research approaches are typically more flexible, that is, they allow greater 
spontaneity and adaptation of the interaction between the researcher and the study 
participants. In addition, the relationship between the researcher and the participant is often 
less formal than in a quantitative research approach (Mack, Woodsong, MacQueen, Guest, 
& Namey, 2005; Graziano & Raulin, 2013). 
 
Qualitative approach emphasises the uniqueness of individuals or special populations 
preferring narrative summaries or descriptions. Additionally, it seeks to understand a given 
research problem or topic from the perspectives of the local population it involves. 
Qualitative research is specifically effective in obtaining culturally specific information about 
the values, opinions, behaviours and social contexts of particular populations (Mack et al., 
2005; Goodman, 2008). A famous useful method among the qualitative methods is the 
phenomenological method. 
 
4.6 PHENOMENOLOGY 
 
The origins of phenomenology can be traced back to Kant and Hegel. Husserl is generally 
viewed as the fountainhead of phenomenology in the 20th century (Groenewald, 2004). The 
phenomenological paradigm to research has its roots in the work of Edmund Husserl (1859-
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1938) at the turn of the 20th century. Husserl developed and named his philosophical 
method „phenomenology‟ – the science of pure „phenomena‟ (Hahn, 2010, p246), for use in 
philosophy and the human sciences. In psychology, this method is a descriptive, qualitative 
study of human experience. It is used to study and learn about phenomena that are difficult 
to observe and measure (Wilding & Whiteford, 2005). Eidetic phenomenology aims to 
determine the form and nature of reality as mediated through and individual experience of it. 
To arrive at this essential structure, Husserl‟s method suggests four fundamental processes: 
intentionality, phenomenological reduction, description, and essence (Wimpenny & Gass, 
2000). 
 
4.6.1 Intentionality  
 
Phenomenological approaches aim to study participants‟ inner experiences, in other words, 
how they perceive and make sense of the world. A phenomenological study aims to faithfully 
conceptualise the processes and structures of mental life, how situations are meaningfully 
lived through as they are experienced, with nothing added and nothing subtracted (Wertz et 
al., 2011). 
 
According to Fouche and Delport (2002), when adopting a phenomenological paradigm, the 
researcher works towards an understanding of an individual‟s perceptions, perspectives and 
an understanding of a given situation. The purpose of a phenomenological study is to 
describe and interpret the experiences of the participants regarding a particular event in 
order to understand the participants‟ meaning ascribed to that event (McMillan & 
Schumacher, 2010). Each individual has a unique position in life, and by joining the 
environment and reality of the individual, the researcher has the opportunity to experience 
the actual phenomena and report on it from the individual‟s perspective (Wilson, 2014).  
 
This study aimed to gain an understanding and describe the experiences of adolescents on 
HAART. Phenomenology is concerned with the study of experience from the perspective of 
the individual, „bracketing‟ taken-for-granted assumptions and usual ways of perceiving. 
Epistemologically, phenomenological approaches are based on a paradigm of personal 
knowledge and subjectivity and emphasise the importance of personal perspective. As such, 
they are powerful for understanding subjective experience, gaining insights into people‟s 
motivations and actions, and cutting through the clutter of taken-for-granted assumptions 
and conventional wisdom (Wertz et al., 2011). Although phenomenological researchers seek 
targeted experiences, they also want to explore the diversity of individual experiences (Polit 
& Beck, 2006; Husserl, 1970). 
91 
 
4.6.2 Consciousness  
 
Merleau-Ponty (1962) describes phenomenology as the study of essences, and according to 
it, all problems amount to ﬁnding deﬁnitions of essences: the essence of perception or the 
essence of consciousness, for example. The lifeworld – Husserl‟s Lebenswelt – is a key 
concept and focus of investigation for phenomenology. It can be defined as the world that is 
lived and experienced – a world that appears meaningfully to consciousness in its 
qualitative, flowing given-ness; not an objective world out there, but a humanly relational 
world (Todres, Galvin, & Dahlberg, 2006). The researcher‟s project is, in the infamous words 
of Husserl (1970), to return to the things themselves. The „things‟ here refer to the world of 
experience as lived. To return to the things themselves is to return to that world which 
precedes knowledge, of which knowledge always speaks. In the lifeworld, a person‟s 
consciousness is always directed at something in or about the world. Husserl developed 
intentional analysis and eidetic analysis. Intentional analysis is the procedure of reflecting 
on, gaining insight into, and describing the how and the what of experience, how experiential 
processes proceed, and what is experienced through them. Intentionality denotes the 
transcendental quality of consciousness, which is consciousness of something (Husserl & 
Heidegger, 1927). 
 
Edmund Husserl rejected the behaviouristic belief that objects in the external world exist 
independently and that information about objects is reliable. He contended that people can 
be certain about how things appear in, or present themselves to, their consciousness. To 
arrive at certainty, anything outside immediate experience must be ignored, and in this way 
the external world is reduced to the contents of personal consciousness. Realities are thus 
treated as pure phenomena and the only absolute data from where to begin (Eagleton, 
2011).  
 
In the lifeworld, a person‟s consciousness is always directed at something in or about the 
world. In this way, subject and object are joined together in mutual co-constitution. This 
important phenomenological concept is called intentionality, and it is a key focus for research 
(Creswell, 2003). In this study, the researcher‟s aim was to explicate this intentionality that 
has to do with the directedness of the participants‟ consciousness (what they are 
experiencing and how). 
 
Put another way, the focus is on the intentional relationship between the person and the 
meanings of the things they are focusing on and experiencing. Phenomenology asks, “What 
is this kind of experience like?” “What does the experience mean” and “How does the lived 
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world present itself to me (or to my participant)?” The challenge for phenomenological 
researchers is twofold: how to help participants express their world as directly as possible, 
and how to explicate these dimensions such that the lived world – the lifeworld – is revealed. 
Meanings uncovered by the researcher emerge out of the researcher‟s attitude and the way 
the researcher poses questions (Finlay, 2012, p22). 
 
This important phenomenological concept that is being referred to is called intentionality, and 
it is a key focus for research, as already indicated (Creswell, 2003). Wertz et al. (2011) go on 
to describe the phenomenological attitude as reflective. It selectively turns from the 
existence of objects to the processes and meanings through which they are subjectively 
given. Phenomenology investigates the person‟s ways of being-in-the-world by descriptively 
elaborating the structures of the self, ways of experiencing and the meaningful ways in which 
the world is experienced (Todres et al., 2006). 
 
4.6.3 Philosophical Existence 
 
Phenomenology is a philosophy which puts essences back into existence and does not 
expect to arrive at an understanding of man and the world from any starting point other than 
that of their „facticity.‟ It is a transcendental philosophy which places in abeyance the 
assertions arising out of the natural attitude, to better understand them. However, it is also a 
philosophy that the world is always „already there‟ before reﬂection begins, as an inalienable 
presence, and all its efforts are concentrated on re-achieving a direct and primitive contact 
with the world and endowing that contact with a philosophical status. It is the search for a 
philosophy which shall be a rigorous science, but it also offers an account of space, time and 
the world as people „live‟ them. It endeavours to give a direct description of a person‟s 
experience as it is, without taking account of its psychological origin and the causal 
explanations which the scientist, the historian or the sociologist may be able to provide 
(Merleau-Ponty, 1962). 
 
4.7 RESEARCH PROCEDURE 
 
Qualitative research approaches raise ethical issues, as they encroach on personal spheres 
of the participants. Ethical issues to consider when conducting qualitative research include 
consent, protection of rights of institutions, privacy, confidentiality and potential to harm 
(Ramcharan & Cutcliffe, 2001). Letters of permissions and consent forms have been 
included as appendices. 
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4.7.1 Gaining Access to Participants  
 
Permission to carry out this research was requested and granted by the chief executive 
officer (CEO) of the Tembisa Hospital. Appendix A, Request Letter and Appendix B, 
Approval Letter from hospital management, are attached. The initial contact was negotiated 
with the medical team at Masakhane Clinic, as they are the gatekeepers to the clinic. Since 
permission was given for research by the hospital authority, the researcher then liaised with 
the medical personnel to refer willing patients for research.  
 
The referral process was treated with much care to avoid issues of confidentiality being 
compromised. This also included the power and influence which can be abused by referring 
sources. As health care providers, they can represent a powerful authority which can make 
potential participants be submissive and lose their power and right to give informed consent 
and be discouraged from withdrawing should they want to. Therefore, the medical team 
provided contact details but did not recommend participation in the study to avoid biasness 
from their side. Additionally, the health care providers did not have the identity of the 
adolescents who would be part of the study in order to protect participants from any form of 
prejudice from the health care system. 
 
As soon as the adolescent arrived at the hospital‟s psychology department, they were invited 
to voluntarily take part in the research project. First, the purpose of the research was 
explained to both the guardians and the adolescents, which is to explore the experiences of 
adolescents who are on long-term HAART treatment in Tembisa. Secondly, their 
cooperation was requested to take part in the study. Thereafter, the guardians or parents 
were requested to complete a consent form for research. The willing participants were then 
booked in for a follow-up session where the research interview was then conducted.  
 
4.7.2 Privacy and Confidentiality 
 
Informed consent means that those interviewed or observed should give permission having 
full knowledge of the purpose of the research and the consequences of them taking part 
(Flewitt, 2005). A written informed consent form was signed by the parents, guardians and 
caregivers. The parents, guardians and caregivers of the adolescent participants were 
requested to complete the consent form on behalf of their children. The participants were 
given time to discuss the consent between parent/guardian and the adolescent. It was 
further explained in their own home language so that they could not miss any information.  
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Participants were also made aware that their participation in the study will not automatically 
carry any treatment benefit. This was done to ensure that participation is open, transparent 
and under no false intent. Following the consultation between parent/guardian and 
participant regarding the processes and procedure the study would follow, the parent was 
requested to wait outside so as to allow the interview between the researcher and participant 
to take place in a private environment. The researcher then consulted with the adolescent 
participant to find out if they understood the research, and their willingness to participate was 
verified once more. Each and every participant during the interviews was constantly 
reminded that the research was not a therapy or counselling session.  
 
According to the Children‟s Act (2005), the parent or guardian of a child under the age of 18 
years can give consent to the performance of a surgical operation and any other medical 
treatment; therefore, parental consent formed the initial consent for this study. The 
researcher made it clear to participants, their parents and guardians about their rights to 
decline to participate and reassured them that there would be no negative consequences if 
they chose not to participate and that they could answer any questions they are able to. It 
was important to emphasise to the adolescent participants that they could choose whether to 
take part or not and that if they decided to participate, they were always free to change their 
minds for a few minutes, for a whole session or forever.  
 
Assent was thus obtained from adolescent participants younger than 18 years. In case of 
harm or discomfort during the interview or as a result of the interview, debriefing and 
psychosocial support would be made available by the researcher in her capacity as a 
psychologist. However, such capacity would emerge outside the interview process. 
 
As regards child consent, Article 12 of the United Nations Convention on the Rights of the 
Child (UNCRC, 1989) clearly states children‟s rights to express their views on all matters 
that affect them. Some researchers prefer to use the term „assent‟ rather than „consent,‟ 
arguing that minors are unable to give legal consent. However, as Alderson and Morrow 
(2004) point out, in English law, „competent minors‟ under 16 can give valid consent, with 
„competence‟ defined as having sufficient understanding and intelligence to understand what 
is proposed (Flewitt, 2005; Rose, Hagemann, Aburto & Shahnazarian, 2013). 
 
Another common assumption in ethical, social research is confidentiality in the process of 
conducting the research and anonymisation of individuals in reporting. Confidentiality is a 
principle that allows people not only to talk in confidence but also to refuse to allow 
publication of material they think might harm them (Health Professions Council of South 
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Africa [HPCSA], 2006; Wiles &Crow, 2008). All data gathered was treated confidentially. No 
information was released in a way that permits linking specific individuals to specific 
responses. The findings of the research will be published in a document, thesis, and 
submitted to the University of South Africa as well to the hospital authority. The risk of 
submitting favourable findings to suit the interest of the hospital interest was avoided at all 
cost. This has also been communicated during the process of seeking permission to study. 
Seminars and a community workshop were used to disseminate information for the benefit of 
the participants and the population they represent. The identifying information of the 
participants will not feature in any research publications. The raw data will be safeguarded 
and will not be available to any parties except for supervision during the study. 
 
4.7.3 Protection of the Participants 
 
The parents and guardians of these adolescent participants benefited, albeit indirectly. This 
is because once the adolescent participants gained a realistic understanding of their illness, 
they might adhere more to their treatment, thereby improving community participation. 
 
The first interview question was about the general experiences of being on long-term 
HAART. The participants benefited during this research as they stood a chance to express 
their personal experience. The adolescent participants dealt with personal pain and trauma 
of their illness, which might have left them emotionally vulnerable. Therefore, the participants 
were informed that a counselling session could be arranged with the researcher for 
debriefing purposes as a result of the emotional impact the research might have on them.  
 
A secondary gain of participating in the study included, but was not limited to, interaction 
with other adolescent participants who are on HAART. Informal support groups were created 
by participants once they knew they are not the only ones receiving HAART. Certain 
misconceptions were cleared during the process, as they gained information relating to the 
reality of HAART. Some adolescent participants were not told the truth about the reasons for 
their taking HAART, and during the research, they stood a chance to know the truth about 
their HIV status. 
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4.8 DATA COLLECTION APPROACH 
 
All the data collection processes were conducted at Tembisa Hospital. The researcher 
collected the data herself through the use of individual in-depth one-to-one interviews. This 
is a one-on-one method of data collection that involves an interviewer and an interviewee 
discussing specific topics in depth (David & Sutton, 2011). In this study, the researcher 
followed a flexible interviewing guide (often called an interview schedule or protocol). In 
addition triangulation of data collection was ensured through the use of a focus group of 
adolescents and questionnaires for health care professional participants. 
 
Data collection methods are an integral part of the research design. Data collection methods 
in this study included face-to-face interviews and questionnaires that were personally 
administered, observation of individuals and events with or without audio recording 
(Sekaran, 2003; Creswell, 2014). Qualitative research methods have preference for open-
ended, unstructured and reactive data collection procedures (Given & Saumure, 2008).  
 
Permission was requested from the interviewees to record the interview. The interviews 
were tape recorded for some and not for others. Interviews were usually audio recorded to 
enhance the quality of data collection. Some objected to the recording of the interview, and 
their rights were thus respected. However, permission was requested to make field notes 
instead and was granted. The advantage of using a tape recorder is that it allowed a much 
fuller record than notes taken during the interview. It also allowed for the researcher to 
concentrate on how the interview proceeded and where it went next. However, the direction 
and duration of the interview were relatively open. As such, the interviewer needed to be 
prepared for an interview that may go on for longer than initially expected. The disadvantage 
of tape recording is that some participants did not feel happy being recorded. In such cases, 
the tape recording did not take place. 
 
4.8.1 Informed Assent and Consent  
 
The researcher contacted and informed the potential adolescent participants about the 
nature of the study and the importance of their contributions. She then requested their 
participation in the study. Informed assent was then obtained (Appendix C) for eight of the 
adolescent participants younger than 18 years from their PGCPs, and consent forms 
(Appendix D) were signed by the two participants who are at least 18 of age (Wiles & Crow, 
2008; HSRC, 2012). Informed consent was obtained for the PGCPs and HCPPs.  
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The participants were not forced to participate and could withdraw from the study at any 
stage without explanation or consequence. They were duly informed of this, and also that 
they would never be punished or harmed if they withdrew at any stage even if they had 
already signed a consent or assent form, or verbally agreed. The participants were also 
informed that they would receive no payment for their participation.  
 
4.8.2 In-depth Individual Semi-structured Interviews 
 
An in-depth interview is a conversation with a purpose. It is focused, discursive and allows 
the researcher and participant to explore an issue. It is used to determine an individual‟s 
perceptions, opinions, facts, forecasts and reactions to initial findings and potential solutions 
(DePoy & Gitlin, 1998). Clarifying questions were used in order to focus the interview on the 
relevant topic. 
 
For the purpose of this study, in-depth interviewing was selected due to its advantages of 
flexibility in terms of adapting, adopting and changing the questions as the researcher 
proceeds with the interviews. Qualitative studies typically employ unstructured or semi-
structured interviews. 
 
Interviewing is the predominant mode of data collection in qualitative research. The 
researcher interviews because they are interested in other people‟s stories. Interviews are 
interactional events and are deeply and unavoidably implicated in creating meanings that 
ostensibly reside within participants (De Vos, Strydom, Fouche, & Delport, 2002). The 
purpose of the phenomenological paradigm is to illuminate the specific, to identify 
phenomena through how they are perceived by the actors, in this case, the adolescents, in a 
situation. In the human sphere, this normally translates into gathering „deep‟ information and 
perceptions through inductive, qualitative methods such as interviews, discussions and 
participant observation, and representing it from the perspective of the research participants 
(Creswell, 2003). Since the study is a qualitative phenomenological method, it was 
preferable to have in-depth research through in-depth interviewing. Open-ended questions 
were used in a mainly semi-structured questionnaire for data collection from the adolescents 
and PGCPs, and structured questionnaire for the HCPPs. 
 
In-depth interviews are an attempt to understand the world from the participant‟s point of 
view, to unfold the meaning of people‟s experiences and to uncover their lived world prior to 
scientific explanations. As Hesse-Biber and Leary (2004) note, an interview is a research 
gathering approach that seeks to create a listening space where meaning is constructed 
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through an interexchange or co-creation of verbal viewpoints in the interest of scientific 
knowledge. Harrell and Bradley (2009) concur that interviews are discussions, usually one 
on one and between an interviewer and an individual, meant to gather information on a 
specific set of topics. Interviews can be conducted in person or over the phone. Interviews 
differ from surveys by the level of structure placed on the interaction. There are one-to-one 
interviews as well as group interviews, referred to as focus groups.  
 
A researcher who employs an in-depth interview in a study is a human being, with a 
distinctive personal style. That being the case, a researcher uses their social view to practice 
in order to conduct an interview that is appropriate to the needs and demands of their 
research question and methodological approach, the context of the interview and the 
individual participant (Braun & Clarke, 2013). 
 
In-depth interviews have the advantage insofar as they allow a well-trained interviewer to 
ask all types of questions. Interviewing allows for complex questions and can use extensive 
probes. Interviews have the advantage that the interviewers can establish rapport with the 
people being interviewed. Interviewers may be able to notice when participants seem to 
misunderstand a question and explain its meaning. Furthermore, an added advantage of 
one-to-one interviews is that they allow the interviewee an opportunity to describe his 
experiences without interference. The disadvantage of interviews is the cost implication. 
Interviews can also be time-consuming.  
 
Interviews involve personal interaction; therefore, cooperation is essential. Interviewees may 
be unwilling or may be uncomfortable sharing all that the interviewer hopes to explore, or 
they may be unaware of recurring patterns in their lives. The interviewer may not ask 
questions that evoke long narratives from participants because of a lack of expertise or 
familiarity with the local language or because of lack of skill. By the same token, she may not 
properly comprehend responses to the questions or various elements of the conversation 
(Marshall & Rossman, 2010).  
 
One-on-one interviews involve one interviewer and one interviewee and more often than not 
entail face-to-face interaction, although telephonic interviews can also be conducted 
(Gravetter & Forzano, 2010). An interview is an interactive process of making meaning and 
co-generating data by means of conversation. Various languages were used for the 
interviews in this study as preferred by the participant, and these languages included 
Tsonga, Venda, Sesotho languages (Sepedi, Setswana, and South Sotho), IsiZulu and 
English. In this study, in particular, in-depth interviews were used to ensure that the study 
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gave insight into the world of another. The approaches helped in gaining insight into the 
lives, experiences, beliefs and knowledge of adolescents on HAART. This process was 
facilitated by the researcher being fluent in speaking and reading the above-mentioned 
languages. 
 
For adolescent participants, an interview guide was created (Appendix E). A pilot study 
consisting of three adolescent participants was conducted. The guide was improved and 
interviews conducted accordingly. The objective of the guide was to explore the experiences 
of the adolescents of the Masakhane Clinic regarding the experiences of the adolescents 
who are on HAART treatment. The main questions were open-ended in nature with some 
profile data included for quantitative analysis. Verbal, face-to-face interviews were conducted 
by the researcher.  
 
The questions included: 
 When did you start taking HAART?  
 Do you know what the treatment is for? 
 What does taking such medication mean to you? 
 What is the meaning of being in HAART treatment for you? 
 What are the challenges you face being on HAART? 
 What do you think are the challenges that adolescents experience as a result of 
being on HAART? 
 What are the benefits you experience as a result of being on HAART? 
 What are the coping mechanisms and strategies you use as a result of being on 
HAART? 
 
An interview guide (Appendix F) was created for PGCPs. The objective of the guide was to 
explore the experiences of the parents, guardians and caregivers of adolescents regarding 
the experiences of the adolescents receiving HAART at Tembisa. The main questions were 
open-ended in nature, with some profile data included for quantitative analysis. Verbal, face-
to-face interviews were also conducted by the researcher with the parents, guardians and 
caregivers.  
 
The questions posed included: 
 As a parent, what has been your experience in dealing with adolescents on HAART? 
 How was the information of his or her status delivered to him or her? 
 How did he or she respond to the information of his or her status? 
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 What do you think is the meaning of being in HAART treatment for him or her? 
 What are the challenges you face as a result of his or her being on HAART? 
 What do you think are the challenges that adolescents experience as a result of 
being on HAART? 
 What do you think are the benefits he or she experience as a result of being on 
HAART? 
 What are the coping mechanisms and strategies he or she uses to cope with being 
on HAART? 
 Would you like to add any other comment that was not addressed by the 
questionnaire? 
 
4.8.3 Structured Questionnaires for HCPPs 
 
How did the researcher go about requesting participation from the HCPPs? Self-completion 
questionnaires, Appendix G, were used for HCPPs. The objective of the questionnaire was 
to explore the experiences of the multidisciplinary team of the Masakhane Clinic regarding 
the experiences of the adolescents that are on HAART. The questions were closed-ended 
(quantitative and profiles) and open-ended in nature. Participants could write as much as 
they could. They could also make use of an extra page if they wished to.  
 
Questionnaires generally consist of open- or closed-ended questions or items that measure 
facts, attitudes, or values. Consequently, a standard questionnaire, namely, “Interview Guide 
for Health Care Professionals,” was developed to gather the desired information. Both 
qualitative and quantitative research use questionnaires to collect data. Closed-ended 
questions elicit a response, score quickly, and are easy to evaluate. To ensure reliability, 
inventories often restate the question or item several times. Open-ended questions allow the 
participant to provide a more complete or comprehensive response (McClure, 2002).  
 
A pretest questionnaire was given to one HCPP in September 2014 to pilot and detect any 
missing important information. On feedback, the questionnaire was improved and handed 
out to 15 HCPPs in December 2014. A total of 11 completed questionnaires were returned. 
This approximately 75% response rate is acceptable (Bailey, 1994). The non-response rate 
of only 27% was sheltered by the diversity of the HCPPs‟ different professions.  
 
Open-ended responses often provide specific and meaningful information (Arhar, Holly, & 
Kasten, 2001; Patton, 2002). Simultaneous administration of questionnaires to multiple 
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people at various locations is one of many positive advantages associated with this 
methodology. Anonymity is another benefit of questionnaires that makes them an effective 
tool for collecting data on sensitive or illegal activities.  
 
Questionnaires generally contain objective items written as multiple-choice, fill in the blank, 
or short answer items (McClure, 2002). The questions or requests from the participants 
included: 
 
 What has been your experience in dealing with adolescents on HAART? 
 Please explain the challenges faced by the adolescents on HAART. 
 Please enlighten on the benefits experienced by the adolescents on HAART. 
 Please spell out the coping mechanisms and strategies being used by the 
adolescents on HAART. 
 Please comment on any issues that were not addressed in the questionnaire. 
 
4.9 DATA STORAGE  
 
Storage of interviews were in the form of tape-recorded conversation, handwritten field notes 
taken during the session, as well as interview transcripts after the analysis. Interviews were 
conducted in Sesotho, Tsonga, Venda, IsiZulu and English. The Sesotho, Tsonga, Venda 
and IsiZulu were then translated into English by the researcher herself. To ensure accuracy 
of translation, a multi-lingual colleague was requested to check for meaning captured and a 
second verification process, thereby ensuring efficiency in translation. These interviews were 
transcribed verbatim in English and stored electronically. As the case with qualitative 
research approaches, transcription of interview data was time-consuming. This was despite 
the researcher using a transcribing machine, but the process was very intensive than 
conducting interviews. 
 
Two of the adolescent participants were reluctant to have the conversation with the 
interviewer tape recorded; because of that, recording did not take place in the case of these 
two participants. However, field notes were taken during the interview session, which the 
researcher used as a point of reference during the transcription of the interview. For HCPPs, 
returned questionnaires were handwritten. The returned questionnaires were scanned and 
saved electronically. The data on them was analysed. Pseudonyms were used so as not to 
disclose the real names of the participants. All information provided was kept confidentially.  
 
102 
 
4.10 DATA ANALYSIS 
 
Data analysis is the process of bringing order, structure and meaning to the mass of 
collected data, thereby transforming data into findings (Somekh & Lewin, 2011). The 
descriptive phenomenological researcher starts with concrete descriptions of lived 
experiences and proceeds by reflectively analysing these descriptions (Husserl & Heidegger, 
1927). Quantitative data was analysed using descriptive statistics analysis methods. 
Histograms and bar charts were used in the analysis. Quantitative data was collected solely 
for biographical information comparison.  
 
Thematic analysis and phenomenological analysis approaches were applied, which share 
the aim of identifying and describing the central ideas (usually referred to as themes or 
categories) occurring in data. Thematic analysis attempted to identify themes from the 
material under study. This material comes from the interview data. The researcher normally 
analyses the material inductively, that is, the themes are derived from the data rather than 
derived beforehand (Wertz et al., 2011). Themes were organised in a hierarchical structure, 
with higher order themes and subthemes. In a true sense, thematic analysis is a qualitative 
analogue of the statistical approaches of factor analysis or cluster analysis, both of which 
aim to describe a complex data set in terms of number of dimensions or groupings (Cooper 
et al., 2012).  
 
Analysis of data in this study was a process of reading and looking for themes and patterns 
of meaning. The researcher read and reread the transcripts to identify emerging themes and 
subthemes that reflect the experiences of adolescents on HAART, and a code list was 
developed which defined the identified themes.  
 
Furthermore, computer program Atlas.ti.7 was co-applied in the creation of codes. It was 
also used subsequently in the generating of themes. 
 
The steps taken followed the guidelines as stipulated in research. Generally, the most usual 
data source is verbatim transcripts of audio-taped interviews, but other sources are 
sometimes used, such as group discussions, written accounts or diaries (Miner-Romanoff, 
2012). 
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Some of the steps taken are as follows: 
 
 Phenomenological reduction and bracketing: No position was taken either for or 
against either the data or any of the researcher‟s own presuppositions. 
 Delineating units of meaning: Those statements that were seen to illuminate the 
researched phenomenon were extracted. The researcher was required to use her 
own judgement while consciously bracketing her own presuppositions. The list of 
units of relevant meaning extracted from each interview was carefully scrutinised, 
and those units that were clearly redundant were eliminated.  
 Units of meaning were clustered to form themes: Having compiled the list of non-
redundant units of meaning, the researcher rigorously examined the lists and tried to 
elicit the essence of meanings of units within the holistic context. Clusters of themes 
were formed by grouping units of meaning together, and the researcher identified 
significant topics, also called units of significance. 
 Summarising each interview and validating it: A summary that incorporated all the 
themes elicited from the data gave a holistic context. 
 Extracting general and unique themes from all the interviews and creating a 
summary: Once the process outlined in the above points had been completed for all 
the interviews, the researcher looked for the themes common to most or all of the 
interviews as well as the individual variations. Care was however taken not to cluster 
common themes when significant differences exist; the unique or minority voices are 
important counterpoints to bring out regarding the phenomenon researched. 
 
4.11 MEASURES TO ENSURE TRUSTWORTHINESS  
 
Ethical decisions are the result of weighing up a myriad of factors in a specific complex, 
social and political situation in which research is conducted. Ethics are about striking the 
balance between protecting the rights of the participants in research as well as guiding the 
researcher‟s actions in the field (Flewitt, 2005). Ethical practice is often defined as „doing no 
harm‟ and aspires to „do good,‟ thereby conducting research that benefits participants in 
positive ways (HPCSA, 2006; Chan, Fung & Chien, 2013). 
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4.11.1 Trustworthiness in Qualitative Research 
 
Research findings are valid to the extent that they resonate with the experiences of others 
who have experienced the phenomenon in question. For the adolescents and the PGCPs, 
the researcher conducted a „validity check‟ by returning to the participants to determine if the 
essence of the interview had been correctly captured. The study was based on the 
assumption that young people have the ability to speak about their experiences and are 
capable of contributing to the worlds in which they reside. In addition to learning about the 
experiences of adolescents related to HAART from the work of other researchers, this study 
explored the issue from the perspectives of young people themselves. 
 
Credibility is enhanced by keeping the focus on questions which the participants can answer, 
that is, on what they experienced rather than why they experienced it. Credibility was also 
strengthened by reflecting the researcher‟s understanding back to participants and by 
repeated interviews. Credibility is the confidence that the study measures what it intends to 
test and the confidence in the findings (Shenton, 2004). The researcher used the appropriate 
methodology for the study; this made it possible to get the participants‟ experiences in detail. 
These participants took part voluntarily, which promoted genuine responses to the 
questions, thus giving confidence in the findings.  
 
The participants were engaged until data saturation occurred. While working on the data 
collection, trustworthiness of the research findings was ensured (Patton, 2002). The 
researcher used a good quality digital voice recorder during data collection and transcribed 
verbatim to make sure that interpretation is based on the original participants‟ responses. 
 
It is important that transferability of the findings forms an element of the research. Shenton 
(2004) explains transferability as showing that the findings can be generalised and 
applicable in other settings. A full description of the context and background information 
about the setting of the study, the population, as well as details on the sample and data 
collection has been given with precision to enable other researchers to determine 
transferability to other contexts. The research also purposively selected the participants, 
given their experiences to conduct the study. 
 
It is crucial that findings in a study are dependable. Dependability generally refers to giving 
fully detailed processes about the study to allow future researchers to repeat the work. It is 
showing that the findings are consistent and can be repeated in other settings (Shenton, 
2004). A full description of what was planned, what was done and how it was done was 
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given in detail in the methodology. The methodology explained how participants were 
recruited, how data collection was done and how the analysis was carried out so that 
interested future researchers can repeat the study and find similar findings. 
 
An aspect not to be overlooked when conducting research is confirmability. Confirmability is 
the extent that the findings of the study are objective and neutrally reflect the experiences 
and ideas of the participants without being influenced by the preferences and interests of the 
researcher (Shenton, 2004). Voice recordings from the group discussions were listened to 
timely even after verbatim transcribing and translating so as to ensure that participants are 
not misinterpreted. Timely debriefing sessions online and face to face were held with the 
research supervisor who served as the sounding board for the researcher to guide 
development of the themes as identified from the transcripts and guide honest 
interpretations. 
 
Furthermore, the method of triangulation was applied. This involved using different data 
sources of information by examining evidence from the sources and using it to build a 
coherent justification for themes. If themes are established based on converging several 
sources of data or perspectives from participants, then this process can be claimed to be 
adding to the validity of the study (Creswell, 2014).  
 
4.11.2 Credibility of the Interview Guides 
 
All interview guides were created by the researcher and supervised by the study promoter 
before use. In the case of HCPPs, participants were given their own space and sufficient 
time to allow for honesty and a favourable response rate. The same questions were asked to 
ensure consistency. In the case of the PGCPs and adolescents, similar questions were 
asked using the interview guides. 
 
4.11.3 Prevention of Bias 
 
When a researcher suspends their own presuppositions and judgements, this is referred to 
as bracketing. From the Husserlian philosophical stance, only from a point of suspended 
judgement can inquiry proceed unencumbered from masked assumptions about the nature 
of the phenomena and conditions observed (Simon, 2011). Bracketing is a method used by 
some researchers to mitigate the potentially deleterious effects of unacknowledged 
preconceptions related to the research and thereby to increase the rigour of the project. 
Given the sometimes close relationship between the researcher and the research topic that 
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may both precede and develop during the process of qualitative research, bracketing is also 
a method to protect the researcher from the cumulative effects of examining what may be 
emotionally challenging material (Tufford & Newman, 2010). 
 
4.12 ETHICAL CONSIDERATIONS 
 
The researcher ensured strict compliance with ethical standards. These included standards 
which were relevant to protecting the rights of the participants as well as institutions where 
data was collected and scientific integrity maintained throughout the study. Approval was 
sought and obtained from both the Tembisa Tertiary Provincial Hospital as well as the Unisa 
Ethics Committee before data collection commenced, see Appendix B and Appendix J 
respectively. 
 
4.13 CHAPTER RÉSUMÉ 
 
This chapter explained the methodology used in this study and justified its use and the 
approaches employed. The population was explained, and the sample selected was also 
described. Phenomenology of qualitative methods of research was given special attention 
because it forms an integral part of the methodology. Data analysis was also described, as 
well as the informed consent approach used in dealing with the participants.  
 
The next chapter presents the findings of the study. 
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CHAPTER 5:PRESENTATION AND DISCUSSION OF FINDINGS 
 
5.1 INTRODUCTION 
 
The previous chapter explained the methodology that was employed in this study. This 
penultimate chapter presents the interview results of the research section of the study, that 
is, research findings. The adolescent participants who participated in the study had been on 
HAART for at least two years, since the study intended to understand the long-term 
experiences of taking the treatment.  
 
The study findings cover the negative and positive experiences and the perceived role of 
HAART treatment over a long period of time. The PGCPs were also requested to describe 
the role they play in the treatment and support of the adolescents under study. Furthermore, 
the PGCPs‟ views about the experiences and coping mechanisms of the adolescent 
participants taking HAART treatment were also included in order to obtain a broader 
understanding. 
 
The various stakeholders involved in the treatment of the adolescent participants on HAART 
treatment were also requested to provide information on their experiences of being involved 
with the HAART treatment for the adolescent under their care at the hospital. These 
collective contributions were required to provide important information on improving 
practices in HAART treatment of the HIV and AIDS adolescent participants. 
 
Pseudonyms were used in capturing the responses in order to ensure anonymity of the 
participants. The findings cover: 
 
(a) experiences of adolescent participants under HAART treatment at Tembisa Hospital;  
(b) experiences of the FGAPs on HAART  treatment,  
(c) experiences of PGCPs of adolescents; and 
(d) experiences of HCPPs involved with these adolescents. 
 
For the demographic data (profiles) of all the four categories, descriptive statistics analysis 
was used to best describe the data. According to Terre Blanche and Durrheim (1999), 
descriptive analysis aims to describe the data by investigating the distribution of scores on 
each variable and by determining whether the scores of different variables are related to one 
another. 
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The interview questions included closed-ended and open-ended questions. This chapter 
presents personal experiences of the adolescent participants under HAART treatment, 
impressions and reactions of the parents, guardians and caregivers of these adolescent 
participants. It also considers the expert inputs of the various professionals involved with the 
adolescent participants. 
 
5.2 PROFILES AND NARRATIVES OF THE ADOLESCENT PARTICIPANTS 
 
This section presents the experiences of the adolescent participants who were taking 
HAART treatment at the Tembisa Hospital at the time of the study. The main critical aspect 
of this section is that the people who were directly involved and who had first-hand 
experiences were the ones sharing their experiences. The HCPPs and PGCPs have shared 
their impressions about these adolescent participants. The consolidated impressions from 
the involved parties were thought to be necessary to enable the parties to understand what 
they could be doing to one another during the treatment, with the hope that there can be 
interventions found that will allow them to cherish all the challenges involved. 
 
5.2.1 Profiles of Adolescent Participants 
 
Seven adolescents who were taking HAART treatment at the Tembisa Hospital participated 
in the study. Significant characteristics among participants included gender, age, education 
level or school grade, and length of time on HAART treatment. The male (43%) and female 
(57%) adolescent participants were distributed almost identically (but this is not clear, as the 
sample sizes used were small); their ages ranged from 13 to 19 years; their school grades 
were from six to nine, and one was at tertiary level; and they had been on HAART treatment 
for periods ranging from five to about eight years. 
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5.2.1.1 Gender Distribution of Adolescent Participants 
 
Table 5.1 and Figure 5.1 show how the gender of participants was distributed. 
 
Table 5.1: Adolescent Participants’ Gender Distribution  
 Male Female 
Frequencies 3 4 
 
 
 
Figure 5.1: Adolescent Participants’ Gender Distribution 
 
 
The type of graph used for the distribution of the adolescent participants into gender 
categories is a pie chart (Figure 5.1), which can easily display categories of adolescent 
participants in few categories. Table 5.1 and Figure 5.1 show the gender distribution of the 
adolescent participants to have been 42.9% male and 57.1% females. Both the table and 
figure indicate that there were more female participants than male participants. 
42,9 
57,1 
Male
Female
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5.2.1.2 Adolescent Participants’ Ages 
 
In Table 5.2 and Figure 5.2, how the adolescent participants‟ ages were distributed is shown. 
 
 
Table 5.2: Adolescent Participants’ Ages 
Adolescent # A B C D E F G 
Ages of adolescents 12 13 14 15 16 18 19 
 
 
 
 
Figure 5.2: Adolescent Participants’ Ages 
 
From Figure 5.2, it can be deduced that the average age of the adolescent participants on 
HAART treatment was 15.3 years. The adolescent participants‟ ages are equally distributed 
between ages 12 and 19 inclusive, with the exception of age 17.  
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5.2.1.3 Adolescent Participants’ Length of Time on HAART 
 
The adolescent participants‟ length of time on HAART treatment is revealed in Table 5.3 and 
Figure 5.3. 
 
Table 5.3: Adolescent Participants’ Length of Time on HAART Treatment 
Adolescent # A B C D E F G 
Period on HAART 8 5 5 5 8 8 7 
 
 
Figure 5.3: Adolescent Participants’ Length of Time on HAART Treatment 
 
The mean or average length of use of HAART treatment by the adolescent participants was 
about 6.6 years. Table 5.3 and Figure 5.3 highlight that the longest usage was eight years, 
and the shortest was five years. The modal lengths of use were both eight and five years, 
coincidentally the longest and the shortest lengths of using HAART treatment. From the 
above subsection, the oldest adolescent participant at the time of the study was 19 years, 
and the youngest was 12 years. This shows that in 2010, when some of them started to take 
HAART treatment and others were already on the programme, four of them were still below 
10 years of age. 
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5.2.1.4 Adolescent Participants’ School Grades 
 
With regard to school grades, the participants‟ school grades are reflected in Table 5.4 and 
Figure 5.4. 
 
Table 5.4: Adolescent Participants’ School Grades 
Adolescent # A B C D E F G 
School Grade 6 6 7 7 8 9 Tertiary 
 
 
Figure 5.4: Adolescent Participants’ School Grades 
 
In Table 5.4 and Figure 5.4, it is illustrated that the lowest grade attended by the bulk of 
these adolescent participants at the time of the study was grade 7, and the highest was 
grade 9. There was an exception of an outlier one who was already at tertiary education 
level. The two modal classes were grade 6 and grade 7, since they appeared more than the 
rest. 
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5.3 PROFILES AND NARRATIVES OF THE FOCUS GROUP OF ADOLESCENT 
PARTICIPANTS 
 
In this section, the experiences of the FGAPs who were taking HAART medication at the 
Tembisa Hospital at the time of the study will be presented. The main importance of the 
section was to consolidate impressions of another set of adolescents who were directly 
involved and had first-hand experiences, in a group setting.  
 
5.3.1 Profiles of Adolescent Focus Group of Adolescent Participants 
 
Three adolescents who were taking HAART treatment at the Tembisa Hospital were 
involved in the focus group. Their other characteristics were gender, age, education level or 
school grade, and length of time on HAART treatment. There were two males and one 
female. The adolescents‟ ages ranged from 14 to 17 years; their school grades were from 7 
to 10; and they had been on HAART treatment for periods ranging from 7 to about 10 years. 
 
5.3.1.1 Gender Distribution  
The gender distribution of the FGAPs is presented in Table 5.5 and Figure 5.5. 
 
Table 5.5: Focus Group of Adolescent Participants’ Gender Distribution 
 Male Female 
Frequencies 2 1 
 
 
Figure 5.5: Focus Group of Adolescent Participants’ Gender Distribution 
67% 
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The type of graph used for the distribution of the adolescents into gender categories is a pie 
chart (Figure 5.5), which can easily display categories of the participants in a few categories. 
A pie chart is useful when one wants to show relative proportions or contributions to a whole 
(Walkenbach, 2015). Table 5.5 and Figure 5.5 show the gender distribution of the 
participants to have been 66.7% male and 33.3% female. In this case, it appears that the 
number of males participating exceeded that of females. 
 
5.3.1.2 Focus Group of Adolescent Participants’ Ages  
 
The participants‟ ages were distributed as shown in Table 5.6 and Figure 5.6. 
 
Table 5.6: Focus Group of Adolescent Participants’ Ages 
FGAP # FGAP (A) FGAP (B) FGAP (C) 
Ages in Years 14 16 17 
 
 
 
Figure 5.6: Focus Group of Adolescent Participants’ Ages 
 
According to the statistics in Table 5.6 and Figure 5.6, the average age of the adolescents 
on HAART treatment was worked out to be 15.7 years. The adolescents‟ ages are equally 
distributed between age 14 and 17 inclusive, with the exception of age 15.  
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5.3.1.3 Focus Group of Adolescent Participants’ Length of Time on HAART Treatment 
 
The length of time that the FGAPs have been on HAART treatment is depicted in Table 5.7 
and Figure 5.7. 
 
Table 5.7: Focus Group of Adolescent Participants’ Length of Time on HAART 
Treatment 
FGAP # FGAP (A) FGAP (B) FGAP (C) 
Length of Use 7 9 10 
 
 
Figure 5.7: Focus Group of Adolescent Participants’ Length of Time on HAART 
Treatment 
 
The average length of use of HAART treatment by the adolescents was about 8.7 years. 
Table 5.7 and Figure 5.7 indicated that the longest usage was 10 years, and the shortest 
was 7 years. The length of period is equally distributed. From the above subsection, the 
oldest participant in the focus group was 17 years, and the youngest was 14 years of age. 
This shows that in 2008, when some of them started to take HAART treatment and others 
were already on the programme, all of them were still below the age of seven. 
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5.3.1.4 Focus Group Adolescent Participants’ School Grades  
 
The FGAPs‟ school grades were distributed as reflected in Table 5.8 and Figure 5.8. 
 
Table 5.8: Focus Group Adolescent Participants’ School Grades 
FGAP # FGAP (A) FGAP (B) FGAP (C) 
School Grade 7 9 10 
 
 
Figure 5.8: Focus Group Adolescent Participants’ School Grades 
 
Each FGAP belongs in his or her own grade. Table 5.8 and Figure 5.8 show that the lowest 
grade that an FGAP was in is grade 7 and the highest is grade 10.  
 
5.3.2 Themes Identified From the Focus Group of Adolescent Participants 
 
The subsection that follows presents the themes identified from the focus group session. 
  
5.3.2.1 Access to HAART Treatment 
5.3.2.1.1 HAART treatment initiation 
The majority of the FGAPs had been on HAART treatment for a long period of time and did 
not remember from memory when they had initiated the treatment. FGAP (C), after trying to 
recall, said: 
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―… I do not know when I started; I just remember drinking them ...‖ 
 
FGAP (B) supported the idea by adding:  
 
―I also don‘t remember exactly the date, but I know I was still small and before I even started 
school.‖ 
 
All FGAPs were still very young at the time of HAART initiation. This is echoed by this 
comment: 
 
―I was still very small. But the treatment card will show …‖ 
 
FGAP (A) remembered the specific year he had initiated HAART treatment:  
 
―I started taking the treatment in 2006.‖ 
 
The majority of the FGAPs cannot recall from memory when they initiated the treatment. 
 
5.3.2.1.2 Experiences with HAART tablets 
The FGAPs‟ concern with the tablets was the bitterness of the taste and the difficulty in 
swallowing them. FGAP (B) started by simply saying: 
 
―The problem was the swallowing of the bitter tablets.‖ 
 
FGAP (A) added: 
 
… the tablets are hard to swallow, they are bitter when you have to swallow, and it is 
not nice. I used to drink many tablets, maybe ten tablets two times a day. I had to 
swallow all of them like that. I used to just put all of them in my mouth at the same 
time and drink water, but some of them would be stuck on the throat [indicating the 
throat with her hand], and it was hard to drink but I must drink. 
 
This is when FGAP (B) continued:  
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Me too, ‗nami futhi, aya baba lamapilisi‘ (meaning, me too, I find the tablets to be 
bitter), so it was difficult but now I don‘t take as many tablets as before, now I take 
two tablets at 7 o‘clock in the morning and 7 o‘clock at night. Now it is easier to take 
the tablets. 
 
The transition from multiple tablets to one tablet per day proved to be a pleasant introduction 
to the participants:  
 
Now I only have to take one tablet per day, and it does not get stuck on my throat, 
and it is easier to take the tablets. My weight has increased and the tablet that you 
take once a day, you must weigh a certain weight before they can give you that 
tablet, so because I was drinking the many tablets before and I am gaining weight so 
the doctors at the clinic decided I can start taking the one tablet per day, added 
FGAP (A). 
 
5.3.2.1.3 Purpose for HAART treatment 
All of the FGAPs knew their purpose for taking treatment. This is exemplified by FGAP (A) 
who stated:  
 
―I know I am taking the treatment for HIV … I respect and I know I am HIV positive.‖ 
 
FGAP (C) also reported:  
 
―I know I am HIV positive, and I must take this treatment.‖ 
 
Furthermore, the remarks of FGAP (B) were:  
  
―I know I have this illness, HIV, and if I don‘t take treatment, I will fall sick. I know that I am 
taking treatment for HIV.‖ 
 
The FGAPs understood that if they did not take the medication, they would fall sick.  
 
5.3.2.1.4 Significance of HAART treatment 
The participants seemed to understand the significance of being on HAART as seen from 
FGAP (B)‟s utterances. 
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FGAP (B) revealed: 
 
―The treatment is important because it keeps us healthy. So taking the treatment means we 
can stay alive.‖ 
 
The FGAPs believed that the treatment keeps them healthy and alive. In her words, FGAP 
(A) stated:  
 
―I must drink because I want to be alive.‖ 
 
The knowledge of family members who had passed on successfully through HIV encouraged 
the participants to adhere to their treatment. FGAP (A) went on to disclose:  
 
―… my Mom died because of this disease and so I must take medication so I can stay alive.‖ 
 
The benefits of HAART treatment was physically visible to the adolescents, thus giving them 
encouragement to adhere to treatment. 
 
5.3.2.1.5 Challenges of HAART treatment 
HAART treatment seems to get in the way of the adolescents‟ social life, as adolescent 
participants must make time to take their medication even when out with friends, which is not 
always practical.  
 
FGAP (A) put this into words when stating: 
 
―For me, you see I have friends, and I stay out late hanging with my friends on the streets 
chilling and sometimes time flies by and I come home and the time for medicine is gone.‖ 
 
HAART treatment is a lifelong commitment which is viewed by most of the adolescents as 
hindering social life. The limited choice to either adhere or fall sick leaves the adolescents 
with unresolved issues that could lead to poor adherence to the HAART treatment.  
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5.3.2.1.6 Benefits of HAART treatment 
The FGAPs understood the benefits of being on HAART treatment.  
 
FGAP (B) shared:  
 
―I know I am healthy because of the medication, so it helps me a lot.‖ 
 
FGAP (C) reported sufficient understanding of the benefits of HAART treatment as seen in 
the following quote:  
 
―I am also ok, I know if I was not taking the medication I would not be like this; maybe I 
would be sick.‖ 
 
HAART treatment seemed to give the participants hope and ambitions.  
 
FGAP (A) brought this out when highlighting:  
 
―I must drink because I want to … grow up and be a chef.‖ 
 
The effects of HAART treatment were visible to the adolescent. Their physical growth was 
positively linked to HAART treatment, leading to sustained adherence and a sense of 
hopefulness. 
 
5.3.2.2 Disclosure, Stigma and Denial 
 
Although it was not easy for the family members to disclose to the FGAPs, the guardians 
seem to be the ones who were left with the task of disclosing to the FGAPs. 
  
FGAP (B) recalled: 
 
―… my aunt told me about it.‖ 
 
Sometimes health care professionals have to be the messengers, as FGAP (C) narrated:  
 
My grandmother told me I am HIV positive. I was always sick, attending hospital in 
and out frequently. Grandmother was told by the doctors about my HIV status and 
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they tried to withhold information from me and I asked them to be honest with me 
because it is my life after all. I even asked the doctors, though they were reluctant to 
tell me, but finally I persuaded them to tell me, and they told me. 
 
Disclosure is of importance to the focus group adolescent participants. Given a choice, the 
FGAPs would prefer disclosure to be done by someone who would be in a position to 
answer their follow-up questions. 
 
5.3.2.2.1 Death of parents 
Some of the parents of the focus group adolescent participants have passed away. The 
sense of bereavement towards loss of parents is experienced at a young and vulnerable 
stage of development. 
 
―My mom passed away,‖ responded FGAP (B), when asked about biological parents.  
 
FGAP (A) lamented:  
 
―My mom died of this illness, and she left me when I was very small. Many people are dying 
of this illness; that is why I don‘t like talking about it.‖ 
 
Two of the FGAPs‟ biological mothers had passed away. The FGAPs felt a sense of being 
abandoned by their mothers, whether they had passed on or not. FGAP (C) had a different 
recollection of her mother:  
 
… she took me to the hospital one day. When we were at the hospital, she said I 
must wait for her by the corner; she is coming back; she is going to buy me some 
sweets. She never came back. I was small, and now I am sixteen and a half years 
old, and she has not come back from the sweets. 
 
The only living mother of the FGAPs did not live with her child and was also HIV positive: 
 
―Mom also has this HIV … my mom has three other children, and she does not stay with any 
of her children,‖ said FGAP (C). 
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The topic of biological fathers did not come up in the group discussion. This might suggest 
that not every adolescent was struggling with the loss of a parent or the father‟s 
whereabouts were unknown. 
 
The support from significant family members contributes to enhanced adolescents‟ 
adherence to HAART treatment. Support targeted specifically at FGAPs such as emotional 
and related support encourage adherence to HAART treatment. 
 
5.3.2.2.2 Parents, guardians and caregivers of adolescent participants on HAART 
treatment 
All FGAPs were under the care of guardians. The guardians of these FGAPs included an 
aunt, a grandmother and a house mother in a children‟s home. The FGAPs narrated, with 
FGAP (C) initiating: 
  
―I stay with my aunt.‖ 
 
FGAP (B), on the other hand, noted: ―I have been staying in a Children‘s Home.‖  
 
The FGAPs spoke fondly of their guardians and recognised the support and encouragement 
they received from their guardians. FGAP (B) recalled affectionately:  
 
―The house mother also encourages us and supports us. She makes sure there is food to 
eat before we take the medication.‖ 
 
The focus group adolescent participants appreciated the support given by their parents, 
caregivers and guardians. This support contributed to sustained adherence to HAART 
treatment with visible health benefits. 
 
5.3.2.2.3 Coping mechanisms used by FGAPs 
Having peers who are also on HAART treatment was comforting for FGAPs. This idea was 
supported by the following statement by FGAP (A):  
 
―At school, I have some friends, and some of them are taking treatment and we are like ok, 
we don‘t have problems.‖ 
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By supporting one another and reminding one another of their medication was a coping 
mechanism; that is what FGAP (C) had to say:  
 
―The other children in the home are also taking medication, so we all come together at 7 
o‘clock to take medication, and we remind each other when it is time for medication.‖ 
 
There have also been indications that friends, in the form of humans and pets, formed an 
important part of the FGAPs‟ network, as FGAP (B) explained:  
 
―My friend has some dogs next door, so I spend a lot of time with him looking after the dogs 
and I don‘t always remember that I am HIV positive.‖ 
 
To the majority of the participants‟ friends were found to be supportive and non-judgemental. 
The fact that the FGAPs knew of other people on HAART treatment, they saw being on 
HAART treatment as normal, as indicated by FGAP (B): 
 
―… my friends are nice about my HIV status. You know many people take medication, so it is 
like it is a normal thing around our street.‖ 
 
The FGAPs did not easily disclose their status to their intimate partners. Condom usage was 
used as a coping strategy to protect each other from reinfection and disclosure avoidance. 
As explained by FGAP (C):  
 
―I also have a girlfriend, and we must use the condom, and I must use the condom because I 
don‘t talk about the HIV with her, and I don‘t know if she has the HIV or not.‖ 
 
Emotional coping is found in different sources. Some of the adolescents found a special 
bond with pets such as a dog. It appears pets performed a soothing role for some of the 
adolescents. Still for others, having a human person to talk with was a preferable means of 
support. 
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5.3.2.2.4 Role of religion  
Most of the FGAPs reported that religion was a huge source of support, anchoring them 
through rough times as demonstrated by FGAP (C): 
 
―But at the Children‘s Home, we do Bible reading, and we each read a verse before we go to 
sleep, and we go to church on Sundays, so the praying helps a lot.‖ 
 
Some adolescents found a connection with a higher being to play a hope-instilling role. As 
long as they practiced their prayers and went to church from time to time, a sense of 
purpose and hope was instilled which helped make day-to-day life a lot easier to cope with. 
 
5.3.3 Themes Identified from Individual Adolescent Participants’ Interviews 
 
Thematic analysis of the individual adolescent participants‟ interviews resulted in the 
identification of the categories and themes that follow.  
 
5.3.3.1 Access to HAART Treatment 
 
The category access to HAART treatment relates to purpose upon which the following 
themes were developed: purpose of HAART; initiation of HAART; availability of HAART; 
multiple tablets; multiple times of taking HAART; fixed-dose combination; as well as 
adherence or non-adherence to HAART. 
 
5.3.3.1.1 HAART treatment initiation  
The majority of adolescent participants in the study raised concerns that serious and 
continuous sickness, initially unidentified, led them to be taken to the hospital.  
 
This is what participant E said: 
 
… in the beginning I was sick for a long time, so my aunt took me to the hospital and 
they took my blood, and they told us I must come back next week. And when we 
came back, they spoke to us that I am sick, and I must take this treatment. 
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Some adolescent participants were still very young at the time of HAART treatment initiation. 
They claim that blood tests were taken, tests done on them, and that these were used to 
diagnose them positively with HIV and AIDS. Adolescent participant D brought this out: 
 
―I was constantly sick and weak and had to be in hospital many times until they tested my 
blood and told me I had HIV.‖ 
 
―I started taking treatment in October 2007. Initially, I was very sickly and at some point I had 
to be taken to the hospital …‖ 
 
The initial process of HAART treatment commenced while being inpatients at the hospital. 
After being discharged, continuing HAART treatment was prescribed. Sometimes the 
adolescent participants did not know or remember when they started the treatment because 
it was too long ago and they were very young, as demonstrated by adolescent participant E:  
 
―I was still very young; my grandmother just told me I must drink medication in the morning 
and in the evening.‖ 
 
Some adolescent participants initiated the HAART treatment at a very early age. Other 
participants started the treatment as inpatients at the hospital; then they continued the 
treatment as a prescription.  
 
5.3.3.1.2 First time experience of HAART tablets 
The adolescent participants‟ first time experience of prolonged HAART treatment included 
the pressure to terminate sporting activities because of being weak and having to 
concentrate on the treatment as adolescent participant F explained:  
 
―HIV frustrates my life plans. I love playing soccer and sometimes when I am weak I must 
stop playing soccer and take medication.‖ 
 
The HAART treatment tablets were also considered to be too many and taken too many 
times.  
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Adolescent participant G reported his experience as follows: 
 
―I take my tablets two times a day. I take three tablets in the morning and one tablet in the 
evening. My aunt reminds me to take my tablets most of the times.‖ 
 
The HAART treatment seemed to annoy these adolescents because sometimes the time for 
pills arrived when there was no food or thick meal to eat, as adolescent participant E noted:  
 
―… sometimes, I take my pills before I eat because the food is not ready, sometimes there is 
no bread to eat.‖ 
 
Taking the medication before eating would make the pill uncomfortable in the adolescent‟s 
stomach such as feeling like vomiting, and sometimes it led to dizziness, as noted by 
adolescent participant F:  
 
―… sometimes, the pills make me vomit.‖ 
 
The sentiment was shared by adolescent participant A, who stated: 
 
―… sometimes I must take my pills, and there is no food. So I take pills, but I feel dizzy, like I 
vomit.‖ 
 
The majority of the adolescents reported that in the initial introduction of HAART treatment, 
the treatment was viewed with disgust, especially the taste of the tablets. Furthermore, the 
many tablets that had to be swallowed were experienced as traumatic and discouraging 
towards adherence.  
 
5.3.3.1.3 Purpose for HAART treatment 
Some of these adolescent participants reported that they were told or instructed in a harsh 
manner to drink the prescribed medication, while others experienced it as polite. The 
purpose of taking HAART treatment was initially not disclosed to the majority of the 
adolescents. This is exemplified by adolescent participant A, who indicated:  
 
―… the doctors told me I must take treatment because I am HIV positive.‖ 
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The foregoing suggests that the negative attitude towards following HAART treatment was 
influenced by the manner in which they were introduced to the process. The harshness 
might have instilled fear and a feeling of hopelessness. As a result, they felt discouraged 
from the onset of the treatment process. The human element, therefore, is at the centre 
stage when adolescents resume their HAART treatment. Adolescent participant B also 
reported: 
 
―I know I must take this treatment because I am HIV positive, and the treatment will help to 
improve my life so that I am not ill.‖ 
 
The medication helped to improve their health, as noted by adolescent participant A: 
 
―I now feel that the treatment helps a lot; maybe if there was no treatment, I would have 
passed away like my mother.‖ 
 
When the participants took the treatment as prescribed, they stayed healthy or did not fall 
sick. Adolescent participant D noted:  
 
―I understand I must take my pills to keep well, otherwise I will die.‖ 
 
She also went on to say:  
 
―… before, I was not happy about the treatment. I was scared I would die like my parents. I 
used to receive a grant, but now the grant has stopped because my viral load is high.‖ 
 
The medication was only not working well when it was not taken regularly. Some of the 
adolescent participants knew that the reason for taking treatment earlier is that they are HIV 
positive. Apparently if they all knew beforehand, many would have acknowledged their HIV 
positive status. They drank the medication mainly because they were told to do so. In the 
earlier years of taking the medication, they always remembered to drink the medication. As 
time passed, the prolonged taking of the medication upsets the adolescent participant users. 
Drinking twice often felt like it was too many times. The information that they were HIV 
positive reached adolescent participants when they read their hospital file. 
 
Drinking HAART treatment evidently helped these adolescent participants. Because of the 
medication, the adolescent participants sometimes felt as if they were no longer sick. 
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5.3.3.1.4 Challenges of HAART treatment 
Most of the adolescent participants reported that drinking times of the medication proved to 
be a boundless challenge for most of these adolescent participants. The times of drinking 
were believed to be fixed, and the adolescents used to miss them due to other commitments 
and drank them later. Sometimes because of forgetting, or being in a rush to go somewhere, 
the adolescent would also miss a dose. Missing the medication can be dangerous.  
 
As already expressed, many of these adolescent participants sometimes forgot to drink their 
medication. Adolescent participant A expressed it this way:  
 
―I set the alarm on my phone, and I usually remember to take medication; when I am late, I 
am late by 10 minutes.‖ 
 
While there was the challenge that the adolescents hated to take the treatment, these 
adolescents also hated to be sick. Adolescent participant E describes the challenges he has 
with HAART treatment as follows:  
 
I don‘t like this treatment. It is a burden to take treatment. Sometimes when I have to 
go somewhere, I must take my treatment with me. Sometimes I go somewhere, and I 
don‘t come back on time, and I must worry about the treatment, it is not nice. 
 
The problem experienced by these adolescent participants with HAART treatment was 
mostly when many tablets had to be taken many times. However, when one tablet a day was 
used, the adolescents seemed a little more comfortable. Adolescent participant 4 explained: 
 
―I used to forget to take my pills, and we went to the hospital, and the doctors gave me pills 
that I must take only once a day, so it helps now.‖ 
 
The adolescent participants have largely realised that the treatment was helpful.  
 
5.3.3.1.5 Negative approach to HAART treatment 
Some adolescent participants felt inconvenienced or burdened by the treatment, but they 
had to live with it because it kept them alive. Adolescent participant F commented on his 
dissatisfaction when frankly stating: 
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―I don‘t like this treatment.‖ 
 
Adolescent participant E reiterated similar sentiments: 
 
―… it is a burden to take treatment.‖ 
 
Taking treatment sometimes made them sad. When these adolescents had to travel, they 
needed to take the medication along. Adolescent participant E went to mention:  
 
―Sometimes when I have to go somewhere, I must take my treatment with me.‖ 
 
Some of the problems experienced included forgetting medication at home when they 
travelled: 
 
―Sometimes I go somewhere, and I don‘t come back on time, and I must worry about the 
treatment.‖ 
 
Adolescent participant E concludes: 
 
―It is a burden to take treatment. Sometimes when I have to go somewhere, I must take my 
treatment with me.‖ 
 
FGAP (C) remarked that it is easier to take treatment at home where there is support: 
 
The other children in the home are also taking medication so we all come together at 
7 o‘clock to take medication, and we remind each other when it is time for 
medication. The house Mother also encourages us and support us; she makes sure 
there is food to eat before we take the medication. 
 
The treatment reminds the adolescents that they are sick, and that reminder depresses 
them. As 19-year-old adolescent participant G stated:  
 
―Sometimes, when I take the medication, it reminds me I am sick, but I just have to take the 
medication.‖ 
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The burden of medication versus maintaining wellness is the ultimate point of consideration. 
The consequences of not adhering to treatment need to be emphasised so the adolescent 
participants may understand the value of HAART. 
 
5.3.3.2 Disclosure, Stigma and Denial 
 
The issue of disclosure, be it partial or full disclosure, was identified by most of the 
adolescent participants.  
 
5.3.3.2.1 Death of parents 
Some adolescent participants‟ parents in the same condition had passed away when many 
of the ones who participated in the study were still very young. This expression highlights 
that fact:  
 
―My mother passed away when I was small; my mom passed away in 2003, she was sick for 
a long time.‖ 
 
Furthermore, another adolescent participant G stated:  
 
―My dad also died of HIV illness in 2001.‖ 
 
Some of those who lived with their parents were also on HIV treatment. Adolescent 
participant E described it this way: 
 
―My mom had to go back to Zimbabwe because she was so sick. My father stays in 
Limpopo, and he does not take treatment.‖ 
 
The causes of the parents‟ deaths were sometimes unknown, but in some cases, it was 
believed to have been caused by AIDS. This is evidenced through the conversation with 
adolescent participant D:  
 
I believe I got my illness from my mom because I was sick long time before I started 
having a girlfriend. In 2003, my mother died because she was sick of HIV. My dad 
also died of HIV illness in 2001. 
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The feeling that participants had that other children were able to speak to their biological 
parents while they could not speak to theirs also caused them some frustration. Adolescent 
participant D remarked: 
 
―Sometimes I wish my mother was alive, at least I would know certain things unlike now.‖ 
 
Some of the adolescent participants expressed missing their biological parents. They wished 
that their biological parents were alive, and maybe their lives would have turned out 
differently. 
 
5.3.3.2.2 Effect on interpersonal life  
There were those who were scared to play with peers. Adolescent participant D states 
regarding sharing their information about HIV and AIDS and treatment:  
 
―I was reluctant to play with other kids before; I was scared of their reactions.‖ 
  
The thought of telling friends scared them because they felt they may be laughed at. Some 
adolescent participants did not trust their friends and did not tell them about their status or 
treatment, as they did not want them to know. Adolescent participant C captures this 
experience as follows:  
 
―my friends, I don‘t tell them about my HIV status because I am scared they will laugh at me 
when I tell them.‖ 
 
Also, some of the adolescent participants did not trust their friends mainly because when 
they talked, they seemed to be judgemental, and especially about people who are HIV 
positive. For example, a participant disclosed:  
 
―I have friends and schoolmates, but they do not know about my HIV status. I don‘t feel safe 
disclosing my status to them because they like criticising this disease.‖ 
 
The above is the experience of adolescent participant D. However, some adolescent 
participants experienced good feedback and support from their peers, as adolescent 
participant B states:  
 
―My friends are helpful.‖  
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In addition, adolescent participant F compares:  
 
―… when I have problems, I rather speak to my friends than my aunt …‖ 
 
Adolescent participant F found her friends to be informative: 
  
―… my friend told me the ARVs don‘t kill, they are to help me with my life and not for dying.‖ 
 
Having friends in the same status is a comfort irrespective of whether they used the same 
treatment or not. Sharing stories was seen as very easy. Adolescent participant D relates 
her experience as follows:  
 
―I have two friends, ones takes ARVs like me, and the other does not take ARVs but is also 
HIV positive. And we share our stories, and so it becomes easier to drink treatment.‖ 
 
Relating with friends who are experiencing similar health concerns led them to not feeling 
alone, thus creating some sense of group support. Adolescent participants preferred to chat 
with fellow adolescents on health concerns, and this was seen as positive by the adolescent 
participants. 
 
The professionals at the hospital seemed to have been a common factor in comforting these 
adolescents. This is the case because those who felt disrespected as well as those who felt 
treated well at their homes found comfort at the hospital.  
 
Most of the adolescent participants talked and shared with friends as a coping mechanism 
for the HAART. Adolescent participant D finds talking with friends to be a way of dealing with 
her HIV status:  
 
―I have two friends, one takes ARVs like me, and the other does not take ARVs but is also 
HIV positive. And we share our stories, and so it becomes easier to drink treatment.‖ 
 
A female adolescent participant B felt her friends are the only coping mechanisms she has. 
She frankly mentioned:  
 
―I just talk to my friends.‖ 
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Some adolescent participants mentioned that they use drugs as a way of dealing with their 
reality. In this regard, adolescent participant C stated: 
 
―I use drugs and dagga as a means of coping.‖ 
 
The use of drugs and talking with friends was seen as a way of coping with the reality of 
being HIV positive by some of the adolescent participants.  
 
5.3.3.3 Psychosocial Support 
 
Support systems for the adolescent participants were reported as an important element in 
ensuring consistent adherence to HAART treatment. The support could come from various 
areas of their lives, be it from within themselves, or from parents, guardians or caregivers or 
friends and peers, as well as support systems from the government. There were negative 
and positive responses to parental support in relation to HAART treatment. 
 
5.3.3.3.1 Parental support for adolescent participants on HAART treatment 
Some participants perceived support from their significant others as hostile. Some of these 
adolescent participants felt that their guardians and caregivers were too harsh when dealing 
with them, such as shouting at them discourteously in the presence of other children in the 
house or friends they interact with in the streets. For example, this comment was made by 
adolescent participant F:  
 
―One day, my grandmother was very angry with me because of my carelessness … during 
my periods … she just shouted.‖ 
 
Such treatment seemed to confuse the adolescent participants. Adolescent participant F 
continued:  
 
―She just shouted at me in front of all my cousins, and I was so shocked. I think I 
must have been about 15 or 16 years old when this happened; I was angry and 
wondered why she did not tell me this before.‖ 
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Guardians did not necessarily help, as some are unapproachable. The following comment by 
adolescent participant F illustrated this point:  
 
―My aunt is not approachable, and when I have problems, I rather speak to my friends than 
my aunt. She likes shouting a lot.‖ 
 
While others, though helping to take medication, made negative comments that could hurt a 
young adolescent. In contrast to negative and harsh family support, some participants felt 
their guardians treated them kindly and were very supportive, as supported by adolescent 
participant C:  
 
―I have encouragement and support from grandmother, aunt and my big sister and an older 
brother.‖ 
 
The foregoing was supported by adolescent participant A, who stated:  
 
―… my paternal aunt treats us well, and she tries her best to provide most of our material 
needs, like going to school and having food. Today, she accompanied me to the clinic visit.‖ 
 
Most of the adolescent participants felt discouraged when their caregivers shouted at them. 
For the most part, a gentle approach was preferred by the adolescent participants, yet they 
were not as cooperative when the gentle approach was used and were in opposition to 
harsh treatment. 
 
The guardians of these adolescent participants included family members such as aunts, 
grandparents (for example, grandmothers), and step parents, among others. For instance, 
adolescent participant B reported:  
 
―I stay with my mom‘s mom …‖ 
 
Adolescent participant C and adolescent participant F remarked as follows, respectively: 
 
―I am under the guardianship of my mother‘s older sister.‖ 
 
―I stay with my sister now.‖ 
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There are usually other children in the homes in which the adolescent participants lived.  
 
―I have encouragement from my grandmother, aunt and big sister who has two kids,‘ 
adolescent participant C emphasised. 
 
She continued to say: 
 
―I stay with my aunt and her four children.‖ 
 
The presence of a loving caregiver seemed to offer emotional support to the adolescent 
participant who is taking HAART treatment. 
 
5.3.3.3.2 Sexual relations and condom usage while on HAART treatment 
Even an intimate partner may scare an adolescent from sharing their stories. The use of a 
condom during sex is sometimes not pursued, as demonstrated by adolescent participant G: 
 
Having a girlfriend sometimes, it is hard to tell the girlfriend. The doctor told me 
various ways of getting HIV infection: accident, unprotected sex and from your 
mother. Sometimes, the condom can work and sometimes it is not so easy you see. I 
know I must be protected, but sometimes, it does not happen. I had a girlfriend 
before, and I told her about my HIV status, so she know, and we would use condoms 
most of the times, but the relationship ended, and now I don‘t have a girlfriend. 
 
Pregnancy occurred among this group – who did not use a condom – and without the 
adolescent participant imagining it would occur. It could also points out that as young HIV-
infected people, the adolescents engaged in unprotected sex without a condom. There were 
some adolescent participants who used protection almost always when they wanted to have 
sexual intercourse.  
 
5.3.3.3.3 Role of religion in the adolescent participants‘ lives 
Some adolescent participants seemed to have started to doubt the ability of religion to 
intervene. The 16-year-old participant seemed conflicted by the role of religion versus 
HAART treatment, as quoted from adolescent participant F:  
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―I struggle a lot with religion and treatment because I believe in the healing power of prayer 
and God, and my sister does not understand that, so sometimes we fight about that.‖ 
 
Sometimes it was the adolescent disbelieving that religion or God could help, since they had 
been sick for too long. Adolescent participant B disclosed: 
 
―I am a Christian, and they teach us to believe in God at church. Sometimes, when I take 
treatment, it is like I don‘t believe that God can heal me.‖ 
 
Some of the adolescent participants were left questioning the value and role of religion 
versus their illness. They questioned the role of God, and this usually led to arguments with 
close members as well as to poor adherence to HAART treatment. 
 
Still, for other adolescent participants, religion was viewed as important and instilling hope. 
For the positively inclined adolescent participants, hope was seen, and adherence to HAART 
treatment was much higher. 
 
5.3.3.3.4 School performance 
School attendance generally suffered for most of the adolescent participants. They tended to 
be more absent from school, having to go to hospital for medical check-up and treatment 
collection. As a result, some of the adolescents would experience feelings of 
discouragement and hopelessness about the prospects of their own lives.  
 
Adolescent participant A felt hopeless about life. She felt that she was already behind in her 
grades, and her life was not an easy one. She expressed her feelings as follows:  
 
I feel so hopeless, and l just want to give up on my own life. I doubt I will even pass 
Grade 9. I am 18 years old and in Grade 9. I will fail Grade 9 because I don‘t really 
have a very easy life. 
 
Adolescent participant C echoed adolescent participant A‟s bleak view: 
 
Because of my sickness when I was younger, one time I stayed in hospital for two 
months and I missed out so much from school, and I had to repeat Grade 3. I also 
repeated Grade 5, and I am only doing Grade 9 now, and most people my age are 
finishing Matric. So I sometimes feel that this sickness makes me slow at school. 
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Illness and hospital visits and check-ups lead to disruption in the adolescent participants‟ 
school attendance, thus leaving them feeling that they constantly have to play catch-up as 
far as schooling is concerned. 
 
5.4 PROFILES AND NARRATIVES OF PARENTS, GUARDIANS AND CAREGIVER 
PARTICIPANTS 
 
This section presents the profiles and narratives of PGCPs on adolescents‟ HAART 
treatment. This entails people who were taking care of the adolescents who were on HAART 
treatment at the Tembisa Hospital at the time of the study. Three PGCPs participated in the 
study. 
 
5.4.1 Profiles of the Parents, Guardians and Caregiver Participants 
 
The PGCPs who participated in the study were distributed across 100% of females. Their 
employment status was about 33% unemployed (but previously employed) and about 67% 
employed. All those who were working were in a health facility and consisted of nurses. They 
also consisted of guardians at homes and children‟s homes and stepmothers.  
 
The PGCPs needed to have been involved in caring and/or interacting with these 
adolescents being treated for a long period, preferably over a year to match the required 
period of the adolescents on which they were expected to narrate. They all indicated so, and 
others were known to be satisfying the profile specified. However, for this study, it was not 
necessary to report on the exact period they had been in these roles, as it was only enough 
to confirm that they had been involved for more than a year. 
 
5.4.2 Themes Identified with the Parents, Guardians and Caregiver Participants 
 
The PGCPs of adolescents taking HAART treatment were included in the research. 
Adolescents taking HAART treatment often need the emotional support of their PGCPs in 
order to ensure adherence. As such, the views of the PGCPs thus became vital in order to 
attain a relatively complete experience of adolescents as viewed by those who are 
responsible for their well-being. The next subsection presents adolescents‟ experiences as 
seen from the viewpoint of the parents, guardians and caregivers. 
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5.4.2.1 Access to HAART Treatment 
5.4.2.1.1 Durations since initiating HAART treatment 
The adolescents started taking HAART treatment when they were as young as six years old. 
Some started in 2006, while others in 2010. Some started six to eight years ago. Some 
came to the orphanage after being dropped by a parent. 
 
5.4.2.1.2 Adolescents‘ knowledge of the HAART treatment 
The narratives of PGCPs highlighted the fact that adolescents seemed to know the reasons 
for being on HAART treatment, as they had been informed by the hospital professionals and 
the caregivers who were looking after them. PGCP (B) stated:  
 
―… she knows because I personally made sure I inform her. I also brought her to the hospital 
so that the doctors can talk to her.‖ 
 
It has been a common experience shared by PGCPs that most adolescents were informed 
that the treatment was for maintaining good health and preventing sickness deterioration. 
 
5.4.2.1.3 Meaning of being on HAART treatment as understood by adolescents 
The PGCPs‟ narratives indicated that the adolescents were very sick before they started the 
treatment. They would frequent the hospital many times. However, at the time of the study, 
many of the adolescents were showing notable improvement in their health. 
 
Some PGCPs indicated their doubts about the adolescents‟ understanding of being on 
HAART treatment. The concern is captured by PGCP (B) as follows:  
 
―… sometimes I think he understands, but then he turns around and not take treatment; then 
I wonder if he understands.‖ 
 
The way the adolescents behaved on treatment discipline made the PGCPs doubt if they 
understood the purpose of the HAART treatment. The PGCPs‟ impressions were that these 
adolescents knew and understood reasons for the treatment. At some point, they were 
wondering if the adolescent really knew as they were defaulting on treatment. PGCP (C) 
states her frustration with the adolescent as follows:  
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―… she does not seem to be responding well because she refuses to take treatment, and 
when we ask her does she realise the medication is keeping her healthy, she just shrugs 
and keeps quiet.‖ 
 
There was probably some consolation the adolescent participants derived when they used 
the medication, and that could in all likelihood be a major incentive for many of them to 
tolerate the treatment. High CD4 counts bothered the PGCPs. The PGCPs, however, 
seemed to know the meaning of being on HAART treatment.  
 
5.4.2.1.4 PGCPs‘ challenges about adolescents on HAART treatment 
PGCPs faced challenges about adolescents on HAART treatment, in addition to the 
challenges of parenting. Long working hours seem to have prevented regular monitoring of 
the adolescents taking HAART treatment, as noted in the interview with PGCP (A):  
 
―I used to work long hours at my previous job. I would not be sure he is taking his 
medication.‖ 
 
Another challenge was that the adolescents would pretend to take the pill through the mouth 
but immediately threw it down the drain trying to flush it. PGCP (B) reported this when she 
revealed about the adolescent:  
 
―she throws away the tablets.‖ 
 
The aforementioned was supported by PGCP (C) who reported: 
 
―sometimes I see her throwing the tablets into the kitchen sink.‖ 
 
Consequently, defaulting bothered the PGCPs.  
 
Based on parents and caregivers‟ perspective, the adolescents also stayed out of the house 
up to late hours, and medication time often passed without them taking it. The following was 
PGCP (A)‟s assertion:  
 
―I have to go looking for him, and this makes it hard for me because I have my own children 
that I have to take care of.‖ 
140 
 
 
There was therefore the challenge of having to look for the adolescent to come and take 
their HAART treatment. It was hard for the PGCP, as their own children also needed care.  
 
Another challenge was these adolescents‟ refusal to talk when confronted about their 
defaulting behaviours. PGCP (C) commented:  
 
―… and when I talk to her, she just keeps quiet.‖ 
 
These adolescents under study were said to be unapproachable. As a result, it was 
extremely difficult to talk to them.  
 
Some of these adolescents seemed to have been in denial, arguing that they were not sick. 
For example, PGCP (C) indicated:  
 
―when we remind her it is medication time, she becomes angry, and her facial expression 
changes, and she is not approachable anymore. She tells us she is not sick, and so she 
does not have to take tablets.‖ 
 
Another challenge for the PGCPs was to get the adolescents on HAART treatment to 
appreciate the treatment for their own health. The adolescents needed to be encouraged to 
take medication, as stated by PGCP (C): 
 
When we remind her it is medication time, she becomes angry, and her facial 
expression changes and she is not approachable. Most of the times, when we insist 
she takes the medication, she puts it in the mouth and then she spits the tablets out. 
 
―I used to work long hours at my previous job. I would not be sure he is taking his medication 
ok, so I resigned so l can be able to monitor his treatment closely,‖ stated PGCP (A). 
 
Behavioural difficulties by the adolescents lead to failure to take treatment at the required 
time. Sometimes when the adolescents are at home, they pretend to be taking treatment, 
only to spit out the medication later, thus rendering the treatment ineffective. The PGCPs 
seemed to get frustrated by the behaviours of these adolescents. They pointed out that 
these adolescents could help themselves by making it easy for the PGCPs to help them. 
This was an acknowledgement that the adolescents were not doing enough to help 
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themselves, and this was confirmed by constant forgetting of the adolescents to take 
medication. 
 
5.4.2.1.5 Challenges experienced by adolescents on HAART treatment 
According to PGCPs who took part in the study, peers and friends seemed to bother the 
adolescents. Adolescents followed patterns of their peers, without knowing if the peers had 
similar ailment problems. PGCP (A)‟s concern is noted in the following statement:  
 
―he follows peer pressure too much, and he just does what other children do, and he does 
not know if the other children have the same problem as he does.‖ 
 
Peer pressure was mainly a problem identified by PGCPs. The adolescents‟ lives seemed to 
have changed for the worse. They found it difficult when observing healthy children around 
them. They ruled themselves to be different from other children and were perturbed by 
having to take lifelong medical treatment. They also seemed to have lagged behind with 
schooling, as reflected by PGCP (C)‟s words:  
 
―… she is 14 years, and only now she is in Grade 4.‖ 
 
Some PGCPs indicated that school attendance for adolescents under HAART treatment was 
also very difficult. They had been sick for too long, leading to falling behind in their grades. 
HAART treatment has implications for school going, and it becomes a double-edged sword 
to choose whether to go to school and forfeit medical care or attend to medical care and 
forfeit school lessons.  
 
5.4.2.1.6 Benefits experienced by adolescents on HAART treatment 
Based on the experiences of PGCP, the adolescents showed signs of satisfactory recovery 
health wise for those who were taking medication properly. PGCP (B) thus indicated:  
 
―I know treatment will keep her healthy and well. Sometimes I look at her, and I see how 
much well she looks.‖ 
 
There were also positive signs that the adolescents who were confirmed to be taking the 
medication properly had developed physique and had also shown to have gained weight. 
The remark of PGCP (B) captures this accurately:  
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―… look how tall and strong; she looks older than 12 years.‖ 
 
The positive effects of HAART treatment on physical growth are seen as evidence of the 
treatment functioning, therefore encouraging further adherence. 
 
5.4.2.2 Disclosure, Stigma and Denial 
 
Disclosure, stigma and denial are detrimental to the consistent process of HAART treatment. 
Some adolescents are told partially about their illness; they are told that they are sick, 
therefore need to take treatment, without fully disclosing the nature of the illness. For some 
adolescents, they are fully informed of their HIV positive status and the reasons they should 
take HAART treatment. The responses to such partial or full disclosure are discussed below. 
 
5.4.2.2.1 Reaction to being told of being HIV positive 
As reflected from the narratives of PGCPs, the majority of adolescents seemed to have been 
upset by being told of their HIV positive status. Regarding the response to being told of their 
HIV positive status, the adolescents‟ response fluctuated from indifference to anger. In the 
case of PGCP (C)‟s experience, she noted:  
 
―… we told her that she is HIV positive, and she needs to be on treatment so that she does 
not get sick. In the beginning, she was taking the medication, and now she refuses to take 
medication.‖ 
 
Some of these adolescents seemed to have been refusing to take medication sometimes. 
These refusals seemed to have angered some parents and also frustrated them. Many of 
the adolescents seemed to have failed to assist the PGCPs as they refused or got angry 
arbitrarily. 
 
5.4.2.2.2 Mode of information delivery to adolescent regarding adolescent‘s status 
In some cases, the information regarding the HIV positive status and their taking of HAART 
treatment was passed on to the adolescents by PGCPs and hospital professionals. In other 
cases, the PGCP did not know if the adolescents had been told about their status. PGCP (C) 
gave this report:  
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―the Head Mom is the one who broke the news to her, according to what I hear.‖ 
 
My grandmother told me about my HIV positive status. I was always sick, attending 
hospital in and out frequently. Grandmother was told by the doctors about my HIV 
status, and they tried to withhold information from me, and I asked them to be honest 
with me because it is my life after all. I even asked the doctors, though they were 
reluctant to tell me, but finally I persuaded them to tell me and they told me. 
 
The manner of disclosing to the adolescents about their HIV positive status could make or 
break the extent to which adherence to HAART will play out as the adolescent grows up. 
Those who were given open and honest disclosure were much more likely to adhere to 
treatment once developmental conflicts came into play. 
 
5.4.2.3 Psychosocial Support 
5.4.2.3.1 Changes of adolescents‘ homes 
PGCPs pointed out that some previous caregivers of the adolescents who participated in the 
study (could be as many as four), that is, before them, who were on HAART treatment died. 
They indicated that the adolescents were staying with their parents (mainly mothers) before 
and grandparents. PGCP (B) explained:  
 
―Her mother passed away some six years back, and she stayed with her paternal 
grandparents, and since last year, she is with us, her dad and I.‖ 
 
PGCP (A) also describes the constant movement in terms of the adolescent‟s living 
environment:  
 
He used to stay with his mom who passed away, and then he stayed with his dad, 
who also passed away. He then had to stay with my mom, and she also passed 
away last year. So I started staying with him after my mom passed away. 
 
Judging from the experiences of PGCPs, some adolescents who originally stayed with their 
parents had to stay with their grandparents after their parents died. Such adolescents would 
have been cared for by multiple caregivers, and the caregiver at the time of the study was 
the most recent one. There would also be a child belonging to the family, who was not taking 
the treatment. 
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5.4.2.3.2 Peers on HAART treatment 
The concern raised by most PGCP was that most adolescents were at the time of the study 
the only ones under HAART treatment in their households. Being the only one taking 
medication made it hard for them to accept their status. PGCP (C) put it in these words:  
 
―… at one point, we had another child, same age group who was taking medication, and this 
child would take tablets so well and even reminded the other to take medication …‖ 
 
When the adolescents used medication alone, they did not find it encouraging. The support 
of other adolescents who are in the same health condition as them gave them the courage to 
continue taking HAART treatment. 
 
5.4.2.3.3 Father involvement in adolescent regarding adolescent‘s status 
Fathers were found not to be helping in these adolescents‟ welfares. PGCP (B) frankly 
revealed: 
  
―You know how men are. He is not involved at all. He does not even know how many tablets 
she has to take or where the hospital is.‖ 
 
The participating PGCPs were all female, and fathers who were around the environment of 
treatment did not help in any way. Fathers knew nothing about the adolescents‟ schooling. 
   
 
5.4.2.3.4 Coping mechanisms and strategies 
According to PGCPs‟ narratives, the only noticeable coping and intervention methods for 
survival of these adolescent participants were the HAART treatment. For the majority of the 
adolescent participants, medication is the trusted hope to good health for them. As a result, 
due to refusals by some to take medication properly, those who defaulted were showing 
signs of health deterioration. There were rumours of deaths in the past of some who had 
defaulted, but this was not pursued, as participants did not want to share that sensitive point.  
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5.5 PROFILES AND NARRATIVES OF THE HEALTH CARE PROFESSIONAL 
PARTICIPANTS 
 
This section describes the profiles of the HCPPs who were giving treatment to the 
adolescents on HAART treatment at the Tembisa Hospital at the time of the study. 
 
5.5.1 Health Care Professional Participants’ Demographic Characteristics 
 
Table 5.9: Genders of Health Care Professional Participants 
 
 Male  Female  
Percentages  18.2 81.8 
 
 
 
 
 
Figure 5.9: Genders of Health Care Professional Participants in Percentages 
 
The pie chart used in Figure 5.9 easily displays categories of the participants in few 
categories. Table 5.9 and Figure 5.9 show the gender distribution of the HCPPs to have 
been 18% male and 82% females. This highlights that the HCPPs comprised mainly 
females. 
 
18,2 
81,8 
Male
Female
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Table 5.10: Ages of Health Care Professional Participants 
Years (25-30) (30-35) (35-40) (40-45) (45-50) (50-55) 
Percentage  27.3 9.1 18.2 9.1 27.3 9.1 
 
 
 
 
Figure 5.10: Ages of Health Care Professional Participants 
 
The ages in Figure 5.10 were displayed on a histogram, which is suitable for continuous 
random variables (Johnson & Wichern, 2002). Table 5.10 and Figure 5.10 depict the ages of 
the participants. From the table and figure, it is evident that about 27% of HCPPs were 
between 25 and just below 30 years old. Additionally, about 9% of them were 30 to just 
below 35 years old, and about 18% of them were 35 to just below 40 years old. It is further 
indicated that about 9% of the HCPPs were 40 to just below 45 years old, whereas about 
27% of them were 45 to just below 50 years old. Finally, about 9% of the HCPPs were 55 to 
just below 60 years old. 
 
Furthermore, the descriptive statistics on the ages of the HCPPs are calculated from 
grouped data as follows: 
 
Let    denote the class midpoint of class interval number , and    be the corresponding 
frequency. 
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Estimating the mean of grouped age data 
According to Newbold, Carlson, and Thorne (2009), an estimate of the mean of the 
population, denoted by  from which the data is drawn, can be calculated from the grouped 
data as: 
 
 
 
 
 
 
Estimating the standard deviation of grouped age data 
An estimate of the standard deviation, according to Ghahramani (2000), is given by: 
 
 
 
 
 
Estimating the coefficient of variation of grouped age data 
According to Reed, Lynn, and Meade (2002), the coefficient of variation (  ) is defined as 
the ratio of the standard deviation s to the mean m: 
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A small coefficient of variation indicates stability. From this data, the coefficient of variation is 
estimated as: 
 
 
 
 
 
The ages are not too widespread (according to a small value of the coefficient of variation), 
even though there are advantages of youth (for future and succession) and notable maturity 
age. 
 
Estimating the median from grouped age data 
 is the lower class boundary of the class interval containing the median;  is the total 
number of data;  is the cumulative frequency of the class interval before the median class; 
 is the frequency of the median class; and  is the class width. According to Harris 
(2000), an estimate of the median of the population, denoted by  from which the data is 
drawn, can be calculated from the grouped data as: 
 
 
 
The median class is (35-40), , , , , and . The value 
of the estimate of the median is: 
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Estimating the mode from grouped age data 
 is the lower class boundary of the class interval containing the median;  is the 
frequency of the class interval before the modal group;  is the frequency of the median 
class;  is the frequency of the class after the modal class; and  is the class width. 
According to Albert and Jay (2001), an estimate of the mode of the population, denoted by 
 from which the data is drawn, can be calculated from the grouped data as: 
 
 
 
Two modal classes are (25-30) and (45-50). The first modal class values are based on 
, , ,  and . The mode for these is: 
 
 
    
 
For the second modal class, , , ,  and . The 
mode for these is: 
 
 
    
 
 
5.5.2 Health Care Professional Participants’ Work Experiences 
 
The work experiences of the HCPPs are captured in Table 5.11 and Figure 5.11. 
 
Table 5.11: Health Care Professional Participants’ Work Experiences 
Years < 5 (5-10) (10-15) (15-20) (20-25) 
Percentage  18.2 45.5 9.1 9.1 18.2 
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Figure 5.11: Health Care Professional Participants’ Work Experiences 
 
The histogram used in Figure 5.11 for the distribution of years of experiences of the health 
care professionals is applicable in continuous data categories, or class intervals. Table 5.11 
and Figure 5.11 indicate the years of experience of the participants. It is noted that 18% of 
the participants had experience below 5 years, while 46% had 5 to just below 10 years of 
work experience. In addition, about 9% had from 10 to just below 15 years of experience. 
Moreover, about 9% had 15 to just below 20 years of experience, whereas about 18% had 
20 to just below 25 years of experience. 
 
Furthermore, the descriptive statistics on the work experience of the HCPPs are calculated 
from grouped data as next indicated. 
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Estimating the standard deviation of grouped experience data 
 
 
 
 
 
Estimating the coefficient of variation of grouped experience data 
 
 
 
 
 
Estimating the median from grouped experience data 
 
 
 
 
 
Estimating the mode from grouped experience data 
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5.5.3 Health Care Professional Participants’ Qualifications 
 
The qualifications of the HCPPs will be covered in Table 5.12 and Figure 5.12. 
 
Table 5.12: Qualifications of Health Care Professional Participants 
Qualification M M + 3 M + 4 Postgraduate 
Percentage  9.1 27.3 54.5 9.1 
 
 
 
Figure 5.12: Qualifications of Health Care Professional Participants 
 
Figure 5.12 used for the distribution of the health care professionals into qualifications is in 
the form of a bar chart, which is a suitable method for displaying categorical data of nominal 
random variables (Crowther & Lancaster, 2012). Table 5.12 and Figure 5.12 highlight the 
distribution of the participants according to their qualifications. The table and figure show that 
about 9% had matric (M); about 27% had three-year degrees or diplomas (M+3); about 54% 
had four-year degrees (M+4); while about 9% had postgraduate degrees. 
 
5.5.4 Health Care Professional Participants’ Specific Professions 
 
To provide a good background of the HCPPs, the specific professions of the HCPPs are 
shown in Table 5.13 and Figure 5.13. 
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Table 5.13: Health Care Professional Participants’ Professions 
Profession Social 
Worker 
Dietician Pharmacist Coun-
sellor 
Nurse Medical 
Doctor 
Phlebo-
tomist 
Percentage  18.2 9.1 9.1 9.1 18.2 27.3 9.1 
 
 
 
Figure 5.13: Health Care Professional Participants’ Professions 
 
The bar chart used in Figure 5.9 for the distributions of the health care professionals into 
professions is a suitable method for displaying categorical data of nominal random variables 
(Creswell, 2009). Table 5.13 and Figure 5.13 illustrate the distribution of the participants 
according to their professions. The distribution of the HCPPs is as follows: 18% of them are 
social workers and nurses; 9% of them are dieticians, pharmacists, counsellors and 
phlebotomists, whereas 27% of the HCPPs are medical doctors. 
 
5.5.5 Review on Closed-ended Questions 
 
It was indicated in Table 5.9 and Figure 5.9 that much more female professionals (about 
82%) than males participated in the study.  
 
In terms of the ages, there was a balance of experience, with about 27% each for those who 
were between 25 and 30 years of age and those between 45 and 50 years of age. 
Furthermore, Table 5.10 and Figure 5.10 showed the balance of experience at about 18% 
for those between 35 and 40 and fewer of about 9% in the ages of 30 to 35 years, 40 to 45 
years and 50 to 55 years each. The modal ages (the ones appearing most compared to 
others) were therefore 25 to 30 years and 45 to 50 years. 
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Regarding their experience, most (over 45%) of the participants have between 5 and 10 
years‟ service, about 18% each have experiences of less than 5 years and between 20 and 
25 years‟ experiences. Furthermore, about 9% each have experiences of between 10 and 15 
years and between 15 and 20 years‟ experiences (Table 5.11; Figure 5.11). 
 
Qualifications were also distributed widely. Only about 9% had matric, over 27% had a three-
year qualification (national diploma or bachelor‟s degree) beyond matric. About 55% had 
four-year degrees, and over 9% had postgraduate qualifications (Table 5.12; Figure 5.12). 
 
The professions were widely distributed across social workers, dieticians, pharmacists, 
counsellors, medical doctors and phlebotomists (Table 5.13; Figure 5.13). The modal ones 
were the medical doctors who made up over 27%. Social workers and nurses were the next 
in highest frequencies at just over 18% frequencies each, while the rest were all equal at 
about 9% occurrences each. 
 
5.5.6 Themes Identified from HCPPs’ Responses 
 
Themes identified from the HCPPs are provided in this subsection. 
 
5.5.6.1 Experience on Dealing with Adolescents on HAART Treatment 
 
According to the HCPPs, the adolescents who have to take HAART treatment for as long as 
they are alive face a lifelong challenge which tests their sense of commitment to the 
treatment. HCPP1 stated: 
 
―For me, I find that adolescents are having a big challenge dealing with issues of 
adolescence and dealing with the fact of being HIV positive and taking ARTs forever.‖ 
 
His sentiments were shared by HCPP3 who maintained: 
 
Usually, what I have seen during counselling is that these kids they do not know why 
they have to take this treatment of ARVs. It is not easy dealing with adolescents; 
sometimes I feel it is difficult to have to tell them they are HIV positive. 
 
HCPP5 also supports the assertion of experiencing difficulties when talking with adolescents 
on HAART treatment and reports: 
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My experience on dealing with adolescents who come here for ARV is mostly not so 
pleasant. It is hard to have a sensible conversation with these kids. They are mostly 
unresponsive, and they are forced to come to hospital without even understanding 
why. 
 
The conversation about HAART treatment seems to be compounded by developmental 
changes. Adolescence is an emotionally taxing period, let alone having to deal with issues of 
chronic treatment.    
 
5.5.6.2 Stigma and Disclosure of HIV positive Status 
 
According to the majority of HCPPs, the disclosure of HIV positive status to an adolescent is 
seen as a challenge and everyone hopes everyone would have disclosed to the adolescent. 
The assumption that having a conversation on disclosure with someone who has been on 
HAART treatment for over three years that they know they are HIV positive must be replaced 
by having the conversation and asking the adolescent why they are taking treatment. As 
highlighted by HCPP3: 
 
―Most adolescents have an attitude towards taking their medication correctly or even taking 
the medication; this leads to under or overdosing. The above is led by peer pressure and 
stigma from family members and friends or even the community.‖ 
 
Some difficulties regarding disclosure have been expressed by HCPP8 as follows: 
 
As a person who draws their blood for testing, I observe parents not informing their 
children why they are being tested. They tell the adolescent it is for flu, etc. As a 
professional, I am not allowed to tell the child why I am taking their blood, all I say is 
that the blood is taken for testing. Partial or no disclosure is the challenge I have 
observed. These children then become angry when they find out later; it is better to 
tell them the truth. 
 
Over and above that, HCPP8 maintains: 
 
Some parents did not inform their children on why they were tested, and why they 
had to drink the medication. Some parents told these adolescents that the medication 
was for flu. Some then became angry and end up being angry even for the 
medication when they found out at a later stage. 
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HCPP3 supports the above assertions as follows: 
 
―Some of the adolescents seem to be unaware of reasons for taking the medication, 
apparently because the parents did not explain to them. Others who take medication cannot 
tell their boyfriends or girlfriends. Others blame their parents.‖ 
 
HCPP5 provided this synopsis: 
 
―One challenge was failure to disclose to girlfriends and boyfriends. Poor adherence was 
also identified when there was no supervision. Absenteeism from school was also a factor.‖ 
 
HCPP7 stated: 
 
To be on long-term treatment was a challenge to sustain the interest in the 
medication, and compliance on everyday basis was difficult. These adolescents were 
also challenged by how to have safe sex without unnatural means. Disclosure was 
their other worry, and denial was common. Hence, the result would be defaulting on 
the medication. 
 
Stigma was a challenge. The adolescents felt they were stigmatised, had peer pressure, late 
disclosure of status from family or parents, and social problems, as some people had passed 
away who could have given them support. The issue of disclosure of the reasons why the 
adolescents come to hospital and the reason they have to take treatment is noted as a 
potential stumbling block to effective adherence to HAART. Most found it difficult to accept 
their HIV status, questioned how they were infected with HIV, stigma and discrimination, and 
difficulty accepting that they were HIV positive. 
 
5.5.6.3 Challenges Experienced by Adolescents on HAART Treatment 
 
Disputes regarding adherence to HAART treatment arise whereby the adolescents insist 
they are taking HAART versus the results of blood testing which reveals declining CD4 
counts as well as increasing viral load. This brings to question whether the adolescents fully 
comprehend the meaning of HAART treatment versus their well-being. 
 
HCPP11 made this expression:  
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―A mixture of frustration when lack of disclosure led to poor adherence and relief when 
adherence was confirmed through blood tests. It becomes satisfying seeing a child who was 
severely sick improve over time.‖ 
This is supported by HCPP11 who contended:  
 
It can also be frustrating when your hands are tied by the adolescent and their family 
themselves when adherence is not as it should be and you know that medically, this 
child‘s life could be much better but cooperation is not forthcoming and there is 
different stories all the time. 
 
HCPP4‟s observation was: 
 
Non-compliance is probably due to many psychosocial reasons: such as denial, 
anger, irresponsibility, lack of insight about complications and prognostics of HIV. 
Sexual life with no sense of responsibility. Subsequently, virological and treatment 
failure. Many do not reach age of 25 years. 
 
HCPP6 revealed:  
 
Because of the identity crisis, adolescents tend to default on treatment more often. In 
most cases they have anger issues regarding how they got exposed to HIV because 
the majority of them got exposed from birth. They often blame their parents for 
infecting them. Recently there have been challenges of high pregnancy rate among 
adolescents. 
 
HCPP9 shared the sentiment this way: 
 
―The issue of anger and resentment towards the parent who has infected the adolescent. 
The unresolved anger leads to refusal to take treatment which further puts the health of the 
adolescent in danger.‖ 
 
HCPP5 makes this disclosure: 
 
Lifestyle barriers, such as being away from home, busy, forgetting and varied 
schedules, school attendance, watching TV, behavioural and cognitive challenges 
impact on adherence. When they feel well, they neglect the ART. Poor nutrition 
increase disease progression and hinder treatment effectiveness. 
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HCPP4 identified the following point: 
 
Non-compliance was one reality about them, probably due to many psychological 
reasons, such as denial, anger, irresponsibility, lack of insight about complications 
and prognostics of HIV. Also, one challenge was imagining sexual life with no sense 
of responsibility. Virology treatment failure and many who did not reach age of 25 
years. 
 
Other challenges such as peer pressure, lack of disclosure from parents, tolerance of side 
effects, and some chats through social media were sometimes discomforting. To remember 
to take the medication was also a challenge. The challenge of trying to keep someone 
healthy without their participation emerges once more as the obstacle to adherence. 
Adolescence is generally a rough period in one‟s life. Having to deal with HAART on a 
chronic basis can be emotionally demanding for the adolescent.  
 
5.5.6.4 Benefits Experienced by Adolescents on HAART Treatment 
 
There has been a strong assertion by most HCPPs that HAART treatment improves the 
adolescent‟s health, and reduces the risk of severe infections and lowers the chances of 
transmitting HIV to others. HAART treatment programme improves their lives medically, 
nutritionally, psychologically, and socially. 
 
―A better lifestyle and improved healthy lifestyle-immune system. Good and quality 
knowledge in understanding HIV and ART. Reduction in infection – high CD4-count and low 
viral load.‖ 
 
HCPP2 and HCPP3 support this respectively as follows: 
  
―They believe ART is working for them. They think while there‘s no medication how can they 
be. Also knowing the ARV prolonged their lifespan. Also, benefit immune system increase 
instead of decrease.‖ 
 
Long-term adherence to treatment lead to CD4 count improving exceedingly and thus 
viral load being suppressed, hence lifespan increasing accordingly because of less 
chances of contracting detrimental opportunistic infections, that is, cryptococcal 
meningitis, pneumonia. The benefits of proper adherence to HAART are highlighted 
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by productivity at school and workplace, and less tendency of absenteeism as 
individual will be living a healthy lifestyle. 
 
HCPP9 remarked: 
 
―Lifespans were increased; health status improved, school attendance improved and they 
received support from other children and Health Care Professionals.‖ 
 
According to the HCPPs, some adolescents on HAART treatment knew that without HAART 
treatment they would have been long dead. Others also were grateful because they could 
not imagine how bad they would have been if it was not because of HAART treatment. Some 
complain, but they realise that their health was showing improvement and good virological 
response, and good treatment response. The benefit was a healthy lifestyle. Their lifestyles 
improved and were safer, their health improved, and their immune systems improved. They 
gained quality knowledge on managing their status and could help to reduce infections. Their 
viral loads had decreased and immune system improved. 
 
5.5.6.5 Psychosocial Support and Coping Mechanisms 
 
The big benefit was achieved most of the time through proper support structures with family 
members, social workers, psychologists, and help groups. HAART treatment assisted in 
improving life quality and well-being, especially after a serious illness. There was an 
understanding and knowledge about HIV. Coping mechanisms and strategies relate to 
actions that an adolescent takes in order to make living with HIV positive diagnosis a little 
easier. These range from individual actions to group and team action through which 
participation can lead to a relatively positive life. 
 
In light of the foregoing, HCPP1 stated: 
  
―They participate in support group activities, set reminder alarms for taking ART, and they 
improve their treatment knowledge and understanding of the benefits of taking ART.‖ 
 
HCPP2 made this observation:  
 
―Support groups, support camps and counselling are the mechanisms used to cope for most 
adolescents on HAART.‖ 
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HCPP5 went further to state:  
 
Mechanisms included support structure provided by family and support groups with 
fellow adolescents. There was also a lower pill burden because of these mechanisms 
and strategies. Another effective mechanism to them is knowing that there was 
privacy about their status. 
 
HCPP6 pronounced: 
 
Support groups help to talk about the challenges they were having. They also 
learned from each other regarding how to cope with side effects of treatment. 
Adolescents often go on camp trips, just to reassure them that they were like other 
children of their ages, and to make them feel loved and to educate them more about 
HAART‖ 
 
Along similar lines, HCPP10 commented: 
 
Mechanisms and strategies for coping included support groups that encouraged 
them to cope. Disclosing to friends and family, as well as outing for holidays by the 
support groups were helping. They participated in youth activities such as sport and 
recreational activities such as playing drama and accepting the status. 
 
The role of psychosocial support was identified as crucial where HAART treatment 
adherence is concerned. The more positive the psychosocial support, the higher the 
likelihood of consistent adherence. 
 
5.6 INTEGRATION AND DISCUSSION OF STUDY FINDINGS 
 
The aim of the study was to explore the nature of experiences of adolescents who are on 
long-term HAART treatment in Tembisa, Gauteng province. 
 
The objectives of the study are restated as follows: 
 
 to gain an understanding of the adolescents‟ perspective of being on HAART 
treatment; 
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 to gain broader insight of experiences leading to adherence and non-adherence to 
HAART treatment; 
 to investigate factors contributing to adherence and non-adherence to HAART 
treatment; and 
 to explore the meaning attached to HAART treatment. 
 
This section integrates the findings of the study with recent literature survey on the 
experiences of adolescence and HIV and AIDS, as well as HAART treatment. The 
discussion of these themes is used to address the aim and objectives of the research study. 
The main themes extracted from the findings were classified as access to HAART treatment; 
disclosure, stigma and denial; and psychosocial support. 
 
The subsection that follows presents an integrated discussion on the experiences of HAART 
treatment from the viewpoint of adolescent participants, both from the focus group and 
individual interviews. 
 
5.6.1 Disclosure of HIV Positive Status and Stigma  
 
The majority of the adolescents who took part in this study expressed their experiences of 
HAART treatment and HIV positive status openly and freely. A few adolescent participants 
responded hesitantly and eventually choosing not to participate any further in the interview. 
This is in line with the 2013 study by the World Health Organization, where it was found that 
adolescents would prefer to be involved in conversations about their own health, especially 
relating to HIV and AIDS. Adolescents are the most knowledgeable about their lives. Most 
adolescents find participating in conversations about their own health to be an empowering 
experience and therefore prefer talking about their own health (WHO, 2013). 
 
Learning about their HIV positive status, severe health problems and hospitalisations were 
experienced as traumatic. The majority of the adolescents came to know about their HIV 
positive status just as they were entering the stage of adolescence. Nabukeera-Barungi et 
al. (2007) discovered the benefits of full disclosure of the adolescent‟s HIV positive status in 
that it allows for ownership of the adherence to HAART treatment. In some cases, access to 
treatment leads to reduced sense of stigma, thus enhancing the likelihood for adherence 
(Barrero & Castro, 2005; Ross et al., 2010).  
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A different study conducted in sub-Saharan Africa reports that HIV-status disclosure enabled 
adolescents to engage effectively with their HAART treatment and support groups, which, in 
turn, provided them with a sense of confidence and control over their lives. Although the 
adolescents in the two studies were still experiencing stigma from peers and community 
members, most did not internalise these experiences in a negative way but retained hope for 
the future and felt pity for those untested and uninformed of their own HIV status. The 
conclusion was that disclosure and good HIV related services provide an important platform 
for HIV-infected adolescents to resist and cope with HIV stigma (Midtbo et al., 2012). 
 
Furthermore, all the adolescent participants expressed a high sense of difficulty when it 
came to accepting the news that they were in fact diagnosed as HIV positive. A study 
conducted in Zimbabwe found that adolescents struggle with being told about their HIV 
positive status. Shock and denial are generally the initial response to learning about their 
HIV positive status. Some of the adolescents reported feeling suicidal upon learning of their 
HIV positive status. However, this initial state of shock and denial progressed into 
acceptance with the result that the adolescent decided to help other adolescents come to 
terms with their own HIV positive status through participation in support groups (Kidia et al., 
2014). The adolescents hated not to be told about their HIV positive status. However, when 
told, they got angry with the PGCPs who told them or denied that they were HIV positive. 
 
Although the adolescents preferred being open and fully informed about their HIV positive 
status, the news came as a shock and a burden to them. Anger was the resultant persistent 
feeling which unfortunately was generally associated with less chance for adherence with 
HAART treatment. A Zambian study discovered that disclosure had various outcomes at the 
individual and interpersonal levels. At the individual level, some adolescents described being 
anxious, depressed and blaming themselves after being told they had HIV. At the 
interpersonal level, disclosure created opportunities for adolescents to access adherence 
support and other forms of psychosocial support from family members and peers. At the 
same time, it occasionally strained adolescents‟ sexual relationships, although it did not 
always lead to rejection (Mburu et al., 2014). 
 
The issue of disclosure of their HIV positive status was seen as even more personal when it 
came to disclosing to intimate partners. Most of the adolescents preferred not to disclose 
their HIV positive status to intimate partners, as they feared rejection and being stigmatised. 
A study conducted in Port Elizabeth revealed that adolescents avoided the use of condoms 
in sexual intercourse because of fear of being suspected of being HIV positive (Jena, 2014). 
Adolescents feared being stigmatised. Some of the adolescent participants on HAART 
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treatment were sexually active and seemingly did not disclose to their partners what their 
health condition was with reference to HIV, and as a result, they agreed to engage in 
unprotected sex. The use of protection is part of the counselling that adolescent participants 
on HAART treatment need to receive on a continuous basis. Regarding adolescents‟ 
disclosure to others, a study in Zambia found that adolescents living with HIV and AIDS 
expressed a desire to control whether and to whom to disclose their HIV status. Disclosure is 
something that one should choose to do. It is one‟s choice whether to tell about it or not 
(Midtbo et al., 2012; Mburu et al., 2014). 
 
The biggest fear for the adolescents was informing peers about their HIV positive status. 
Fear of stigma and rejection led to the decision not to easily disclose their HIV positive status 
to people outside of the immediate family. This is in line with a study in Uganda that found 
that most adolescents do not disclose outside of the family, and even within the family 
disclosure is limited to one or two trusted members. Among adolescents who know their 
status, fears surrounding disclosure were high, and few adolescents disclosed to more than 
one or two people. Friends seem not to be trusted for disclosure, due to fears of gossip 
(Musisi, Kinyanda, Nakasujja, & Nakigudde, 2007). 
 
The predominant experience of HAART treatment and HIV was one that entailed the issue of 
disclosure of their HIV positive status and the associated stigma. The most commonly cited 
reason for non-disclosure among adolescents is stigma. In particular, adolescents report 
fearing the pointing of fingers by other people and involuntary disclosure, especially in the 
school environment (Musisi & Kinyanda, 2009). Stigma in the school environment is serious, 
and it is perpetuated by fellow students and teachers alike. In some cases, access to 
treatment leads to reduced sense of stigma, thus enhancing the likelihood of adherence 
(Barrero & Castro, 2005; Ross et al., 2010).  
 
According to Fielden, Chapman, and Cadell (2011), young people living with HIV and AIDS 
experience isolation, fear and shame as a result of their HIV positive diagnosis. Once they 
learn about their status, young people living with HIV and AIDS need to make difficult 
decisions about whether or not to stay silent or disclose to friends, sexual partners, family 
members and other significant people in their lives. Moreover, a study conducted in Zambia 
identified fear of HIV stigma and an underlying presumption that adolescents would not 
understand the consequences of an HIV diagnosis on their lives and relationships. 
Respecting adolescents‟ disclosure of their HIV status to their sexual partners, the same 
study identified fear of rejection as a common barrier. In rare cases, open family 
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conversations about HIV helped adolescents come to terms with an HIV diagnosis (Mburu et 
al., 2014). 
 
5.6.2 Early Childhood Experience of Parental Death 
 
Some of the parents of the adolescent participants have passed away. Some adolescents 
had either one or both of their parents dying of an HIV and AIDS-related illness. Some 
adolescents get to see their parents sick. When a parent or caregiver approaches the end 
stages of AIDS, a plan of care must be created for the surviving children. This process is 
referred to as permanency planning. When this step is not taken, children are left in a state 
of uncertainty about who will care for them, which can compound the loss felt by the child 
after a parent‟s death. The child may be separated from siblings and may experience 
frequent shifts from place to place in search of a proper home. Children whose parents do 
not complete permanency planning are at increased risk of developing emotional and 
behavioural problems. Several things should be considered when creating a permanency 
plan. It is best to start with the needs expressed by the dying caregiver (Close, 2006). 
 
The suspicion and/or knowledge about the cause of parental death may lead to a hanging 
burden and awareness on children about their own mortality. Maternal death is considered to 
have a far more significant negative impact on the well-being of the adolescent (Olsson, 
2013). Mothers are far more able to mediate the challenges that their offspring face, thus 
giving their children and adolescent a fighting chance in life. Trauma from the death of 
parents and loss of parental guidance and support may lead to the child being unable to 
perform at school and, in turn, affecting the decision to attend school (Sharma, 2006).  
 
Parental loss due to HIV and AIDS during childhood causes children to experience 
significant emotional pain. The grieving process starts when the parent or family member 
who is infected with HIV becomes sick. Adolescents are generally traumatised with the death 
of a parent. Bereavement of a parent who died in a cloud of secrecy about their illness or 
after having disclosed to their adolescent becomes complicated and laden with anger and 
resentment. The death of their parents becomes a shame because of the stigma attached to 
dying of AIDS and people‟s lack of knowledge regarding the spread of AIDS, which 
increases stigma and results in the isolation of orphaned children (UNICEF, 2006).  
 
The loss of a parent in early childhood, at school age and in early or late adolescence affects 
children differently, both psychologically and developmentally. As a result of the death of a 
parent or parents, adolescents find themselves having to leave with other relatives or family 
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members. More often, the adolescents are forced to leave the homes they shared with their 
parents to join other relatives or family members. Because of the complexities of some 
families, conflict often arises when an adolescent on HAART treatment, who is not an 
original member of the family, has to take space of the members of the family. In some 
cases, the adolescent would come with their own styles and patterns of behaviour which are 
not tolerated by everyone in the household, thus creating conflict.  
 
The extended family remains as the predominant caring unit for orphans in communities with 
severe HIV and AIDS epidemics. Extended families involve a large network of connections 
among people extending through varying degrees of relationship including multiple 
generations, over a wide geographic area and involving reciprocal obligations (Foster & 
Williamson, 2000). The adolescents receive support from these relatives pertaining to living 
with HIV and AIDS at home, mostly in the form of physical support and assistance with 
adherence to HAART treatment (Pienaar & Visser, 2012). 
 
In light of the foregoing discussion, adolescents find themselves having to deal with some 
bitter consequences after losing a parent. Adolescents are forced to grow up and get on with 
the business of living, often forgoing the luxury of bereavement, which generally tends to 
lead to unresolved emotional issues later on. 
 
5.6.3 Challenges of Taking HAART Treatment 
 
The challenges of taking HAART treatment experienced by adolescent participants are 
complex. Longstanding HIV infection acquired when the immune system was not developed 
results in distinctive chronic clinical complications that cause severe morbidity. As well as 
dealing with chronic illness, HIV-infected adolescents have to confront psychosocial issues, 
maintain adherence to drugs and learn to negotiate sexual relations while undergoing rapid 
physical and psychological developments (Lowenthal et al., 2014).  
 
The fact that HAART treatment consisted of many doses a day led to the adolescents 
missing the taking of the medication. There were complaints that the medication needed to 
be taken many times and for lengthy periods of time. The adolescent participants were in 
favour of one dose a day at night. They preferred HAART treatment to be presented as a 
fixed-dose combination. This would ease the burden of having to take several medications 
that were not enchanting. A complicated dosing regimen that requires 100% adherence was 
in itself an introduction to adherence failure. Additionally, side effects compromised 
adherence and trust in the health care process (Taddeo et al., 2008). Many of them would 
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have preferred a single tablet containing all the medicine than having to swallow many types 
of medicine. Prolonged HAART treatment was frustrating for the adolescents.  
 
The majority of adolescents were delayed in schooling as a result of the frequent amount of 
absenteeism from school to follow up on health checks at hospitals. There were also some 
indications that these adolescent participants were not passing their grades easily, as they 
were missing classes reasonably often. Their schooling was disrupted. The impact of the 
HIV and AIDS pandemic has become an issue of not only health but also of cross-sectional 
importance affecting other major cornerstones in society such as education (Rosenthal, 
Waters, & Glaun, 1995; Olsson, 2013).  
 
School absenteeism was common among the adolescents on HAART treatment, since many 
of them stayed in hospital for long periods. Some adolescent participants were older in their 
grades than most learners because they had been delayed. However, there were others who 
did not stay away for too long. These ones were coping well with schooling and were in their 
normal grades, but they were in the minority.  
 
Adolescents on HAART treatment were at a relatively higher risk of experiencing mental 
health conditions. Some adolescent participants reported that they had lost hope. Other 
adolescents were sometimes experiencing feelings of suicide as a result of realising that 
their lives were going to depend on medication. Living with a long-term chronic condition 
also leads a patient to experience burnout. With burnout, a patient may feel depressed and 
isolated. He or she becomes frustrated with the medication regimen and the constant 
requirement to maintain greater than 95% adherence (Close, 2006). Life was experienced as 
not easy and not fair. The emotional effects of coping with HIV infection can be severe, and 
the frequency of psychiatric admissions compounds their already burdened developmental 
challenges (Rudy, Murphy, Harris, Muenz, & Ellen, 2009; Lowenthal et al., 2014). 
 
Adolescence is an emotionally challenging and confusing period with conflicts between 
adolescents and their parents or caregivers. Moving towards independence from their 
parents, adolescents typically want to make their own choices and have a sense of control 
over their lives. Having a disease may make them feel powerless, and they may try to gain 
control by not taking their medications, missing appointments or not following dietary 
restrictions. Sometimes, the parents may have developed an overprotective parenting style, 
which can delay the teen‟s ability to take responsibility for his or her treatment or cause 
frustration for the adolescent. Thus, low adherence can be a way of confronting the authority 
of parents and professionals (Taddeo et al., 2008). 
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The adolescent participants reported feeling frustrated by parents, caregivers and guardians. 
The guardians sometimes shouted at the adolescents for not taking HAART treatment or for 
being late at taking it. This sometimes made the adolescent feel disliked or undermined, 
especially when it happened in the presence of other children in the household. Emotional 
support seemed to be limited though, as they could not discuss their experiences with family 
members (Pienaar & Visser, 2012). Some of the guardians, according to the adolescent 
participants, needed to soften up, as they were experienced as being unapproachable 
wardens. Some adolescents were despondent with the treatment they were receiving from 
their caregivers to a point that they were contemplating finding other ways of coping outside 
the home. An adolescent living with HIV and AIDS experienced greater life stressors and 
family conflict (Wu et al., 2008). 
 
Some adolescent participants experienced a sense of not being trusted by health care 
providers when it came to their adherence to HAART treatment. The health care workers 
would remark that judging by the adolescent participants‟ declining CD4 count and high viral 
load, it appears that the adolescent participants were not adhering to the HAART treatment. 
The adolescent participants would insist that they are indeed adhering to HAART treatment. 
The adolescents identified mistrust, lack of communication and impersonal interactions with 
health care providers as barriers to disease management (Sanne et al., 2009; Pienaar & 
Visser, 2012). 
 
All the aforementioned challenges require psychosocial support and patience which most 
parents or caregivers are not privy to. Adolescents are required to participate in their own 
self-care in order to enhance the quality of their own lives. The findings created an 
awareness of the challenges and dilemmas that adolescent participants have to contend 
with, such as disclosure, adherence to treatment, disease management and lack of support. 
 
5.6.4 Factors Influencing Adherence to HAART Treatment 
 
Adherence to HAART treatment entails taking all ARV pills in the correctly prescribed doses, 
at the right time and in the right way, observing any dietary restriction. To achieve effective 
treatment and realise the benefits of treatment, strict adherence to treatment instructions are 
very critical (Nyambura, 2009). 
 
Understanding the purpose of taking HAART treatment facilitated adherence in the sense 
that once they knew what the medication was for, they were less hesitant to adhere. 
Adolescents regarded their antiretroviral treatment positively, recognising that the pills were 
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an important and beneficial part of their daily lives (Li, 2009). Adolescents exhibited a better 
understanding about the importance of their tablets and were aware of the role that they 
played in attaining and maintaining physical well-being. These participants recognised that 
antiretroviral treatment helped them to stay strong and healthy. A number of adolescents 
also demonstrated comprehension about the importance of adherence (Li, 2009). 
 
Fixed-dose combination meant that the adolescent had one tablet to take instead of multiple 
tablets, which facilitated adherence. The goal of combination ARV therapy is first to 
suppress HIV viral load in plasma to below the limit of detection and secondly to restore 
immune function, as demonstrated by an increased number of CD4+ T-cells (Chen, Hoy & 
Lewin, 2007). Most of the adolescents in the study reported that it was easier to adhere to 
HAART treatment when the multiple three times a day tablets were replaced by one tablet 
once a day. A conjoint study of fixed-dose combination undertaken in Malawi and Zambia 
presented findings that fixed-dose combination increases the chance of adherence to 
HAART treatment (Kayitare et al., 2009; German, Warren, West, Hui, & Keaney, 2010). 
 
Parental support played a crucial role in adherence to HAART treatment by adolescents. Li‟s 
study described that adolescents recognised the central role that their families played in 
helping them cope with both their illness and life in general. Many of the participants had lost 
one or both of their biological parents to AIDS, with only 23% of the adolescents living with 
both their mother and father, and 42% being cared for by a relative or an institution (Li, 
2009). Adolescents who felt supported, cared for and loved were more likely to adhere to 
HAART treatment, as they felt their lives meant something to someone other than 
themselves. 
 
5.6.5 Factors Influencing Non-adherence to HAART Treatment 
 
Some adolescent participants felt inconvenienced or burdened by the treatment but had to 
live with it because it kept them alive. There was interference with normal day-to-day 
activities. The experience of prolonged HAART treatment included the pressure to terminate 
sporting activities because of being weak and having to concentrate on the treatment. A 
study done in Pretoria, South Africa discovered that adolescents had conflicting ideas about 
antiretroviral therapy and the restrictions it placed on their lives. All of the adolescents 
battled with the conflict between being normal and being different. All of them tried to live a 
normal life by having friends and participating in sport, and most described future identities 
(Pienaar & Visser, 2012). 
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Poor support from parents, guardians and caregivers led to a sense of isolation. Pienaar and 
Visser (2012) went on to identify that most of the adolescents assumed primary 
responsibility for taking their medication. Emotional support seemed to be limited though, as 
they could not discuss their experiences with family members.  
 
Another factor that led to non-adherence to HAART treatment related to the direct effect of 
the medication on the adolescent. The study at Brown University points to similar factors. It 
identified three common themes that arose for non-adherence on a daily basis: regimen 
complexity (for example, too many pills or taking pills in relationship to meals), toxic side 
effects, and simply forgetting to take the pills. For many of the adolescents interviewed, 
these factors were linked. The more complex regimens were often more difficult to 
remember and had more toxic side effects, thus compounding the tendency towards non-
adherence (Pugatch, Bennett, & Patterson, 2009). 
 
5.6.6 The Impact of Religion on HAART Treatment Adherence 
 
For the majority of the adolescent participants, religion played some role in adherence to 
treatment or lack thereof. Those with strong religious beliefs were helped to cope with living 
with HIV and AIDS and adhering to HAART treatment (Naidoo, 2011). However, there was 
one adolescent participant who believed that his belief in God should be good enough to 
cure him, and so he struggled with adherence to HAART treatment. He believed that taking 
medication was an indication of lack of faith and trust in God. 
 
Van Wyngaard (2013) discovered that people with a high believe in God tend to have 
resilience in times of hardship. He described someone‟s experience as having feeling 
accepted by God after his pastor spoke to him about repentance. The feeling that God loves 
them despite their HIV positive status gave them a sense of acceptance and peace with their 
HIV positive status, which led to a higher likelihood of adherence to treatment. Some 
adolescents with HIV were more likely to endorse feeling God‟s presence; they were more 
likely to feel that they were part of a larger force, and they were also more likely to feel at 
times that God had abandoned them. Religion was thus viewed as leading to an increase in 
spiritual distress (Bernstein et al., 2012). In a different study, spirituality was not associated 
with the decision to use intensive life-prolonging care. The belief that HIV is a punishment 
from God was associated with significantly less medication adherence and less spiritual 
quality of life (Lyon et al., 2011). 
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Religion can have a mitigating influence in day-to-day decision-making. Some adolescents 
view religion as helping them stay safe insofar as it preached no sex before marriage, thus 
protecting them from risky behaviour and further spread of HIV. Furthermore, the burden of 
HIV and AIDS is viewed as being shifted to a higher being who takes the load over, thus 
freeing them of guilt, blame and anger feelings (Lyon et al., 2011).  
 
Religion can take the place of psychiatric treatment, thereby helping them cope with issues 
of depression and improving their mental health. Any method of coping that helps improve 
the quality of life of adolescents on HAART treatment can be appreciated, as it takes more 
than one approach to provide health care. 
 
5.7 CHAPTER RÉSUMÉ 
 
This chapter presented the research findings as collated from the collected data. The 
prolonged use of HAART treatment was a great factor because when it started, before it 
could prolong, the adolescents seemed to have been happy to take it. They were also not 
asking much about the treatment, and they did not forget to take the medication. Only when 
prolonged, all these distresses emerged.  
 
The findings suggest that adolescents who are on HAART treatment over an extended 
period of time experience drug fatigue. Drug fatigue has far-reaching implications for the 
health of adolescents, as it has a higher likelihood that poor adherence or even complete 
refusal to take HAART treatment will occur. Poor adherence or refusal to take HAART 
treatment will most likely lead to cross infection and further spread of the HIV.  
 
Moreover, the role of psychosocial support was identified as the deal breaker where HAART 
treatment adherence is concerned. The more positive the psychosocial support, the higher 
the likelihood of consistent adherence. 
 
The next chapter focuses on conclusions drawn from the research process, themes 
determined and discussions of the semi-structured interviews, as well as the literature and 
theoretical review. Recommendations are also based on the research study and findings. 
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
6.1 INTRODUCTION 
 
In the penultimate chapter, discussion and integration of study findings were presented. In 
this chapter, the conclusions and recommendations that emerged from the deliberations of 
the research study are presented. The research study was undertaken to explore the nature 
of experiences of adolescents who are on long-term HAART treatment in Tembisa, Gauteng 
province.  
 
6.2 RESEARCH FINDINGS SUMMARY 
 
The research findings established that disclosing HIV positive status to an adolescent is the 
preliminary point and needs to be addressed courteously in order to assist with acceptance 
of their HIV positive status. Based on the narratives of adolescent participants, the issue of 
disclosure of their HIV positive status poses a number of challenges. Adherence to HAART 
treatment depends on how disclosure of HIV and AIDS-positive status has been managed 
by significant others including health professionals. It is important that family members 
disclose the HIV positive status of adolescents to adolescents directly and allow for a follow-
up discussion with health care workers who can explain the medical perspective of HAART 
so as to enhance understanding.  
 
Disease knowledge is a crucial element of the management of HAART treatment and self-
care. Where adolescents trusted the medication, treatment was taken consistently, leading 
to relatively good health. They knew the reasons for taking the medications on a regular 
basis. The only thing they did not know was that they are taking treatment because they 
have been infected by HIV and AIDS virus. They could only speculate that they had the 
disease from parents who had died of the disease. However, it was immaterial to them how 
the HIV and AIDS virus was acquired. All they were focusing on was to get better from the 
HAART treatment they received. 
 
The main reason adolescents adhere to HAART treatment was the belief that their medical 
condition would improve. Their problem was more about their HIV positive status; they felt 
aggrieved by the fact that they were HIV positive. Moreover, most of the adolescent 
participants reported receiving encouraging support from home. Most guardians took good 
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care of them. This was not the case in families where there was poverty. However, they did 
not seem to be humiliated through being stigmatised. 
 
The diagnosis with HIV positive status initially angered and saddened them, but they 
eventually accepted their HIV positive status. Some of the adolescent participants had 
delayed schooling due to failure to cope and lack of support. The adolescent participants still 
had ambitions for the future and were hoping to become helpers through professions in the 
medical field, such as medical doctors, when they grow up. 
 
The findings of the study also highlighted issues related to coping mechanisms used by 
adolescent participants after resuming HAART. Coping mechanisms included a company of 
friends, but dangerous methods such as drugs and dagga use were also mentioned. The 
adolescent participants reported that they followed treatment. However, sometimes the 
doctors deduced that the patients had defaulted through blood tests. This angered the 
adolescent participants, as they were convinced that they honoured the prescriptions. These 
adolescent participants trusted the treatment and were looking forward to improved health. 
The treatment gave them hope. 
 
The positive findings of the study relate to the adolescent participants‟ understanding of the 
role of sex. Some of them considered the use of a condom as an option when they become 
sexually active, although in practice it was a completely different situation. They would 
consider having unprotected sexual intercourse if it meant hiding possible suspicion about 
their HIV positive status when condom usage was not negotiated. One of the female 
participants was pregnant at the time of the study, indicating that it is difficult for adolescent 
females to negotiate safe sex. The sexually active male in the study was already reported to 
be exercising the concept of condom usage during sexual intercourse. This signifies the 
extent to which the gender of the adolescent participant influences their ability to negotiate 
for safe sex. The study reveals that males are in a better position to negotiate the use of 
condoms, whereas females feel powerless and end up giving into unsafe sex in order to be 
accepted by their sexual partners. 
 
6.3 LIMITATIONS OF THE STUDY 
 
The context-specific features of the research setting have limited the generalisation of the 
research study results. The study was based at a clinical unit in Tembisa with a 
homogeneous population. Therefore, its findings cannot be generalised to other races, 
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provinces or other diverse biographical populations. However, other areas in South Africa 
may experience similar characteristics.  
 
A further limitation of the research study is the duration of the study data collection. A 
longitudinal study would have produced an additional set of results in comparison to the 
cross-sectional study. Data for the individual adolescents was collected within a period of 
three months while that of parent, guardian and caregiver participants was within two weeks. 
HCPPs returned the questionnaire within a period of two weeks, while the focus group met 
only once.  
 
The sample size for parent, guardian and caregiver participants was limited to three due to 
poor willingness and withdrawal from participation. This sample was identified based on 
phenomenological research principles which recommend small sizes of the participants; 
however, for future research, more participants can be included. The focus group size was 
planned to be between six and eight participants. However, only three participants arrived for 
the scheduled interview and were willing and open to participate. Bigger samples would 
have resulted in more diverse responses and findings.  
 
Conducting the interviews in a mixture of English and the participants‟ vernacular language 
and then transcribing and translating into English can be considered as a limitation, as some 
meaning might have been lost during the process.  
 
6.4 STRENGTHS OF THE STUDY 
 
Perceptions and experiences were explored from individual adolescent participants; a focus 
group of adolescent participants; parent, guardian and caregiver participants; and finally the 
health care professional participants. This multi-dimensional research study gave strength to 
the findings and results.  
 
The size of the individual adolescent participants was initially planned at 10 participants. 
However, this number was stopped at seven after reaching saturation point. Although some 
of the participants who initially agreed eventually did not show up at the agreed interview 
appointment, resulting in the need to recruit new participants, a sample of seven meant that 
a varied set of opinions was discovered.  
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As far as health care professionals were concerned, 15 questionnaires were handed out, 
and 11 were returned. The hope was that at least eight participants would complete and 
return the questionnaires, yet a total of 11 questionnaires were returned. The element of 
optimism was duly noted and considered in the analysis of the responses. 
 
6.5 RECOMMENDATIONS FOR PRACTICE AND POLICY  
 
Based on the findings, the recommendations that follow were put forward. 
 
6.5.1 Timely and Developmentally Appropriate Disclosure of HIV positive Status 
 
Disclosure to an adolescent about their own HIV positive status has implications for long-
term HAART adherence. It is therefore important that disclosure is done as early as 
possible. At the time of HIV positive diagnosis, disclosure should be made using the 
language and description that the child or adolescent can understand with full disclosure and 
explanation as they grow and develop. In this way, the knowledge of HIV positive status and 
AIDS is known from initiation of HAART so as to prevent a sense of betrayal that is 
experienced when disclosure is only made when the adolescent is older.  
 
It is recommended that strategies to enable earlier disclosure of HIV positive status and 
AIDS to the concerned children and adolescents be implemented as a matter of urgency. 
The bio-psychosocial team at the hospital should allocate a designated „Disclosure Agent,‟ 
whose main job is to ensure that every young person diagnosed with HIV positive status is 
informed of their status at the initial time of diagnosis.  
 
6.5.2 Establishment of a Hospital-based Education Unit 
 
Most adolescent participants reported the fact that they lag behind with their schooling as a 
result of constant hospital check-ups and hospitalisation. The recommendation for this 
challenge is the introduction of a hospital-based school. An education unit that focuses on 
assisting hospitalised learners with catch-up programmes should be set up within the 
hospital. Dedicated and qualified facilitators who visit the various children‟s wards to assist 
with catch-up programmes should be allocated so that students do not miss out on 
schooling. 
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6.5.3 School Outreach Programmes by Health Care Professionals 
 
A further recommendation is for the hospital to introduce school outreach programmes 
whereby health care professionals visit various schools to carry out routine medical check-
ups as well as roll out HAART treatment for adolescent learners. It is possible that such 
school-based outreach programmes will initially experience stigmatisation. Therefore, these 
outreach programmes should be used for psychoeducation which will, in the long run, 
desensitise stigma, thus leading to higher HAART treatment adherence. 
 
6.5.4 Adolescent-tailored Services 
 
Considering the findings of this study, there is a need for a welcoming, reassuring and open-
minded environment as well as convenient appointment scheduling and confidentiality. 
 
6.5.4.1 After-hours Appointments and Support Groups 
 
The Masakhane Clinic should schedule school adolescents‟ medical doctor and HAART 
treatment collection appointments after school hours and/or on weekends. Furthermore, 
instead of the present monthly prescription refill, the adolescent learners should be 
scheduled for prescription refill and blood works at the hospital quarterly, thereby increasing 
the likelihood of school attendance. During these days, peer support groups and group 
activities where adolescents will have an opportunity to share their HAART treatment 
experiences with people of the same age group should be arranged. In this way, time spent 
away from the classrooms will be kept at a minimum while maximising disease management 
education.  
 
6.5.4.2 Community-based Support Programme 
 
The practice of group activities and peer education should be incorporated into community-
based support programmes for adolescents. Home-based visits are a commonly practiced 
routine when it comes to most social ills. This system must be introduced for adolescents 
who are on HAART treatment. The hospital social workers already perform such services for 
mental health care users, and they could extend their services to cater for the adolescents 
receiving HAART treatment. 
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6.5.4.3 Establishment of Adolescent and Youth Centre 
 
The hospital should create a youth and adolescent-friendly centre whereby a section of the 
clinic will be designated for adolescents and youth in general for the provision of services 
that are sensitive to adolescents‟ various stages of development. Without tailored adolescent 
services, adolescents are likely to fall through the health care cracks, and when mixed with 
adults from the same communities, adolescents on HAART treatment are likely to withdraw 
their participation when adults are present. 
 
6.5.4.4 Use of Technology and Social Media 
 
Furthermore, use of technology and social media, such as Facebook, WhatsApp groups and 
Twitter feeds, should be used to interact with adolescents. Social media reminders should be 
sent to adolescent participants to remind them about follow-up dates for check-ups, 
treatment follow-ups and any events related to their welfare. 
 
6.5.4.5 Fixed-dose Treatment Roll-out 
 
Lastly, the hospital should introduce a fixed-dose combination treatment as a prominent 
treatment modality to encourage adherence and discourage treatment fatigue for 
adolescents. 
 
6.6 RECOMMENDATIONS FOR FURTHER RESEARCH STUDIES 
 
The following suggestions are made as recommendations for future studies: 
 
 Conduct a closely related or similar research study in other HAART roll-out facilities 
in and around Tembisa, to explore the perceptions and experiences of adolescents 
growing up on HAART. 
 
 Replicate this research study to other topographical zones for the generality of these 
research results to all adolescents. 
 
 Give attention to reproductive health care needs of adolescents who grow up on 
HAART treatment. 
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 Carry out a relatively global study that includes a bio-psychosocial approach to 
research the adolescent phenomenon together as opposed to researching in silos. 
 
 Consider a multilevel research study to explore measures of lessening stigma and 
discrimination towards HIV and AIDS-positive adolescents. 
 
6.7 RESEARCH STUDY CONCLUSION 
 
This research study explored the experiences of adolescents relating to HAART treatment 
for at least two years. In-depth interviews, as well as a focus group, were used to collect 
data, which was analysed using thematic categorisation. The objectives of the research 
study, those of exploring the experiences of adolescents as far as HAART treatment is 
concerned, were met.  
 
The research study findings covered the negative and positive experiences, and the 
perceived role of HAART treatment over a long period of time. Additionally, the PGCPs‟ 
views about the experiences and coping mechanisms of the adolescent participants taking 
HAART were also included in order to obtain a broader understanding. The various health 
care professionals involved in the treatment of the adolescent participants on HAART 
provided information on their perceptions of the experiences of the adolescents on HAART 
under their care at the hospital. These collective contributions were required to provide 
information regarding the importance of improving practices in HAART of the HIV and AIDS 
adolescent participants. 
 
The predominant themes identified from adolescent participants were disclosure of HIV 
positive status and the stigma surrounding a positive status, early childhood experience of 
parental death, the challenges of taking HAART treatment, the factors influencing adherence 
and non-adherence to HAART treatment, and lastly, the impact of religion on HAART 
treatment adherence. Adolescent participants struggle with the disclosure of their HIV 
positive status. Drug fatigue has far-reaching implications for the health of the adolescents, 
as it determines adherence to HAART treatment. Poor adherence or refusal to take HAART 
treatment will most likely lead to cross infection and further spread of HIV and AIDS. 
 
This study has thus contributed to the body of knowledge regarding experiences of long-term 
HAART treatment by adolescents. 
  
178 
 
LIST OF REFERENCES 
Abdool Karim, S. S., & Abdool Karim, Q. (2010). HIV/AIDS in South Africa. Durban: 
Cambridge Publishers.  
 
Aber, V., & Aboulker, J. P. (1996). Delta: A Randomised Double-Bind Controlled trial 
comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine 
alone in HIV-infected individuals. Lancet, 348(9023), 283-291. 
 
Adler, M. W. (2001). ABC of AIDS. Tavistock Square. London: BML Books. BMJ Publishing 
Group, BMA House. 
 
Adler, M. W., Edwards, S. G., Miller, G. S., & Williams, I. G. (2012). ABC of HIV and AIDS. 
Oxford: Wiley-Blackwell.  
 
Agyarko-Poku, T., Sarkodie, Y. A., & Atakorah-Yeboah, L. (2014). Too bad! Fixed-dose 
combination antiretroviral drugs. BMC Infectious Diseases, 14(2), 80.  
 
Albert, J., & Jay, B. (2001). Curve ball: Baseball, statistics, and the role of chance in the 
game. New York: Springer-Verlag. 
 
Alderson, F., & Morrow, V. (2004). Ethics, Social Research and Consulting with Children and 
Young People. Ilford, United Kingdom. 
 
Arhar, J. M., Holly, M. L., & Kasten, W. C. (2001). Action research for teachers: Travelling 
the yellow brick road. Mishawaka: Prentice Hall. 
 
Davies, N. & Kijko, A. (2003). Seismic risk assessment: with an application to the South 
African insurance industry. South African Actuarial Journal 3: 1–28 
 
Ayopo, J. M. (2009). Exploring Nigerian adolescent students‘ perceptions of HIV/AIDS and 
their attitudes to prevention methods: A psycho of educational perspective. Doctor of 
Education (Psychology in Education) thesis, University of South Africa. 
 
Badri, M., & Bekker, L. G. (2004). Initiating highly active antiretroviral therapy in sub-Saharan 
Africa: An assessment of the revised World Health Organization scaling-up 
guidelines. AIDS, 18(8), 1159-1168. 
179 
 
Bailey, K. D. (1994). Methods of social research. New York: The Free Press. 
 
Barnett, T., & Whiteside, A. (2002). AIDS in the twenty-first century: Disease and 
globalization. Palgrave MacMillan. 
 
Barrero, C. E. A., & Castro, A. (2005). Experiences of stigma and access to HAART in 
children and adolescents living with HIV/AIDS in Brazil. Social Science and  
Medicine, 62(5), 1219-1228. doi:10.1062; Socsimed. 2005.07.006 
 
Bartlett, J. G., Gallant, J. E., & Conradie, F. M. (2008). Medical management of HIV 
infection. Pretoria: Foundation for Professional Development. 
 
Beal, J., Orrick, J. J., Lora, M., & Vandokelaar, A. (2011). ARV therapy in adults and 
adolescents. ARV Card.  
 
Becker, M. H. (1974). The health belief model and personal health behaviour. Health 
Education Monographs, 2, 324-473. 
 
Bekker, L-G and Hosek, S. (2015). HIV and adolescents: focus on young key populations. 
Journal of the International AIDS Society. Source:PubMe 
DOI:10.7448/IAS.18.2.20076  
 
Bell, C., Devarajan, S., & Gersbach, H. (2003). The long-run economic costs of AIDS: 
Theory and application to South Africa. Washington: World Bank. 
 
Berkow, R., Beers, M. H., Bogin, R. M., & Fletcher, M. B. (1997). The Merck Manual of 
Medical Information. Home Edition. Merck Research Laboratories. Merck and Co., 
Inc. Whitehouse Station, N.J. 
 
Bernstein. K., D‟Angelo., L. J., & Lyon. M. E. (2012). An Exploratory Study of HIV+ 
Adolescents‟ Spirituality: Will You Pray with Me? Original Paper 123. J Relig Health. 
doi:10.1007/s10943-012-9565-1 
 
Bezuidenhout, C., Elago, H., Kalenga, E., Klazen, S., Nghipondoka, K., & Ashton, D. (2005). 
The Psychosocial Impact of HIV/AIDS: People are more than just statistics. Future 
Leaders Summit. 
 
180 
 
Bikaako-Kajura, W., Luyirika, E., Purcell, D. W., Downing, J., Kaharuza, F., Malamba, S., & 
Bunell, R. (2006). Disclosure of HIV status and adherence to daily drug regimens 
among HIV-infected children in Uganda. AIDS Behaviour, 10(Suppl.), S85-S93. 
 
Bill, R. (2006). The politics of civil society in confronting HIV/AIDS international affairs. 
HIV/AIDS-Special, 82(2), 285-295. 
 
Blanchardt, C. M., Courneya, K. S., Rodgers, W. M., Fraser, S. N., Murray, T. C., Daub, B., 
& Black, B. (2003). Is the theory of planned behaviour a useful framework for 
understanding exercise adherence during phase ii cardiac rehabilitation? Journal of 
Cardiopulmonary Rehabilitation, 23, 29-39. 
 
Bowen, G. A. (2008). Naturalistic inquiry and the saturation concept: A research note. 
Qualitative Research. 
 
Boyce, C. B., & Neale, P. (2006). Conducting In-depth Interviews: A Guide for Designing and 
Conducting In-depth Interviews for Evaluation Input. Pathfinder International Tool 
Series. Monitoring and Evaluation-2. 
 
Brahmbhatt, H., Kigozi, G., Wabwire-Mangen, F., Serwadda, D., Lutalo, T., Nalugoda, F., 
Sewankambo, N., Kiduggavu, M., Wawer, M., & Gray, R. (2006). Mortality in HIV-
infected and uninfected children of HIV-infected and uninfected mothers in rural 
Uganda. J Acquir Immune Defic Syndr, 41(4), 504-508. 
 
Braun, V., & Clarke, V. (2013). Successful qualitative research: A practical guide for 
beginners. Washington DC: Sage. 
 
Brown, L. K., DiClemente, R. J. & Reynolds, L. A. (1991). HIV prevention for the adolescent: 
Utility of the health belief model. AIDS Education and Prevention, 3 (1), 50 - 59 
 
Brown, L. K., Lourie, K. J., & Pao, M. (2000). Children and adolescents living with HIV and 
AIDS: A review. J. Child Psychol Psychiatry, 41(1), 81-96. 
 
Burns, N., & Grove, S. K. (2005). The practice of nursing research: Conduct, critique and 
utilisation. Philadelphia: WB Saunders. 
 
181 
 
Carpenter, C. J. (2010). A meta-analysis of the effectiveness of health belief model variables 
in predicting behavior. HealthCommun, 25, 661–669. 
Chan,.Z.C.Y, Fung, Y-L. & Chien, W-T. (2013). Bracketing in Phenomenology: Only 
Undertaken in the Data Collection and Analysis Process? The Qualitative Report, 
18(59), 1-9. 
 
Chen, L. F., Hoy, J., & Lewin, S. R. (2007). Ten years of Highly Active Antiretroviral Therapy 
for HIV infection. MJA, 2007(3), 146-151. 
 
Children‟s Act 38 of 2005. Consolidated Regulations Pertaining to the Children‟s Act, 2005. 
 
Claxton, R., & Harrison, T. (1991). Caring for children with HIV and AIDS. London 
Melbourne-Auckland: Hodder and Stoughton. 
 
Close, K. L. (2006). Psychosocial aspects of HIV/AIDS: children and adolescents. In: HIV 
Curriculum for the Health Professionals. Baylor College of Medicine, USA. 
 
Cluver, L., & Gardner, F. (2000). Psychological Distress Amongst AIDS-orphaned Children 
in Urban South Africa. Journal of Child Psychology and Psychiatry, 48(8), 755-763. 
doi:10. 1111/j, 469-760.2007.01757.x 
 
Colby, D. G., & Baker, D. G. (1988). State policy responses to the AIDS epidemic. Oxford 
Journals-Social Sciences. Publius, 18(3), 113-130. 
 
Conner, M. (2010) Cognitive Determinants of Health Behavior. Handbook of Behavioral 
Medicine Methods and Applications. Ed Steptoe A XXIV: 1073. 
 
Cooper, H., Camic, P. M., Long, D. L., Panter, A. T., Rindskopf, D., & Sher, K. J. (2012). 
APA Handbook of Research Methods in Psychology. Volume 2: Research Designs; 
Quantitative, Qualitative, Neuropsychological and Biological. American Psychological 
Association. Washington, DC.  
 
Cooper, S. E., Risley, C. L., Drake, L. J., & Bundy, D. A. (2007). HIV as part of children and 
youth, as life expectancy increases: Implications for education. Journal of 
International Cooperation in Education.  
 
182 
 
Corcoran, N. (2013). Communicating health strategies for health promotion. Los Angeles. 
London. New Delhi. Singapore. Washington DC: Sage. 
 
Cotton, S., Puchalski, C. M., Sheraman, S. N., Mrus, J. M., Peterman, A. H., Feinberg, J., 
Pargament, K. I., Justice, A. C., & Tsevat, J. (2006). Spirituality and religion in 
patients with HIV/AIDS. J Gen Intern Med, 24(8), 994. 
 
Creswell, J. W. (1998). Qualitative research design: choosing among five traditions. 
Thousand Oaks: Sage. 
 
Creswell, J. W. (2003). Research design: Qualitative, quantitative and mixed methods 
approaches (International Student ed.). University of Nebraska, Lincoln: Sage 
Publications. 
 
Creswell, J. W. (2009). Research design: Qualitative, quantitative and mixed methods 
approaches. University of Nebraska, Lincoln: Sage Publications. 
 
Creswell, J. W. (2014). Research design: Qualitative, quantitative and mixed methods 
approaches. University of Nebraska, Lincoln: Sage Publications. 
 
Crowther, D., & Lancaster, G. (2012). Research methods: A concise introduction to research 
in management and business consultancy. Oxford: Routledge. 
 
Dabis, F., & Ekpini, E. R. (2006). HIV-1/Aids and maternal and child health in Africa. Lancet, 
359(9323), 2097-2104. 
 
Dagnew, Y. W. (2009). Factors influencing antiretroviral therapy adherence in Ethiopia. 
Master of Public Health dissertation, University of South Africa. 
 
David, M., & Sutton, C. D. (2011). Social research: An introduction. Sage Publications.  
 
De Baets, A. J., Sifovo, S., Parsons, R., & Pazvakavambwa, I. F. (2007). HIV disclosure and 
discussions about grief with Shona children: A comparison between health care 
workers and community members in Eastern Zimbabwe. Social Science and 
Medicine, 66, 479-491. 
 
183 
 
De Vos, A. S., Strydom, H., Fouche, H. C. B, & Delport, C. S. L. (2002). Research at grass 
roots. For the social sciences and human service professions. Hatfield, Pretoria. 
 
DePoy, E and Gittlin, L.N. 1998. Multiple Strategies for Health and Human Sciences 2nd ed 
 
Denzin, N. K. (1970). The Research Act in Sociology. Chicago: Aldine. 
 
DiMatteo M.R., Haskard K.B., Williams S. L. (2007). Health beliefs, disease severity, and 
patient adherence: A meta-analysis. Medical Care 45: 521–528. 
 
Dogar, I. A. (2007). Bio-psychosocial Model. A.P.M.C., 1(1).  Department of Psychiatry and 
Behavioural Sciences.  
 
DoH. (2008). Department of Health, South Africa. Trainer‟s Manual for the Psychosocial 
Care of Babies and Young Children Living with HIV and AIDS. 
 
DoH. (2014). National Consolidated Guidelines for the preventions of mother-to-child 
transmission of HIV (PMTCT) and the management of HIV in Children, adolescents 
and adults. Department of Health. Republic of South Africa. 
 
Dohertey, J., & Colvin, P. (2004). HIV/AIDS in South Africa, the prevalence of infection, risk 
factors and social context. South African health review. Durban, South Africa. Health 
System Trust, 13(2), 25-27. 
 
Durham, J. D., & Lashley, F. R. (2010). The persons with HIV/AIDS: Nursing perspectives. 
New York: Springer Publishing Company. 
 
Edwards, S. D. (2001). A phenomenological investigation into the experience of being fit: 
community implications. In A. Papaioannou, M. Goudas & Y. Theodorakis (Eds.), In 
the dawn of the new millennium. Proceedings of the 10th World Congress of Sport 
Psychology. 1. 105-107. Thessaloniki: Christodoulidi. 
 
Eagleton, T. (2011). Literary theory: An introduction. Oxford: Wiley.  
 
Ehman, J. W., Ott, B. B., Short, T. H., Ciampa, R. C., & Hansen-Flaschen, J. (1999). Do 
Patients want physicians to enquire about their spiritual or religious beliefs if they 
become gravely ill? Arch Internal Medicine, 159(15), 1803-1806. 
184 
 
 
Engel, G. L. (1977). The need for a new medical model: A challenge for Biomedicine. 
SCIENCE, 196(4286), 129-135. 
 
Engel, G. L. (1980). American Journal of Psychiatry Clinical application of the bio-
psychosocial model. Am J Psychiatry, 137, 535-544. 
 
Epstein, R. M. and Borrell - Carrio, F. (2005). The biopsychosocial model: exploring six 
impossible things. Families, Systems & Health  
 
Fair, C. D., Osherow, J., Albright, J., & McKeone, D. (2014). Medication adherence among 
adolescents with HIV: A case study of social work interventions. Journal of HIV/AIDS 
and Social Services, 13, 26-45. 
 
Fair, C. D., Wiener. L., Sima Zadeh, S., Albright, J., Mellins, C. A., Mancilla, M., Vicki 
Tepper, V., Trexler, C., Julia Purdy, J. P., Lovelace, S., & Kapetanovic, S. (2013). 
Reproductive health decision-making in perinatally HIV-infected adolescents and 
young adults. Methodological Notes 123. Matern Child Health J, 17, 797-808. 
doi:10.1007/s10995-012-1070-3 
 
Fargher, M., & Dooley, H. (2010). The adolescent storm: A handbook for parents. South 
Africa: Penguin Books. 
 
Feldman, S. S., & Elliot, G. R. (1990). At the threshold: The developing adolescent. 
Cambridge, Massachusetts, and London, England: Harvard University Press. 
 
Fielden, S. J., Chapman, G. E., and Cadell, S. (2011). Managing stigma in adolescent HIV: 
silence, secrets and sanctioned spaces, culture, health and sexuality. An 
International Journal for Research, Intervention and Care, 13(03), 267-281. 
doi:10.1080/13691058.2010.525665 
 
Finlay, L. (2012). Debating phenomenological methods. Hermeneutic Phenomenology in 
Education, 17-37. Sense Publishers. 
 
Flewitt, R. (2005). Conducting research with young children: Some ethical considerations. 
Early Childhood Development and Care, 175(6), 553-565. 
 
185 
 
Foster, G., & Williamson, J. (2000). A review of current literature of the impact of HIV/AIDS 
on children in sub-Saharan Africa. AIDS 2000, 14(Suppl. 3), S275-S284. 
 
Fouche, C. B., & Delport, C. S. L. (2002). The place of theory and the literature review in the 
qualitative approach to research. In A. S. De Vos, Research at grass roots: For the 
social sciences and human service professions. Pretoria: Van Schaik. 
 
Garvie, P. A., He, J., Wang, J., D‟Angelo, L. J., & Lyon, M. (2012). An exploratory survey of 
end-of-life attitudes, beliefs and experiences of adolescents with HIV/AIDS and their 
families. J Pain Symptom Manage, 44(3), 373-385. 
 
Gaughan, D. M., Hughes, M. D., Oleske, J. M., Malee, K., Gore, C. A., & Nachman, S. 
(2004). Psychiatric hospitalizations among children and youths with human 
immunodeficiency virus infection. Pediatrics, 113(6), 544-551. 
 
Geffen, N. (2010). Debunking delusions: The inside story of Treatment Action Campaign. 
Auckland Park: Jacana Media Publishing. 
 
German, P., Warren, D., West, S., Hui, J., & Keaney, P. (2010). Pharmacokinetics and 
Bioavailability of an Integrase and Novel Pharmaco-enhancer-Containing Single-
Tablet Fixed-Dose Combination Regimen for the Treatment of HIV. J Acquir Immune 
Defic Syndr, 55, 323-329. 
 
Ghahramani, S. (2000). Fundamentals of probability. New Jersey: Prentice Hall. 
 
Given, L. M., & Saumure, K. (2008). The Sage Encyclopaedia of Qualitative Research 
Methods. Volumes 1 + 2. A Sage Reference Publication. SAGE. London. 
 
Goodman, C. J. (2008). Research in psychology: Methods and design. London,UK: Wiley  
 
Gravetter, F. J., & Forzano, L. B. (2010). Research methods for the behavioral sciences. 
Wadsworth: Cengage Learning. 
 
Graziano, A. M., & Raulin, M. L. (2013). Research methods: A Process of Inquiry (Pearson 
International ed.). Always Learning.  
 
186 
 
Green, J. A. and Shellenberger, R. (1991) The Dynamics Of Health And Wellness: A 
Biopsychosocial Approach. Fort Worth, TX: Holt and Rinehart and Winston. 
 
Groenewald, T. (2004). A phenomenological research design illustrated. International 
Journal of Qualitative Methods, 3(1), 4. 
 
Gubrium, J. F., & Hostein, J. A. (2000). Analyzing interpretive practice. In N.Y. Denzin & Y. 
Lincoln (Eds.), Handbook of qualitative research (pp. 487-508). Thousand Oaks, CA: 
Sage. 
 
Guilfoile, P. G. (2011). Deadly diseases and epidemics: HIV/AIDS. Chelsea House: An 
Infobase Learning Company. 
 
Hahn, C. J. (2010). Edmund Husserl, The Basic Problems of Phenomenology: From the 
Lectures, Winter Semester, 1910-1911. Springer, Dordrecht,  
 
Hall, J. C., Hall, B. J., & Cockerell, C. J. (2011). HIV/AIDS in the post-HAART era: 
Manifestations, treatment and epidemiology. USA Shelton, Connecticut: People‟s 
Medical Publishing House. 
 
Hans, M. L., Spiegel, M. D., Donna, C., & Futterman, M. D. (2009). Adolescents and HIV: 
Prevention and clinical care. Albert Einstein College of Medicine, Adolescent AIDS 
Program, Montefiore Medical Center. 
 
Harper, G. W., & Riplinger, A. J. (2012). HIV prevention interventions for adolescents and 
young adults: What about the needs of gay and bisexual males? AIDS Behav, 17, 
1082-1095. doi:10.1007/s10461-012-0178-1  
 
Harper. G. W., Fernandez, I. M., Bruce, D., Sybil, G., Hosek, S. G., & Jacobs, R. J. (2011). 
The Role of Multiple Identities in Adherence to Medical Appointments Among 
Gay/Bisexual Male Adolescents Living with HIV 123. AIDS Behav, 17, 213-223. 
doi:10.1007/s10461-011-0071-3  
 
Harrell, M. C., & Bradley, M. A. (2009). Data Collection Methods: Semi-Structured Interviews 
and Focus Groups. Training Manual. Prepared for the U.S. Government approved for 
public release; distribution unlimited National Defense Research Institute. 
 
187 
 
Harris, R. (2000). Information graphics: A comprehensive illustrated reference. New York: 
Oxford University Press. 
 
Haslam, S. A., & McGarty, C. (2003). Research methods and statistics in psychology. 
London: Sage Publications. 
 
Hayden, J. (2009). Introduction to Health Behaviour Theory. Department of Public Health 
William Paterson University. Sudbury. Massachusetts. Boston. Toronto. London. 
Singapore: Jones and Bartlett Publishers. 
 
Haynes, R. B. (1979). Introduction. In R. B. Haynes, D. W. Taylor & D. L. Sackett (Eds.), 
Compliance in health care (pp. 1-7). Baltimore: John Hopkins. 
 
Health Policy Project. (2013). Basics of Health Policy. 
 
Hennink, M., Hutter, I., & Bailey, A. (2011). Qualitative research methods. Sage Publications 
Ltd. 
 
Hesse-Biber, S. N., & Leavy, P. (2004). Approaches to qualitative research: A reader on 
theory and practice. New York, Oxford: Oxford University Press. 
 
Hochbaum, G. M. (1958). Public Participation in Medical Screening Programs: A Socio-
Psychological Study. Department of Health Education and Welfare, PHS Publ no. 
572. Washington, DC: US Government Printing Office. 
 
Holmbeck, G. N., and Kendall, P. C. (2002). Introduction to the special section on clinical 
adolescent psychology: Developmental psychopathology and treatment. Journal of 
Consulting and Clinical Psychology, 70(1), 3–5. 
 
Howell, K. E. (2013). Introduction to the philosophy of methodology. London: Sage 
Publications. 
 
HPCSA, (2006). Professional Board for Psychology: Roles of Conduct Pertaining Specifically 
to the Profession of Psychology. Pretoria: HPCSA. 
 
HSRC. (2009). The HIV and AIDS epidemic in South Africa: Where are we? 
 
188 
 
HSRC. (2012). Human Sciences Research Council. Informed Consent Guidelines re Minors 
(including orphans and vulnerable children OVC) and Parental Substitutes. 
 
Husserl, E. (1970). The crisis of European sciences and transcendental phenomenology: An 
introduction to phenomenological philosophy. Northwestern University Press. 
 
Husserl, E., & Heidegger, M. (1927). Phenomenology. In Encyclopedia of Britannica. 
 
Ijadunola, K. T., Abiona, T. C., Odu, O. O., & Ijadunola, M. Y. (2007). College students in 
Nigeria underestimate their risk of contracting HIV/AIDS infection. Eur J Contracept 
Reprod Health Care, 12(2), 1, 31-37. 
 
Isithembiso. (2011). Official Newsletter of Tembisa Hospital, July. Tembisa, Ekurhuleni: 
Department of Health. 
 
Jaeger, R. A., & Halliday, T. R. (1998). On Confirmatory versus Exploratory Research. 
Herpetologica, 54(Suppl.), S64-S66. The Herpetologists‟ League, Inc. 
 
Jaspan, H. B., Li, R., Johnson, L., & Becker, L. G. (2009). The emerging need for 
adolescent-focused HIV care in South Africa. Desmond Tutu HIV Centre, Institute of 
Infectious Diseases and Molecular Medicine, University of Cape Town.  
 
Jena, P. P. (2014). Exploring the lived experiences of adolescents living with vertically 
acquired HIV. Masters dissertation, Department of Social and Behavioural Sciences, 
University of South Africa, Pretoria. 
 
Jones, P. K., Jones, S. L. & Katz, J. (1987). Improving compliance for asthma patients 
visiting the emergency department using a health belief model intervention. Journal 
of Asthma 24, 199–206. 
 
Kagee, A. (2007). Adherence to Antiretroviral Therapy in the context of the national roll-out 
in South Africa: Defining a research agenda for Psychology. Psychological Society of 
South Africa. South African Journal of Psychology, 38(2), 413-428. 
 
189 
 
Kalichman, S. C. (2013). HIV Treatments as Prevention (TasP): Primer for Behaviour-Based 
Implementation. Springer Briefs in Public Health. Centre for HIV Intervention and 
Prevention, University of Connecticut, Storrs, CT USA. 
 
Kambale, H. N. (2013). Factors that affect adherence to antiretroviral therapy among 
adolescent patients at selected Palapye Clinics. Masters dissertation, Faculty of 
Economic and Management Sciences, University of Stellenbosch. 
 
Karamagi, Y. E. M. (2007). Outcome of Highly Active Antiretroviral Therapy (HAART) among 
HAART naive HIV-infected children under 6 years at the Mildmay Centre, Uganda. 
M.A. Public Health dissertation, University of Limpopo (Medunsa Campus). 
 
Kasedde, S., Luo, C., McClure, C., & Chandan, U. (2013). Reducing HIV and AIDS in 
adolescents: Opportunities and challenges. Current HIV/AIDS. 
 
Kayitare, E., Vervaet, V., Ntawukulilyayo, J. D., Seminega, B., Bortel, V & Remon, J. P. 
(2009). Development of fixed-dose combination tablets containing zidovudine and 
lamivudine for paediatric application. International Journal of Pharmaceutics, 370(1-
2), 41-46. 
 
Keller, D. M. (2011). Adolescents with HIV Have More Neurocognitive Disorders. Medscape 
Medical News Paper presented at the13th European AIDS Conference of the 
European AIDS Clinical Society (EACS): Abstract PS4/2. Presented October 13, 
2011. 
 
Kidia, K. K., Mupambireyi, Z., Cluver, L., Ndhlovu, C. E., Borok, M., & Ferrand, R. A. (2014). 
HIV status disclosure to perinatally-infected adolescents in Zimbabwe: A qualitative 
study of adolescent and healthcare worker perspectives. PloS one 9:e87322. 
doi:10.1371/journal.pone.0087322147 
 
Kip, E. (2008). Factors Influencing patients‘ adherence to Antiretroviral Therapy in four 
selected health facilities in Botswana. Doctor of Literature and Philosophy (Health 
Studies) thesis, University of South Africa, Pretoria. 
190 
 
Krauss, B. J., Letteney, S., Da Baets, A. J, Baggaley, R. & Okro, A. (2013). Disclosure of 
HIV status to HIV positive children 12 and under: A systematic cross-national review 
of implications for health and well-being. Vulnerable Children and Youth Studies: An 
International Interdisciplinary Journal for Research, Policy and Care. 
 
LaGreca, A. M. (1990). Issues in adherence with pediatric regimens. J Pediatric Psych, 15( 
4):423-436. 
 
Lam, D., Seekings, J., & Sparks, M. (2006). The Cape Area Panel Study: Overview and 
Technical Documentation for Waves 1-2-3. Cape Town: University of Cape Town. 
 
Lerner, R. M., & Steinberg, L. (2009). Muus, 1990 Handbook of Adolescent Psychology. 1: 
Individual Bases of Adolescent Development. John Wiley and Sons, Inc. 
 
Leshem, S., & Vernon Trafford, V. (2007). Oranim Academic College of Education, Israel; 
Anglia Ruskin University, UK. Innovations in Education and Teaching International, 
44(1): 93-105. 
 
Levine, A. (1998). Antiretroviral therapy: Adherence. Medscape HIV/AIDS eJournal, (4)2.  
 
Li, R. (2009). Growing up on HAART: The Experiences and Needs of HIV Positive 
adolescents in care and treatment in the Western Cape Province of South Africa. 
CSSR Working Paper No. 249. 
 
Lippman, l. H., & McIntosh, H. (2010). The Demographics of Spirituality and Religiosity 
Among Youth: International and US Patterns Child Trends. Research Brief. 
Publication #2010-21 4301 Connecticut Avenue, NW, Suite 350, Washington, DC. 
 
Lizewski, L. (2010). The Health Belief Model. Wayne State University. Communication 
Theory. 
 
Lowenthal, E.D., Bareeka-Kitaka, S., Marukutira, T., Chapman, J., Goldrath, K., & Ferrand, 
R. A. (2014). Perinatally Acquired HIV infection in Adolescents from sub-Saharan 
Africa: A review of emerging challenges. The Lancet Infectious Diseases, 14(7), 627-
639. 
 
191 
 
Lyon, M. E., Garvie, P., He, J., Malow, R., McCarter, R., & D‟Angelo, L. J. (2012). Spiritual 
well-being among HIV-infected adolescents and their families. Journal of Religious 
Health. doi:10.1007/s10946-012-9657-y 
 
Lyon, M. E., Garvie, P., Kao, E., Briggs, L., He, J., Malow, R., McCarter, R., & D‟Angelo, 
L. J. (2011). An exploratory study of spirituality in HIV-infected adolescents and their 
families: FAmily CEntered Advance Care Planning and Medication Adherence J 
Adolesc Health. J Adolesc Health, 48(6), 633-636. 
doi:10.1016/j.jadohealth.2010.09.006 
 
Maartens, G., Cotton, M., Wilson, D., Venter, F., Meyers, T., & Bekker, L. G. (2012). 
Handbook of HIV Medicine. Oxford University Press. 
 
Machi, L. A., & McEvoy, B. T. (2012). The literature review: Six steps to success. Corwin, 
California: Sage. 
 
Machtinger, E. L., & Bangsberg, D. R. (2006). Adherence to HIV Antiretroviral Therapy. HIV 
In Site Knowledge Base Chapter. San Francisco: University of California. Retrieved 
from http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09 
 
Mack, N., Woodsong, C., MacQueen, K., Guest, G., & Namey, E. (2005). Qualitative 
research methods: A data collector‘s field guide. Family Health International. 
Research Triangle Park, North Carolina. USA. USAID. 
 
Maggiolo, F., Airoldi, M., Trotta, M. P., Sette, P., Bisi, L., Mussini, C., Bai, F., Bini, T., 
Orofino, G., & Gori, A. (2008). Effect of a fixed-dose combination of emtricitabine, 
tenofovir and efavirenz on adherence and treatment acceptability (ADONE study). 
Journal of the International AIDS Society, 11, 167. 
 
Marandu, E. E. (2009). Testing The Theory of Reasoned Action and its Extensions: 
Predicting Intention To Use Condoms. Organisation for Social Science Research in 
Eastern and Southern Africa. 
 
Marshall, C., & Rossman, G. B. (2010). Designing qualitative research. California: SAGE 
Publications.  
 
192 
 
Masokoane, K. Q. (2009). Adherence and non-adherence to AntiRetroviral Treatment in HIV 
positive people in Port Elizabeth. Masters dissertation, Nelson Mandela Metropolitan 
University, Port Elizabeth.  
  
Mayer, C. (2007). Non-adherence to treatment: A psychological and communications 
perspective. 
 
Mburu, G., Hodson, I., Kalibala, S., Haamujompa, C., Cataldo, F., Lowenthal, E. D., & Ross, 
D. (2014). Adolescent HIV disclosure in Zambia: Barriers, facilitators and outcomes. 
Journal of the International AIDS Society, 17, 18866. 
 
Mburu, G., Ram, M., Oxeham, D., Haamujompa, C., Iorpenda, K., & Ferguson, L. (2001). 
Responding to adolescents living with HIV in Zambia: A social-ecological approach. 
 
McCleary-Sills, J., Anjala, K, Brakarsh, J & Browky, S. (2013). Foundation for the Future: 
Meeting the Psychosocial Needs of Children Living With HIV in South Africa and 
Uganda. Article in Journal of HIV/AIDS & Social Services 12(1)  
 
McClure, R. D. (2002). Common Data Collection Strategies Effective in Qualitative Studies 
Using Action Research in Technical/Operational Training Programs. 
 
McCree, D. H., Wingood, G. M., DiClemente, R., Davies, S., & Harrington, K. F. (2002). 
Religiosity and risky sexual behavior in African-American adolescent females. 
Journal of Adolescent Health, 33(1), 2-8.  
 
McLaren, N. (1998). A critical review of the Bio-psychosocial Model. Australian and New 
Zealand Journal of Psychiatry, 32, 86-92. 
 
McMillan, J. H., & Schumacher, S. (2010). Research in education: Evidence-based inquiry. 
Boston: Pearson Education. 
 
McNeely, C. & Blanchard, J. (2009). The teen years explained: a guide to healthy adolescent 
development. Johns Hopkins University. Bloomberg School of Public Health, 
Baltimore. 
 
193 
 
Merchant, R. H., & Lala, M. M. (2012). Common clinical problems in children living with 
HIV/AIDS: Systemic approach. Symposium of Pediatric HIV/AIDS. Indian J Pediatr, 
79(11), 1506-1513. 
 
Merleau-Ponty, M. (1962). Phenomenology of perception. London and New York: Routledge. 
 
Midtbo, V., Shirima, V., Skodval, M., & Daniel, M. (2012). How disclosure and antiretroviral 
therapy help HIV-infected adolescents in sub-Saharan Africa cope with stigma. 
African Journal of AIDS Research, 11(3), 261-271. 
 
Mills, E. J., Nachega, J. B., & Buchan, I. (2009). Adherence to Antiretroviral Therapy in sub-
Saharan Africa and North America: A Meta-analysis. JAMA. 
 
Miner-Romanoff. (2012). Interpretive and critical phenomenological crime studies: A model 
design. The Qualitative Report 2012, 17(54), 1-32. 
 
Mofenson, L. M., & Cotton, M. (2013). The challenges of success: Adolescents with perinatal 
HIV infection. Journal of the International AIDS Society, 16, 18650.  
 
Mook, D. G. (2001). Psychological research: The ideas behind the methods. New York, 
London: W.W. Norton and Company. 
 
Mothi, S. N., Swamy, V. H. T., Mamatha, M. Lala., Karpagam, S., &. Gangakhedkar, R. R. 
(2012). Adolescents living with HIV in India: The clock is ticking. Symposium on 
Pediatric HIV/AIDS. Indian J Pediatr, 79(12), 1642-1647. doi:10.1007/s12098-012-
0902-x 
 
Munro, S, Lewin, S, Swart, T & Volmink, J. 2007. A review of health behaviour theories: how 
useful are these for developing interventions to promote long-term medication 
adherence for TB and HIV/AIDS? 
 
Murphy, D. A., Belzer, M., Durako, S. J., Sarr, M., Wilson, C. M., & Muenz, L. R. (2005). 
Longitudinal antiretroviral adherence among adolescents infected with Human 
Immunodeficiency Virus. Arch Pediatr Adolesc Med, 159(8), 764-770. 
 
194 
 
Musisi, S., & Kinyanda, E. (2009). Psychiatric problems of HIV/AIDS and their management 
in Africa. Kampala, Uganda: Fountain Publishers. 
 
Musisi, S., Kinyanda, E., Nakasujja, N., & Nakigudde, J. (2007). A comparison of the 
behavioral and emotional disorders of primary school-going orphans and non-
orphans in Uganda. Africa Health Science, 7, 202-213. 
 
Nabukeera-Barungi, N., Kaylesubula, I., Kekitjinwa, A., Byakika-Tusiime, L., & Musoke, P. 
(2007). Adherence to antiretroviral therapy in children attending Mulago Hospital, 
Kampala. Annals of Tropical Paediatrics, 27(2), 123-133. 
 
Naidoo, P. (2011). Focus group discussion with private sector doctors in the eThekwini 
Metro of KwaZulu-Natal on the management of HIV/AIDS patients (Pharmacology) 
School of Pharmacy and Pharmacology, College of Health Sciences, University of 
KwaZulu-Natal, South Africa. S Afr Fam Pract, 53(2). 
 
Nassir Ghaemi, S. (2009). The rise and fall of the bio-psychosocial model. British Journal of 
Psychiatry BJP, 195, 3-4. 
 
Nattrass, N. (2007). Mortal combat AIDS and the struggle for antiretrovirals in South Africa. 
Durban: University of KwaZulu-Natal Press. 
 
Ndubuka, N. O. (2008). Factors Influencing Treatment Adherence among Adult Patients 
Receiving Antiretroviral Therapy at Extension 15 Clinic, Gaborone, Botswana. Master 
of Public Health. Pretoria: University of South Africa. 
 
Neville, C. (2007). Effective learning service: Introduction to Research and research 
methods. Bradford University School of Management.  
 
Newbold, P., Carlson, W., & Thorne, B. (2009). Statistics for business and economics. 
Pearson Education. 
 
Nichols, S. (2013). Neuropsychology of HIV in children and adolescents. American 
Psychological Association.  
 
195 
 
Norman, P. & Brain, K. (2005). An application of an extended health belief model to the 
prediction of breast self-examination among women with a family history of breast 
cancer. Br J Health Psychol. 10(1):1-16. 
 
Nyambura, A. W. (2009). Factors that influence non-adherence to antiretroviral therapy 
among HIV and AIDS patients in Central Province, Kenya. Masters of Public Health 
(Epidemiology and Disease Control) thesis, School of Health Sciences of Kenyatta 
University. 
 
Ojikvth, B. O., & Zheng, H. (2008). Predictors of mortality in patients initiating antiretroviral 
therapy in Durban. South African Medical Journal, 98(30), 204-208. 
 
Olsson, F. (2013). The Impact of Orphanhood and HIV/AIDS on school enrolment: Evidence 
from Zambia. School of Business, Economics and Law. Sweden: University of 
Gothenburg.  
 
Palmer, A. (2011). HIV-infected adolescents have multiple risk factors for mental illness. HIV 
Clinician, 23(3), 1-4. 
 
Parsons, R. (2012). Growing up with HIV in Zimbabwe: One day this will all be over. James 
Currey Weaver Press. 
 
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, 
M. M., & Singh, N. (2000). Adherence to Protease Inhibitor Therapy and Outcomes in 
Patients with HIV infection. Ann Intern Med, 133, 21-30. 
 
Patton, M. Q. (1990). Qualitative evaluation and research methods. Newbury Park CA: 
Sage. 
 
Patton, M. Q. (2002). Qualitative research and evaluation methods. London: Sage 
Publication. 
 
Patton, M. Q., & Cochran, M. (2002). A guide to using qualitative research methodology. UK: 
Medecins Sans Frontiers 
196 
 
Petersen, I., Bhana, A., Myeza, A., Alicea, S., John, S., Holst, H., McKay, M., & Mellins, C. 
(2010). Psychosocial challenges and protective influences for socio-emotional coping 
of HIV+ adolescents in South Africa: A qualitative investigation. AIDS Care: 
Psychological and Socio-medical Aspects of AIDS/HIV, 22(8), 970-978. 
 
Pettifor, A. E., Rees, H. V., Kleinschmidt, I., Steffenson, A. E., MacPhail, C., Hlongwa-
Madikizela, L., Vermaak, K., & Padian, N. S. (2005). Young People‟s sexual health in 
South Africa: HIV prevalence and sexual behaviours from a nationally representative 
household survey. AIDS,19(14), 1525-1534. 
 
Pharoah, R. (2004). A generation at risk? HIV/AIDS, vulnerable children and security in 
Southern Africa. ISS Monograph Series 109. 
 
Phiri, S., & Webb, D. (2002). The Impact of HIV/AIDS on orphans and program and policy 
responses. In G. A. Cornia (Ed.), AIDS, public policy and child well-being.  
 
Pienaar, L., & Visser, M. J. (2012). Exploration of the experience of adolescents living with 
HIV. Children and Youth Studies. An International Interdisciplinary Journal for 
Research, Policy and Care, 7(1), 66-74. doi:10.1080/17450128.2011.647731  
 
Polit, D. F., & Beck, C. T. (2006). Essentials of nursing research: Methods, appraisals, and 
utilization. Philadelphia: JB Lippincott. 
 
Pontali, E., Feasi, M., Toscanini, F., Bassetti, M., De Gol, P., Nuzzolese, A., & Bassetti, D. 
(2001). Adherence to Combination Antiretroviral Treatment in Children. HIV Clin 
Trials, 2(6), 466-473. 
 
Pope, C., White, R. T., & Malow, R. (2009). HIV/AIDS: Global frontiers in 
prevention/intervention. New York: Routledge Taylor & Francis Group.  
 
Preda, A. (2005). AIDS, rhetoric, and medical knowledge. University of Edinburgh: 
Cambridge University Press. 
 
Pressley, M., & McCormick, C. B. (2007). Child and adolescent development for educators. 
New York: The Guilford Press. 
 
197 
 
Pugatch, D., Bennett, L., & Patterson, D. (2009). HIV medication adherence in adolescents: 
A qualitative study. Journal of HIV/AIDS Prevention and Education for Adolescents 
and Children, 5, 1-2, 9-29. doi: 10.1300/J129v05n01_02 
 
Pujari, S., Dravid, A., Gupte, N., Joshi, K., & Belle, V. (2008). Effectiveness and Safety of 
Generic Fixed-Dose Combination of Tenofovir / Emtricitabine / Efavirenz in HIV-1-
Infected Patients in Western India. Journal of the International AIDS Society, 10, 196. 
 
Punch, K. F. (2014). Introduction to social research: Quantitative and qualitative approaches. 
London: Sage Publications. 
 
Ramcharan, P., & Cutcliffe, J. R. (2001). Judging the ethics of qualitative research: 
Considering the „ethics‟ as process model. Health and Social Care in the Community, 
9(6), 358-366. 
 
Reed, J. F., Lynn, F., & Meade, B. D. (2002). Use of coefficient of variation in assessing 
variability of quantitative assays. Clin Diagn Lab Immunol., 9(6), 1235-1239. 
 
Reeves, J. D., & Derdeyn, C. A. (2007). Entry Inhibitors in HIV Therapy: Milestones in Drug 
Therapy (MDT). Birkhauser Verlag. Basel. Boston. Berlin. 
 
Regnerus, M., Smith, C., & Smith, B. (2004). Social context in the development of 
adolescent religiosity. Applied Developmental Science, 8, 27-38. 
 
Rice, F. P., & Dolgin, K. G. (2008). The adolescent: Development, relationships, and culture. 
Boston: Allyn and Bacon. 
 
Richter, L. (2001). A generation at risk? HIV/AIDS, vulnerable children and security in 
Southern Africa.  
 
Rolando, M. V., Peralta, L., Aldrovandi, G., Kapogiannis, B. G., Mitchell, R., Spector, S. A., 
Lie, Y. S., Weidler, J. M., Bates, M. P., & Liu, N. (2016). Prevalence of Primary HIV-1 
Drug Resistance among Recently Infected Adolescents: A Multicenter Adolescent 
Medicine Trials Network for HIV/AIDS Interventions Study. The Journal of Infectious 
Diseases, 194(11), 1505-1509. 
 
198 
 
Rose, L., Hagemann, J., Aburto, M & Shahnazarian, D. (2013). Student Handbook: Making 
Sense of Human Subjects Research. University of Southern California 
 
Rosenstock, I. M., Strecher, V. J., & Becker, M. H. (1994). The Health Belief Model and HIV 
Risk Behaviour Model. AIDS Prevention and Mental Health, 5-24. 
 
Rosenthal, D., Waters, L., & Glaun, D. (1995). What do pre-adolescents and adolescents 
understand about HIV/AIDS? Psychology and Health, 10, 507-522. 
 
Ross, A. C., Camacha-Gonzalez, A., Henderson, S., Abanyie, F., & Chakraborty, R. (2010). 
The HIV-infected adolescent. Springer Science and Business Media, LLC. 
 
Rotheram-Borus, M. J., Stein, J., & Lester, P. (2006). Adolescent adjustment over 6 years in 
HIV-affected families. Journal of Adolescent Health, 39, 174-182. 
 
Rudy, B. J., Murphy, D. A., Harris, D. R., Muenz, L., & Ellen, J. (2009). Patient-related risks 
for nonadherence to Antiretroviral Therapy among HIV-infected youth in the United 
States: A study of prevalence and interactions. AIDS Patient Care and STDs, 23(9), 
185-194. doi:10.1089=apc.2008.0162 
 
Ryan, S., & Carr, A. (2010). Applying the bio-psychosocial model to the management of 
rheumatic disease. Elsevier Ltd. doi: 10.1016/B978-0-443-06934-5.00005-X 2 
 
Sadock, B. J., & Sadock, V. A. (2007). Kaplan 7 Sadock‘s Synopsis of Psychiatry: 
Behavioural Sciences / Clinical Psychiatry. Philadelphia: Wolters Kluwer. 
 
SAJHIVMED. (2013). South African Journal of HIV Medicine. Advice Document: Fixed-dose 
combination for adults accessing antiretroviral therapy, 14(1)(Suppl.). 
 
Sande, M. A., & Volberding, P. A. (1999). The medical management of AIDS. London: W.B. 
Saunders Company.  
 
Sanne, I. M., Westreich, D., Macphail, A., Rubel, D., Majuba, P., & Van Rie, A. (2009). Long 
term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South 
Africa: A prospective cohort study. Journal of the International AIDS Society. 
doi:10.1186/1758-2652-12-38 
 
199 
 
Sarno, J.E. (2007). The mind body prescription: healing the body, healing the pain. New 
York, NYC: Little, Brown and Company 
 
Schietinger, H., Sawyer, M., Futterman, D., & Rudy, D. (1999). Helping adolescents with HIV 
adhere to HAART. Adolescent HIV Initiative, Children‟s Hospital Philadelphia. 
 
Sekaran, U. (2003). Research methods for business: A skills building approach. New York, 
NY: John Wiley. 
 
Sendangala, S. (2011). Factors affecting the adherence to anti-retroviral therapy by HIV 
positive patients treated in a community-based HIV/AIDS Care Programme in rural 
Uganda. A Case of Tororo. Master of Public Health thesis, University of South Africa.  
 
Sharma, M. P. (2006). Orphanhood and Schooling Outcomes in Malawi. American Journal of 
Agricultural Economics, 88(5), 1273-1278. 
 
Shaughnessy, J. J., Zechmeister, E. B., & Zechmeister, J. S. (2012). Research methods in 
psychology. McGraw-Hill International. 
 
Shearer, W. T., & Hanson, I. C. (2003). Medical management of AIDS in children. 
Saunders: An Imprint of Elsevier Science. 
 
Shenton, A. K. (2004). Strategies for ensuring trustworthiness in qualitative research 
projects. Education for Information, 22(2), 63-75. 
 
Shisana, O., Rehle, T., Simbayi L. C., Zuma, K.,  Jooste, S., Zungu N., Labadarios, D., 
Onoya, D.  & the Team (2014) South African National HIV Prevalence, Incidence and 
Behaviour Survey, 2012. Cape Town, HSRC Press. 
 
Shrestha, S., Sudenga, S. L., Smith, J. S., Bachmann, L. H., Wilson, C. M., & Kemp, M. C. 
(2010). The impact of highly active antiretroviral therapy on prevalence and incidence 
of cervical human papillomavirus infections in HIV positive adolescents. Bio-Medical 
Central. Journal of Infectious Disease, 10, 295. 
  
200 
 
Sieleunou, I., & Souleymanou, M. (2009). Determinants of survival in AIDS patients on 
antiretroviral therapy. Tropical Medicine and International Health, 14(1), 36-43. 
 
Sigelman, C., & Rider, E. (2009). Life-Span Human Development. UK: Cengage Learning. 
 
Simon, M. (2011). Dissertation and scholarly research recipe: Recipe for success. Seattle, 
WA. Dissertation Success, LLC. 
 
Simons-Morton, B. (2007). Social influences on adolescent substance use. Am J Health 
Behav, 672-684. 
 
Sinclair, M. (2007). Editorial: A guide to understanding theoretical and conceptual 
frameworks. Evidence Based Midwifery, 5(2), 39. 
 
Sneed, S.D. 2008. Adolescent Communication About Sex: The Impact of Content and 
Comfort on Adolescent Sexual Behaviour. Journal of HIV/AIDS Prevention in 
Children & Youth, 9;1, 70-83. 
 
Soloway, B., & Friedland, G. (2000). Antiretroviral Failure: A Bio-psychosocial Approach 
NEJM Journal Watch HIV/AIDS Clinical Care. 
 
Somekh, B., & Lewin, C. (2011). Theory and methods in social research. London: Sage 
Publications. 
 
Spata, A. V. (2003). Research methods: Science and diversity. John Wiley and Sons, Inc. 
 
Steele, R. G., Nelson, T. D., & Cole, B. P. (2007). Psychosocial functioning of children with 
AIDS and HIV infection: Review of the literature from a socioecological framework. J. 
Dev Behav Pediatr, 28(1), 58-69. 
 
Steinberg, L. (2008). Adolescence. New York, NY: McGraw-Hill. 
 
Steinberg, L. (2011). You and your adolescent: The essential guide for ages 10 to 20. New 
York: Simon and Schuster.  
 
Taddeo, D., Egedy, M., & Frappier, J. Y. (2008). Adherence to treatment in adolescents. 
Paediatr Child Health, 13(1), 19-24. 
201 
 
Tashima, K. T., & Mitty, J. A. (2006). Once-daily therapies for the treatment of HIV infection. 
Current HIV/AIDS Reports 2006, 3, 86-92. Current Science Inc.  
 
Terre Blanche, M., & Durrheim, K. (1999). Research in Practice. Cape Town: University of 
Cape Town Press. 
 
Todres, L., Galvin, K., & Dahlberg, K. (2006). Scientific Contribution. Lifeworld-led 
healthcare: Revisiting a humanising philosophy that integrates emerging trends. 
Medicine, Health Care and Philosophy, 10, 53-63. doi:10.1007/s11019-006-9012-8 
 
Treisman, G. J., & Angelino, A. F. (2004). The Psychiatry of AIDS: A Guide to Diagnosis and 
Treatment. Department of Psychiatry and Behavioral Sciences. The John Hopkins 
School of Medicine, Baltimore, Maryland and London. 
 
Trochim, W.M.K. (2001). Research methods knowledge base. Cincinnati, OH : Atomic Dog 
Publishing.  
 
Tucker, J. D., Bien, C. H., Easterbrook, P. J., Doherty, M. C., Penazzato, M., Victorai, M., & 
Peeling, R. W. (2014). Optimal strategies for monitoring response to antiretroviral in 
HIV-infected adults, adolescents, children and pregnant women: A systemic review. 
AIDS, 28(Suppl. 2), S151-S160. 
 
Tufford, L., & Newman, P. (2010). Bracketing in Qualitative Research. Qualitative Social 
Work, 11(1), 80-96. doi: 10.1177/1473325010368316 
 
Turner, B. J. (2002). Adherence to Antiretroviral Therapy by Human Immunodeficiency 
Virus-Infected Patients. The Journal of Infectious Diseases, 185(Suppl. 2), S143-
S151. Human Immunodeficiency Challenges; New Directions.  
 
UNCRC, (1989). United Nations Conventions on the Rights of the Child.  
 
UNAIDS. (1997). The case for expanding access to highly active antiretroviral therapy to 
curb the growth of the HIV epidemic. UNAIDS point of view: October 1997. 
 
UNAIDS. (2007). AIDS Epidemic Update 
 
202 
 
UNICEF. (2004). The framework for the protection, care and support of orphans and 
vulnerable children living in a world with HIV and AIDS. 
 
UNICEF. (2006). Caring for children affected by HIV and AIDS. New York, NY: UNICEF. 
 
USC LibGuide (2014). Organising your social science research paper: Theoretical 
Framework. Guide information 2014. University of South California. 
http://libguides.usc.edu/c.php?g=235034&p=1561763 
 
Van Dyk, A. (1999). AIDS care and counselling. Pinelands Cape Town: Maskew Miller 
Longman. 
 
Van Dyk, A. (2012). HIV and AIDS: Education, care and counselling: A multidisciplinary 
approach. Pinelands, Cape Town: Pearson Education SA. 
 
Van Sighem, A. I., Van de Wiel, M. A., Ghani, A. C., Jambroes, M., Reiss, P., Gyssens, I. C., 
Brinkman, K., Lange, J., & De Wolf, F. (2003). Mortality and progression to AIDS 
after starting highly active antiretroviral therapy. AIDS, 17, 2227-2236. 
 
Van Wyngaard, A. (2013). Addressing the spiritual needs of people infected and affected by 
HIV and AIDS in Swaziland. Journal of Social Work in End-of-Life and Palliative 
Care, 9, 226-240.  
 
Velasco-Hernandez, J. X. (2002). Could widespread use of combination  antiretroviral 
therapy eradicate HIV epidemics? The Lancet, 2(8), 451-508. 
 
Venter, F. (2006). AIDS in Our Lives. Treatment Action Campaign: A handbook for people 
living with HIV and treatment advocates in support groups, clinics and communities. 
 
Walkenbach, J. (2015). Excel 2016 Bible. City, State: Wiley and Sons. 
 
Wanjohi, N. A. (2009). Factors influencing non-adherence to antiretroviral therapy among 
HIV and AIDS patients in Central Province, Kenya. Masters dissertation, Department 
of Public Health, Kenyatta University. 
203 
 
Wertz, F., Charmaz, K., McMullen, L. M., Josselson, R., Anderson, R., & McSpadden, E. 
(2011). Five ways of doing qualitative analysis: Phenomenological psychology, 
grounded theory, discourse analysis, narrative research and intuitive inquiry. New 
York, London: The Guilford Press. 
 
White, P. (2005). Biopsychosocial medicine: An integrated approach to understanding 
illness. New York: Oxford University Press.  
 
WHO. (2004). World Health Organization Standards for Quality HIV Care: A Tool for Quality 
Assessment, Improvement and Accreditation. Report of a WHO Consultation Meeting 
on the Accreditation of Health Service Facilities for HIV Care, 10-11 May 2004, 
Geneva, Switzerland. 
 
WHO. (2007a). World Health Organization mental health: Strengthening mental health 
promotion.Retrieved from http://www.who.int/mediacentre/factsheets/fs220/en/ 
 
WHO. (2007b). World Health Report, 2007 – A Safer Future: Global Public Health in the 21st 
century. 
 
WHO. (2010). World Health Organization Global Report: UNAIDS report on the global AIDS 
epidemic, 2010. Geneva, Switzerland: World Health Organization. 
 
WHO. (2013a). The Voices, Values and Preference of Adolescent on HIV Testing and 
Counselling: Consultation for the Development of World Health Organization HIV 
Testing and Counselling. 
 
WHO. (2013b). World Health Organization HIV and Adolescents: Guidance for Testing and 
Counselling and Care for Adolescents Living with HIV. Recommendations for a 
Public Health Approach and Considerations for Policy Makers and Managers. 
Geneva, Switzerland. 
 
WHO. (2013c). Guidelines: Consolidated Guidelines on the Use of Antiretroviral Drugs for 
Treating and Preventing HIV Infection: Recommendations for Public Health 
Approach. Geneva. 
 
Wilding, C., & Whiteford, G. (2005). Phenomenological research an exploration of 
conceptual, theoretical, and practical issues. OTJR, 25(3). 
204 
 
 
Wiles, R. & Crow, G. (2008). Managing Anonymity and Confidentiality in Social Research: 
The Case of Visual Data in Community Research. ESRC National Centre for 
Research Methods: NCRM Working Paper Series 8/08. 
 
Williams, P. G., Holbeck, G. N., & Greenley, R. N. (2002). Adolescent health psychology. J 
Consult Clin Psychology, 70(3), 828-842. 
 
Wilson, A. M. E. (2014). Mentoring student nurses and the educational use of self: A 
hermeneutic phenomenological study. Nurse Education Today, 34, 313-318. 
 
Wimpenny, P. & Gass, J. (2000). Interviewing in Phenomenology and Grounded Theory: Is 
there a Difference? Journal of Advanced Nursing, 2000, 31(6), 1485-1492. 
 
Wu, N., Slocum, S., Comulada, S., Lester, P., Semaan, A., & Rotheram-Borus, M. J. (2008). 
Adjustment of adolescents of parents living with HIV. Journal of HIV/AIDS Prevention 
in Children and Youth, 9(1), 34-51. doi:10.1080/10698370802124076 
 
Zechmeister, J., Zechmeister, E., & Shaugnessey, J. (2000). Essentials of research methods 
in psychology. New York, NY: McGraw-Hill Education. 
 
Zikmund, W., & Babin, B. (2012). Essentials of marketing research. New York: Cengage 
Learning. 
 
Zuurmond, M. (2008). Adherence to ARVs – challenges and successes: A consultation with 
CAFOD partners and members of the Catholic HIV and AIDS Network (CHAN), 
Nigeria. Zambia.  
 
 
205 
 
APPENDIX A: REQUEST FOR PERMISSION TO HOSPITAL 
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APPENDIX B: PERMISSION GRANTED TO CONDUCT RESEARCH  
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APPENDIX C: ASSENT FORM 
 
RESEARCH PARTICIPANT ASSENT FORM 
TEMBISA HOSPITAL 
 
I, _____________________________, the client/patient, hereby give assent to Musa 
MaseTshaba, who is a Clinical Psychologist, to conduct personal interview with me.  
 
This interview is for the purpose of a Research Study for Doctoral Studies titled: 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT BY 
ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
 I will provide my personal experiences to the best of my knowledge relating to 
HAART. 
 I have the right to terminate my involvement in this research as I may so desire. 
 The Researcher will treat this information as confidential and your names will not be 
published. 
 The outcome of the research will be in a form of Thesis which will be submitted to the 
University of South Africa. 
 I further acknowledge that I was duly informed that the interview will be recorded for 
research purpose. 
 
I, ___________________________________, understand and accept the above conditions. 
Client/Patient 
 
___________________________________ 
    Musa MaseTshaba (Researcher) 
 
 
Date (DD) ______ (MMM) __________________ (YYYY) _____________  
208 
 
APPENDIX D: CONSENT FORM 
 
RESEARCH PARTICIPANT CONSENT FORM 
TEMBISA HOSPITAL 
 
I, _____________________________, the client/patient, hereby give consent to Musa 
MaseTshaba, who is a Clinical Psychologist, to conduct personal interview with me.  
 
This interview is for the purpose of a Research Study for Doctoral Studies titled:  
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL 
TREATMENT BY ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
 I will provide my personal experiences to the best of my knowledge relating to 
HAART. 
 I have the right to terminate my involvement in this research as I may so desire. 
 The Researcher will treat this information as confidential and your names will not be 
published. 
 The outcome of the research will be in a form of Thesis which will be submitted to the 
University of South Africa. 
 I further acknowledge that I was duly informed that the interview will be recorded for 
research purpose. 
 
I,___________________________________, understand and accept the above conditions. 
Client/Parent 
 
___________________________________ 
    Musa MaseTshaba (Researcher) 
 
 
Date (DD) ______ (MMM) __________________ (YYYY) _____________  
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APPENDIX E: INTERVIEW GUIDE FOR INDIVIDUAL ADOLESCENTS 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL 
TREATMENT BY ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the adolescents of the Masakhane Clinic regarding 
the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Verbal, face-to-face interviews 
conducted. 
 
Gender: _______   Age: _______   
School Grade:____________________ Place: ____________________ 
Period on HAART:______________  
 
Interviewer: Duration since HAART was started.  
Interviewer: When did you start taking HAART?  
Interviewer: The treatment you are taking, what is it for? 
Interviewer: Do you know what the treatment is for? 
Interviewer: What does taking such medication mean to you? 
Interviewer: What is the meaning of being in HAART treatment for you? 
Interviewer: Who have you disclosed your status to?  
Interviewer: What are the challenges you face being on HAART? 
Interviewer: What do you think are the challenges that adolescents experience as a result 
of being on HAART? 
Interviewer: What do you think are the benefits you experience as a result of being on 
HAART? 
Interviewer: What are the coping mechanisms and strategies you use as a result of being 
on HAART? 
Interviewer: Would you like to add any other comment that was not addressed by the 
questionnaire?  
 
 
THANK YOU  
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APPENDIX F: INTERVIEW GUIDE FOR PARENTS, GUARDIANS AND 
CAREGIVERS 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL 
TREATMENT BY ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the parents, guardians and caregivers of 
adolescents receiving HAART at Tembisa. 
 
Method: The questions are open ended in nature. Verbal, face-to-face interviews 
conducted. 
 
Gender:_______ Age: _______ Employment :____________________ 
 
Relationship to Adolescent:______________ Place:  ____________________ 
 
Interviewer: Duration since HAART was started.  
Interviewer: When did the adolescent start taking HAART?  
Interviewer: Does the adolescent know what the treatment he or she is taking is for? 
lnterviewer: As a parent, what has been your experience on dealing with adolescents on 
HAART? 
Interviewer: How was the information of his or her status delivered to her/her? 
Interviewer: How did he or she respond to the information of her/her status? 
Interviewer: What do you think the meaning of being in HAART treatment for her/him? 
Interviewer: What are the challenges you face as a result of his or her being on HAART? 
Interviewer: What do you think are the challenges that adolescents experience as a result 
of being on HAART? 
Interviewer: What do you think are the benefits he or she experience as a result of being 
on HAART? 
Interviewer: What are the coping mechanisms and strategies he or she uses to cope with 
being on HAART? 
Interviewer: Would you like to add any other comment that was not addressed by the 
questionnaire? 
THANK YOU  
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APPENDIX G: INTERVIEW GUIDE FOR FOCUS GROUP OF 
ADOLESCENT PARTICIPANTS 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL 
TREATMENT BY ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the adolescents in a focus group at the 
Masakhane Clinic regarding the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Verbal, face-to-face interviews 
conducted. 
 
Focus group interview with adolescents attending HAART Clinic at Masakhane Clinic, 
Tembisa Hospital, Tembisa Township (ages between 12 and 19 years old). 
 
Group Members Biographical Details: 
Gender:_______ Age: _______ School Grade:____________________ 
Period on HAART: _______________ Place:  ____________________ 
Number in a Group: _____________ Duration of session: ______________ 
 
Focus Group Introduction and Welcome Message 
 
Thanks for agreeing to be part of the focus group. We/I appreciate your willingness to 
participate. 
 
INTRODUCTIONS:  Moderator 
 
PURPOSE OF FOCUS GROUPS .We/I have been asked by _________________to 
conduct the focus groups. The reason we are having these focus groups is to find 
out_______________. We/I need your input and want you to share your honest and open 
thoughts with us/me.  
 
SETTING OF GROUND RULES 
1. WE/l WOULD LIKE YOU TO DO THE TALKING: We/I would like everyone to participate. I 
may call on you if I haven‟t heard from you in a while.  
212 
 
2. THERE ARE NO RIGHT OR WRONG ANSWERS: Every person‟s experiences and 
opinions are important. Speak up whether you agree or disagree. We/I want to hear a wide 
range of opinions.  
 
3. WHAT IS SAID IN THIS ROOM STAYS HERE: We/I want folks to feel comfortable 
sharing when sensitive issues come up.  
 
4. WE WILL BE TAPE RECORDING THE GROUP  We/I want to capture everything you 
have to say.  We/I don‟t identify anyone by name in our report. You will remain anonymous.  
 
Group Member 1:    Group Member 5: 
Group Member 2:    Group Member 6: 
Group Member 3:    Group Member 7: 
Group Member 4:    Group Member 8: 
 (depending on number of group members) 
Interviewer: When did you start taking HAART?  
Interviewer: The treatment you are taking, what is it for? 
Interviewer: Do you know what the treatment is for? 
Interviewer: What does taking such medication mean to you? 
lnterviewer: How has your experience been on HAART? 
Interviewer: What is the meaning of being in HAART treatment for you? 
Interviewer: Who have you disclosed your status to?  
Interviewer: What are the challenges you face being on HAART? 
Interviewer: What do you think are the challenges that adolescents experience as a result 
of being on HAART? 
Interviewer: What are the benefits you experience as a result of being on HAART? 
Interviewer: What are the coping mechanisms and strategies you use as a result of being 
on HAART? 
Interviewer: Would you like to add any other comment that was not addressed by the 
questionnaire? 
 
THANK YOU 
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APPENDIX H: INTERVIEW GUIDE FOR HEALTH CARE 
PROFESSIONALS 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL 
TREATMENT BY ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the multidisciplinary team of the Masakhane Clinic 
regarding the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Participants can write as much as they 
can and make use of an extra page should they wish to.  
 
SECTION A: PROFILES OF PARTICIPANTS 
1. Gender 
 Female  Male  
   
 
2. Age  
Years <25 25 to 30 30 to 35 35 to 40 40 to 45 45 to 50 55 to 60 60 to 65 ≥65 
          
 
3. Qualification (Please tick highest you have) 
 Matric M + 3 M + 4 Postgraduate qualification (Please specify) 
     
 
4. Profession of the person filling the form 
 Soc Worker Med Doctor Dietician Nurse  Physiotherapist Other (please specify) 
       
 
5. Experience in the profession (in years): 
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
           
 
6. Length of time since giving services in a HAART roll-out centre:  
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
           
 
7. Length of time since you started at the Masakhane Clinic: 
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
           
 
8. Did you receive any HAART- specific specialised training?  
 Yes No  
   
 
If „Yes‟: 
8.1 what training?   ___________________ 
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8.2 at which institution?  ___________________ 
 
If „No‟, please explain how you obtained the skill and/or knowledge you are applying in your 
work in this environment. 
___________________________________________________________________ 
 
SECTION B: OPEN-ENDED QUESTIONS 
 
 What has been your experience on dealing with adolescents on HAART? 
___________________________________________________________________
_________________________________________________________ 
 
 Please explain the challenges faced by the adolescents on HAART 
_________________________________________________________________________
_____________________________________________________________ 
 Please enlighten on the benefits experienced by the adolescents on HAART 
_________________________________________________________________________
_____________________________________________________________ 
 Please spell out the coping mechanisms and strategies being used by the 
adolescents on HAART 
_________________________________________________________________________
_____________________________________________________________ 
 Please comment on any issues that were not addressed in the questionnaire 
_________________________________________________________________________
_____________________________________________________________ 
THANK YOU  
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APPENDIX I: SAMPLE INTERVIEWS 
HEALTH CARE PROFESSIONAL PARTICIPANT 11 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT BY 
ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: 
To explore the experiences of the multidisciplinary team of the Masakhane Clinic regarding 
the experiences of the adolescents who are on HAART. 
 
Method: 
The questions are open ended in nature. Participants can write as much as they can and 
make use of an extra page should they wish to.  
 
SECTION A: PROFILES OF PARTICIPANTS 
1. Gender 
 Female  Male  
  X 
2. Age  
Years <25 25 to 30 30 to 35 35 to 40 40 to 45 45 to 50 55 to 60 60 to 65 ≥65 
  X        
3. Qualification (Please tick highest you have) 
 Matric M + 3 M + 4 Postgraduate qualification (Please specify) 
  X  NURSING DIPLOMA 
4. Profession of the person filling the form 
 Soc Worker Med Doctor Dietician Nurse  Physiotherapist Other (please specify) 
    X 
 
  
5. Experience in the profession (in years):  
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
 X          
6. Length of time since giving services in a HAART roll-out centre:  
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
 X          
7. Length of time since you started at the Masakhane Clinic: 
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
 X          
8. Did you receive any HAART- specific specialised training?  
 Yes No  
 X  
If ‘Yes’: 
8.1 what training?   
8.2 at which institution?   
If ‘No’, please explain how you obtained the skill and/or knowledge you are applying 
in your work in this environment.  
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I went for HIV course- Basic HIV training; Adherence Counselling; Management of HIV; 
Guidelines on PMTCT- Prevention of mother to child transmission. Pre-post counselling and 
debriefing. 
 
SECTION B: OPEN-ENDED QUESTIONS 
 What has been your experience on dealing with adolescents on HAART? 
Dealing with adolescents taking ARVs can be both a positive and negative. It is positive 
when you see the adolescent who was so sick improving and even gaining weight. You 
somehow feel that you have made a difference in the life of this child. It can also be 
frustrating when your hands are tied by the adolescent and their family themselves when 
adherence is not as it should be and you know that medically, this child‟s life could be much 
better but cooperation in not forth coming and there is different stories all the time. 
 
 Please explain the challenges faced by the adolescents on HAART 
Most adolescents find it difficult to accept their statuses due to lack of understanding how 
they contracted HIV. Most parents find it hard to explain to their children about HIV and 
treatment. Stigma and discrimination affect them because their peers don‟t understand and 
how one can contract HIV, so it is hard for them to accept their statuses. 
 
 Please enlighten on the benefits experienced by the adolescents on HAART 
A better lifestyle and improved healthy lifestyle-immune system. Good and quality 
knowledge in understanding HIV and ART. Reduction in infection-High CD4-count and low 
viral load. 
 
 Please spell out the coping mechanisms and strategies being used by the 
adolescents on HAART 
Through continuation of sessions on counselling and support through support groups, they 
learn to accept and understand HIV and how to live with HIV and adhere to treatment. 
Changes are observed through the outcomes brought forward by adolescents on HAART 
through activities done by them, eg. drama, poems and singing. 

 Please comment on any issues that were not addressed in the questionnaire 
 
Most adolescents who default treatment are those who don‟t attend support groups and they 
have not been told why they take treatment. At an early stage, anger of 9-12 child and to be 
told about their statuses and by then they learn to accept and know about their health. 
END 
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HEALTH CARE PROFESSIONAL PARTICIPANT 8 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT BY 
ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the multidisciplinary team of the Masakhane Clinic 
regarding the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Participants can write as much as they 
can and make use of an extra page should they wish to.  
 
SECTION A: PROFILES OF PARTICIPANTS 
 
1. Gender 
 Female  Male  
 X  
2. Age  
Years <25 25 to 30 30 to 35 35 to 40 40 to 45 45 to 50 55 to 60 60 to 65 ≥65 
      X    
3. Qualification (Please tick highest you have) 
 Matric M + 3 M + 4 Postgraduate qualification (Please specify) 
   X Registered Nurse and Phlebotomist 
4. Profession of the person filling the form 
 Soc Worker Med Doctor Dietician Nurse  Physiotherapist Other (please specify) 
    X  Phlebotomist 
5. Experience in the profession (in years):  
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
   X X       
6. Length of time since giving services in a HAART roll-out centre:  
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
  X         
7. Length of time since you started at the Masakhane Clinic: 
Years <5 5 to 10 10 to 15 15 to 20 20 to 25 25 to 30 30 to 35  30 to 35 30 to 35 ≥35 
  X         
8. Did you receive any HAART- specific specialised training?  
 Yes No  
  X 
 
If ‘Yes’: 
8.1 what training?    
8.2 at which institution?   
 
If ‘No’, please explain how you obtained the skill and/or knowledge you are applying 
in your work in this environment.  
 
I have been working with HIV blood testing for the past 10years; I am now employed by 
National Health Laboratory Services as a Phlebotomist but I am a professional registered 
nurse by training. I have been a nurse for over twenty years. 
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SECTION B: OPEN-ENDED QUESTIONS 
 
 What has been your experience on dealing with adolescents on HAART? 
Dealing with adolescents on HAART my job is to draw blood from them and so I don‟t 
engage so much in conversations with them. Whether the results comes back positive or 
negative, I don‟t get to disclose to them because that part of telling them whether they are 
HIV positive or negative, falls on the shoulders of the Doctors. Sometimes you find 
adolescent who ask questions about why are you taking my blood and I simply tell them to 
test their blood and then refer them back to the Doctors. I do see some adolescents who are 
struggling with their status and I do explain the basics about blood and then refer accordingly 
for further clarity. 
 
 Please explain the challenges faced by the adolescents on HAART 
As a person who draws their blood for testing, I observe parents not informing their children 
why they are being tested. They tell the adolescent it is for flu, etc. As a professional, I am 
not allowed to tell the child why I am taking their blood, all I say is that the blood is taken for 
testing. Partial or no disclosure is the challenge I have observed. These children then 
become angry when they find out later, it is better to tell them the truth. 
 
 Please enlighten on the benefits experienced by the adolescents on HAART 
Fewer HIV related illnesses. 
CD-4 count rise and remain above the baseline count. 
Viral load become undetectable. 
Support from families, health workers, etc.  

 Please spell out the coping mechanisms and strategies being used by the 
adolescents on HAART 
I have also seen a few adolescents who know they are HIV positive, and they are better 
cooperative during the blood test. Some even state they have protected sex. Anger-they 
fight a lot with parents, especially if they do not inform them accordingly of their HIV status. 
Playing soccer, and the support group run by the Social Workers, helps the children to 
accept their status. 
 
 Please comment on any issues that were not addressed in the questionnaire 
THANK YOU 
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PARENTS, GUARDIANS AND CAREGIVERS PARTICIPANT B 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT BY 
ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the parents, guardians and caregivers of the 
Masakhane Clinic regarding the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Verbal, face-to-face interviews 
conducted. 
 
Gender of adolescent: Female    Age of Adolescent: 14 years 
Employment: Student-Enrolled Nurse 
Relationship to Adolescent: Step-mom   Place: Tembisa Hospital  
 
Interviewer: Duration since HAART was started.  
Participant: She started taking treatment in 2010. I am her step-mom, and I recently, last 
year, I took her to come and stay with myself and her dad. She did start on treatment in 
2010, but she was staying with her paternal grandmother and did not take treatment so well. 
Her mother passed away in some six years back and she stayed with her paternal 
grandparents and since last year, she is with us, her dad and I and we have another child. 
 
Interviewer: Does the adolescent know what the treatment he or she is taking is for? 
Participant: She knows because I made sure I inform her myself. I also brought her to the 
hospital so that the doctors can talk to her. She seems to understand the one moment and 
the next she is something else. She throws away the tablets. I don‟t know what to do 
sometimes. 
 
Interviewer: How does her father take part in this treatment? 
Participant: You know how men are. He is not involved at all. He does not even know how 
many tablets she has to take or where the hospital is. I was the one who suggested we take 
her in to stay with us. She is 14 years and only now she is in grade 4 because she started 
school late after I insisted she gets registered at school. Her father just left her in the village 
in Limpopo and would see her once a year and he did not even ask whether she goes to 
school or not. There is another sister, older to this one, but luckily she is not HIV positive and 
she is at least in high school. 
 
Interviewer: How was the information of his or her status delivered to her/her? 
Participant: She used to be sick a lot. She would be in and out of hospital for many times. 
It was during one of her hospital visit that she was told she was sick and must take 
treatment, but I am not sure she was told it was HIV sickness. 
 
Interviewer: How did he or she respond to the information of her/her status? 
It is hard to know how she feels but I suspect she is not ok with it because sometimes she 
does not take her medication. But now she knows and I am sure because I am the one who 
takes her to the clinic for blood tests and treatment collection but still she does not drink her 
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treatment well. Sometimes I see her throwing the tablets into the kitchen sink and when I talk 
to her she just keeps quiet. 
 
Interviewer: What do you think is the meaning of being in HAART treatment for 
her/him? 
Participant: I have learnt what HIV is as part of my studies as an Enrolled Nurse, I know 
treatment will keep her healthy and well. Sometimes I look at her and I see how much well 
she looks but when we get to hospital and they take her blood and they tell us her CD4 
count is very high and I become worried. 
 
Interviewer: What are the challenges you face as a result of her being on HAART? 
Participant: Sometimes when I shout at her she thinks I don‟t love her because she is not 
my child. I have a six year old with her father and so we have two children at home, and it 
becomes difficult to talk with her. 
 
Interviewer: What do you think are the challenges that adolescents experience as a 
result of being on HAART? 
Participant: Her life is not the same as that of other children. She has to take this 
treatment every day for the rest of her life, I think that is not so easy especially for children 
you see. She was sick for a long time and she is behind when it comes to school grades and 
today she did not go to school because she must come to the hospital, it is not so easy 
sometimes. 
 
Interviewer: What do you think are the benefits he or she experience as a result of 
being on HAART? 
Participant: Treatment will help her to not be sick, 
 
Interviewer: What are the coping mechanisms and strategies he or she uses to cope 
with being on HAART? 
Participant: This one, I am not sure,  
 
Interviewer: What is your experience regarding your interaction with adolescent on 
HAART? 
Participant: Well, this child has been through so much, losing her mother and not going to 
school alright. Now I am in her life because I am with her dad, and her dad makes it difficult 
because he seems like he does not care and I must be the mom and I am not her real mom. 
Sometimes I feel I am alone on this and if I get tired, she has no one to help her. As a 
student nurse, I understand medication but it is hard to make the people I live with to help 
them understand and, ja man.  
 
Interviewer: Would you like to add any other comment that was not addressed by the 
questionnaire? 
Participant: No. 
THANK YOU 
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FOCUS GROUP OF ADOLESCENT PARTICIPANTS 
 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT BY 
ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the adolescents in a focus group at the 
Masakhane Clinic regarding the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Verbal, face-to-face interviews in a group 
setting were conducted. 
 
Focus Group Participants 
Three adolescents took part in the focus group 
FGAPA    FGAPB   FGAPC 
Age     Age    Age 
17 years    14 years   16 years 
Gender    Gender   Gender 
Male     Male    Female 
School Grade   School Grade  School Grade 
Grade 10    Grade 7   Grade 9 
Duration on HAART   Duration on HAART  Duration on HAART 
Since 2006    Since 2005   Since 2008 
 
Interviewer: When did you start taking HAART?  
FGAPC:  Mmmhh, he-e, I do not know when I started, I just remember drinking 
them, I was still very small. But the treatment card will show, „takes out treatment card; 
FGAPB:  I also don‟t remember exactly the date but I know I was still small and 
before I even started school. 
FGAPA:  I started taking the treatment in 2006. 
 
Interviewer: The treatment you are taking, what is it for? 
FGAPA:  I know I am taking the treatment for HIV because I am HIV positive. It 
is not easy for me to talk about this HIV status, I respect and I know I am HIV positive and 
since 2006 I started taking this treatment. I do not want to go there, I do not like taking about 
it ‗he started crying-then we had a moment of quietness.‘ 
 
Interviewer: Is it too painful for you to talk about this? 
FGAPA:  Ya, ‗head bowed down, looking down‘, maybe you can ask the others. 
FGAPC:  Me, I know that I am HIV positive and I must take this treatment. You 
see, my Mom also has this HIV and she took me to the hospital one day. When we were at 
the hospital she said I must wait for her by the corner she is coming back she is going to buy 
me some sweets. She never came back. I was small and now I am sixteen and a half years 
old and she has not come back from the sweets. I have been staying in a Children‟s Home, 
and I have since learnt that my mom has three other children and she does not stay with any 
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of her children. I have visited her before and she keeps saying she will come and fetch me, 
but now I don‟t think she will come. You see, she is also sick, I think it is the HIV and she 
does not work. 
 
Interviewer: And you B, (referring to the 14 year boy) do you know what the 
treatment you are taking is for? 
FGAPB: I know I have this illness, HIV and if I don‟t take treatment I will fall sick. My 
mom passed away and I stay with my aunt. I know that I am taking treatment for HIV, my 
aunt told me about it. 
 
Interviewer: How has your experience been on HAART? 
FGAPA: The treatment is okay, it‟s just that the tablets are hard to swallow, they are 
bitter when you have to swallow and it is not nice. I used to drink many tablets, maybe 10 
tablets two times a day. I had to swallow all of them like that. I used to just put all of them in 
my mouth at the same time and drink water but some of them would be stuck on the throat 
‗indicating the throat with her hand‘, and it was hard to drink but I must drink because I want 
to be alive and grow up and be a chef. 
FGAPB: Me too, ‗nam futhi, aya baba lamapilisi‘, so it was difficult but now I don‟t take 
as many tablets as before, now I take two tablets at 7 o‟clock in the morning and 7 o‟clock at 
night. Now it is easier to take the tablets. 
FGAPC: Now I only have to take one tablet per day and it does not get stuck on my 
throat and it is easier to take the tablets. My weight has increased and the tablet that you 
take once a day, you must weigh a certain weight before they can give you that tablet, so 
because I was drinking the many tablets before and I am gaining weight so the Doctors at 
the clinic decided I can start taking the one tablet per day. 
 
Interviewer: What about you, you are quiet, how is this treatment for you? (refering 
to the 17 year old boy) 
FGAPA: This treatment, I don‟t like it and I don‟t like talking about it. My grandmother 
told me about I am HIV positive. I was always sick, attending hospital in and out frequently. 
Grandmother was told by the doctors about my HIV status and they tried to withhold 
information from me and I asked them to be honest with me because it is my life after all. I 
even asked the doctors though they were reluctant to tell me but finally I persuaded them to 
tell me and they told me. My mom died of this illness and she left me when I very small. 
Many people are dying of this illness that is why I don‟t like talking about it. You see I take 
the medication, three tablets at 7 o‟clock at night.  
 
Interviewer: What does taking such medication mean to you? 
FGAPB: The treatment is important because it keeps us healthy. So taking the 
treatment means we can stay alive. 
FGAPA: For me, it reminds me I am sick and ‗keeps quiet and changes topic‘, can I 
leave? 
 
Interviewer: I have two more questions, and I would appreciate your opinion, but yes 
you can leave if it gets too much for you, I see this is not comfortable for you. 
FGAPA: Ok, you see this disease, my Mom died because of this disease and so I must 
take medication so I can stay alive. 
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Interviewer: What are the challenges you face being on HAART? 
FGAPB: The problem was the swallowing of the bitter tablets but now that problem is 
gone.  
FGAPA: For me, you see I have friends and I stay out late hanging with my friends on 
the streets chilling and sometimes time flies by and I come home and the time for medicine 
is gone.  My grandmother will tell me I am late and what what and this is making stress for 
me and I smoke dagga to make the stress go away.  
I also have a girlfriend and we must use the condom and I must use the condom because I 
don‟t talk about the HIV with her and I don‟t know if she has the HIV or not (looks at his 
watch and asks to be excused). 
 
Interviewer: Thank you for your time, I appreciate the information you shared. 
FGAPA: Sure sure guys, see you next time neah (looking at the two participants). 
FGAPC and FGAPB: sharp „waving their hands in unison‘ 
 
Interviewer: What are the benefits you experience as a result of being on HAART? 
FGAPB: I know I am healthy because of the medication, so it helps me a lot. 
FGAPC: I am also ok, I know if I was not taking the medication I would not be like this, 
maybe I would be sick. 
 
Interviewer: What are the coping mechanisms and strategies you use as a result of 
being on HAART? 
FGAPC: At school, I have some friends and some of them are taking treatment and we 
are like ok, we don‟t have problems. But at the Children‟s Home, we do Bible reading and we 
each read a verse before we go to sleep and we go to church on Sundays so the praying 
helps a lot. The other children in the home are also taking medication so we all come 
together at 7 o‟clock to take medication and we remind each other when it is time for 
medication. The house Mother also encourages us and support us, she makes sure there is 
food to eat before we take the medication. 
FGAPB: My friend has some dogs next door, so I spend a lot of time with him looking 
after the dogs and I don‟t always remember that I am HIV positive and my friends are nice 
about my HIV positive status. You know many people take medication so it is like it is a 
normal thing around our street. 
Interviewer: Would you like to add any other comment that was not addressed by the 
questionnaire? 
FGAPC: No,  
FGAPB: Nuh, 
THANK YOU 
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ADOLESCENT PARTICIPANT F 
EXPERIENCES OF LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT BY 
ADOLESCENTS IN TEMBISA, GAUTENG PROVINCE 
 
Objective: To explore the experiences of the adolescents of the Masakhane Clinic regarding 
the experiences of the adolescents who are on HAART. 
 
Method: The questions are open ended in nature. Verbal, face-to-face interviews 
conducted. 
 
Gender:   Female  Age: 18 years School Grade:  09 
Period on HAART: Since  October 2007   Place:  Tembisa Hospital 
 
Interviewer: When did you start taking HAART?  
Participant: I started taking treatment in October 2007. Initially, I was very sickly and at some 
point I had to be taken to the hospital you see. When I was in hospital, they drew my blood to 
have it tested and I was given treatment at the hospital. When I was discharged, I had to 
continue taking treatment.  
 
Interviewer: The treatment you are taking, what is it for? 
Participant: (avoiding eye contact—looking at the ceiling and walls), I was still very young, my 
grandmother just told me I must drink medication in the morning and in the evening. You see, 
she would always remind me to take my medication and I always took my medication on time 
and every day when I was small. I did not know what the medication was for, I just drank it 
because my grandmother told me to. 
 
But when I was in Grade 6, I gradually pieced together the story of me drinking tablets so many 
times. I started reading my hospital file when we went to fetch my treatment and that is how I 
learnt that I am drinking medication for HIV and AIDS and I discovered I am HIV positive but I 
just left it there, I did not talk to anyone or ask anyone about it.  
 
Then when I started having my periods, I did not understand all this blood business and I was 
careless looking after my blood stained panties. One day, my grandmother was very angry with 
me because of my carelessness with my panties during my periods and she just shouted „you will 
make us all sick with your sickness because of this blood of yours‘, so I was very confused and I 
asked her what she was talking about. She just shouted at me in front of all my cousins and I 
was so shocked. I think I must have been about 15 or 16 years old when this happened, I was 
angry and wondered why she did not tell me this before.  
 
Interviewer: What does taking such medication mean to you? 
Participant: Drinking my medication helps me because I am not so sick anymore like before 
and my body (you see—pointing at her body from head to toe, with a faded smile), my body 
looks healthy and I am ok. My health has improved. 
 
Interviewer: What are the challenges you face being on HAART? 
Participant: My problem with drinking this medication is that sometimes I forget, especially in 
the mornings. I take my medication at 07:00 in the morning and at 19:00 in the evening. The 
morning dose is a bit of a problem because sometimes I am bathing at that time and so I end up 
taking medication a bit later. Sometimes, because I am in a rush in the morning, I am not able to 
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drink. So I asked the Clinic Dr to please put me on the treatment which l take only once, if I take 
that one in the evening only, I think it will be better and easier for me because I don‟t have 
forgetting problems in the evening like I do in the morning (Fixed-dose combination). 
 
Because of my sickness when I was younger, one time I stayed in hospital for two months and I 
missed out so much from school and I had to repeat Grade 3. I also repeated Grade 5 and I am 
only doing Grade 09 now, and most people my age are finishing Matric. So I sometimes feel that 
this sickness makes me slow at school. 
 
Interviewer: I notice your file says you are 3 months pregnant, how do you feel about 
that? 
Participant: (some sniffles, pauses before responding, teary eyed).It is true, you see, I now 
stay with my Aunt, my mother‟s older sister. My mother passed away when I was small, and I 
then I had to stay with my grandmother and in 2012 I asked to come stay with my Aunt in 
Tembisa. My grandmother stays in Mpumalanga. I am scared of my Aunt and so I don‟t talk 
much with her about life issues and problems. Sometimes I wish my mother was alive, at least I 
would know certain things unlike now.  
 
Interviewer: Things like what? 
Participant: Things like getting pregnant. I did not think I would get pregnant when I had sex 
with my boyfriend. 
 
Interviewer: In Life Orientation at school, don‟t they teach you about sex? 
Participants: They teach us about sex and HIV and AIDS, but if you have an adult that you talk 
to at home, it is better. My aunt is not approachable and when I have problems I rather speak to 
my friends than my aunt. She likes shouting a lot. 
 
Interviewer: How much can your friends tell you about life problems? 
Participant: My friends are helpful sometimes because, you see, like now, I talked to them 
about pregnancy and they talk to their moms about it and they come back to me to tell me to go 
to the hospital. 
 
Interviewer: Pregnancy means there was no condom use, not so. 
Participant: Yes, the thing is my boyfriend, but he is not my boyfriend anymore. We broke up 
before I found out I was pregnant, but I told him I am pregnant and he says it is not his baby and 
I am so hurt and feeling bad. My ex-boyfriend did not want to use a condom. I would tell him to 
use a condom but he refused, so I just ended up just agreeing because I did not want to lose 
him. The problem is that he has so many girlfriends and he is always having so many girlfriend 
and I sometimes suspect he is HIV positive so we are all the same and it does not matter you 
see. Sometimes I give up on my life and I feel it does not matter. I feel so hopeless and I thing 
dying would be better, like in the beginning of the year, I decided I wanted to die and I took an 
overdose of my ARVs only to wake up the next day and I am still alive. So my friend told me the 
ARVs don‟t kill, they are to help me with my life and not for dying. 
 
Interviewee: Have you had another thought of killing yourself since your attempt? 
Participant: Not anymore, I feel bad for trying to kill myself, so I have not tried again. So, I 
also talk to my brother, he is older than me but he does not always help. He stays in a shack in 
Ivory Park and he uses Nyaope. He is not very helpful and not reliable. My aunt does not like him 
and she does not let him visit us a lot. He does piece jobs sometimes and makes money to buy 
nyaope. 
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Interviewer: Do you know your brother’s HIV status? 
Participant: He is older than me. He is 27 years old and he is HIV negative. He is actually my 
half-brother from my mother‟s side. We share a mother but I don‟t know his father and I don‟t 
know my own father. They tell me my father died whilst my mother was pregnant with me and I 
think this is how I got my HIV from my mother.  
 
Interviewer: How do you feel about your life, considering your HIV status and 
pregnancy, how will this impact on your schooling? 
Participant: It is a tough life. I feel so hopeless and l just want to give up on my own life. I 
doubt I will even pass Grade 9. I am 18 years old and in Grade 9. I will fail Grade 9 because I 
don‟t really have a very easy life. I stay with my aunt and her four children and her husband and 
life is not so nice for me. She looks after me but it is not the same. Sometimes I feel I want to go 
back to my grandmother in Mpumalanga and I have not seen my Mpumalanga relatives since I 
came to stay with my aunt. My aunt does not like our relatives in Mpumalanga so when I am 
here, I don‟t talk to her about anything that relates to Mpumalanga. 
Next year when the baby comes, who will look after the baby when I go to school? This school 
issue, I doubt I will finish school. My life is a bit mixed up 
 
Interviewer: What are the coping mechanisms and strategies you use as a result of 
being on HAART? 
Participant: I just talk to my friends.  
 
Interviewer: You will need to talk to the Antenatal people about the HIV and pregnancy 
so that they will help you with treatment so you can prevent mother-to-child transmission 
and the sooner the better before pregnancy grows further. Also, I would also like to speak 
with your aunt, so I can get a perspective from her side how she sees the ARV treatment 
and you.  Would you be ok with that? 
Participant: Will you tell her what I just told you? 
Interviewer: No. I won’t tell her what we discussed, it would be better for you to tell her 
yourself or if you want me to tell her, you will have to give me permission and we agree to 
a meeting for you and her to talk together in my presence, otherwise, I would not tell her. I 
would like to know what she thinks and your social support, things like that.  
 
I will come back next week to start with the once a day tablet, they said I must bring my aunt, so 
when we come we will also come and see you, maybe next week or that other week if my aunt 
agrees. 
 
Interviewer: Would you like to add any other comment that was not addressed by the 
questionnaire? 
Participant: Nothing else. 
END 
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ADOLESCENT PARTICIPANT G 
 
Biographical Information 
Gender : Male 
Age   : 19 years 
Race   : African 
Level of education : Technikon 
Accompanied by : Maternal Aunt 
Place of interview : Tembisa Hospital 
Period on HAART : since 2007 (6 years) 
 
Interviewer : Please take me through your experience of taking HAART. 
Participant : I was constantly sick and weak and had to be in hospital many times until they 
tested my blood and told me I had HIV. I believe I got my illness from my mom 
because I was sick long time before I started having a girlfriend. In 2003 my 
mother died because she was sick of HIV. My dad also died of HIV illness in 
2001. Now I live with my grandmother. 
 
Interviewer : How has HAART treatment been for you? 
 
Participant : I take my tablets two times a day. I take three tablets in the morning and one 
tablet in the evening. My aunt reminds   me to take my tablets most of the times. 
Before, I was not happy about the treatment. I was scared I would die like my 
parents. I was reluctant to play with other kids before, I was scared of their 
reactions. But now I am ok with it. I have two friends, one takes ARVs like me 
and the other does not take ARVs but is also HIV positive. And we share our 
stories and so it becomes easier to drink treatment.  
Interviewer : What kind of challenges did you go through since you started HAART? 
Participant : Having a girlfriend sometimes, it is hard to tell the girlfriend.  The Doctor told me 
various ways of getting HIV infection; accident, unprotected sex and from your 
mother. Sometimes, the condom can work and sometimes it is not so easy you 
see.  I know I must be protected, but sometimes, it does not happen. I had a 
girlfriend before and I told her about my HIV status, so she know and we would 
use condoms most of the times but the relationship ended and now I don‟t have a 
girlfriend. 
 
Interviewer : How does it feel to be constantly taking HAART? 
Participant : For me, I am fine with the treatment. I used to get Care Dependency grant, R1 
200.00, but now the grant has stopped because my viral load is high. Now my 
aunt and grandmother receive grant so we are ok at home. I study at TUT, 
student loan is helping me. 
 
Interviewer : What does taking such medication mean to you? 
Participant : Sometimes, when I take the medication, it reminds me I am sick but I just have 
to take the medication. Before, I used to have big breast like I am a girl and I did 
not like that. But I told the Doctor and they changed my medication, so now my 
breast is going back to normal. Sometimes, I hear my ears are not working like 
before, I hear people when they shout and that is because of the medication.  
END 
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APPENDIX K: LANGUAGE EDITOR’S REPORT 
 
